https://news.bms.com/generated by Q4Sun, 10 May 2026 15:43:04 -0400Copyright Q4 Inc. All rights reserved.a616c5e1-eade-4f1f-a730-0a4ac3033db2https://news.bms.com/news/details/2026/Bristol-Myers-Squibb-Receives-European-Commission-Approval-of-Sotyktu-deucravacitinib-for-the-Treatment-of-Active-Psoriatic-Arthritis-in-Adults/default.aspxFri, 08 May 2026 06:59:00 -0400e2736720-f162-47d7-8150-2ff647ca08d7https://news.bms.com/news/details/2026/Bristol-Myers-Squibb-to-Participate-in-the-Bank-of-America-Securities-Healthcare-Conference-2026/default.aspxWed, 06 May 2026 06:59:00 -04005e973fda-ed23-4c96-9581-66523055714ahttps://news.bms.com/news/details/2026/Bristol-Myers-Squibb-Launches-Wont-Lose-Media-Campaign-Ahead-of-FIFA-World-Cup-2026/default.aspxMon, 04 May 2026 06:59:00 -04009e3ac483-8ecb-4643-8bf8-9170d6652a64https://news.bms.com/news/details/2026/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results-for-2026/default.aspxThu, 30 Apr 2026 06:59:00 -040001a28146-52d9-48b0-937f-0228d2ad0a2dhttps://news.bms.com/news/details/2026/Bristol-Myers-Squibb-and-Pfizer-to-Make-Eliquis-apixaban-Available-via-Mark-Cuban-Cost-Plus-Drug-Company/default.aspxFri, 24 Apr 2026 06:59:00 -040080efd939-fe5d-4aff-9d29-1031eded3a5ahttps://news.bms.com/news/details/2026/Bristol-Myers-Squibb-Evolves-and-Expands-Standing-in-the-Gaap-to-Advance-More-Equitable-Care-in-Multiple-Myeloma-as-Program-Marks-Ten-Years/default.aspxTue, 31 Mar 2026 06:59:00 -040069349a7e-d280-4010-8b50-3998d984a5b7https://news.bms.com/news/details/2026/Bristol-Myers-Squibb-Presents-Positive-Results-from-Phase-3-SCOUT-HCM-Trial-Demonstrating-Efficacy-and-Safety-of-Camzyos-mavacamten-in-Adolescents-with-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-oHCM/default.aspxSun, 29 Mar 2026 11:45:00 -0400b4f2f3e1-9caa-4630-a483-053df442b91fhttps://news.bms.com/news/details/2026/Open-Label-Outpatient-Switch-Study-Demonstrates-Symptom-Stability-During-Transition-from-Oral-Atypical-Antipsychotics-to-Cobenfy-xanomeline-and-trospium-chloride/default.aspxSat, 28 Mar 2026 07:00:00 -0400d82b81f4-9bf9-41e6-b081-f937e11de706https://news.bms.com/news/details/2026/Bristol-Myers-Squibb-Reinforces-Leadership-in-oHCM-with-New-Camzyos-mavacamten-Data-at-American-College-of-Cardiology-Annual-Scientific-Session--Expo-2026-ACC-26/default.aspxMon, 23 Mar 2026 06:59:00 -04001f902e71-26c6-41a9-8006-2b6b764e36echttps://news.bms.com/news/details/2026/Bristol-Myers-Squibb-Transforms-the-Classical-Hodgkin-Lymphoma-Treatment-Paradigm-with-Expanded-U-S--and-EMA-Approvals-for-Opdivo-nivolumab/default.aspxFri, 20 Mar 2026 16:42:00 -0400bb971307-22fd-4d5a-9567-472a5fb67b4ehttps://news.bms.com/news/details/2026/Bristol-Myers-Squibb-to-Report-Results-for-First-Quarter-2026-on-April-30-2026/default.aspxThu, 19 Mar 2026 06:59:00 -0400bd8e8845-7b58-4ec2-8c15-00df460b1e7ahttps://news.bms.com/news/details/2026/Bristol-Myers-Squibb-Announces-Positive-Phase-3-Results-from-the-SUCCESSOR-2-Study-of-Oral-Mezigdomide-in-Relapsed-or-Refractory-Multiple-Myeloma/default.aspxMon, 09 Mar 2026 06:59:00 -04005419d892-197f-454d-bb1c-6695f4c781dehttps://news.bms.com/news/details/2026/U-S--FDA-Approves-Bristol-Myers-Squibbs-Sotyktu-deucravacitinib-for-the-Treatment-of-Adults-with-Active-Psoriatic-Arthritis/default.aspxFri, 06 Mar 2026 21:59:00 -05008cb2795d-8434-4162-81d5-d2fd77af2d69https://news.bms.com/news/details/2026/Bristol-Myers-Squibb-Announces-Dividend/default.aspxMon, 02 Mar 2026 16:16:00 -0500296303c6-8307-4868-94fd-1ca4c992f86ehttps://news.bms.com/news/details/2026/SystImmune-and-Bristol-Myers-Squibb-Highlight-Positive-Phase-III-Interim-Topline-Results-for-izalontamab-brengitecan-Iza-bren-in-Previously-Treated-Unresectable-Locally-Advanced-or-Metastatic-Triple-Negative-Breast-Cancer/default.aspxThu, 26 Feb 2026 06:59:00 -0500af4366c3-a256-4f94-9c08-bfc47d7e7015https://news.bms.com/news/details/2026/Bristol-Myers-Squibb-to-Participate-in-the-TD-Cowen-46th-Annual-Health-Care-Conference/default.aspxMon, 23 Feb 2026 16:16:00 -0500ddcb18d3-609f-4e58-ad19-de68c227b19fhttps://news.bms.com/news/details/2026/Bristol-Myers-Squibb-Announces-Positive-Top-Line-Results-from-Registrational-Phase-2-Study-of-Luspatercept-in-Adults-with-Alpha--Thalassemia/default.aspxMon, 23 Feb 2026 06:59:00 -05007a5fe6f8-d4f2-46e1-960a-ca7c3c35f4fchttps://news.bms.com/news/details/2026/U-S--Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-New-Drug-Application-for-Iberdomide-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma/default.aspxTue, 17 Feb 2026 06:59:00 -0500cac45e87-5d85-4b3d-8b0a-0c1121a3ccf9https://news.bms.com/news/details/2026/Bristol-Myers-Squibb-to-be-Inaugural-Partner-for-Life-Science-Cares-National-Campaign-to-Advance-Health-Equity-and-Fight-Food-Insecurity-/default.aspxThu, 12 Feb 2026 12:00:00 -050075da67e0-66a8-4b0e-9677-0cd42d9cd563https://news.bms.com/news/details/2026/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2025/default.aspxThu, 05 Feb 2026 06:59:00 -050002e88783-942d-4399-80c1-37889237ecf3https://news.bms.com/news/details/2026/Bristol-Myers-Squibb-Teams-Up-with-Kasey-Keller-to-Share-His-Lymphoma-Journey-with-Breyanzi/default.aspxWed, 04 Feb 2026 06:59:00 -05002e1f045b-62c1-4ea9-9942-ddc09745e66dhttps://news.bms.com/news/details/2026/Bristol-Myers-Squibb-Introduces-Change-the-Target--Change-Whats-Possible--to-Highlight-Unmet-Needs-in-Cardiovascular-and-Thromboembolic-Care/default.aspxTue, 03 Feb 2026 06:59:00 -050021b2ec6b-452d-4de5-ad03-1ed16f3d2824https://news.bms.com/news/details/2026/Bristol-Myers-Squibb-Announces-Collaboration-with-Microsoft-to-Advance-AI-Driven-Early-Detection-of-Lung-Cancer/default.aspxTue, 20 Jan 2026 06:59:00 -050082e57e7a-3721-4850-8c95-5d566529cea9https://news.bms.com/news/details/2026/Bristol-Myers-Squibb-Foundation-Launches-National-Program-to-Bolster-Mental-Health-Diversion-Initiatives-2026-feNgxXtwl0/default.aspxThu, 15 Jan 2026 09:00:00 -0500627fb632-aad7-4707-8e84-6443080463f3https://news.bms.com/news/details/2026/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Phase-3-SCOUT-HCM-Trial-Evaluating-Camzyos-mavacamten-in-Adolescents-with-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-oHCM/default.aspxMon, 12 Jan 2026 06:59:00 -05008e053a96-af21-44b4-bac1-9b2c8b836f2fhttps://news.bms.com/news/details/2026/Bristol-Myers-Squibb-to-Present-at-J-P--Morgans-44th-Annual-Healthcare-Conference/default.aspxFri, 02 Jan 2026 06:59:00 -0500612645e8-c48a-4735-aaf7-a31b8bc54f52https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Announces-Agreement-with-U-S--Government-to-Improve-Affordability-and-Access-to-Critical-Medicines-for-Americans/default.aspxFri, 19 Dec 2025 15:05:00 -050006d859bb-96d6-4734-97d6-368074916513https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-to-Report-Results-for-Fourth-Quarter-2025-on-February-5-2026/default.aspxThu, 18 Dec 2025 06:59:00 -0500856e72bd-dc31-4296-a996-a7264427e4c5https://news.bms.com/news/details/2025/U-S--Food-and-Drug-Administration-FDA-Grants-Priority-Review-to-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-Plus-Chemotherapy-Combination-for-Classical-Hodgkin-Lymphoma/default.aspxThu, 11 Dec 2025 06:59:00 -05008697c374-f2ba-467a-9ca8-9818b11a70aahttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Announces-Dividend-Increase/default.aspxWed, 10 Dec 2025 16:16:00 -050047cdf557-35fc-4846-96cf-b0e8e4b630adhttps://news.bms.com/news/details/2025/BioNTech-and-Bristol-Myers-Squibb-Present-First-Global-Phase-2-Data-for-PD-L1xVEGF-A-Bispecific-Antibody-Pumitamig-Showing-Encouraging-Efficacy-in-Advanced-Triple-Negative-Breast-Cancer/default.aspxTue, 09 Dec 2025 07:00:00 -050064a38321-082f-4c1d-892a-db8419406a19https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Advances-Lymphoma-Research-with-New-Targeted-Protein-Degradation-and-Cell-Therapy-Data-at-ASH-2025/default.aspxMon, 08 Dec 2025 16:30:00 -0500d1eba225-38df-4bb8-a8fa-a73e2d20917ahttps://news.bms.com/news/details/2025/Bristol-Myers-Squibbs-Breyanzi-Approved-by-the-U-S--FDA-as-the-First-and-Only-CAR-T-Cell-Therapy-for-Adults-with-Relapsed-or-Refractory-Marginal-Zone-Lymphoma-MZL/default.aspxThu, 04 Dec 2025 20:15:00 -050091d957eb-c34f-4361-9cea-a08c04385be0https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Announces-Continuation-of-ADEPT-2-Phase-3-Study-in-Psychosis-Associated-with-Alzheimers-Disease/default.aspxWed, 03 Dec 2025 06:59:00 -05009652ee29-9260-4e39-a544-52869f1fe63fhttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Data-at-ASH-2025-Showcase-Potential-of-Hematology-Pipeline-and-Build-Momentum-for-Next-Generation-Portfolio/default.aspxMon, 01 Dec 2025 06:59:00 -0500483631f6-bfdd-410a-91e2-b3c2a5deef41https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-to-Participate-in-Citis-2025-Global-Healthcare-Conference/default.aspxWed, 26 Nov 2025 06:59:00 -0500c6516d1d-16ad-45d0-9460-9a6a71080659https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Receives-Approval-from-the-European-Commission-to-Expand-Use-of-CAR-T-Cell-Therapy-Breyanzi-for-Relapsed-or-Refractory-Mantle-Cell-Lymphoma/default.aspxMon, 24 Nov 2025 17:00:00 -0500d740778e-4f4f-45e2-b2fb-b1569a634ef3https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-to-Host-Hematology-Focused-Investor-Event/default.aspxMon, 24 Nov 2025 06:59:00 -05004d2ffd81-9684-409c-9d30-76d25df910f9https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Announces-Accepted-Amounts-and-Pricing-Terms-of-its-Tender-Offers/default.aspxTue, 18 Nov 2025 14:25:00 -05009f74389e-f0c2-4e40-8192-86f207e21170https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Announces-Early-Participation-Results-Amendment-and-Early-Settlement-of-Tender-Offers/default.aspxMon, 17 Nov 2025 22:33:00 -05003b4c46e0-ac67-4f6c-990c-0e3bb8e1b9fchttps://news.bms.com/news/details/2025/Update-on-Phase-3-Librexia-ACS-Trial/default.aspxFri, 14 Nov 2025 06:59:00 -05009bf56d6d-f20d-4db5-9a9c-002e1ac38333https://news.bms.com/news/details/2025/Sarah-Cannon-Research-Institute-and-Bristol-Myers-Squibb-Expand-Strategic-Collaboration-to-Accelerate-Patient-Enrollment-and-Broaden-Access-to-Innovative-Cancer-Research/default.aspxWed, 12 Nov 2025 09:00:00 -050022345e74-f22a-493a-9ce7-46181b8e5d1bhttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Prices-5-Billion-of-Senior-Unsecured-Notes/default.aspxWed, 05 Nov 2025 14:47:00 -0500059c60f7-cf4b-43a1-b13b-24743531b8ebhttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Showcases-New-Long-Term-and-Real-World-Data-From-Cardiovascular-Portfolio-at-the-American-Heart-Association-Scientific-Sessions-2025/default.aspxMon, 03 Nov 2025 06:59:00 -05002a776708-1375-4065-ba76-d6bd7148bb9chttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Announces-Cash-Tender-Offers-to-Purchase-Certain-Notes/default.aspxMon, 03 Nov 2025 04:55:00 -050034a11d1a-237a-4f31-8c63-8f9322ac6e97https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Reports-Third-Quarter-Financial-Results-for-2025/default.aspxThu, 30 Oct 2025 06:59:00 -04000cb103b7-dbfc-4943-8b0f-96d4e6db4e81https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Presents-Two-Late-Breaking-Presentations-Demonstrating-Sotyktu-deucravacitinib-Efficacy-in-Psoriatic-Arthritis-and-Systemic-Lupus-Erythematosus/default.aspxMon, 27 Oct 2025 06:59:00 -0400de87dfba-6d99-4899-84bb-5f75424fcbbfhttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Presents-Encouraging-Data-from-Phase-1-Breakfree-1-Study-of-CD19-NEX-T-CAR-T-Cell-Therapy-in-Three-Chronic-Autoimmune-Diseases-at-ACR-Convergence-2025/default.aspxSat, 25 Oct 2025 11:00:00 -040041906306-3ef7-4f85-b94b-cfdc93e8e50fhttps://news.bms.com/news/details/2025/SystImmune-Inc--and-Bristol-Myers-Squibb-Announce-First-Global-Phase-I-Results-of-Iza-bren-an-EGFR-x-HER3-Bispecific-Antibody-Drug-Conjugate-in-Patients-with-Advanced-Solid-Tumors-at-ESMO-2025/default.aspxFri, 17 Oct 2025 10:00:00 -04000afc1508-163a-42e6-be60-2b111517542ehttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Foundation-Announces-1-Million-Donation-to-Patient-Advocate-Foundation-2025-15TLKbpsUL/default.aspxWed, 15 Oct 2025 07:00:00 -040019861937-3cd0-449b-919c-79a3c337a1ffhttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-to-Present-Data-at-ESMO-2025-Showcasing-Progress-of-Oncology-Portfolio-Across-Diverse-Tumor-Types/default.aspxMon, 13 Oct 2025 06:59:00 -0400c77561cc-e9cd-4150-80bb-d7c03539f01dhttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Strengthens-and-Diversifies-Cell-Therapy-Portfolio-with-Acquisition-of-Orbital-Therapeutics/default.aspxFri, 10 Oct 2025 06:59:00 -040033d4da5c-7aec-4ac6-a18f-48aef3ccfb64https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-and-TV-Host-Gail-Simmons-Tackle-Stigma-in-Schizophrenia-with-New-Initiative-Spotlighting-the-Power-of-Support-and-Connection/default.aspxFri, 10 Oct 2025 06:45:00 -04004702988a-895a-4af0-aa80-a59fb8d01f36https://news.bms.com/news/details/2025/Bristol-Myers-Squibbs-Anti-MTBR-Tau-Targeting-Antibody-BMS-986446-Granted-Fast-Track-Designation-by-U-S--FDA-for-the-Treatment-of-Alzheimers-Disease/default.aspxWed, 01 Oct 2025 06:59:00 -040070dc2794-e191-46e9-bf4b-b039fac12227https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Builds-on-Eliquis-apixaban-Direct-to-Patient-Program-Announces-New-BMS-Patient-Connect-Platform-Offering-Sotyktu-deucravacitinib/default.aspxThu, 25 Sep 2025 06:59:00 -04009a12e4f3-67f1-45cc-bc0c-05df37562da0https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Announces-Phase-3-EXCALIBER-RRMM-Study-Evaluating-Iberdomide-in-Combination-with-Standard-Therapies-Demonstrated-a-Significant-Improvement-in-Minimal-Residual-Disease-Negativity-Rates-in-Relapsed-or-Refractory-Multiple-Myeloma/default.aspxTue, 23 Sep 2025 06:59:00 -04001c42c383-e691-4195-a951-17eeaf21d637https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-to-Report-Results-for-Third-Quarter-2025-on-October-30-2025/default.aspxFri, 19 Sep 2025 06:59:00 -0400e3e68e7d-be45-4eb4-85bd-8055c498962fhttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Announces-Dividend-d2f7061a4/default.aspxWed, 17 Sep 2025 06:59:00 -040064afa0ca-01b9-4ca8-ac63-713bec006828https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-to-Participate-in-the-Bernstein-Insights-Healthcare-Leaders-and-Disruptors---2nd-Annual-Healthcare-Forum/default.aspxTue, 16 Sep 2025 06:59:00 -04000fd351c9-52ba-4483-8213-6fd0a97e3d0fhttps://news.bms.com/news/details/2025/First-Disclosure-of-Global-Interim-Phase-2-Data-for-BioNTech-and-Bristol-Myers-Squibb-PD-L1xVEGF-A-Bispecific-Antibody-Pumitamig-BNT327-BMS986545-in-Patients-with-Extensive-Stage-Small-Cell-Lung-Cancer-Shows-Encouraging-Antitumor-Activity/default.aspxMon, 08 Sep 2025 08:00:00 -040089064b9b-bd8b-4ef9-a028-9198d67650a7https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Presents-Real-World-Outcomes-of-Camzyos-mavacamten-Across-Four-Continents-at-the-European-Society-of-Cardiology-ESC-Congress-2025/default.aspxFri, 29 Aug 2025 07:35:00 -0400a7fdd1fc-00bf-4144-b803-1d6581990e65https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-to-Participate-in-the-Morgan-Stanley-23rd-Annual-Global-Healthcare-Conference/default.aspxFri, 29 Aug 2025 06:59:00 -040074436113-b25a-4521-9070-2262fcfec75ehttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-to-Present-New-Clinical-and-Real-World-Data-at-the-European-Society-of-Cardiology-Congress-2025/default.aspxMon, 25 Aug 2025 06:59:00 -04006f226035-94dd-4d1f-8f03-afe1ba9b50aahttps://news.bms.com/news/details/2025/Izalontamab-Brengitecan-EGFRxHER3-ADC-Granted-Breakthrough-Therapy-Designation-by-U-S--FDA-for-Patients-with-Previously-Treated-Advanced-EGFR-Mutated-Non-Small-Cell-Lung-Cancer/default.aspxMon, 18 Aug 2025 07:00:00 -0400049b245d-be9b-4752-b96d-7f52e758496ehttps://news.bms.com/news/details/2025/Bristol-Myers-Squibbs-Application-for-Breyanzi-lisocabtagene-maraleucel-Accepted-for-Priority-Review-by-U-S--Food-and-Drug-Administration-FDA-in-Fifth-Cancer-Type-for-Relapsed-or-Refractory-Marginal-Zone-Lymphoma-MZL/default.aspxMon, 04 Aug 2025 16:16:00 -040046bec5ac-acca-4264-8a7d-55e9345df018https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Reports-Second-Quarter-Financial-Results-for-2025/default.aspxThu, 31 Jul 2025 06:59:00 -0400172fa25f-2fee-473a-be65-8d2ece1f90f5https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-and-Bain-Capital-Create-New-Company-Dedicated-to-Developing-Innovative-Immunology-Therapies-that-Address-the-Unmet-Medical-Needs-of-Patients/default.aspxMon, 28 Jul 2025 16:16:00 -040014f92121-c0cd-40de-80b1-4c3584e66682https://news.bms.com/news/details/2025/Cristian-Massacesi-M-D--Joins-Bristol-Myers-Squibb-as-Executive-Vice-President-Chief-Medical-Officer-and-Head-of-Development/default.aspxFri, 25 Jul 2025 06:59:00 -04002722b468-c9cc-4151-8dd8-306fdc5518d8https://news.bms.com/news/details/2025/Bristol-Myers-Squibbs-Supplemental-New-Drug-Application-sNDA-for-Sotyktu-deucravacitinib-for-the-Treatment-of-Adults-with-Active-Psoriatic-Arthritis-Accepted-for-Review-Across-Four-Regions-Globally/default.aspxMon, 21 Jul 2025 06:59:00 -0400cec887e6-3b57-4767-8331-eb075b84ddc2https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Announces-Topline-Results-from-Phase-3-INDEPENDENCE-Trial-for-Reblozyl-luspatercept-aamt-in-Adult-Patients-with-Myelofibrosis-Associated-Anemia/default.aspxFri, 18 Jul 2025 06:59:00 -0400bfdbc20a-dce3-4fbd-bf8e-080490764ef0https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-and-Pfizer-Announce-Direct-to-Patient-Eliquis-apixaban-Option/default.aspxThu, 17 Jul 2025 06:59:00 -040022460068-caf5-49ca-8d81-d0ab03a1382dhttps://news.bms.com/news/details/2025/U-S--Food-and-Drug-Administration-Approves-Streamlined-Patient-Monitoring-Requirements-and-Removal-of-REMS-Programs-within-Bristol-Myers-Squibbs-Cell-Therapy-Labels/default.aspxThu, 26 Jun 2025 22:05:00 -04006253b6ac-7cc1-4b4e-a632-c0a3b94dc7d1https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Announces-Dividend-54d68b0a2/default.aspxTue, 17 Jun 2025 16:16:00 -0400ecf8d8c8-8802-4aed-ad23-05cd2e08651dhttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Presents-First-Data-from-the-Marginal-Zone-Lymphoma-Cohort-of-the-Transcend-FL-Trial-Demonstrating-Deep-and-Durable-Responses-with-Breyanzi-lisocabtagene-maraleucel/default.aspxMon, 16 Jun 2025 06:59:00 -040084bab056-4ef9-46a7-8223-3af271de28b3https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Presents-Data-Across-Targeted-Protein-Degradation-Research-Including-CELMoD-Agents-and-BCL6-Ligand-Directed-Degrader-at-EHA-2025/default.aspxThu, 12 Jun 2025 06:59:00 -040048363b56-02eb-4431-b078-d079d1d22300https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-to-Report-Results-for-Second-Quarter-2025-on-July-31-2025/default.aspxThu, 12 Jun 2025 06:45:00 -0400dfd956f0-a46d-4a61-a556-9bd885f8fe49https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Presents-Late-Breaking-Data-from-Pivotal-Phase-3-POETYK-PsA-1-Trial-Demonstrating-Superiority-of-Sotyktu-deucravacitinib-Compared-with-Placebo-in-Adults-with-Psoriatic-Arthritis/default.aspxWed, 11 Jun 2025 06:59:00 -040009472d9b-e995-4716-945e-06def824049chttps://news.bms.com/news/details/2025/BioNTech-and-Bristol-Myers-Squibb-Announce-Global-Strategic-Partnership-to-Co-Develop-and-Co-Commercialize-Next-generation-Bispecific-Antibody-Candidate-BNT327-Broadly-for-Multiple-Solid-Tumor-Types/default.aspxMon, 02 Jun 2025 06:45:00 -04003fd155ae-133d-49c5-acf6-37e3dc76b635https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-to-Participate-in-the-Goldman-Sachs-46th-Annual-Global-Healthcare-Conference/default.aspxWed, 28 May 2025 06:59:00 -040064d15ac1-f25a-4870-a978-496b179c63cchttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-the-Subcutaneous-Formulation-of-Opdivo-nivolumab-Across-Multiple-Solid-Tumor-Indications/default.aspxWed, 28 May 2025 06:55:00 -04005b618bf8-1693-4375-9f02-9d0fcf3daff1https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-to-Present-Data-at-ASCO-2025-Highlighting-Differentiated-Research-Platform-of-Oncology-Treatments-and-Innovative-Research-Pipeline/default.aspxThu, 22 May 2025 17:05:00 -0400f6689828-29bc-48a7-a210-6424d24768bchttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-to-Participate-in-the-Bernstein-41st-Annual-Strategic-Decisions-Conference/default.aspxWed, 21 May 2025 06:59:00 -040071bd24be-1cda-4d76-90fa-7aa5fd39036chttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Perioperative-Regimen-of-Neoadjuvant-Opdivo-nivolumab-and-Chemotherapy-Followed-by-Adjuvant-Opdivo-for-Resectable-High-Risk-Non-Small-Cell-Lung-Cancer-with-PD-L1-Expression-1/default.aspxFri, 16 May 2025 06:59:00 -0400c5f55790-4879-4f53-9c4f-3af475b7593chttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Appoints-Cari-Gallman-as-Executive-Vice-President-General-Counsel-and-Chief-Policy-Officer/default.aspxTue, 06 May 2025 06:59:00 -0400868f5210-5f78-4cea-8391-34fdf798dc23https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results-for-2025/default.aspxThu, 24 Apr 2025 06:59:00 -04004374defa-3c94-4d05-a184-6923b0d53ea5https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Announces-Topline-Results-from-Phase-3-ARISE-Trial-Evaluating-Cobenfy-xanomeline-and-trospium-chloride-as-an-Adjunctive-Treatment-to-Atypical-Antipsychotics-in-Adults-with-Schizophrenia/default.aspxTue, 22 Apr 2025 16:15:00 -0400a96a93e0-603f-4419-b8da-13d7cd2da7f6https://news.bms.com/news/details/2025/U-S--Food-and-Drug-Administration-Updates-CAMZYOS-mavacamten-Label-to-Reduce-Echocardiography-Monitoring-Requirements-and-Contraindications/default.aspxThu, 17 Apr 2025 20:21:00 -04006b5e0773-ebe0-4cae-a2dc-122255f5a41ahttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Provides-Update-on-Phase-3-ODYSSEY-HCM-Trial/default.aspxMon, 14 Apr 2025 16:15:00 -0400a4102c61-2ec4-4497-b73c-d50bef665083https://news.bms.com/news/details/2025/U-S--Food-and-Drug-Administration-Approves-Opdivo-nivolumab-plus-Yervoy-ipilimumab-as-a-First-Line-Treatment-for-Unresectable-or-Metastatic-Hepatocellular-Carcinoma/default.aspxFri, 11 Apr 2025 15:49:00 -0400b700c574-e5b3-47da-83ae-5816fd3fb457https://news.bms.com/news/details/2025/U-S--Food-and-Drug-Administration-Approves-Opdivo-nivolumab-plus-Yervoy-ipilimumab-as-a-Treatment-for-Patients-with-Previously-Untreated-Microsatellite-Instability-High-or-Mismatch-Repair-Deficient-Unresectable-or-Metastatic-Colorectal-Cancer1/default.aspxTue, 08 Apr 2025 15:36:00 -040079ec5b28-6a2e-4ddc-93c6-23bf6b5f64echttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Perioperative-Regimen-of-Neoadjuvant-Opdivo-nivolumab-and-Chemotherapy-Followed-by-Surgery-and-Adjuvant-Opdivo-for-Resectable-Non-Small-Cell-Lung-Cancer-in-Patients-with-Tumor-Cell-PD-L1---/default.aspxFri, 28 Mar 2025 08:53:00 -0400011b0a95-351b-4210-9cf5-b8695cd394bbhttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-the-Subcutaneous-Formulation-of-Opdivo-nivolumab-Across-Multiple-Solid-Tumor-Indications/default.aspxFri, 28 Mar 2025 08:00:00 -0400afc379f8-596e-48e2-b50e-d74fe7d72cbdhttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Receives-Approval-from-the-European-Commission-to-Expand-Use-of-CAR-T-Cell-Therapy-Breyanzi-for-Relapsed-or-Refractory-Follicular-Lymphoma/default.aspxFri, 14 Mar 2025 06:59:00 -0400fb2ee81b-f909-4cb8-a7ce-2689c76c78d6https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-to-Report-Results-for-First-Quarter-2025-on-April-24-2025/default.aspxThu, 13 Mar 2025 06:59:00 -04003978f373-d480-4700-97aa-d5c0e8c00b87https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Presents-Late-Breaking-Data-from-Phase-3-POETYK-PsA-2-Trial-Demonstrating-Superiority-of-Sotyktu-deucravacitinib-Compared-with-Placebo-in-Adults-with-Psoriatic-Arthritis/default.aspxSat, 08 Mar 2025 09:01:00 -0500cf666a67-5825-4bbb-9731-0339f186b9e5https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-plus-Yervoy-ipilimumab-for-the-First-Line-Treatment-of-Adult-Patients-with-Unresectable-or-Advanced-Hepatocellular-Carcinoma/default.aspxFri, 07 Mar 2025 06:59:00 -0500c143665f-f203-4184-9a13-d807cfc1a5abhttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Announces-Dividend/default.aspxMon, 03 Mar 2025 16:16:00 -0500af36af31-5774-4e14-9b16-40a8330d65e7https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-to-Participate-in-Upcoming-Investor-Conferences/default.aspxTue, 25 Feb 2025 06:59:00 -05007db939f6-eb61-4204-92e8-431719fa123dhttps://news.bms.com/news/details/2025/U.S.-Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-Supplemental-Biologics-License-Application-for-Opdivo-Plus-Yervoy-for-Patients-with-Unresectable-or-Metastatic-Microsatellite-Instability-High-or-Mismatch-Repair-Deficient/default.aspxMon, 24 Feb 2025 06:59:00 -0500d5454473-3c1b-4ecb-96fa-9c4c8a2a4a4dhttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Announces-Opdivo-Plus-Chemotherapy-as-the-First-and-Only-Neoadjuvant-Only-Immuno-Oncology-Therapy-to-Demonstrate-Statistically-Significant-and-Clinically-Meaningful-Overall-Survival-in-Resectable-Non-Small-Cell-Lung-Cancer/default.aspxWed, 19 Feb 2025 06:59:00 -0500b7ba453f-151d-4ed3-8651-cb0c2461a262https://news.bms.com/news/details/2025/New-Five-Year-Sotyktu-deucravacitinib-Data-Show-Consistent-Safety-and-Durable-Response-Rates-in-Moderate-to-Severe-Plaque-Psoriasis/default.aspxSun, 16 Feb 2025 06:59:00 -050093aca8ee-2a1f-404f-b02f-89265849c001https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Provides-Update-on-Phase-3-RELATIVITY-098-Trial/default.aspxThu, 13 Feb 2025 16:16:00 -0500fca2a476-57ec-4586-87a3-830ef53d1120https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-for-Breyanzi-lisocabtagene-maraleucel-in-Adult-Patients-with-Relapsed-or-Refractory-Marginal-Zone-Lymphoma/default.aspxMon, 10 Feb 2025 06:59:00 -0500903534f4-3c18-4000-955a-50536b19c024https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2024/default.aspxThu, 06 Feb 2025 06:59:00 -05001162bc36-0644-474a-9c7f-255d98698cfbhttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Opdivo-nivolumab-plus-Yervoy-ipilimumab-as-a-First-Line-Treatment-Option-for-Adult-Patients-with-Unresectable-or-Advanced-Hepatocellular-Carcinoma/default.aspxFri, 31 Jan 2025 06:59:00 -0500aaef4135-bbe4-44af-b64e-7a009e0764bahttps://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-CAR-T-Cell-Therapy-Breyanzi-for-Relapsed-or-Refractory-Follicular-Lymphoma/default.aspxFri, 31 Jan 2025 06:50:00 -050034e0c569-017c-4525-b0eb-01bf5f0efd46https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Presents-Results-from-CheckMate--8HW-Analysis-Evaluating-Opdivo-nivolumab-plus-Yervoy-ipilimumab-Compared-to-Opdivo-Monotherapy/default.aspxSat, 25 Jan 2025 10:02:00 -0500c4c21f6d-3b4d-4273-8e50-c9421e9e4058https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-to-Present-at-J.P.-Morgans-43rd-Annual-Healthcare-Conference/default.aspxFri, 03 Jan 2025 06:59:00 -0500d344f316-49ac-422a-84b8-72b98903d11fhttps://news.bms.com/news/details/2024/US-Food-and-Drug-Administration-Approves-Opdivo-Qvantig-nivolumab-and-hyaluronidase-nvhy-Injection-for-Subcutaneous-Use-in-Most-Previously-Approved-Adult-Solid-Tumor-Opdivo-nivolumab-Indications12/default.aspxFri, 27 Dec 2024 17:37:00 -0500818dc7a1-fdc1-4847-a1da-0152c5d24bc7https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Two-Pivotal-Phase-3-Trials-Evaluating-Sotyktu-deucravacitinib-in-Adults-with-Psoriatic-Arthritis/default.aspxMon, 23 Dec 2024 06:59:00 -05009671d7b0-76c9-4059-9cb2-48eb1638d93dhttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-plus-Yervoy-ipilimumab-for-the-First-Line-Treatment-of-Adult-Patients-with-Microsatellite-InstabilityHigh-or-Mismatch-Repair-Deficient-Metastatic-Colorectal-Cancer/default.aspxMon, 23 Dec 2024 06:45:00 -0500ed011800-cec2-4076-91d4-112ece68c3a1https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-to-Report-Results-for-Fourth-Quarter-2024-on-February-6-2025/default.aspxThu, 19 Dec 2024 06:59:00 -05005372df0e-8db9-4761-b4f8-fdbade8c251bhttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Announces-Dividend-Increase/default.aspxWed, 11 Dec 2024 16:17:00 -05000d0eaa63-4e7e-4758-87d1-2f736dd9ded1https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Highlights-Progress-of-Cell-Therapy-Portfolio-at-ASH-2024-with-Long-Term-Survival-Data-and-Results-from-Expanding-Pipeline/default.aspxMon, 09 Dec 2024 17:45:00 -0500236eb0a7-85a7-4030-9cb3-cd5d5d048da7https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-to-Participate-in-Citis-2024-Global-Healthcare-Conference/default.aspxTue, 26 Nov 2024 06:59:00 -0500eac36b43-5353-47c5-83c6-2f57c6d70422https://news.bms.com/news/details/2024/Bristol-Myers-Squibbs-Presentations-at-ASH-2024-Reinforce-Strength-of-Hematology-Portfolio-and-Scientific-Advances-in-Differentiated-Research-Platforms/default.aspxTue, 19 Nov 2024 06:59:00 -05003ea3111e-0ead-45a1-b0d3-4a823586c72chttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Opdivo-nivolumab-plus-Yervoy-ipilimumab-for-the-First-Line-Treatment-of-Adult-Patients-with-Microsatellite-InstabilityHigh-or-Mismatch-Repair-Deficient-Metastatic-Colorectal-Cancer/default.aspxFri, 15 Nov 2024 08:23:00 -0500e0cc7e97-dc1b-45c3-bcdb-e6771bda1c2fhttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Repotrectinib-for-the-Treatment-of-Advanced-ROS1-Positive-Non-Small-Cell-Lung-Cancer-and-Advanced-NTRK-Positive-Solid-Tumors/default.aspxFri, 15 Nov 2024 06:59:00 -050005a99911-923f-4bf9-8a3e-c1f73b31f4f2https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Showcases-the-Continued-Strength-of-its-Cardiovascular-Portfolio-with-New-Clinical-and-Real-World-Data-at-American-Heart-Association-Scientific-Sessions-2024/default.aspxMon, 11 Nov 2024 06:59:00 -05008f698e65-2722-4457-ba9a-f60f67bb1575https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-to-Participate-in-Upcoming-Investor-Conferences-05ed384f0/default.aspxTue, 05 Nov 2024 17:00:00 -05003a8a7322-5b24-4ae8-9944-6938a241387bhttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Presents-New-Long-term-Data-from-the-EMERGENT-Program-Evaluating-COBENFY-xanomeline-and-trospium-chloride-in-Adults-with-Schizophrenia-at-Psych-Congress-2024/default.aspxThu, 31 Oct 2024 16:16:00 -04000c7536ad-7f81-4bba-aa96-811a7dab96c6https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Reports-Third-Quarter-Financial-Results-for-2024/default.aspxThu, 31 Oct 2024 06:59:00 -040070519e94-f53f-4a02-9c47-60c95729b9aahttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-to-Present-New-Clinical-and-Health-Economics-and-Outcomes-Research-Data-at-Psych-Congress-2024/default.aspxMon, 28 Oct 2024 06:59:00 -0400ce7542f0-b546-4c73-80fe-d0f980b0d322https://news.bms.com/news/details/2024/U.S.-Food-and-Drug-Administration-Approves-Perioperative-Treatment-of-Neoadjuvant-Opdivo-nivolumab-and-Chemotherapy-Followed-by-Surgery-and-Adjuvant-Single-Agent-Opdivo-for-Resectable-Non-Small-Cell-Lung-Cancer-NSCLC/default.aspxThu, 03 Oct 2024 17:35:00 -0400aee50da7-9ae4-463f-826f-a22b0ce64f83https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Presents-New-Data-from-Two-Trials-Demonstrating-Sotyktu-deucravacitinib-Efficacy-in-both-Moderate-to-Severe-Scalp-Psoriasis-and-in-a-Real-World-Setting/default.aspxFri, 27 Sep 2024 11:06:00 -0400fb32f7e5-2305-4b08-889d-82c9d4b3910bhttps://news.bms.com/news/details/2024/U.S.-Food-and-Drug-Administration-Approves-Bristol-Myers-Squibbs-COBENFY-xanomeline-and-trospium-chloride-a-First-In-Class-Muscarinic-Agonist-for-the-Treatment-of-Schizophrenia-in-Adults/default.aspxThu, 26 Sep 2024 21:05:00 -0400478c777a-7848-4ec8-b6fe-6e7e555a0de9https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Statement-on-Oncologic-Drugs-Advisory-Committee-ODAC-Meeting-Regarding-Class-Evaluation-of-PD-L1-Expression-Levels-for-Immune-Checkpoint-Inhibitors-in-Gastric-and-Esophageal-Cancers-/default.aspxThu, 26 Sep 2024 21:00:00 -0400acd7dd14-c21d-4177-a149-6f06bd0bee39https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-and-2seventy-bio-Provide-Update-on-KarMMa-9-Trial-of-Abecma-in-Patients-with-Newly-Diagnosed-Multiple-Myeloma/default.aspxWed, 25 Sep 2024 06:00:00 -0400db6ed9df-aa5c-4523-b2f0-b2c1ea8ad6f5https://news.bms.com/news/details/2024/New-Long-Term-Zeposia-ozanimod-Data-Demonstrate-Durable-Efficacy-and-Consistent-Safety-in-Relapsing-Forms-of-Multiple-Sclerosis/default.aspxWed, 18 Sep 2024 06:59:00 -04003724353a-3ba3-4ece-b6e1-b8bd2b044f80https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Presents-Landmark-10-Year-Follow-Up-Data-from-CheckMate--067-Which-Showed-Continued-Durable-Long-Term-Survival-Benefit-with-Opdivo-plus-Yervoy-in-Advanced-Melanoma/default.aspxSun, 15 Sep 2024 08:55:00 -04005dca1d38-a473-4d89-bce6-476d190008d0https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-to-Report-Results-for-Third-Quarter-2024-on-October-31-2024/default.aspxThu, 12 Sep 2024 06:59:00 -04002aab32ef-74b0-4158-ac4d-cf2073758665https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Announces-Dividend-db0843461/default.aspxTue, 10 Sep 2024 17:45:00 -0400cd35364f-996c-4dea-afb3-c99d13d6658ehttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-to-Present-Data-at-ESMO-Demonstrating-Ongoing-Leadership-in-Immuno-Oncology-and-Progression-of-Assets-from-Its-Differentiated-Research-Platforms/default.aspxMon, 09 Sep 2024 06:59:00 -04006c35e94f-7110-4a16-ba12-fa21d53e255chttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Employees-to-Relay-Nearly-3000-Miles-Cross-Country-Aspiring-to-Raise-Over-1-Million-for-the-V-Foundation-for-Cancer-Research/default.aspxFri, 06 Sep 2024 07:00:00 -040067db9af6-9e7a-44cc-abbc-3e209e0000aehttps://news.bms.com/news/details/2024/Long-Term-Follow-Up-Data-from-Phase-3-Study-of-CAMZYOS-mavacamten-Underscores-Established-Efficacy-and-Safety-Profile-in-Patients-with-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-oHCM/default.aspxSun, 01 Sep 2024 03:33:00 -040076c0df75-c29c-4f13-8e30-6e784949c6b1https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-to-Participate-in-Upcoming-Investor-Conferences-92c0e26e8/default.aspxTue, 27 Aug 2024 06:59:00 -0400e8fc5362-0369-4364-98b9-6927ae334f69https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-to-Present-Data-Across-Cardiovascular-Portfolio-at-the-European-Society-of-Cardiology-Congress-2024/default.aspxMon, 26 Aug 2024 06:59:00 -0400f2fe9e8e-d25b-4049-84ae-ab50dac8a917https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Statement-on-Oncologic-Drugs-Advisory-Committee-ODAC-Meeting-to-Discuss-PD-L1-Expression-Levels-in-Gastric-and-Esophageal-Cancers/default.aspxThu, 22 Aug 2024 14:45:00 -04001b19cc36-4a94-4837-947c-9daf5b5fb050https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Receives-U.S.-Food-and-Drug-Administration-sBLA-Acceptance-for-First-Line-Treatment-of-Unresectable-Hepatocellular-Carcinoma/default.aspxWed, 21 Aug 2024 06:59:00 -04005f426e03-91bd-4a1a-aeac-b9e894d4f07fhttps://news.bms.com/news/details/2024/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Application-for-CAR-T-Cell-Therapy-Breyanzi-for-Relapsed-or-Refractory-Follicular-Lymphoma/default.aspxMon, 19 Aug 2024 06:59:00 -040017a79ccc-4071-47e6-beea-b05e819ce4ebhttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Reports-Second-Quarter-Financial-Results-for-2024/default.aspxFri, 26 Jul 2024 06:59:00 -04004506736c-9b39-4e31-bc24-5af99c06a2fehttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Receives-European-Medicines-Agency-Validation-of-Application-for-Opdivo-nivolumab-plus-Yervoy-ipilimumab-for-First-Line-Treatment-of-Unresectable-or-Advanced-Hepatocellular-Carcinoma/default.aspxFri, 19 Jul 2024 06:59:00 -0400f3a6778e-d8f1-44db-82d8-262a220aa92chttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Reaches-Major-Milestone-in-Environmental-Sustainability/default.aspxThu, 18 Jul 2024 09:00:00 -0400ff7b5409-ff8e-45c7-9ebb-eda8e168a312https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-to-Participate-in-UBS-Virtual-Targeted-Protein-Degradation-Day/default.aspxMon, 08 Jul 2024 06:59:00 -04004888edfe-adee-40f8-ab58-dc004430678chttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Announces-U.S.-FDA-Accelerated-Approval-of-KRAZATI-adagrasib-in-Combination-with-Cetuximab-for-Adult-Patients-with-Previously-Treated-KRAS-G12C-Mutated-Locally-Advanced-or-Metastatic-Colorectal-Cancer-CRC/default.aspxFri, 21 Jun 2024 19:30:00 -040084134c79-bacf-4b8a-a696-193a70cceb8ahttps://news.bms.com/news/details/2024/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Application-for-Subcutaneous-Nivolumab/default.aspxFri, 21 Jun 2024 06:59:00 -04004fcb9311-0f1d-4f32-b5b8-bcac303a96b7https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-to-Report-Results-for-Second-Quarter-2024-on-July-26-2024/default.aspxThu, 20 Jun 2024 06:59:00 -040087024b7b-9d63-49cc-9843-af3e96f31a19https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Elects-Michael-R.-McMullen-to-Board-of-Directors/default.aspxTue, 18 Jun 2024 16:16:00 -04007615ff61-e9ed-4e17-9be0-1175d726629fhttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Announces-Dividend-4e99b1cd7/default.aspxTue, 18 Jun 2024 06:59:00 -04005e75256b-7a52-45d4-89a9-49220dcb5d48https://news.bms.com/news/details/2024/U.S.-Food-and-Drug-Administration-Approves-Augtyro-repotrectinib-a-Next-Generation-Tyrosine-Kinase-Inhibitor-TKI-for-the-Treatment-of-Patients-with-NTRK-Positive-Locally-Advanced-or-Metastatic-Solid-Tumors/default.aspxThu, 13 Jun 2024 16:46:00 -0400566b31aa-07f6-46b3-8c50-3427c24c0c74https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Announces-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Significantly-Improved-Overall-Survival-Compared-to-Lenvatinib-or-Sorafenib-as-First-Line-Treatment-for-Patients-with-Advanced-Hepatocellular-Carcinoma-in-CheckMate--9DW-Trial/default.aspxTue, 04 Jun 2024 08:00:00 -0400349fc479-1f37-41a2-aa40-4bffe48f648bhttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-to-Participate-in-the-Goldman-Sachs-45th-Annual-Global-Healthcare-Conference/default.aspxTue, 04 Jun 2024 06:59:00 -0400c6502df5-7a28-4694-9d26-f0e3125bf070https://news.bms.com/news/details/2024/Bristol-Myers-Squibbs-Breyanzi-Demonstrates-Clinically-Meaningful-Outcomes-Across-Broad-Range-of-B-Cell-Malignancies-in-New-Data-Presented-at-2024-ASCO-Annual-Meeting/default.aspxMon, 03 Jun 2024 10:13:00 -0400dd71fa65-7c8d-486d-9b30-81d3eabce9ebhttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Presents-Multiple-New-Analyses-at-2024-ASCO-Annual-Meeting-Highlighting-Opdivo-and-Opdivo-based-Combinations-in-Early-and-Advanced-Stages-of-Non-Small-Cell-Lung-Cancer/default.aspxMon, 03 Jun 2024 08:00:00 -040042891a76-993f-4152-96e7-5e39facfeaffhttps://news.bms.com/news/details/2024/KRAZATI-adagrasib-Demonstrated-Statistically-Significant-Improvement-in-Progression-Free-Survival-in-Patients-with-Pretreated-Locally-Advanced-or-Metastatic-KRASG12C-Mutated-Non-Small-Cell-Lung-Cancer/default.aspxSat, 01 Jun 2024 08:00:00 -040033e4471d-da89-4e36-b5bb-ca71de917cb2https://news.bms.com/news/details/2024/U.S.-Food-and-Drug-Administration-Approves-Bristol-Myers-Squibbs-Breyanzi-as-a-New-CAR-T-Cell-Therapy-for-Relapsed-or-Refractory-Mantle-Cell-Lymphoma/default.aspxThu, 30 May 2024 11:51:00 -0400626f3c26-e71e-4c35-a69a-e8e0f9933c72https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-in-Combination-with-Cisplatin-and-Gemcitabine-for-the-First-Line-Treatment-of-Adult-Patients-with-Unresectable-or-Metastatic-Urothelial-Carcinoma/default.aspxWed, 29 May 2024 06:59:00 -0400ee514a7d-c923-4678-a56a-f945adf0f76chttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-to-Present-Data-at-ASCO--EHA-from-More-Than-130-Studies-Across-25-Diseases-Supporting-Expansion-into-New-Indications-Demonstrating-Long-Term-Survival-and-Highlighting-Novel-Modalities-and-Research-Platforms/default.aspxThu, 23 May 2024 17:05:00 -040079b27be0-1b03-4898-b017-ed5569a68c51https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-to-Present-Data-at-the-2024-American-Society-of-Clinical-Psychopharmacology-Annual-Meeting/default.aspxThu, 23 May 2024 06:59:00 -0400446d7b6d-834e-4a2f-84a8-af3ea8bb5817https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Announces-10-Year-Strategy-to-Reach-More-Patients-in-Low--and-Middle-Income-Countries/default.aspxWed, 22 May 2024 06:59:00 -040086d7cc16-aa44-406a-8116-7fcff2f39fcdhttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Taye-Diggs-and-Schizophrenia-Community-Partner-to-Empower-People-with-Schizophrenia-Through-Live-Your-PosSCZible-Campaign/default.aspxTue, 21 May 2024 08:45:00 -04003411e8ce-0d1f-42c4-add1-047aefdad8cdhttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Announces-Updated-Action-Date-by-the-U.S.-Food-and-Drug-Administration-for-Subcutaneous-Nivolumab-nivolumab-and-hyaluronidase/default.aspxTue, 21 May 2024 06:59:00 -04004b457b24-4b37-45f1-a768-7dab4d11d895https://news.bms.com/news/details/2024/New-Four-Year-Sotyktu-deucravacitinib-Data-Demonstrate-Durable-Response-Rates-and-Consistent-Safety-in-Moderate-to-Severe-Plaque-Psoriasis/default.aspxThu, 16 May 2024 10:26:00 -0400b1ee581e-612e-454c-8480-2e6676754d54https://news.bms.com/news/details/2024/Bristol-Myers-Squibbs-CAR-T-Cell-Therapy-Breyanzi-Approved-by-the-U.S.-Food-and-Drug-Administration-for-Relapsed-or-Refractory-Follicular-Lymphoma/default.aspxWed, 15 May 2024 20:57:00 -0400a9d4d966-d600-440c-8d81-bdd9645e32e3https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Provides-Update-on-Phase-3-CheckMate--73L-Trial/default.aspxFri, 10 May 2024 16:30:00 -04008f55286e-0056-48f4-be25-4c6ee6907b6bhttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-to-Participate-in-Upcoming-Investor-Conferences-dcf067764/default.aspxTue, 07 May 2024 06:59:00 -0400f5d7379b-5d51-4c70-8d92-08b151fd5b33https://news.bms.com/news/details/2024/U.S.-Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-Application-for-Subcutaneous-Nivolumab-nivolumab-and-hyaluronidase/default.aspxMon, 06 May 2024 06:59:00 -040025fe1ffe-7d84-4409-9419-abaaffa52e52https://news.bms.com/news/details/2024/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-for-the-First-Line-Treatment-of-Adult-Patients-with-Microsatellite/default.aspxMon, 06 May 2024 06:59:00 -0400dcd4f582-7364-4f28-b7ed-cdb23c52e6e9https://news.bms.com/news/details/2024/CHMP-Adopts-Positive-Opinion-Recommending-Approval-of-Bristol-Myers-Squibbs-Opdivo-nivolumab-in-Combination-with-Cisplatin-and-Gemcitabine-for-the-First-Line-Treatment-of-Adult-Patients-with-Unresectable-or-Metastatic-Urothelial-Carcinoma/default.aspxFri, 26 Apr 2024 06:59:00 -04005ec90fa7-8b75-44ef-9e7b-0a15bbe14936https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results-for-2024/default.aspxThu, 25 Apr 2024 06:59:00 -040039b5fe3f-6a06-41ec-a1c3-d274786603b7https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-and-Cellares-Announce-a-380M-Worldwide-Capacity-Reservation-and-Supply-Agreement-for-the-Manufacture-of-CAR-T-Cell-Therapies-to-Bring-the-Promise-of-Cell-Therapy-to-More-Patients-Faster/default.aspxMon, 22 Apr 2024 06:59:00 -0400cd8d6f3c-8a67-4eed-9961-f6e3088625a5https://news.bms.com/news/details/2024/KRAZATI-adagrasib-in-Combination-with-Cetuximab-Demonstrates-Clinically-Meaningful-Activity-as-a-Targeted-Treatment-Option-for-Patients-with-Previously-Treated-KRAS-G12C-Mutated-Locally-Advanced-or-Metastatic-Colorectal-Cancer-CRC/default.aspxMon, 08 Apr 2024 11:30:00 -0400e0ca6d4b-59e2-4388-9152-58cee369565ehttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Presents-New-Pooled-Interim-Long-Term-Safety-and-Metabolic-Outcomes-Data-from-the-EMERGENT-Program-Evaluating-KarXT-in-Schizophrenia-at-the-2024-Annual-Congress-of-the-Schizophrenia-International-Research-Society/default.aspxSat, 06 Apr 2024 13:15:00 -0400db8984d3-8f4c-4e8b-951a-7e28950dff74https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Presents-New-Interim-Long-Term-Efficacy-Data-from-the-EMERGENT-4-Trial-Evaluating-KarXT-in-Schizophrenia-at-the-2024-Annual-Congress-of-the-Schizophrenia-International-Research-Society/default.aspxSat, 06 Apr 2024 13:15:00 -040006b510b4-3b5c-4392-ad1d-32e0ad58ccadhttps://news.bms.com/news/details/2024/U.S.-FDA-Approves-Bristol-Myers-Squibb-and-2seventy-bios-Abecma-for-Triple-Class-Exposed-Relapsed-or-Refractory-Multiple-Myeloma-After-Two-Prior-Lines-of-Therapy/default.aspxFri, 05 Apr 2024 09:05:00 -040065bf409d-b3c7-4579-8ea1-7cf660fc72f6https://news.bms.com/news/details/2024/European-Commission-Expands-Approval-of-Bristol-Myers-Squibbs-Reblozyl-luspatercept-to-Include-First-Line-Treatment-of-Transfusion-Dependent-Anemia-in-Adults-with-Lower-Risk-Myelodysplastic-Syndromes-LR-MDS/default.aspxTue, 02 Apr 2024 20:08:00 -04001c494d90-d210-4e4d-92a9-2ef964adfa85https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Releases-2023-Environmental-Social-and-Governance-Report-Demonstrating-Progress-and-Setting-New-Long-Term-Goals/default.aspxTue, 02 Apr 2024 06:59:00 -0400ec8ab0b8-7939-44c3-a630-460cd1a1f9c2https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Announces-Pivotal-KRYSTAL-12-Confirmatory-Trial-Evaluating-KRAZATI-adagrasib-Meets-Primary-Endpoint-of-Progression-Free-Survival-for-Patients-with-Pretreated-KRAS-G12C-Mutated-Locally-Advanced-or-Metastatic-Non-Small-Cell-Lung-/default.aspxThu, 28 Mar 2024 16:05:00 -0400b9cca464-ad8e-4b66-87e7-75a86181f282https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Provides-Update-on-the-First-Phase-3-YELLOWSTONE-Trial-Evaluating-Oral-Zeposia-ozanimod-in-Patients-with-Moderate-to-Severe-Active-Crohns-Disease/default.aspxThu, 28 Mar 2024 16:01:00 -04002d18a995-850e-44d9-9b05-e8379e297142https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Expands-Health-Equity-Grant-Initiatives-to-Improve-Health-Outcomes/default.aspxTue, 26 Mar 2024 06:59:00 -040017187332-dcb5-4029-af4e-6cc9f0d7e32ahttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-to-Present-Data-at-the-American-College-of-Cardiology-Annual-Scientific-Session-2024-Reinforcing-Extensive-Body-of-Evidence-in-Clinical-and-Real-World-Settings-Across-Cardiovascular-Portfolio/default.aspxMon, 25 Mar 2024 08:00:00 -0400da5333fd-edf8-4b68-b6d9-e4d29f0a188chttps://news.bms.com/news/details/2024/Bristol-Myers-Squibbs-Abecma-idecabtagene-vicleucel-Becomes-First-CAR-T-Cell-Therapy-Approved-in-the-European-Union-in-Earlier-Lines-for-Triple-Class-Exposed-Relapsed-and-Refractory-Multiple-Myeloma/default.aspxWed, 20 Mar 2024 16:45:00 -04005448b2a4-e9f4-4810-8d69-5ae4092d4534https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Announces-CheckMate--9DW-Trial-Evaluating-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Meets-Primary-Endpoint-of-Overall-Survival-for-the-First-Line-Treatment-of-Advanced-Hepatocellular-Carcinoma/default.aspxWed, 20 Mar 2024 06:59:00 -0400a7e713f4-47aa-4747-b600-83558415977fhttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-and-Ted-Danson-Empower-Those-with-Plaque-Psoriasis-to-Take-Action-in-SO-Have-You-Found-It-Campaign/default.aspxTue, 19 Mar 2024 06:59:00 -0400feab7dd0-3541-4b25-af14-5f8b872d3b89https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Completes-Acquisition-of-Karuna-Therapeutics-Strengthening-Neuroscience-Portfolio/default.aspxMon, 18 Mar 2024 08:44:00 -0400cb8e46f2-74c8-4546-9448-fd5120c66549https://news.bms.com/news/details/2024/FDA-Advisory-Committee-Votes-in-Favor-of-Bristol-Myers-Squibbs-and-2seventy-bios-Abecma-for-Triple-Class-Exposed-Multiple-Myeloma-in-Earlier-Lines-of-Therapy/default.aspxFri, 15 Mar 2024 18:27:00 -0400700b760a-9538-4b9a-815a-77c75fe12c50https://news.bms.com/news/details/2024/U.S.-FDA-Approves-Bristol-Myers-Squibbs-Breyanzi--as-the-First-and-Only-CAR-T-Cell-Therapy-for-Adults-with-Relapsed-or-Refractory-Chronic-Lymphocytic-Leukemia-CLL-or-Small-Lymphocytic-Lymphoma-SLL/default.aspxThu, 14 Mar 2024 21:35:00 -04001e34fb70-8598-40a5-8684-6fabfd56ae0ahttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-to-Report-Results-for-First-Quarter-2024-on-April-25-2024/default.aspxMon, 11 Mar 2024 16:16:00 -04009c00968f-4f12-4e1f-bbd8-c7258372234dhttps://news.bms.com/news/details/2024/U.S.-Food-and-Drug-Administration-Approves-Opdivo--nivolumab-in-Combination-with-Cisplatin-and-Gemcitabine-for-First-Line-Treatment-of-Adult-Patients-with-Unresectable-or-Metastatic-Urothelial-Carcinoma/default.aspxThu, 07 Mar 2024 14:23:00 -0500c2c1b71c-1c25-475e-8b0c-b13ad79d036ahttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-to-Participate-in-Upcoming-Investor-Conferences/default.aspxWed, 06 Mar 2024 16:17:00 -0500b38b963a-b3bd-4cd3-acbb-d0b83d136cdchttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Announces-Dividend/default.aspxFri, 01 Mar 2024 16:16:00 -05005aed09c2-583c-4658-890d-190a527fa148https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Announces-New-Data-from-the-Long-Term-DAYBREAK-Study-Reinforcing-Efficacy-and-Safety-of-Zeposia-ozanimod-in-Patients-with-Relapsing-Forms-of-Multiple-Sclerosis/default.aspxThu, 29 Feb 2024 06:59:00 -05009e224fed-a725-4187-b6cb-97930d947046https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-to-Participate-in-the-TD-Cowen-44th-Annual-Health-Care-Conference/default.aspxMon, 26 Feb 2024 16:16:00 -050058535d14-f12e-462b-bedd-50241409bf1dhttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Completes-Acquisition-of-RayzeBio-Adding-Differentiated-Actinium-Based-Radiopharmaceutical-Platform/default.aspxMon, 26 Feb 2024 08:35:00 -05008df5a094-db9d-472d-9595-2274af5dd799https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Announces-Expiration-of-RayzeBio-Tender-Offer/default.aspxFri, 23 Feb 2024 06:59:00 -0500234aec64-c55d-4520-a81b-c8dd14197fafhttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Reblozyl--luspatercept-for-Treatment-of-Adults-with-Transfusion-Dependent-Anemia-due-to-Low--to-Intermediate-Risk-Myelodysplastic-Syndromes-MDS/default.aspxFri, 23 Feb 2024 06:59:00 -05002ae1b80c-d3e9-4c0e-8625-0368903133fchttps://news.bms.com/news/details/2024/U.S.-Food-and-Drug-Administration-FDA-Accepts-Supplemental-New-Drug-Application-for-KRAZATI-adagrasib-in-Combination-with-Cetuximab-as-a-Targeted-Treatment-Option-for-Patients-with-Previously-Treated-KRAS-G12C-Mutated-Locally-Advanced-or/default.aspxTue, 20 Feb 2024 06:59:00 -05008b6df363-26b5-427a-b15c-fc65fd27f35ahttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Prices-13-Billion-of-Senior-Unsecured-Notes/default.aspxWed, 14 Feb 2024 19:57:00 -050060c964d2-81cb-49f0-917e-7345c8355965https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Recommends-Stockholders-Reject-Mini-Tender-Offer-by-Tutanota-LLC/default.aspxWed, 14 Feb 2024 16:16:00 -05009a052acd-0cb9-4d5f-9109-361834564799https://news.bms.com/news/details/2024/U.S.-Food-and-Drug-Administration-Accepts-for-Priority-Review-Bristol-Myers-Squibbs-Application-for-Augtyro-repotrectinib-for-the-Treatment-of-Patients-with-NTRK-Positive-Locally-Advanced-or-Metastatic-Solid-Tumors/default.aspxWed, 14 Feb 2024 06:59:00 -05004f322d3f-fa88-4bee-aa7c-d007dd10396bhttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-and-RayzeBio-Announce-Expiration-of-HSR-Act-Waiting-Period/default.aspxMon, 12 Feb 2024 06:59:00 -0500bf49e680-84d4-468a-925b-b240768f442ahttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Announces-Acceptance-of-U.S.-and-EU-Regulatory-Filings-for-Neoadjuvant-Opdivo-nivolumab-and-Chemotherapy-Followed-by-Surgery-and-Adjuvant-Opdivo-in-Resectable-Non-Small-Cell-Lung-Cancer/default.aspxWed, 07 Feb 2024 06:59:00 -05002b34be97-a419-4db6-bfbe-dd98f1783fb5https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Named-One-of-Americas-Most-JUST-Companies-by-JUST-Capital-and-CNBC/default.aspxMon, 05 Feb 2024 09:00:00 -0500cbed82c7-7915-4d2b-8616-5d9bd7074ec7https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-and-2seventy-bio-Share-Update-on-U.S.-FDA-Oncologic-Drugs-Advisory-Committee-Meeting-for-Abecma-in-Triple-Class-Exposed-Multiple-MyelomaBased-on-KarMMa-3-Study/default.aspxMon, 05 Feb 2024 06:59:00 -05007c834d1d-e029-4b23-8905-d1d7bd26781ahttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2023/default.aspxFri, 02 Feb 2024 06:59:00 -0500fcfa3492-09bb-4264-81eb-20eaa3e46132https://news.bms.com/news/details/2024/Regulatory-Applications-Accepted-in-the-U.S.-and-Japan-for-Bristol-Myers-Squibbs-Breyanzi-lisocabtagene-maraleucel-in-Relapsed-or-Refractory-Follicular-Lymphoma-FL-and-Relapsed-or-Refractory-Mantle-Cell-Lymphoma-MCL/default.aspxTue, 30 Jan 2024 06:59:00 -05004c6a19de-f2e4-4040-b0c7-3c30dd84c209https://news.bms.com/news/details/2024/Subcutaneous-Nivolumab-nivolumab-and-hyaluronidase-Shows-Noninferiority-Compared-to-Intravenous-Opdivo-nivolumab-in-Advanced-or-Metastatic-Clear-Cell-Renal-Cell-Carcinoma-in-CheckMate--67T-Trial/default.aspxSat, 27 Jan 2024 10:00:00 -050034b0ff24-d333-4301-9d9e-37ed2d455489https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-CAR-T-Cell-Therapy-Abecma-idecabtagene-vicleucelin-Earlier-Lines-of-Therapy-for-Triple-Class-Exposed-Relapsed-and-Refractory-Multiple-Myeloma/default.aspxFri, 26 Jan 2024 07:13:00 -05004b3aafe5-acba-4982-aff1-f35afad7e4b9https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Completes-Acquisition-of-Mirati-Therapeutics-Strengthening-and-Diversifying-Oncology-Portfolio/default.aspxTue, 23 Jan 2024 08:30:00 -0500ad3d5ea5-ed64-401c-8405-0837fb574886https://news.bms.com/news/details/2024/Eight-Year-Data-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Continue-to-Demonstrate-Longest-Survival-Benefit-vs.-Sunitinib-Reported-in-Patients-with-Previously-Untreated-Advanced-or-Metastatic-Renal-Cell-Carcinoma/default.aspxMon, 22 Jan 2024 17:05:00 -05000762f93a-b048-489e-9042-30fd443e4031https://news.bms.com/news/details/2024/Opdivo-nivolumab-in-Combination-with-CABOMETYX-cabozantinib-Demonstrates-Long-Term-Survival-Benefits-After-Four-Years-of-Follow-Up-in-the-CheckMate--9ER-Trial-in-First-Line-Advanced-Renal-Cell-Carcinoma/default.aspxMon, 22 Jan 2024 17:00:00 -0500985e86ad-9fcd-4c42-adba-bbf58e13cf31https://news.bms.com/news/details/2024/Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Reduced-the-Risk-of-Disease-Progression-or-Death-by-79-Versus-Chemotherapy-in-Patients-with-Microsatellite-Instability-High-or-Mismatch-Repair-Deficient-Metastatic-Colorectal-Cancer-in-CheckMate--8HW-Trial/default.aspxSat, 20 Jan 2024 10:00:00 -050039fd97f2-f8ca-4ba1-a5cf-0ea955c0fecbhttps://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Data-at-ASCO-GU-2024-Showcase-Transformative-Research-in-the-Treatment-of-Genitourinary-Cancers/default.aspxWed, 17 Jan 2024 06:59:00 -050028f3e498-0a8b-4ff2-b6d7-22928a5c63f2https://news.bms.com/news/details/2024/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Application-for-Repotrectinib-for-the-Treatment-of-Locally-Advanced-or-Metastatic-ROS1-Positive-Non-Small-Cell-Lung-Cancer-and-NTRK-Positive-Solid-Tumors/default.aspxTue, 02 Jan 2024 06:59:00 -050047b34ea9-1dfc-4acc-ac8a-66f3cf1cb875https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Adds-Premier-Radiopharmaceutical-Platform-with-Acquisition-of-RayzeBio/default.aspxTue, 26 Dec 2023 06:59:00 -05009f767ed8-b9a8-406d-a8fe-733971eec835https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Present-at-J.P.-Morgans-42nd-Annual-Healthcare-Conference/default.aspxFri, 22 Dec 2023 06:59:00 -050093c17b6a-d6c9-4f1a-8313-ca2dc697b34ahttps://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Strengthens-Neuroscience-Portfolio-with-Acquisition-of-Karuna-Therapeutics/default.aspxFri, 22 Dec 2023 06:59:00 -050000ba1876-3f1d-4c6c-8667-33af415cce08https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Participate-in-the-2024-Goldman-Sachs-Healthcare-C-Suite-Unscripted-Conference/default.aspxWed, 20 Dec 2023 16:16:00 -050002b7bb9e-c26d-45d5-8dc7-21498c2ea04chttps://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Provides-Update-on-RELATIVITY-123-Trial-Evaluating-the-Fixed-Dose-Combination-of-Nivolumab-and-Relatlimab-in-Patients-with-Previously-Treated-Metastatic-Microsatellite-Stable-MSS-Colorectal-Cancer/default.aspxFri, 15 Dec 2023 16:54:00 -0500d7478ed0-9c82-4000-ab80-585da5eaed78https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Report-Results-for-Fourth-Quarter-2023-on-February-2-2024/default.aspxFri, 15 Dec 2023 06:59:00 -05009fecdb58-df82-45ec-a343-b9acb81fdf5dhttps://news.bms.com/news/details/2023/Two-Early-Studies-Evaluating-Potential-First-in-Class-CELMoD-Agent-Golcadomide-for-the-Treatment-of-Non-Hodgkin-Lymphomas-Presented-at-ASH-2023/default.aspxMon, 11 Dec 2023 21:00:00 -0500c2410721-7806-4a38-8a85-a4c21a542450https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Announces-Data-at-ASH-2023-from-Diverse-Multiple-Myeloma-Pipeline-Underscoring-Range-of-Tailored-Treatment-Approaches-to-Address-Unique-Patient-Needs/default.aspxMon, 11 Dec 2023 20:30:00 -05008e444bd9-4b90-47d5-9724-fda927d026f4https://news.bms.com/news/details/2023/Abecma-Delivers-Sustained-Progression-Free-Survival-Versus-Standard-Regimens-in-Earlier-Lines-of-Therapy-for-Relapsed-and-Refractory-Multiple-Myeloma-Based-on-Longer-Term-Follow-up-from-KarMMa-3/default.aspxMon, 11 Dec 2023 19:30:00 -0500ea152bf9-a885-45d5-8272-2aa1d24bdb3dhttps://news.bms.com/news/details/2023/SystImmune-and-Bristol-Myers-Squibb-Announce-a-Global-Strategic-Collaboration-Agreement-for-the-Development-and-Commercialization-of-BL-B01D1/default.aspxMon, 11 Dec 2023 16:15:00 -05002df08003-b89e-47de-8fb6-656d20963a17https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Presents-New-Data-at-ASH-2023-Demonstrating-Clinical-Benefit-Across-B-cell-Malignancies-with-Breyanzi-as-a-Second-Line-Treatment-in-High-Risk-Follicular-Lymphoma-and-in-Relapsed-or-Refractory-Chronic-Lymphocytic-Leukemia/default.aspxSun, 10 Dec 2023 21:26:00 -0500ac6d396b-c2d0-46ab-80dd-b94ef8df8b9fhttps://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Presents-Primary-Efficacy-and-Safety-Analysis-of-the-Phase-3-COMMANDS-Trial-of-Reblozyl-for-Treatment-of-Anemia-in-Erythropoiesis-Stimulating-Agent-Nave-Patients-with-Lower-Risk-Myelodysplastic-Syndromes-at-ASH-2023/default.aspxSat, 09 Dec 2023 17:00:00 -05005f2414ce-b831-4dfc-aa10-0c1be87d87abhttps://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Announces-Phase-3-CheckMate--8HW-Trial-Evaluating-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Compared-to-Chemotherapy-in-Microsatellite-InstabilityHigh-or-Mismatch-Repair-Deficient-Metastatic-Colorectal-Cancer-Meets-Primary/default.aspxThu, 07 Dec 2023 06:59:00 -0500c3e8f5db-a7b5-4d2c-b80d-7cfaa469ba3dhttps://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Announces-Additional-3-Billion-Share-Repurchase-Authorization/default.aspxThu, 07 Dec 2023 06:30:00 -050050c68fee-8f9a-4870-9daf-8da6d00a03e3https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Announces-Dividend-Increase/default.aspxWed, 06 Dec 2023 16:16:00 -050026e03453-dae2-41eb-85b5-7b05ca46b957https://news.bms.com/news/details/2023/Bristol-Myers-Squibbs-Abecma-Becomes-First-CAR-T-Approved-for-Use-in-Earlier-Lines-of-Therapy-for-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma-in-Japan/default.aspxWed, 06 Dec 2023 06:59:00 -0500c3da002c-29c8-4bcf-8b1e-e72b4900e826https://news.bms.com/news/details/2023/U.S.-Food-and-Drug-Administration-Accepts-for-Priority-Review-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-in-Combination-with-Cisplatin-Based-Chemotherapy-for-the-First-Line-Treatment-of-Adult-Patients-with-Unresectable-or-Metastatic/default.aspxTue, 05 Dec 2023 06:59:00 -05006c934710-6cb7-4f55-8559-e7adcf40c3e6https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-and-2seventy-bio-Provide-Update-on-U.S.-FDA-Review-of-sBLA-for-Abecma-idecabtagene-vicleucel-in-Earlier-Lines-of-Therapy-for-Triple-Class-Exposed-Relapsed-or-Refractory-Multiple-Myeloma/default.aspxMon, 20 Nov 2023 06:59:00 -0500392c3f95-2f34-4b6a-ad69-9891d2fccf44https://news.bms.com/news/details/2023/US-Food-and-Drug-Administration-Approves-Augtyro/default.aspxWed, 15 Nov 2023 19:20:00 -0500d140bc8f-e83e-45b1-9c24-90ada9bfc38ehttps://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Participate-in-the-2023-Jefferies-London-Healthcare-Conference/default.aspxThu, 09 Nov 2023 16:18:00 -0500317baa14-cc02-45c0-9a87-81f705c35608https://news.bms.com/news/details/2023/U.S.-Food-and-Drug-Administration-Accepts-for-Priority-Review-Bristol-Myers-Squibbs-Application-for-Breyanzi-lisocabtagene-maraleucelfor-Relapsed-or-Refractory-Chronic-Lymphocytic-Leukemia-CLL-or-Small-Lymphocytic-Lymphoma-SLL/default.aspxThu, 09 Nov 2023 10:14:00 -0500238245e6-8d20-43b7-8d69-143ee588748fhttps://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Present-Data-from-Innovative-Cardiovascular-Portfolio-at-the-American-Heart-Association-Scientific-Sessions-2023/default.aspxMon, 06 Nov 2023 06:59:00 -0500688b33cc-bb8a-43e2-955b-fb13b943eb9dhttps://news.bms.com/news/details/2023/Bristol-Myers-Squibbs-First-Disclosures-and-New-Data-at-ASH-2023-Highlight-Companys-Leadership-and-Progress-in-Cell-Therapy-Targeted-Protein-Degradation-and-Novel-Approaches-in-Hematology/default.aspxThu, 02 Nov 2023 11:34:00 -0400a7f4166e-1325-4b36-856a-55e850ecbcd6https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Participate-in-the-2023-UBS-BioPharma-Conference/default.aspxThu, 02 Nov 2023 06:59:00 -04005cee5940-692f-4657-b409-4ee25c81f890https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Appoints-Christopher-Boerner-Ph.D.-to-Chair-of-the-Board-of-Directors-Effective-April-1-2024/default.aspxTue, 31 Oct 2023 18:25:00 -0400041d38e4-b1ec-45e7-ba7a-0f10ee2ab205https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Prices-4.5-Billion-of-Senior-Unsecured-Notes/default.aspxMon, 30 Oct 2023 20:19:00 -04003f827276-5fca-4b65-9caa-7d9f4e641870https://news.bms.com/news/details/2023/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-in-Combination-with-Cisplatin-Based-Chemotherapy-for-the-First-Line-Treatment-of-Adult-Patients-with-Unresectable-or-Metastatic-Urothelial-Carcinoma/default.aspxMon, 30 Oct 2023 06:59:00 -0400e5d67c13-7bb1-4a5d-bda9-eaab19a724b3https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Reports-Third-Quarter-Financial-Results-for-2023/default.aspxThu, 26 Oct 2023 06:59:00 -040012b799e1-2ac5-458c-b6e3-2acdf1038340https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Announces-U.S.-FDA-Breakthrough-Therapy-Designation-for-Investigational-LPA1-Antagonist-for-Progressive-Pulmonary-Fibrosis/default.aspxTue, 24 Oct 2023 06:59:00 -040024e55d98-20e9-47a1-afb1-10c9ee42a5f6https://news.bms.com/news/details/2023/Phase-3-CheckMate--67T-Trial-of-Subcutaneous-Nivolumab-nivolumab-and-hyaluronidase-Meets-Co-Primary-Endpoints-in-Advanced-or-Metastatic-Clear-Cell-Renal-Cell-Carcinoma/default.aspxThu, 19 Oct 2023 06:59:00 -04000c647275-a702-4d5c-84a5-de826ca53156https://news.bms.com/news/details/2023/The-Robert-A.-Winn-Diversity-in-Clinical-Trials-Award-Announces-Third-Group-of-Physicians-in-Program-to-Increase-Diversity-in-Clinical-Trials/default.aspxWed, 18 Oct 2023 16:15:00 -0400c2fd082f-152b-403a-9c57-d9959b0da461https://news.bms.com/news/details/2023/Neoadjuvant-Opdivo-nivolumab-with-Chemotherapy-Provides-Benefits-for-Patients-with-Resectable-Non-Small-Cell-Lung-Cancer-Across-PD-L1-Expression-Levels-with-Three-Year-Follow-Up-in-CheckMate--816-Trial/default.aspxTue, 17 Oct 2023 15:51:00 -04002431bea8-7ba5-4e39-b081-78e96b0cd631https://news.bms.com/news/details/2023/Opdivo-nivolumab-in-Combination-with-Cisplatin-Based-Chemotherapy-Followed-by-Opdivo-Demonstrates-Significant-Survival-Benefits-for-Cisplatin-Eligible-Patients-with-Unresectable-or-Metastatic-Urothelial-Carcinoma-in-Phase-3-CheckMate--901-Trial/default.aspxTue, 17 Oct 2023 15:48:00 -0400a837e477-6aa6-443a-8621-ecea314d41d3https://news.bms.com/news/details/2023/Perioperative-Regimen-of-Neoadjuvant-Opdivo-nivolumab-and-Chemotherapy-Followed-by-Adjuvant-Opdivo-Shows-Significant-Improvement-in-Event-Free-Survival-for-Patients-with-Resectable-Non-Small-Cell-Lung-Cancer-in-Phase-3-CheckMate--77T-Trial/default.aspxTue, 17 Oct 2023 15:23:00 -0400ac7a408a-afd2-4e45-9d8e-79562e3deab0https://news.bms.com/news/details/2023/U.S.-Food-and-Drug-Administration-Approves-Opdivonivolumab-as-Adjuvant-Treatment-for-Eligible-Patients-with-Completely-Resected-Stage-IIB-or-Stage-IIC-Melanoma1/default.aspxFri, 13 Oct 2023 21:18:00 -04007403617a-27a1-4b16-93a0-659df2aa45c8https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Showcase-Data-Demonstrating-Improved-Outcomes-in-Earlier-Stages-of-Cancer-Durable-Long-Term-Benefits-with-Opdivo-Based-Regimens-and-Addressing-High-Unmet-Needs-in-Multiple-Tumor-Types-at-ESMO-2023/default.aspxThu, 12 Oct 2023 07:15:00 -0400fb1d9b54-91e1-4b47-9bc7-c918672c8874https://news.bms.com/news/details/2023/Sotyktu-deucravacitinib-Long-Term-Data-Demonstrate-Durable-Efficacy-and-Consistent-Safety-for-up-to-Three-Years-in-Moderate-to-Severe-Plaque-Psoriasis/default.aspxWed, 11 Oct 2023 18:01:00 -0400e4ed28de-508e-4b5a-b8e7-6641f7a601a0https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Presents-New-Zeposia-ozanimod-Data-on-Long-Term-Disease-Progression-and-Cognition-in-Patients-with-Relapsing-Forms-of-Multiple-Sclerosis/default.aspxWed, 11 Oct 2023 02:01:00 -0400cf051cf7-597b-4e7d-994e-947721a0f0c5https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Strengthens-and-Diversifies-Oncology-Portfolio-With-Acquisition-of-Mirati-Therapeutics/default.aspxSun, 08 Oct 2023 17:16:00 -0400a1c01164-e033-4474-b76d-e0dc8bffb17chttps://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Report-Results-for-Third-Quarter-2023-on-October-26-2023/default.aspxTue, 26 Sep 2023 06:59:00 -0400cefb9042-63b6-4fd7-8868-c0979e80b556https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Announces-Perioperative-Regimen-of-Neoadjuvant-Opdivo-nivolumab-and-Chemotherapy-Followed-by-Adjuvant-Opdivo-Significantly-Improves-Event-Free-Survival-in-Patients-with-Resectable-Non-Small-Cell-Lung-Cancer/default.aspxFri, 22 Sep 2023 06:59:00 -04009b856f0c-b252-405e-8d96-6cbaf315b490https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Announces-Dividend-ee257cea2/default.aspxWed, 20 Sep 2023 06:59:00 -0400e67fe731-2b40-4d4d-9860-cc4af91b0e55https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Highlights-Advancing-Pipeline-and-Differentiated-Research-Platforms-to-Support-Long-Term-Sustainable-Growth-at-RD-Day/default.aspxThu, 14 Sep 2023 08:30:00 -0400ee0ae237-1b1a-444a-9941-bfa44002bd0fhttps://news.bms.com/news/details/2023/Six-Year-Outcomes-from-Phase-3-CheckMate--227-Trial-Show-Durable-Long-Term-Survival-with-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-in-the-First-Line-Treatment-of-Patients-with-Metastatic-Non-Small-Cell-Lung-Cancer/default.aspxMon, 11 Sep 2023 06:59:00 -0400bf975665-1c88-4e49-b4e9-ef1a57ef4ff2https://news.bms.com/news/details/2023/Bristol-Myers-Squibbs-Investigational-LPA1-Antagonist-Reduces-Rate-of-Lung-Function-Decline-in-Progressive-Pulmonary-Fibrosis-Cohort-of-Phase-2-Study/default.aspxSat, 09 Sep 2023 18:01:00 -0400e107f17a-4ae5-47e7-904f-7185eedfa2c4https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Celebrates-a-Decade-of-Its-Coast-2-Coast-4-Cancer-Cross-Country-Bike-Ride-in-Support-of-the-V-Foundation-for-Cancer-Research/default.aspxThu, 07 Sep 2023 07:00:00 -0400b0b61d3b-1dc3-4964-a563-b6035baf8a20https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Participate-in-the-Morgan-Stanley-21st-Annual-Global-Healthcare-Conference/default.aspxFri, 01 Sep 2023 06:59:00 -0400d3b4f041-3b59-4aa6-ba77-0f6621d03895https://news.bms.com/news/details/2023/U.S.-FDA-Approves-Bristol-Myers-Squibbs-Reblozyl-luspatercept-aamt-as-First-Line-Treatment-of-Anemia-in-Adults-with-Lower-Risk-Myelodysplastic-Syndromes-MDS-Who-May-Require-Transfusions/default.aspxMon, 28 Aug 2023 22:00:00 -04008fe80965-f89b-4427-9f52-900fe8e5facehttps://news.bms.com/news/details/2023/Long-Term-Follow-Up-Data-from-Two-Phase-3-Studies-of-CAMZYOS-mavacamten-Demonstrate-Consistent-and-Durable-Response-in-Patients-with-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-HCM/default.aspxMon, 28 Aug 2023 11:26:00 -04001ad67f7e-a795-4ae2-b59e-e37d341a757bhttps://news.bms.com/news/details/2023/Retrospective-Observational-Study-Assessing-Real-World-Clinical-Impact-of-Switching-or-Continuing-Eliquis-or-Rivaroxaban-Presented-at-the-European-Society-of-Cardiology-ESC-Congress-2023/default.aspxFri, 25 Aug 2023 10:22:00 -0400d9e91d44-6ff7-492c-8cd2-5f874885d433https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Shares-Progress-Toward-Its-Environmental-Social-and-Governance-Initiatives-and-Its-Health-Equity-Commitments/default.aspxWed, 23 Aug 2023 07:55:00 -04001cd372fe-c1cb-44a1-8b55-3c92b51d43f5https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-as-an-Adjuvant-Treatment-for-Patients-with-Completely-Resected-Stage-IIB-or-IIC-Melanoma/default.aspxTue, 22 Aug 2023 16:18:00 -04002c03905b-f4f5-4894-a12e-dea1dd713157https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Showcase-Data-Across-its-Innovative-Cardiovascular-Portfolio-at-the-European-Society-of-Cardiology-Congress-2023/default.aspxMon, 21 Aug 2023 06:59:00 -040048895480-950c-456d-bf3a-e299567e7c28https://news.bms.com/news/details/2023/Updated-Data-from-TRIDENT-1-Trial-Show-Durable-Efficacy-Benefits-with-Repotrectinib-for-Patients-with-Locally-Advanced-or-Metastatic-ROS1-Positive-Non-Small-Cell-Lung-Cancer/default.aspxWed, 16 Aug 2023 10:19:00 -0400c9c9ace4-3a84-499b-a67a-1119b70dff05https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Inducted-into-the-Billion-Dollar-Roundtable-Expands-Supplier-Diversity-Efforts/default.aspxThu, 10 Aug 2023 07:01:00 -040041c6d3af-2a02-424d-9490-1cec4474dc07https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Enters-Into-4-Billion-Aggregate-Accelerated-Share-Repurchase-Agreements/default.aspxThu, 10 Aug 2023 06:59:00 -04002a8b6724-2ef0-42fb-b059-b3b410a6ddd3https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Launches-Clear-Understanding-Campaign-to-Reveal-the-Plain-Truth-About-Living-with-Moderate-to-Severe-Plaque-Psoriasis/default.aspxTue, 08 Aug 2023 06:59:00 -04002c7db866-1540-4b96-958b-0710fe725d90https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Reports-Second-Quarter-Financial-Results-for-2023/default.aspxThu, 27 Jul 2023 06:59:00 -0400c0e238b1-30a9-47e0-94db-32f2afd5e85ehttps://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Approval-for-Opdivo-nivolumab-as-an-Adjuvant-Treatment-for-Patients-with-Completely-Resected-Stage-IIB-or-IIC-Melanoma/default.aspxFri, 21 Jul 2023 06:59:00 -04004f424867-884b-4d18-bd2b-dafac53ed054https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Launches-Supporting-You-with-UC-with-Womens-World-Cup-Commentator-Former-Professional-Soccer-Player-and-Ulcerative-Colitis-Patient-Rosie-White/default.aspxWed, 12 Jul 2023 06:59:00 -040099b44c57-1735-4a6a-8dc7-b596e3348f89https://news.bms.com/news/details/2023/Opdivo-nivolumab-in-Combination-with-Cisplatin-Based-Chemotherapy-Shows-Overall-Survival-and-Progression-Free-Survival-Benefit-for-Cisplatin-Eligible-Patients-with-Unresectable-or-Metastatic-Urothelial-Carcinoma-in-the-Phase-3-CheckMate--901-Trial/default.aspxTue, 11 Jul 2023 06:59:00 -04006b3f8238-84f4-4ebc-a141-9c91445f3001https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-with-Chemotherapy-as-Neoadjuvant-Treatment-of-Resectable-Non-Small-Cell-Lung-Cancer-at-High-Risk-of-Recurrence-in-Patients-with-Tumor-Cell-PD-L1-Expression-1/default.aspxThu, 29 Jun 2023 06:59:00 -040010bbd3f2-b8e2-4082-b43c-b2628e13ef95https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-European-Commission-Approval-of-CAMZYOS-mavacamten-for-the-Treatment-of-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-HCM/default.aspxMon, 26 Jun 2023 16:01:00 -0400a243bbd3-4da5-4d59-80ea-71474715ea49https://news.bms.com/news/details/2023/Bristol-Myers-Squibbs-Breyanzi-lisocabtagene-maraleucel-Delivers-Deep-and-Durable-Responses-in-Relapsed-or-Refractory-Follicular-Lymphoma-and-Mantle-Cell-Lymphoma-in-TRANSCEND-Clinical-Trials-Presented-at-ICML-2023/default.aspxSat, 17 Jun 2023 05:30:00 -040065ff0cd7-f80b-45a5-a55c-fa6202900daehttps://news.bms.com/news/details/2023/U.S.-Food-and-Drug-Administration-Approves-Addition-of-Positive-Data-from-Phase-3-VALOR-HCM-Study-to-CAMZYOS-mavacamten-Label/default.aspxThu, 15 Jun 2023 20:23:00 -040094e2543e-1839-4a0f-8818-c4faa30c320chttps://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Announces-Dividend-67bb6215e/default.aspxWed, 14 Jun 2023 16:16:00 -0400cd30bbbe-e500-486e-9115-77684d409114https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-U.S.-FDA-Approval-of-New-State-of-the-Art-Cell-Therapy-Manufacturing-Facility-in-Devens-Massachusetts/default.aspxThu, 08 Jun 2023 16:16:00 -0400b68b37e2-c2cc-47d1-8e45-ba1cf8997bcehttps://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Report-Results-for-Second-Quarter-2023-on-July-27-2023/default.aspxThu, 08 Jun 2023 06:59:00 -0400ce9b708a-116d-4474-9996-6ec41ebac1c8https://news.bms.com/news/details/2023/Four-Year-Outcomes-from-Phase-3-CheckMate--9LA-Trial-Show-Durable-Long-Term-Survival-with-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-with-Two-Cycles-of-Chemotherapy-for-Patients-with-Metastatic-Non-Small-Cell-Lung-Cancer/default.aspxSun, 04 Jun 2023 08:00:00 -040036f5b3ea-f1da-4985-80dc-9f5f29df643bhttps://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Participate-in-Upcoming-Investor-Conferences/default.aspxThu, 01 Jun 2023 06:59:00 -0400faa6dc75-978b-4c58-8bf7-3462c428c116https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Hold-RD-Day-on-September-14/default.aspxWed, 31 May 2023 06:59:00 -04002959e0b2-f1b8-4392-9cff-d34eec57021fhttps://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Present-Late-Breaking-Data-for-Breyanzi-lisocabtagene-maraleucelin-Relapsed-or-Refractory-Follicular-Lymphoma-and-Mantle-Cell-Lymphomaat-2023-International-Conference-on-Malignant-Lymphoma/default.aspxTue, 30 May 2023 09:24:00 -04007b6795d2-8f4b-41de-92e8-f395a77c536bhttps://news.bms.com/news/details/2023/U.S.-Food-and-Drug-Administration-Accepts-for-Priority-Review-Bristol-Myers-Squibbs-Application-for-Repotrectinib-for-the-Treatment-of-Patients-with-Locally-Advanced-or-Metastatic-ROS1-Positive-Non-Small-Cell-Lung-Cancer/default.aspxTue, 30 May 2023 06:59:00 -0400857d27d1-8ee7-4520-a9dc-ca1665fb9687https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Approval-for-Opdivo-nivolumab-with-Chemotherapy-as-Neoadjuvant-Treatment-of-Resectable-Non-Small-Cell-Lung-Cancer-at-High-Risk-of-Recurrence-in-Patients-with-Tumor-Cell-PD-L1-Expre/default.aspxFri, 26 May 2023 08:10:00 -040022b2adda-a2c2-4a33-a221-cecfd6e70dffhttps://news.bms.com/news/details/2023/Bristol-Myers-Squibbs-Breyanzi-lisocabtagene-maraleucel-is-First-and-Only-CAR-T-to-Deliver-Deep-and-Durable-Efficacy-in-Pivotal-Multicenter-Trial-in-Relapsed-or-Refractory-Chronic-Lymphocytic-Leukemia-Based-on-Data-Presented-at-ASCO-2023/default.aspxThu, 25 May 2023 17:05:00 -040014147352-12de-431b-904c-9c151431f272https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Present-First-Results-at-ASCO-and-EHA-from-Phase-3-COMMANDS-Study-of-Reblozyl-luspatercept-aamt-in-First-Line-Treatment-of-Anemia-in-Adults-with-Lower-Risk-Myelodysplastic-Syndromes-MDS/default.aspxThu, 25 May 2023 17:00:00 -040037125a3b-f01d-4065-9989-fe6df40c2f02https://news.bms.com/news/details/2023/Milvexian-Granted-U.S.-FDA-Fast-Track-Designation-for-All-Three-Indications-Under-Evaluation-in-Phase-3-Librexia-Program-Ischemic-Stroke-Acute-Coronary-Syndrome-and-Atrial-Fibrillation/default.aspxThu, 25 May 2023 06:59:00 -04000435bd28-26da-4a53-8f47-7d3c056326fbhttps://news.bms.com/news/details/2023/Bristol-Myers-Squibbs-Investigational-LPA1-Antagonist-Reduces-the-Rate-of-Lung-Function-Decline-in-Patients-with-Idiopathic-Pulmonary-Fibrosis/default.aspxMon, 22 May 2023 11:01:00 -0400a818e607-c054-4391-9c31-eaefa3c0ed5ehttps://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Highlight-Diversified-Approaches-and-Commitment-to-Improving-Outcomes-for-Patients-with-Cancer-and-Serious-Blood-Disorders-at-ASCO-EHA-and-ICML-2023/default.aspxThu, 11 May 2023 13:41:00 -040097ffb3cd-0de5-474c-bdc0-80bd6328d412https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-CAR-T-Cell-Therapy-Breyanzi-lisocabtagene-maraleucel-for-Relapsed-or-Refractory-Large-B-cell-Lymphoma-After-One-Prior-Therapy/default.aspxWed, 03 May 2023 06:59:00 -0400ffd6f1a3-18c1-4339-afbd-636ed93ca4ebhttps://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Participate-in-Bank-of-America-Securities-2023-Healthcare-Conference/default.aspxTue, 02 May 2023 06:59:00 -0400313629bd-bf67-49f9-9c6e-305723104590https://news.bms.com/news/details/2023/U.S.-FDA-Accepts-for-Priority-Review-Supplemental-Biologics-License-Application-and-EMA-Validates-Application-for-Reblozyl-luspatercept-aamt-as-First-Line-Treatment-of-Anemia-in-Adults-with-Lower-Risk-Myelodysplastic-Syndromes-MDS/default.aspxMon, 01 May 2023 07:05:00 -04001ad24448-3d19-4d28-880c-aad1314bab2dhttps://news.bms.com/news/details/2023/Bristol-Myers-Squibbs-TRANSCEND-FL-and-TRANSCEND-NHL-001-Studies-of-Breyanzi-lisocabtagene-maraleucelin-Relapsed-or-Refractory-Follicular-Lymphoma-and-Mantle-Cell-Lymphoma-Meet-Primary-Endpoint-of-Overall-Response-Rate/default.aspxMon, 01 May 2023 06:59:00 -04009b0173dc-90a9-41eb-b08b-694fe4869823https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results-for-2023/default.aspxThu, 27 Apr 2023 06:59:00 -04000f5b6b78-2341-4b58-856c-47378fd48033https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Announces-Leadership-Transition-Plan/default.aspxWed, 26 Apr 2023 16:14:00 -040067ef7c4f-506b-4e15-a311-f91976710ba8https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Approval-for-CAMZYOS-mavacamten-for-the-Treatment-of-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-HCM/default.aspxWed, 26 Apr 2023 14:42:00 -04001dec4096-1b0d-4d13-b6cd-5a14f0fe8985https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Strengthens-Cell-Therapy-Capabilities-by-Adding-New-U.S.-Manufacturing-Facility-for-Viral-Vector-Production/default.aspxWed, 26 Apr 2023 06:59:00 -0400d8e876e2-ca8c-45eb-baf5-50b7ce1bb59chttps://news.bms.com/news/details/2023/Regulatory-Applications-Accepted-Across-Three-Regions-Globally-for-Abecma-for-Earlier-Use-in-Adults-with-Triple-Class-Exposed-Relapsed-andor-Refractory-Multiple-Myeloma/default.aspxMon, 17 Apr 2023 06:59:00 -04008de7bd6f-f32d-4811-8fb7-eabbd6c3c7behttps://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-CAR-T-Cell-Therapy-Breyanzi-lisocabtagene-maraleucel-for-Relapsed-or-Refractory-Large-B-cell-Lymphoma-After-One-Prior-Therapy/default.aspxFri, 31 Mar 2023 08:07:00 -04001e09a041-a202-4a55-8b76-631d51b6c641https://news.bms.com/news/details/2023/Neoadjuvant-Opdivo-nivolumab-with-Chemotherapy-Demonstrates-Long-Term-Durable-Clinical-Benefits-for-Patients-with-Resectable-Non-Small-Cell-Lung-Cancer-at-Three-Years-in-the-CheckMate--816-Trial/default.aspxThu, 30 Mar 2023 09:10:00 -0400d8c35843-f66c-4ec0-8c02-b4f0795b299chttps://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-European-Commission-Approval-of-Sotyktu-deucravacitinib-a-Once-Daily-Oral-Treatment-for-Adults-With-Moderate-to-Severe-Plaque-Psoriasis/default.aspxTue, 28 Mar 2023 06:59:00 -0400fb40383d-c36b-492b-9e91-2fcb074280bbhttps://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Announces-Progress-Toward-Long-Term-Inclusion--Diversity-Goals-and-Health-Equity-Commitments/default.aspxWed, 15 Mar 2023 06:59:00 -0400400752e2-d859-44b0-975a-52b1cf45a5c0https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Report-Results-for-First-Quarter-2023-on-April-27-2023/default.aspxThu, 09 Mar 2023 06:59:00 -050030bd5af0-72a2-4299-b1c4-dda032880d6dhttps://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Announces-Dividend/default.aspxFri, 03 Mar 2023 16:16:00 -05006bb1e522-c37e-49a3-ba3f-2fc286590192https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-European-Commission-Approval-of-Reblozyl-luspatercept-for-Anemia-in-Adult-Patients-with-Non-Transfusion-Dependent-Beta-Thalassemia/default.aspxFri, 03 Mar 2023 06:59:00 -050028b54537-8111-4cf0-804a-6421b093d506https://news.bms.com/news/details/2023/The-Bristol-Myers-Squibb-Janssen-Collaboration-Launches-Pivotal-Phase-3-Librexia-Clinical-Trial-Program-Evaluating-Milvexian-an-Investigational-Oral-Factor-XIa-Inhibitor/default.aspxThu, 02 Mar 2023 06:59:00 -05005eb9fafe-da82-4f9c-a5f5-4c636e0083e7https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Participate-in-Cowens-43rd-Annual-Health-Care-Conference/default.aspxTue, 28 Feb 2023 06:59:00 -0500b5fdb089-d655-4819-aa55-68e890768b32https://news.bms.com/news/details/2023/U.S.-Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-Supplemental-Biologics-License-Application-and-European-Medicines-Agency-Validates-Application-for-Opdivo-nivolumab-/default.aspxTue, 28 Feb 2023 06:59:00 -0500b545f14c-24e1-4016-933a-6d35c11f9498https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Present-Data-Supporting-its-Cardiovascular-Portfolio-at-the-American-College-of-Cardiology-Annual-Scientific-Session-Together-With-World-Congress-of-Cardiology/default.aspxMon, 27 Feb 2023 06:59:00 -0500b30c1b48-b4f7-4620-867b-6397df423d05https://news.bms.com/news/details/2023/Adjuvant-Opdivo-nivolumab-Continues-to-Provide-Significant-Durable-Clinical-Benefits-for-Patients-with-Radically-Resected-High-Risk-Muscle-Invasive-Urothelial-Carcinoma-After-Three-Years-in-CheckMate--274-Trial/default.aspxFri, 17 Feb 2023 10:00:00 -0500d8b4efd0-1634-411c-a2e1-176349d34f43https://news.bms.com/news/details/2023/Basketball-Legend-Kareem-Abdul-Jabbar-Joins-No-Time-to-Wait-Campaign-to-Raise-Awareness-of-Atrial-Fibrillation-AFib-and-its-Symptoms/default.aspxThu, 16 Feb 2023 07:00:00 -0500f7da2d9e-cd54-49c2-88f0-462c760a7692https://news.bms.com/news/details/2023/Opdivo-nivolumab-in-Combination-with-CABOMETYX-cabozantinib-Shows-Durable-Survival-with-Over-Three-Years-of-Follow-Up-in-the-CheckMate--9ER-Trial-in-First-Line-Advanced-Renal-Cell-Carcinoma/default.aspxMon, 13 Feb 2023 17:00:00 -05005790f026-088c-4b20-b75d-b1b0b376520fhttps://news.bms.com/news/details/2023/Abecma-idecabtagene-vicleucel-Reduced-the-Risk-of-Disease-Progression-or-Death-by-51-Versus-Standard-Regimens-in-Earlier-Lines-of-Therapy-for-Relapsed-and-Refractory-Multiple-Myeloma-Based-on-Results-from-Phase-3-KarMMa-3-Study/default.aspxFri, 10 Feb 2023 11:13:00 -050002356afb-0415-411a-bf2b-96fbca52cac5https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Participate-in-the-Guggenheim-Healthcare-Talks-2023-Oncology-Conference/default.aspxFri, 03 Feb 2023 06:59:00 -0500c4d185cc-22a8-436e-8c09-d2910889a759https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2022/default.aspxThu, 02 Feb 2023 06:59:00 -0500a8b58120-ea22-4dc9-b85d-50f263ed6d15https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Reblozyl-luspatercept-for-Adult-Patients-with-Anemia-Associated-Non-Transfusion-Dependent-NTD-Beta-Thalassemia/default.aspxFri, 27 Jan 2023 07:05:00 -0500ca458dc5-dccf-46c4-87b6-681bf262db04https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Announces-Positive-CHMP-Opinion-for-Once-Daily-Sotyktu-deucravacitinib-as-a-Treatment-for-Adults-With-Moderate-to-Severe-Plaque-Psoriasis/default.aspxFri, 27 Jan 2023 06:59:00 -05005faad6cb-923c-48d8-91f2-71a7f5a00faahttps://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Announces-TRANSCEND-CLL-004-Trial-of-Breyanzi-lisocabtagene-maraleucel-Met-Primary-Endpoint-of-Complete-Response-Rate-in-Patients-with-Relapsed-or-Refractory-Chronic-Lymphocytic-Leukemia/default.aspxThu, 26 Jan 2023 06:59:00 -0500db8aa217-ebb8-4a47-8d53-ee76b44494afhttps://news.bms.com/news/details/2023/The-Robert-A.-Winn-Diversity-in-Clinical-Trials-Award-Program-Established-by-the-Bristol-Myers-Squibb-Foundation-to-Expand-with-Amgens-Commitment-of-8-Million/default.aspxThu, 19 Jan 2023 08:30:00 -0500076ec030-d2fa-4bbe-954b-9dd541612199https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Present-at-J.P.-Morgans-41st-Annual-Healthcare-Conference/default.aspxTue, 03 Jan 2023 07:05:00 -05001b66539f-076e-4fa9-93aa-36d97cceb262https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Completes-Sale-of-Manufacturing-Facility-in-Syracuse-New-York/default.aspxTue, 03 Jan 2023 06:59:00 -0500973af965-36c9-495b-8aeb-c50e58fa4217https://news.bms.com/news/details/2022/CAR-T-Cell-Therapy-Breyanzi-Approved-as-Relapsed-or-Refractory-Large-B-cell-Lymphoma-Second-Line-Therapy-in-Japan/default.aspxTue, 20 Dec 2022 07:00:00 -0500ef7473d1-a04c-4834-bd5f-38f17bab0d9ahttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-to-Report-Results-for-Fourth-Quarter-2022-on-February-2-2023/default.aspxThu, 15 Dec 2022 06:59:00 -0500bb550092-8778-4593-b38d-90fb55c160d7https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Announces-First-Disclosures-and-New-Data-at-ASH-2022-Demonstrating-Commitment-to-Raising-Standards-in-Treatment-Through-Broad-Multiple-Myeloma-Portfolio/default.aspxMon, 12 Dec 2022 06:59:00 -0500f88682e3-4727-4e6c-9b20-9cee39df4721https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Announces-Dividend-Increase/default.aspxThu, 08 Dec 2022 16:16:00 -05008cd2605b-b8f2-443b-9eae-46a943450762https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Data-at-ASH-2022-Highlight-Innovative-Therapeutic-Platforms-Across-a-Range-of-Blood-Diseases/default.aspxMon, 21 Nov 2022 06:59:00 -0500f8d6d983-bd27-479f-a38f-c5f2872283a2https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-to-Participate-in-the-Wolfe-Research-Healthcare-Conference/default.aspxWed, 09 Nov 2022 06:59:00 -05009f55c384-5bf9-480c-b3d2-d8462cefb1a7https://news.bms.com/news/details/2022/Data-Reinforcing-Impact-of-Bristol-Myers-Squibb-Cardiovascular-Portfolio-to-be-Presented-at-American-Heart-Association-Scientific-Sessions-2022/default.aspxWed, 02 Nov 2022 06:59:00 -0400450c7c1c-9c6d-4759-9db2-bb3f3cd21aeehttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-of-Phase-3-COMMANDS-Trial/default.aspxMon, 31 Oct 2022 06:59:00 -04000d65710a-f9e7-44a5-a879-b3bc2410c044https://news.bms.com/news/details/2022/New-Zeposia-ozanimod-Data-Highlight-COVID-19-Outcomes-and-Preservation-of-Long-Term-Cognitive-Function-from-Separate-Analyses-in-Patients-with-Relapsing-Forms-of-Multiple-Sclerosis/default.aspxWed, 26 Oct 2022 02:00:00 -0400b061f099-4ec4-4a74-815c-7b9fa5256184https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Reports-Third-Quarter-Financial-Results-for-2022/default.aspxTue, 25 Oct 2022 19:31:00 -0400a6b4f9b6-f533-4e0a-92ba-829a2e38d8ffhttps://news.bms.com/news/details/2022/The-Robert-A.-Winn-Diversity-in-Clinical-Trials-Award-Program-Announces-the-Second-Group-of-Physicians-to-be-Trained-in-the-114-Million-Program/default.aspxTue, 25 Oct 2022 13:04:00 -04009f6b0265-b770-4826-ba6e-536ff97b5031https://news.bms.com/news/details/2022/New-Data-Presented-at-the-American-College-of-Gastroenterology-Annual-Scientific-Meeting-Demonstrate-Continuous-Zeposia-ozanimod-Treatment-Prevents-Disease-Relapse-Over-One-Year-in-86.1-of-Patients-Who-Respond-at-the-End-of-the-Induction-Period/default.aspxMon, 24 Oct 2022 06:59:00 -0400a12c2d46-95b2-402e-a1d6-50507ced517fhttps://news.bms.com/news/details/2022/U.S.-Food-and-Drug-Administration-FDA-Accepts-Supplemental-New-Drug-Application-for-CAMZYOS-mavacamten-in-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-to-Reduce-the-Need-for-Septal-Reduction-Therapy/default.aspxFri, 21 Oct 2022 06:59:00 -04009253bfd7-a022-4e3c-a63e-e3d45a083059https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Presents-Data-from-CheckMate--76K-Showing-Opdivo-nivolumab-Reduced-the-Risk-of-Recurrence-or-Death-by-58-Versus-Placebo-in-Patients-with-Completely-Resected-Stage-IIB-or-IIC-Melanoma/default.aspxWed, 19 Oct 2022 16:30:00 -0400e1ed77a6-d992-4d09-b60c-989c29f1f9fchttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Announces-Change-to-Earnings-Conference-Call-Dial-In-Information-for-Third-Quarter-2022-Results-Scheduled-for-October-26-2022/default.aspxFri, 07 Oct 2022 06:59:00 -04003c1e61ff-2d8f-4729-af32-49d6b48d8ddfhttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-LAG-3-Blocking-Antibody-Combination-Opdualag-nivolumab-and-relatlimab-for-the-Treatment-of-Unresectable-or-Metastatic-Melanoma-with-Tumor-Cell-PD-L1-Expression--1/default.aspxFri, 16 Sep 2022 16:15:00 -0400936108dd-0d67-4725-af5d-c0cb853b418chttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Announces-Adjuvant-Treatment-with-Opdivo-nivolumab-Demonstrated-Statistically-Significant-and-Clinically-Meaningful-Improvement-in-Recurrence-Free-Survival-RFS-in-Patients-with-Stage-IIBC-Melanoma-in-the-CheckMate--76K-Trial/default.aspxThu, 15 Sep 2022 06:59:00 -04008c6cf7e1-4d44-42f8-8ee4-37e350a946b1https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Announces-Dividend-a39979df9/default.aspxWed, 14 Sep 2022 16:16:00 -0400853ddd28-c120-4df7-9738-36f01b72e06dhttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Announces-New-Sotyktu-deucravacitinib-Long-Term-Data-Showing-Clinical-Efficacy-Maintained-for-Up-to-Two-Years-with-Continuous-Treatment-in-Moderate-to-Severe-Plaque-Psoriasis/default.aspxSat, 10 Sep 2022 02:30:00 -04007db41825-7b0d-486e-a796-3d4617b142c9https://news.bms.com/news/details/2022/U.S.-Food-and-Drug-Administration-Approves-Sotyktu-deucravacitinib-Oral-Treatment-for-Adults-with-Moderate-to-Severe-Plaque-Psoriasis/default.aspxFri, 09 Sep 2022 22:38:00 -0400bb4abd25-8f47-4d89-9fbc-dee214abb546https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Employees-to-Relay-Nearly-3000-Miles-Cross-Country-Aspiring-to-Raise-Over-1-Million-for-the-V-Foundation-for-Cancer-Research/default.aspxWed, 07 Sep 2022 07:00:00 -040045b92127-c781-4ad6-b047-4675629798abhttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-to-Report-Results-for-Third-Quarter-2022-on-October-26-2022/default.aspxWed, 07 Sep 2022 06:59:00 -0400db06c713-6320-47fb-a766-4b68f48a233dhttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-to-Participate-in-the-Morgan-Stanley-20th-Annual-Global-Healthcare-Conference/default.aspxTue, 06 Sep 2022 06:59:00 -0400e8384ba6-39f3-4dd7-a9c6-fb9b9a854537https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Research-at-ESMO-Congress-2022-Highlights-Depth-of-Development-Program-Across-Early--and-Late-Stages-of-Cancer/default.aspxMon, 05 Sep 2022 06:59:00 -040052d38e4c-af63-4edf-b78d-833313e86fdfhttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-to-Participate-in-Citis-17th-Annual-BioPharma-Conference/default.aspxWed, 31 Aug 2022 06:59:00 -040059100bea-b33a-437e-a098-b0b75095cc1ehttps://news.bms.com/news/details/2022/Late-Breaking-Results-From-Phase-2-AXIOMATIC-SSP-Study-of-Milvexian-an-Investigational-Oral-Factor-XIa-Inhibitor-Show-Favorable-Antithrombotic-Profile-in-Combination-With-Dual-Antiplatelet-Therapy/default.aspxSun, 28 Aug 2022 03:36:00 -0400f3d5e3ba-ac56-42f4-8e30-2c66e021ba38https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Completes-Acquisition-of-Turning-Point-Therapeutics-Expanding-Precision-Oncology-Portfolio/default.aspxWed, 17 Aug 2022 08:31:00 -04006bf7ef46-117f-40ac-86a9-9e331147756bhttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-and-Turning-Point-Therapeutics-Announce-Expiration-of-HSR-Act-Waiting-Period-and-Clearance-from-Federal-Cartel-Office-of-Germany-Related-to-Pending-Acquisition-of-Turning-Point-Therapeutics/default.aspxTue, 16 Aug 2022 06:59:00 -04009a8d57a0-e2e9-4578-a406-6fc5ae2de462https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-and-2seventy-bio-Announce-Topline-Results-from-KarMMa-3-Trial-Showing-Abecma-idecabtagene-vicleucel-Significantly-Improves-Progression-Free-Survival-Versus-Standard-Regimens-in-Relapsed-and-Refractory-Multiple-Myeloma/default.aspxWed, 10 Aug 2022 06:45:00 -0400a76d0237-61a1-4632-815a-00b8b29dbdd5https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-to-Host-Virtual-Investor-Event-to-Discuss-ESC-2022-Highlights/default.aspxWed, 03 Aug 2022 16:16:00 -0400c4e6569e-6031-4a07-b917-247aeee7be23https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Provides-Update-on-CheckMate--914-Trial-Evaluating-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-as-Adjuvant-Treatment-of-Localized-Renal-Cell-Carcinoma/default.aspxFri, 29 Jul 2022 06:59:00 -0400bb859d89-aa3e-41dd-ad77-abc6f2ed582ahttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Reports-Second-Quarter-Financial-Results-for-2022/default.aspxWed, 27 Jul 2022 06:59:00 -0400d09dc972-c8fe-4977-b66f-9685212b19c5https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Approval-for-LAG-3-Blocking-Antibody-Combination-Opdualag-nivolumab-and-relatlimab-for-Treatment-of-Patients-with-Unresectable-or-Metastatic-Melanoma/default.aspxFri, 22 Jul 2022 06:59:00 -0400e7f49c8b-819e-4737-adcd-930d5809fd0dhttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Teams-Up-with-Jack-and-Jill-of-America-Inc.-to-Expand-Tomorrows-Innovators-Program-to-Increase-Black-Representation-in-the-Healthcare-Industry/default.aspxThu, 21 Jul 2022 06:59:00 -04001dc459f4-fe1b-4b66-a4d4-e59feabee177https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Launches-Disability-Diversity-in-Clinical-Trials-DDiCT-Initiative-to-Improve-Healthcare-Outcomes-for-People-with-Disabilities/default.aspxWed, 20 Jul 2022 06:59:00 -0400518ee805-3b4b-4fff-9522-b64ecf1b5f26https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Announces-Extension-of-Turning-Point-Tender-Offer/default.aspxTue, 19 Jul 2022 06:59:00 -0400c5b7d96e-d26b-4be6-b086-8cfda1d99544https://news.bms.com/news/details/2022/US-FDA-Approves-Bristol-Myers-Squibbs-CAR-T-Cell-Therapy-Breyanzifor-Relapsed-or-Refractory-Large-B-cell-Lymphoma-After-One-Prior-Therapy/default.aspxFri, 24 Jun 2022 19:05:00 -0400ba904407-35ed-4b9b-8771-2810dc165386https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Presents-New-Data-Showing-Effect-of-Early-Zeposia-ozanimod-Treatment-in-Improving-and-Preserving-Cognitive-Function-in-People-With-Relapsing-Multiple-Sclerosis/default.aspxFri, 24 Jun 2022 12:52:00 -0400e8b1ccd9-046d-4b09-b7b8-2cc65a6c8d6bhttps://news.bms.com/news/details/2022/New-Data-Highlight-Immune-Response-to-COVID-19-Vaccines-in-Individuals-with-Relapsing-Forms-of-Multiple-Sclerosis-Treated-with-Zeposia-ozanimod/default.aspxFri, 24 Jun 2022 12:51:00 -0400dc1a5d42-2c86-4dc6-a5b3-fa692cc4d9c4https://news.bms.com/news/details/2022/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Application-for-CAR-T-Cell-Therapy-Breyanzi-in-Relapsed-or-Refractory-Large-B-cell-Lymphoma-After-First-Line-Therapy/default.aspxMon, 20 Jun 2022 06:59:00 -040075c5c3d5-abad-4d1e-9d15-1dd912cc6c90https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Elects-Deepak-L.-Bhatt-M.D.-M.P.H.-to-Board-of-Directors/default.aspxWed, 15 Jun 2022 16:16:00 -040069c51a6a-46f6-400c-9f5d-df6ab107eb76https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Announces-Dividend-06f4e09a1/default.aspxWed, 15 Jun 2022 16:16:00 -0400ab1b0e19-71cd-4822-93b5-7137cc4d5ce0https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-to-Report-Results-for-Second-Quarter-2022-on-July-27-2022/default.aspxWed, 08 Jun 2022 06:59:00 -0400826ce198-380a-445c-b4e9-da6967299e72https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-to-Participate-in-Goldman-Sachs-43rd-Annual-Global-Healthcare-Conference/default.aspxTue, 07 Jun 2022 06:59:00 -04002c7e9376-83b1-4d6c-bbfa-037292ce2272https://news.bms.com/news/details/2022/Three-Year-Data-from-Phase-3-CheckMate--9LA-Trial-Demonstrate-Long-Term-Durable-Survival-Outcomes-of-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-with-Two-Cycles-of-Chemotherapy-for-Patients-with-Metastatic-Non-Small-Cell-Lung-Cancer/default.aspxMon, 06 Jun 2022 06:59:00 -0400c2bbe72a-442b-41bf-a867-6e7fba92ae56https://news.bms.com/news/details/2022/Landmark-Five-Year-Data-from-Phase-3-CheckMate--227-Trial-Demonstrate-Long-Term-Durable-Survival-Outcomes-with-Opdivonivolumab-Plus-Yervoy-ipilimumab-in-First-Line-Treatment-of-Patients-with-Metastatic-Non-Small-Cell-Lung-Cancer/default.aspxMon, 06 Jun 2022 06:59:00 -0400dbee9a33-f09e-4ec4-9cae-2e5e9cd4da99https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Withdraws-Supplemental-Biologics-License-Application-sBLA-for-Reblozyl-luspatercept-aamt-for-Non-transfusion-Dependent-NTD-Beta-Thalassemia/default.aspxFri, 03 Jun 2022 16:59:00 -0400d0859591-5c88-4dc6-862b-d7e31aba68c2https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-to-Acquire-Turning-Point-Therapeutics-a-Leading-Precision-Oncology-Company/default.aspxFri, 03 Jun 2022 06:59:00 -040014aea729-688f-44ff-8c52-b8a16aba925ehttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Announces-Topline-Results-Showing-Treatment-with-Orencia-abatacept-Improved-Survival-in-People-Hospitalized-with-COVID-19/default.aspxThu, 02 Jun 2022 11:01:00 -0400735ef650-d581-4323-8776-c22c11ac2659https://news.bms.com/news/details/2022/Immatics-and-Bristol-Myers-Squibb-Expand-Strategic-Alliance-to-Develop-Gamma-Delta-Allogeneic-Cell-Therapy-Programs/default.aspxThu, 02 Jun 2022 06:59:00 -0400383dabe5-fdb2-452e-8970-cc51a104eb38https://news.bms.com/news/details/2022/Late-Breaking-Data-at-EULAR-2022-Demonstrate-Deucravacitinib-Significantly-Improved-Disease-Activity-in-Phase-2-PAISLEY-Study-in-Systemic-Lupus-Erythematosus/default.aspxWed, 01 Jun 2022 06:59:00 -0400926631f0-0674-4860-bb8e-09224f9d9e68https://news.bms.com/news/details/2022/U.S.-Food-and-Drug-Administration-Approves-Two-Opdivo-nivolumab-Based-Regimens-as-First-Line-Treatments-for-Unresectable-Advanced-or-Metastatic-Esophageal-Squamous-Cell-Carcinoma/default.aspxFri, 27 May 2022 18:11:00 -0400fba7296a-a677-40cd-a1ed-b0dd04287bb4https://news.bms.com/news/details/2022/Data-from-Phase-2-PILOT-Study-of-Bristol-Myers-Squibbs-CAR-T-cell-Therapy-Breyanzi-Show-Substantial-Durable-Responses-in-Patients-with-Refractory-or-Relapsed-Large-B-cell-Lymphoma-After-First-Line-Therapy/default.aspxThu, 26 May 2022 17:00:00 -0400c1cfcf69-2274-4d9a-baee-861074d7db3fhttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-to-Participate-in-Bernsteins-38th-Annual-Strategic-Decisions-Conference/default.aspxThu, 26 May 2022 06:59:00 -0400f20934ee-5edf-4132-aab7-dd1832d097d7https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Data-at-ASCO-and-EHA-2022-Highlight-Progress-in-Transforming-Treatment-for-Patients-with-Cancer-and-Blood-Disorders/default.aspxThu, 19 May 2022 06:59:00 -04008c8ab26f-a15d-4538-8dbd-e3a9075919achttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Provides-Update-on-CheckMate--901-Trial-Evaluating-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-as-First-Line-Treatment-for-Patients-with-Unresectable-or-Metastatic-Urothelial-Carcinoma/default.aspxMon, 16 May 2022 06:59:00 -0400e6b42294-9f72-4e5c-b835-34c7a0941f75https://news.bms.com/news/details/2022/LOTTE-to-Purchase-Bristol-Myers-Squibb-Manufacturing-Facility-in-East-Syracuse-New-York/default.aspxFri, 13 May 2022 06:59:00 -0400029e7550-2649-42e0-bd46-cf441c889d4ahttps://news.bms.com/news/details/2022/New-Two-Year-Deucravacitinib-Data-Reinforce-Durable-Efficacy-and-Consistent-Safety-Profile-in-Treatment-of-Moderate-to-Severe-Plaque-Psoriasis/default.aspxThu, 12 May 2022 06:59:00 -04005af7df58-a1cd-42c9-b6c8-b7dfea9a155dhttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-to-Participate-in-Bank-of-America-Securities-2022-Healthcare-Conference/default.aspxWed, 04 May 2022 06:59:00 -04005c1d1344-637e-4c86-abf3-a457051c5985https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results-for-2022/default.aspxFri, 29 Apr 2022 06:59:00 -04005159b8dc-2a6f-4923-a69e-a4d86d2abca5https://news.bms.com/news/details/2022/U.S.-Food-and-Drug-Administration-Approves-Camzyos-mavacamten-for-the-Treatment-of-Adults-With-Symptomatic-New-York-Heart-Association-Class-II-III-ObstructiveHypertrophic-Cardiomyopathy-HCM-to-Improve-Functional-Capacity-and-Symptoms/default.aspxThu, 28 Apr 2022 20:01:00 -0400adfe6c43-a917-4334-b8f5-6a0ddb07cc8ehttps://news.bms.com/news/details/2022/Nektar-and-Bristol-Myers-Squibb-Announce-Update-on-Clinical-Development-Program-for-Bempegaldesleukin-BEMPEG-in-Combination-with-Opdivo-nivolumab/default.aspxThu, 14 Apr 2022 16:30:00 -0400a87ee462-9e5d-4cae-985e-e984723fc688https://news.bms.com/news/details/2022/Neoadjuvant-Opdivo-nivolumab-with-Chemotherapy-Significantly-Improves-Event-Free-Survival-in-Patients-with-Resectable-Non-Small-Cell-Lung-Cancer-in-Phase-3-CheckMate--816-Trial/default.aspxMon, 11 Apr 2022 11:15:00 -0400621edd77-7a96-47ca-9fb3-c13de413a374https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Foundation-Honors-Diversity-and-Health-Equity-Leader-By-Naming-Diversity-in-Clinical-Trials-Training-Program-After-Him-Welcomes-Gilead-Sciences-as-Program-Supporter/default.aspxMon, 11 Apr 2022 06:59:00 -0400a0623bfb-8dc2-4e09-9ed4-96f4921a1d1dhttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-CAR-T-Cell-Therapy-Breyanzi-lisocabtagene-maraleucel-for-Certain-Forms-of-Relapsed-or-Refractory-Large-B-cell-Lymphoma/default.aspxTue, 05 Apr 2022 10:33:00 -0400083addd9-3cc1-4e68-8ef0-2f844d2d4c55https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with/default.aspxTue, 05 Apr 2022 06:55:00 -04000aee59c7-f6ee-46b7-9c8a-ba051d3b6875https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-as-First-Line-Treatment-for-Patients-with/default.aspxTue, 05 Apr 2022 06:50:00 -040077297fb2-8463-48be-8955-5042d06a45f6https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-as-Adjuvant-Treatment-for-Patients-with-Radically-Resected-High-Risk-Muscle-Invasive-Urothelial-Carcinoma-with-Tumor-Cell-PD-L1-Expression-1/default.aspxTue, 05 Apr 2022 06:45:00 -0400fa7f9e90-ba3e-4e9b-9d87-9e4f6e6951aahttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Announces-Data-from-EXPLORER-LTE-Demonstrating-Sustained-Improvements-in-Clinically-Meaningful-Cardiovascular-Outcomes-at-Weeks-48-and-84-in-Patients-with-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-Receiving-Mavacamten/default.aspxSun, 03 Apr 2022 09:45:00 -0400d736c5c0-9e78-4b87-8a1d-5849aeae1c99https://news.bms.com/news/details/2022/Mavacamten-Demonstrated-Significant-Reduction-in-Need-for-Septal-Reduction-Therapy-in-Symptomatic-Obstructive-HCM-Patients-in-Phase-3-VALOR-Trial/default.aspxSat, 02 Apr 2022 09:30:00 -040033891e2f-e1e1-486a-8475-29f8e48d9dabhttps://news.bms.com/news/details/2022/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-with-Chemotherapy-as-Neoadjuvant-Treatment-for-Resectable-Non-Small-Cell-Lung-Cancer/default.aspxTue, 29 Mar 2022 06:59:00 -040036ef5d8d-17fd-4b76-87a8-f89b67bba141https://news.bms.com/news/details/2022/Japans-Ministry-of-Health-Labour-and-Welfare-Accepts-Bristol-Myers-Squibbs-Application-for-Breyanzi-lisocabtagene-maraleucel-as-a-Second-Line-Therapy-for-Relapsed-or-Refractory-Large-B-cell-Lymphoma/default.aspxFri, 25 Mar 2022 07:00:00 -040059d1b45b-ef05-4945-9130-565de8e42198https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Announces-New-Prescription-Drug-User-Fee-Act-Goal-Date-for-Reblozyl-luspatercept-aamt-Supplemental-Biologics-License-Application/default.aspxFri, 25 Mar 2022 06:59:00 -0400c552b532-e410-4728-b35e-99d4f547336ahttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-to-Demonstrate-the-Strength-of-its-Growing-Cardiovascular-Portfolio-at-the-American-College-of-Cardiologys-71st-Annual-Scientific-Session/default.aspxMon, 21 Mar 2022 08:00:00 -0400e7a13eb3-0060-40fd-9c47-11f221e4c33chttps://news.bms.com/news/details/2022/U.S.-Food-and-Drug-Administration-Approves-First-LAG-3-Blocking-Antibody-Combination-Opdualag-nivolumab-and-relatlimab-rmbw-as-Treatment-for-Patients-with-Unresectable-or-Metastatic-Melanoma/default.aspxFri, 18 Mar 2022 18:29:00 -0400b13b3c09-b9c7-499b-9b79-c2ef7afa0d4chttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-and-Nektar-Announce-Update-on-Phase-3-PIVOT-IO-001-Trial-Evaluating-Bempegaldesleukin-BEMPEG-in-Combination-with-Opdivo-nivolumab-in-Previously-Untreated-Unresectable-or-Metastatic-Melanoma/default.aspxMon, 14 Mar 2022 06:59:00 -0400620d6001-d2fb-4f4e-a819-4e2aa3d6bccchttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-to-Report-Results-for-First-Quarter-2022-on-April-29-2022/default.aspxFri, 11 Mar 2022 06:59:00 -050061603c41-9b3a-47c5-8e3e-af27f575c8f1https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-to-Participate-in-Upcoming-Investor-Conferences-on-March-16/default.aspxWed, 09 Mar 2022 06:59:00 -0500f27638ef-2f44-4f60-b19a-e6e74e61805dhttps://news.bms.com/news/details/2022/U.S.-Food-and-Drug-Administration-Approves-Opdivo-nivolumab-with-Chemotherapy-as-Neoadjuvant-Treatment-for-Certain-Adult-Patients-with-Resectable-Non-Small-Cell-Lung-Cancer/default.aspxFri, 04 Mar 2022 17:44:00 -050061f6b174-cf8b-4f69-babd-6917c94f1b20https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Announces-Accepted-Amounts-and-Pricing-Terms-of-its-Tender-Offers/default.aspxWed, 02 Mar 2022 15:19:00 -050090b0cfce-4970-45be-80f2-3a77de5cea88https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Announces-Early-Participation-Results-Upsizing-and-Early-Settlement-of-Tender-Offers/default.aspxTue, 01 Mar 2022 21:03:00 -05005c3ffaae-d6eb-452b-a0d9-cee4e18c1511https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Announces-Dividend/default.aspxTue, 01 Mar 2022 16:16:00 -0500d5c1d3a0-d771-401c-804a-20a260fd8425https://news.bms.com/news/details/2022/U.S.-Food-and-Drug-Administration-Accepts-for-Priority-Review-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-Plus-Chemotherapy-as-Neoadjuvant-Treatment-for-Resectable-Non-Small-Cell-Lung-Cancer/default.aspxMon, 28 Feb 2022 06:59:00 -05006a6b377a-17e8-4aa9-8fd3-946630d583f2https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Opdivo-nivolumab-plus-Chemotherapy-for-First-Line-Treatment-of-Patients-with-Unresectable-Advanced-Recurrent-or-Metastatic-Esophageal-Squamous-Cell-Carcinoma-with-Tumor-Cell-PD-L1/default.aspxFri, 25 Feb 2022 06:55:00 -05009dc35f17-fd0e-415d-86cb-30a8dd5d06dehttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Approval-for-Opdivo-nivolumab-plus-Yervoy-ipilimumab-for-First-Line-Treatment-of-Patients-with-Unresectable-Advanced-Recurrent-or-Metastatic-Esophageal-Squamous-Cell-Carcinoma/default.aspxFri, 25 Feb 2022 06:50:00 -050009bae2b0-25ff-4f55-b01c-6984c5ed601fhttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Approval-for-Opdivo-nivolumab-as-Adjuvant-Treatment-for-Patients-with-Radically-Resected-High-Risk-Muscle-Invasive-Urothelial-Carcinoma-with-Tumor-Cell-PD-L1-Expression-1/default.aspxFri, 25 Feb 2022 06:45:00 -050018eeebff-65f8-453b-be3c-82af5ae61448https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Presents-Interim-Results-from-Long-Term-Study-Reinforcing-Maintenance-of-Response-and-Safety-Profile-of-Zeposia-ozanimod-in-Patients-with-Moderately-to-Severely-Active-Ulcerative-Colitis/default.aspxThu, 17 Feb 2022 12:19:00 -05005ea5222e-5522-4c8a-8577-7a8fe8dc5d9ahttps://news.bms.com/news/details/2022/U.S.-Food-and-Drug-Administration-FDA-Accepts-for-Priority-Review-Bristol-Myers-Squibbs-Supplemental-Biologics-License-Application-for-Breyanzi-lisocabtagene-maraleucel-as-a-Second-Line-Therapy-for-Relapsed-or-Refractory-Large-B-cell-Lymphoma/default.aspxThu, 17 Feb 2022 06:59:00 -050048881b8d-e1b1-45f3-a2a9-079de2e87f77https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Phase-3-VALOR-HCM-Trial-Evaluating-Mavacamten-in-Patients-with-Obstructive-Hypertrophic-Cardiomyopathy-Who-are-Eligible-for-Septal-Reduction-Therapy/default.aspxWed, 16 Feb 2022 06:59:00 -0500091c0404-2d0f-4b0c-8548-338f236f1308https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Prices-6-Billion-of-Senior-Unsecured-Notes/default.aspxTue, 15 Feb 2022 16:39:00 -05008df6e690-c838-44fd-86e0-cac9815435e6https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Announces-Tender-Offers-for-an-Aggregate-Purchase-Price-of-Up-to-4.0-Billion/default.aspxTue, 15 Feb 2022 09:04:00 -0500ca90ff8e-8d46-4fd3-8619-64167f5758bfhttps://news.bms.com/news/details/2022/Opdivo-nivolumab-in-Combination-with-CABOMETYX-cabozantinib-Demonstrates-Continued-Survival-Benefits-with-Over-Two-Years-of-Follow-Up-in-the-CheckMate--9ER-Trial-in-First-Line-Advanced-Renal-Cell-Carcinoma/default.aspxMon, 14 Feb 2022 17:00:00 -050044b99727-d837-4322-bf73-501d1a9fe53ahttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Enters-Into-5-Billion-Aggregate-Accelerated-Share-Repurchase-Agreements/default.aspxWed, 09 Feb 2022 06:59:00 -05003ba4582f-c6b4-47cf-a945-eb6b6cdb9828https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Awards-Nearly-8-Million-in-New-Health-Equity-Grants-to-Improve-Access-to-Care-for-Medically-Underserved-Patients-in-U.S/default.aspxTue, 08 Feb 2022 06:59:00 -05004417c1bc-4f22-4be9-bdb1-88ab2759ee7dhttps://news.bms.com/news/details/2022/ADDING-and-REPLACINGBristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2021/default.aspxFri, 04 Feb 2022 08:49:00 -050089eb85d7-afce-4375-8d7d-f8c3700c9b06https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2021/default.aspxFri, 04 Feb 2022 06:59:00 -050004749c91-90c6-4209-921b-34a466c1fb5ahttps://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-CAR-T-Cell-Therapy-Breyanzi-lisocabtagenemaraleucel-for-Relapsed-or-Refractory-DLBCL-PMBCL-and-FL3B/default.aspxFri, 28 Jan 2022 06:59:00 -0500bb372666-f32d-427d-bcdf-259102e9e9d2https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Receives-Approval-for-Abecma-idecabtagene-vicleucel-the-First-CAR-T-Therapy-Approved-for-the-Treatment-of-Multiple-Myeloma-in-Japan/default.aspxThu, 20 Jan 2022 03:00:00 -0500663a002c-1623-40a2-adaa-d1ca4443ea0dhttps://news.bms.com/news/details/2022/Century-Therapeutics-and-Bristol-Myers-Squibb-Enter-into-a-Strategic-Collaboration-to-Develop-iPSC-derived-Allogeneic-Cell-Therapies/default.aspxMon, 10 Jan 2022 06:59:00 -0500e028a2ac-0c97-4a4b-80e6-16b28a4eb2f7https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-to-Highlight-Long-Term-Growth-Strategy-at-J.P.-Morgans-40th-Annual-Healthcare-Conference/default.aspxMon, 10 Jan 2022 06:45:00 -0500de9f5baa-0990-4f75-8164-77274e444f51https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-to-Present-at-J.P.-Morgans-40th-Annual-Healthcare-Conference/default.aspxTue, 04 Jan 2022 06:59:00 -0500a829d9f6-95c7-48ea-9d4e-36645883ace3https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-to-Report-Results-for-Fourth-Quarter-2021-on-February-4-2022/default.aspxFri, 17 Dec 2021 06:59:00 -0500284c91e8-8a49-4167-87e9-a31620fe61behttps://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-Approves-Orencia-abatacept-in-Combination-with-a-Calcineurin-Inhibitor-and-Methotrexate-for-the-Prevention-of-Acute-Graft-Versus-Host-Disease-aGvHD/default.aspxWed, 15 Dec 2021 15:13:00 -05001860472e-836f-4d05-9fc4-631905607736https://news.bms.com/news/details/2021/Immatics-and-Bristol-Myers-Squibb-Enter-Into-Global-Exclusive-License-for-Immatics-TCR-Bispecific-Program-IMA401/default.aspxTue, 14 Dec 2021 06:59:00 -0500e10e003d-f7e7-4806-bcc9-6ea88b1859c3https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Announces-Dividend-Increase-and-Additional-15-Billion-Share-Repurchase-Authorization/default.aspxMon, 13 Dec 2021 06:59:00 -0500b70d939f-35a1-400f-b25c-94748ca064d2https://news.bms.com/news/details/2021/Bristol-Myers-Squibbs-Breyanzi-lisocabtagene-maraleucel-Significantly-Improves-Outcomes-Showing-Superiority-Over-20-Year-Standard-of-Care-in-Second-Line-Relapsed-or-Refractory-Large-B-cell-Lymphoma-Based-on-TRANSFORM-Study-Results/default.aspxSat, 11 Dec 2021 08:30:00 -05006e1be4b5-bc58-4d7e-9cfa-5eee22f13a9ehttps://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-Accepts-for-Priority-Review-supplemental-Biologics-License-Application-for-Reblozyl-luspatercept-aamt-in-Adults-with-Non-Transfusion-Dependent-NTD-Beta-Thalassemia/default.aspxFri, 03 Dec 2021 06:59:00 -05002cffc2af-5bfe-4f43-bf5c-ba33bc4ee9b2https://news.bms.com/news/details/2021/Bristol-Myers-Squibbs-Applications-for-Deucravacitinib-for-the-Treatment-of-Moderate-to-Severe-Plaque-Psoriasis-Accepted-by-U.S.-Food-and-Drug-Administration-and-Validated-by-European-Medicines-Agency/default.aspxMon, 29 Nov 2021 06:59:00 -0500bfc1fc0b-c124-46d7-9993-8fe1667d3febhttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Receives-European-Commission-Approval-of-Zeposia-ozanimod-for-use-in-Adults-with-Moderately-to-Severely-Active-Ulcerative-Colitis/default.aspxTue, 23 Nov 2021 06:59:00 -0500bd0ef9ff-e717-44a7-974f-6f4d29b3dd7ahttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Announces-New-PDUFA-Date-for-Mavacamten/default.aspxFri, 19 Nov 2021 06:59:00 -0500b2f574f4-2479-4b62-a300-534b1d955265https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Awards-Golden-Tickets-to-Promising-Biotechs-for-Residencies-at-LabCentral-BiolabsNYULangone-and-MBC-BioLabs/default.aspxThu, 18 Nov 2021 06:59:00 -050085be64c6-2de1-4213-b876-78907d32de9ahttps://news.bms.com/news/details/2021/Late-Breaking-Phase-2-Data-for-Investigational-Oral-Factor-XIa-Inhibitor-Milvexian-Suggest-Favorable-Antithrombotic-Profile-Across-a-Wide-Range-of-Doses/default.aspxMon, 15 Nov 2021 11:18:00 -05008b764b42-422e-49a1-8499-31b4d46e86eahttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Launches-Could-It-Be-HCM-Campaign-to-Increase-Awareness-of-Hypertrophic-Cardiomyopathy-HCM-the-Most-Common-Inherited-Heart-Disease/default.aspxMon, 15 Nov 2021 07:00:00 -05003fb44392-e0df-47ce-820a-62f62d72b0b3https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-to-Take-Part-in-Wolfe-Research-Virtual-Healthcare-Conference/default.aspxWed, 10 Nov 2021 06:59:00 -050021598b7d-7542-481c-91dd-6030a9035720https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-to-Present-Data-Across-Robust-Cardiovascular-Portfolio-at-American-Heart-Association-Scientific-Sessions-2021/default.aspxMon, 08 Nov 2021 06:59:00 -0500830267c0-c30b-4b00-820d-a990d3a2d88ehttps://news.bms.com/news/details/2021/Neoadjuvant-Opdivo-nivolumab-Plus-Chemotherapy-Significantly-Improves-Event-Free-Survival-in-Patients-with-Resectable-Non-Small-Cell-Lung-Cancer-in-Phase-3-CheckMate--816-Trial/default.aspxMon, 08 Nov 2021 06:59:00 -0500dbe75bda-15e6-4f9a-a898-d772325e651fhttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-to-Highlight-More-than-80-Abstracts-at-ASH-2021-Demonstrating-Strength-of-Innovative-Therapeutic-Platforms-Improving-Outcomes-for-a-Broad-Range-of-Hematologic-Diseases/default.aspxThu, 04 Nov 2021 10:16:00 -040075439e61-9b76-4fdf-b87e-1727b95ea8a9https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Data-at-ACR-Convergence-2021-Illustrate-Scientific-Advances-for-Immune-Mediated-Rheumatic-Diseases/default.aspxWed, 03 Nov 2021 06:59:00 -04003c0095a8-3678-4b39-894a-5c2238f7e571https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Reports-Third-Quarter-Financial-Results-for-2021/default.aspxWed, 27 Oct 2021 06:59:00 -0400eb893db2-02c1-4575-b207-6a58d87b561dhttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Announces-Earnings-Call-Time-Change-Third-Quarter-2021-Earnings-Call-to-Occur-on-October-27-2021-at-10-a.m.-Eastern-Time/default.aspxMon, 25 Oct 2021 06:59:00 -04005a2bb2ea-be9a-4ada-b149-03e70ce6a79chttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab--Chemotherapy-for-Patients-with-HER2-Negative-Advanced-or-Metastatic-Gastric-Gastroesophageal-Junction-or-Esophageal-Adenocarcinoma-/default.aspxThu, 21 Oct 2021 06:59:00 -040098d121eb-145c-4140-833e-78a04ba56acfhttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Zeposia-ozanimod-as-a-Treatment-for-Adult-Patients-with-Moderately-to-Severely-Active-Ulcerative-Colitis/default.aspxFri, 15 Oct 2021 06:59:00 -040075625d44-a5e5-4fee-8094-13f33d8c8ac9https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Announces-Up-to-Five-Years-of-Data-from-Long-Term-DAYBREAK-Study-Reinforcing-Efficacy-and-Safety-Profile-of-Zeposia-ozanimod-in-Patients-with-Relapsing-Forms-of-Multiple-Sclerosis/default.aspxWed, 13 Oct 2021 06:59:00 -040044d5d398-09a6-4985-b165-5e1ec886a816https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Provides-Update-on-Phase-2-Study-of-Deucravacitinib-in-Patients-With-Moderate-to-Severe-Ulcerative-Colitis/default.aspxThu, 07 Oct 2021 06:59:00 -040034e423a2-cb33-4bd0-acc8-0f9e20c6aff5https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-to-Hold-Investor-Event-on-November-16/default.aspxFri, 01 Oct 2021 07:05:00 -04000b8eaf00-c62d-4393-96a3-19cbcfbdfdc9https://news.bms.com/news/details/2021/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Application-for-LAG-3-Blocking-Antibody-Relatlimab-and-Nivolumab-Fixed-Dose-Combination-as-First-Line-Treatment-for-Patients-with-Unresectable-or-Metastatic-Melanoma/default.aspxFri, 01 Oct 2021 07:00:00 -040037fad7d5-0e10-445e-9adf-b3715a48c55bhttps://news.bms.com/news/details/2021/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Application-for-Mavacamten-for-the-Treatment-of-Obstructive-Hypertrophic-Cardiomyopathy/default.aspxFri, 01 Oct 2021 06:59:00 -040097aff34a-216e-435c-8d6b-ad74c9391e45https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Data-at-the-EADV-30th-Anniversary-Congress-Highlight-the-Growing-Body-of-Evidence-on-Deucravacitinib-and-Scientific-Advancements-for-Patients-with-Serious-Dermatologic-Diseases/default.aspxThu, 30 Sep 2021 09:45:00 -0400346f45ee-ddf7-4f50-977c-5a7e2f9ce395https://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-Applications-for-Opdivo-nivolumab--Yervoy-ipilimumab-and-Opdivo--Chemotherapy-for-Unresectable-Advanced-Recurrent-or-Metastatic-Esophageal-Squamous-Cell-Carcinoma/default.aspxMon, 27 Sep 2021 07:06:00 -0400b68a9d0c-f0eb-46bb-88cc-ea1f90b4cfbfhttps://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-Accepts-for-Priority-Review-Bristol-Myers-Squibbs-Application-for-LAG-3-Blocking-Antibody-Relatlimab-and-Nivolumab-Fixed-Dose-Combination-as-Treatment-for-Patients-with-Unresectable-or-Metastatic-Melanoma/default.aspxMon, 20 Sep 2021 06:59:00 -040038850ffb-534d-4d62-a9ed-8cfe62710099https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Opdivo-nivolumab--Chemotherapy-for-Patients-with-HER2-Negative-Advanced-or-Metastatic-Gastric-Gastroesophageal-Junction-or-Esophageal-Adenocarcinoma-whose-Tumors-Express-PD-L1-with-CPS--5/default.aspxFri, 17 Sep 2021 06:59:00 -04005bb14275-0c38-45ef-b24f-55e8daabb652https://news.bms.com/news/details/2021/Five-Year-Data-from-CheckMate--214-Show-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Demonstrates-Longest-Median-Overall-Survival-Currently-Reported-in-Phase-3-Trial-of-Patients-with-Previously-Untreated-Advanced-or-Metastatic-Renal-Cell-Carcinoma/default.aspxThu, 16 Sep 2021 06:59:00 -04002648110a-ac1a-42b2-a67e-7e3d664a31e5https://news.bms.com/news/details/2021/According-to-New-Multinational-Survey-Healthcare-Providers-Believe-Immunotherapy-Has-Potential-to-Positively-Impact-Earlier-Stage-Cancer-Treatment-Landscape-Across-Tumor-Types/default.aspxMon, 13 Sep 2021 07:05:00 -04004eb32b6c-89c2-4c91-9158-7c9c74b36055https://news.bms.com/news/details/2021/Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Demonstrates-Durable-Overall-Survival-at-Three-YearsCompared-to-Chemotherapy-in-First-Line-Unresectable-Malignant-Pleural-Mesothelioma-in-Phase-3-CheckMate--743-Trial/default.aspxMon, 13 Sep 2021 06:59:00 -0400b21be4b4-2900-4360-8aba-36ec2238c630https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Shares-Research-Supporting-Correlation-Between-New-York-Heart-Association-Functional-Class-NYHA-class-and-Mortality-in-Obstructive-Hypertrophic-Cardiomyopathy/default.aspxFri, 10 Sep 2021 20:15:00 -0400569e1e25-3ea6-4446-91c6-bdc4074e9718https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Announces-Dividend-284087eb0/default.aspxThu, 09 Sep 2021 16:16:00 -04000680a3c9-1d78-4d27-941c-869f25681bfbhttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-to-Report-Results-for-Third-Quarter-2021-on-October-27-2021/default.aspxWed, 08 Sep 2021 07:10:00 -0400cceb6feb-b2b8-4421-8bf0-03a71dc13a40https://news.bms.com/news/details/2021/More-than-230-Bristol-Myers-Squibb-Employees-Pedal-Across-the-U.S.-to-Advance-Cancer-Research-in-Seventh-Annual-Coast-2-Coast-4-Cancer-Ride/default.aspxWed, 08 Sep 2021 07:05:00 -040040065810-4dd6-4a16-938b-28d05fea2a42https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Research-at-ESMO-2021-Demonstrates-Clinical-Benefits-of-Immunotherapies-in-Multiple-Hard-to-Treat-Advanced-or-Metastatic-Cancers-and-Reinforces-the-Benefit-of-Opdivo-in-Earlier-Stage-Cancers/default.aspxWed, 08 Sep 2021 06:59:00 -0400cc97c0c5-30f2-477e-81ac-570d5c1f43a2https://news.bms.com/news/details/2021/Updated-Statement-Bristol-Myers-Squibb-on-Coronavirus-COVID-19/default.aspxTue, 07 Sep 2021 14:00:00 -040063d2cdd9-58d4-47ac-a792-2ef49dd40756https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-to-Take-Part-in-Morgan-Stanley-19th-Annual-Global-Healthcare-Conference/default.aspxTue, 07 Sep 2021 06:59:00 -04006903b301-891c-4e92-9eea-67d6de957fd9https://news.bms.com/news/details/2021/The-Bristol-Myers-Squibb-Pfizer-Alliance-is-pleased-with-the-decision-by-the-U.S.-Court-of-Appeals-for-the-Federal-Circuit-upholding-the-Eliquis-Patents/default.aspxFri, 03 Sep 2021 14:00:00 -04005faa9a32-6a6b-4df2-ad87-a6eb6b77bf7ahttps://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-Accepts-for-Priority-Review-Bristol-Myers-Squibbs-Application-for-Orencia-abatacept-for-the-Prevention-of-Acute-Graft-Versus-Host-Disease-aGvHD/default.aspxMon, 23 Aug 2021 06:59:00 -0400412a3957-20ca-4742-aed3-c23d9b53f013https://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-Approves-Opdivo-nivolumab-for-the-Adjuvant-Treatment-of-Patients-with-High-Risk-Urothelial-Carcinoma/default.aspxFri, 20 Aug 2021 11:45:00 -04005857c586-806d-41a4-86de-a4ba4b60a53bhttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Abecma-Idecabtagene-Vicleucel-the-First-Anti-BCMA-CAR-T-Cell-Therapy-for-Relapsed-and-Refractory-Multiple-Myeloma/default.aspxThu, 19 Aug 2021 09:34:00 -0400f895ead7-74b0-4a08-87e4-f119e400d348https://news.bms.com/news/details/2021/EMA-Validates-Bristol-Myers-Squibbs-Applications-for-Opdivo-nivolumab--Yervoy-ipilimumab-and-Opdivo--Chemotherapy-as-First-Line-Treatments-for-Unresectable-Advanced-Recurrent-or-Metastatic-Esophageal-Squamous-Cell-Carcinoma/default.aspxTue, 17 Aug 2021 06:59:00 -0400b983c478-120c-4bd5-9ef1-429d37b9b79fhttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-and-Five-Leading-Historically-Black-Colleges-and-Universities-Launch-Tomorrows-Innovators-to-Create-Custom-Biopharma-Educational-Programming-and-Increase-Recruitment-of-Black-Talent-in-the-Biopharma-Industry/default.aspxTue, 10 Aug 2021 06:59:00 -040046b83bf3-4f9e-48fa-9560-8f99e5cd98c8https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Completes-Sale-of-Manufacturing-Facility-in-Couvet-Switzerland/default.aspxTue, 03 Aug 2021 07:00:00 -040025d901ce-a0af-4b19-8edf-7ea66a5f6d93https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Statement-on-Istodax-romidepsin-Relapsed-Refractory-Peripheral-T-cell-Lymphoma-U.S.-Indication/default.aspxMon, 02 Aug 2021 16:30:00 -0400186f4a7e-0992-47f4-a66e-1f3c8e432623https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-as-Adjuvant-Treatment-for-Esophageal-or-Gastroesophageal-Junction-Cancer-Patients-with-Residual-Pathologic-Disease-Following-Chemoradiotherapy/default.aspxFri, 30 Jul 2021 06:59:00 -04006b4a237e-c120-455e-afff-64f70c97d396https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Reports-Second-Quarter-Financial-Results-for-2021/default.aspxWed, 28 Jul 2021 06:59:00 -0400c58aef0a-4557-4447-8dbf-a94a94da7bdchttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Statement-on-Opdivo-nivolumab-Monotherapy-Post-Sorafenib-Hepatocellular-Carcinoma-U.S.-Indication/default.aspxFri, 23 Jul 2021 18:40:00 -040022e30ad0-e102-4128-99ee-dbbbd9c3000dhttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Provides-Update-on-CheckMate--651-Trial-Evaluating-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Versus-EXTREME-Regimen-as-First-Line-Treatment-for-Squamous-Cell-Carcinoma-of-the-Head-and-Neck/default.aspxFri, 16 Jul 2021 06:59:00 -0400384ab34e-aee0-4086-bc04-e58cdf3ba8f7https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-for-the-Treatment-of-Mismatch-Repair-Deficient-or-Microsatellite-InstabilityHigh-Metastatic-Colorectal-Cancer-After-Prior-Chemotherapy/default.aspxTue, 29 Jun 2021 07:06:00 -040078477b65-1ff8-4a7c-b3a7-20dd38a64ef2https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Opdivo-nivolumab-as-Adjuvant-Treatment-for-Esophageal-or-Gastroesophageal-Junction-Cancer-Patients-with-Residual-Pathologic-Disease-Following-Chemoradiotherapy/default.aspxFri, 25 Jun 2021 06:59:00 -04000d93c48e-a5d1-448d-90f0-0acb4bf34ef9https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Anti-BCMA-CAR-T-Cell-Therapy-Abecma-idecabtagene-vicleucel-for-Relapsed-and-Refractory-Multiple-Myeloma/default.aspxFri, 25 Jun 2021 06:50:00 -0400fadfb4d6-d1e3-4a2f-bb03-8aa44c06b27dhttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Onureg-azacitidine-tablets-as-Frontline-Oral-Maintenance-Therapy-for-Adults-with-Acute-Myeloid-Leukemia/default.aspxFri, 18 Jun 2021 09:34:00 -0400e66ce282-37ed-457a-ac04-20c0ec117724https://news.bms.com/news/details/2021/Eisai-and-Bristol-Myers-Squibb-Enter-Into-Global-Strategic-Collaboration-for-Eisais-MORAb-202-Antibody-Drug-Conjugate/default.aspxThu, 17 Jun 2021 18:30:00 -04000c851bd4-381b-4f05-b694-67a78b2b8a0dhttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Announces-Dividend-1994697dd/default.aspxThu, 17 Jun 2021 16:16:00 -040010f07f20-04b7-4379-ab06-c1171e1d370bhttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-and-Acceleron-Present-First-Results-from-Phase-2-BEYOND-Study-of-Reblozylluspatercept-aamt-in-Adults-with-Non-Transfusion-DependentNTDBeta-Thalassemia/default.aspxFri, 11 Jun 2021 03:00:00 -040065df1429-b264-4214-9f96-eac5583cecc6https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-and-GRYT-Health-Evolve-Virtual-Patient-Advocacy-Experience/default.aspxThu, 10 Jun 2021 16:16:00 -0400655a46bc-cfcc-413c-a72a-a5e87b8fbef2https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-to-Report-Results-for-Second-Quarter-2021-on-July-28-2021/default.aspxThu, 10 Jun 2021 07:05:00 -040042977fa9-aef9-4724-a3a9-a74ae25da57fhttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Phase-3-TRANSFORM-Trial-Evaluating-Breyanzi-lisocabtagene-maraleucel-Versus-Chemotherapy-Followed-by-Stem-Cell-Transplant-in-Second-line-Relapsed-or-Refractory-Large-B-cell-Lymphoma/default.aspxThu, 10 Jun 2021 06:59:00 -0400442b1856-3dd8-4fb8-a4bd-1817a6a114echttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-to-Take-Part-in-Goldman-Sachs-42nd-Annual-Global-Healthcare-Conference/default.aspxFri, 04 Jun 2021 06:59:00 -0400ed4772b3-1ae1-43cd-b8be-15f0759ac877https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Presents-Data-from-CheckMate--648-Showing-Opdivo-plus-Chemotherapy-and-Opdivo-plus-Yervoy-Significantly-Improved-Overall-Survival-Compared-to-Chemotherapy-in-Unresectable-Advanced-or-Metastatic-Esophageal-Squamous-Cell-Carcinoma/default.aspxThu, 03 Jun 2021 17:01:00 -040005694cc2-f652-4cfb-a157-2055b1a94bb0https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Data-at-EULAR-2021-Highlight-Commitment-to-Driving-Advancements-Across-Multiple-Immune-Mediated-Rheumatic-Diseases/default.aspxWed, 02 Jun 2021 06:59:00 -040031844217-10ef-46f7-829b-f0483e8016fchttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-as-First-Line-Treatment-for-Unresectable-Malignant-Pleural-Mesothelioma/default.aspxWed, 02 Jun 2021 06:59:00 -04007a675b1c-ddee-4f72-813e-c85aef5589f8https://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-Approves-Bristol-Myers-Squibbs-Zeposia-ozanimod-an-Oral-Treatment-for-Adults-with-Moderately-to-Severely-Active-Ulcerative-Colitis1/default.aspxThu, 27 May 2021 16:13:00 -04000d61dee9-4b66-47f7-8314-7c0ce827dc2fhttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-to-Take-Part-in-Bernsteins-37th-Annual-Strategic-Decisions-Conference/default.aspxWed, 26 May 2021 06:59:00 -04004f244a4d-f13f-4e27-b40f-8b8202130b9bhttps://news.bms.com/news/details/2021/The-Bristol-Myers-Squibb-Foundation-Announces--First-Global-Cancer-Disparities-Grants-in-Brazil/default.aspxTue, 25 May 2021 08:30:00 -040087428a10-e141-47d8-8fcb-4ad059462d05https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-to-Host-Virtual-Investor-Event-to-Discuss-ASCO-2021-Highlights/default.aspxTue, 25 May 2021 06:59:00 -0400ac2ccfc5-fb22-44c3-8107-b64e44d78475https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Presents-New-Data-at-Digestive-Disease-Week-on-Zeposia-ozanimod-Highlighting-Clinical-Benefits-and-Safety-Profile-in-Patients-with-Ulcerative-Colitis/default.aspxSun, 23 May 2021 11:35:00 -0400b0917b6f-e48c-4a89-aa1b-dfd111a03a1dhttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Opdivo-nivolumab-plus-Yervoy-ipilimumab-for-Treatment-of-Mismatch-Repair-Deficient-or-Microsatellite-InstabilityHigh-Metastatic-Colorectal-Cancer-After-Prior-Chemotherapy/default.aspxFri, 21 May 2021 16:16:00 -04004811eeb2-93db-408b-973a-501c224d723fhttps://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-Approves-Opdivo-nivolumab-as-Adjuvant-Treatment-of-Completely-Resected-Esophageal-or-Gastroesophageal-Junction-Cancer-in-Patients-who-have-Received-Neoadjuvant-Chemoradiotherapy/default.aspxThu, 20 May 2021 13:26:00 -04008085db88-1629-4c21-b7e6-042683c58465https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Elects-Manuel-Hidalgo-Medina-M.D.-Ph.D.-to-Board-of-Directors/default.aspxThu, 20 May 2021 06:59:00 -0400aa6422c4-24ca-4462-a91b-1485329583e7https://news.bms.com/news/details/2021/Long-Term-Data-from-Pivotal-KarMMa-Study-Continue-to-Demonstrate-Deep-and-Durable-Responses-and-Predictable-Safety-Profile-with-Bristol-Myers-Squibb-and-bluebird-bios-Abecma-idecabtagene-vicleucel-in-Relapsed-or-Refractory-Multiple-Myeloma/default.aspxWed, 19 May 2021 17:00:00 -040039e8da98-fad2-4cce-a1c2-6efce6ce5d06https://news.bms.com/news/details/2021/Four-Year-Data-from-Phase-3-CheckMate--227-Trial-Show-Durable-Long-Term-Survival-with-Opdivonivolumab-Plus-Yervoy-ipilimumab-in-Patients-with-Non-Small-Cell-Lung-Cancer-with-PD-L1-Expression-1/default.aspxWed, 19 May 2021 17:00:00 -040060730fbc-20fe-4c7f-b97c-79ca55cf4ccahttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Announces-LAG-3-Blocking-Antibody-Relatlimab-and-Nivolumab-Fixed-Dose-Combination-Significantly-Improves-Progression-Free-Survival-vs.-Opdivo-nivolumab-in-Patients-with-Previously-Untreated-Metastatic-or-Unresectable-Melanoma/default.aspxWed, 19 May 2021 17:00:00 -040046908839-0ccc-457e-88df-c964565f3c1ehttps://news.bms.com/news/details/2021/Six-and-a-Half-Year-Outcomes-for-Opdivo-nivolumab-in-Combination-with-Yervoy-ipilimumab-Continue-to-Demonstrate-Durable-Long-Term-Survival-Benefits-in-Patients-with-Advanced-Melanoma/default.aspxWed, 19 May 2021 17:00:00 -0400e70a5b6a-6af9-4b91-9241-f01deb2a3d80https://news.bms.com/news/details/2021/Opdivo-nivolumab-Plus-Yervoy-ipilimumab-with-Two-Cycles-of-Chemotherapy-Demonstrates-Durable-Overall-Survival-vs.-Chemotherapy-at-Two-Years-in-First-Line-Non-Small-Cell-Lung-Cancer-in-Phase-3-CheckMate--9LA-Trial/default.aspxWed, 19 May 2021 17:00:00 -040024eada26-a1cd-47e7-8f70-5800fbed205bhttps://news.bms.com/news/details/2021/Agenus-and-Bristol-Myers-Squibb-Announce-Exclusive-Global-License---for-Agenus-Anti-TIGIT-Bispecific-Antibody-Program-/default.aspxTue, 18 May 2021 06:59:00 -04007f31c7c7-ed11-4812-a381-d7800d8603bahttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-to-Take-Part-in-UBS-Global-Healthcare-Virtual-Conference/default.aspxTue, 18 May 2021 06:59:00 -04004d95a550-2341-4d2f-aba9-b2e7b356b916https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Presents-Late-Breaking-Phase-3-Data-Demonstrating-Health-Status-Benefits-of-Mavacamten-in-Patients-with-Obstructive-Hypertrophic-Cardiomyopathy-at-American-College-of-Cardiologys-70th-Annual-Scientific-Session/default.aspxSat, 15 May 2021 12:15:00 -0400307149b4-9cac-4dde-b831-fcbfa6cbe9fbhttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Presents-New-Research-at-ASCO-and-EHA-2021-Featuring-Novel-Approaches-and-Demonstrating-Significant-Progress-to-Improve-Survival-in-Cancer-and-Blood-Disorders/default.aspxWed, 12 May 2021 11:43:00 -0400c335798f-edcb-4465-8f47-9584ca9518f4https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-to-Take-Part-in-the-2021-Bank-of-America-Securities-Health-Care-Conference/default.aspxWed, 05 May 2021 06:59:00 -04008586555a-f1f6-4798-8e80-791716854bbehttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Presents-New-Clinical-and-Real-World-Data-on-Mavacamten-and-Obstructive-Hypertrophic-Cardiomyopathy-at-Upcoming-American-College-of-Cardiologys-70th-Annual-Scientific-Session/default.aspxMon, 03 May 2021 09:11:00 -040028783cf5-2dfc-4791-8947-08f795427289https://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-Accepts-for-Priority-Review-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-as-Adjuvant-Treatment-for-Patients-with-Muscle-Invasive-Urothelial-Carcinoma/default.aspxFri, 30 Apr 2021 06:59:00 -040069ac0584-5371-494a-8827-a74911184482https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Statement-on-FDA-Advisory-Committee-Meeting-on-Opdivo-Post-Sorafenib-Hepatocellular-Carcinoma-U.S.-Indication-/default.aspxThu, 29 Apr 2021 20:00:00 -040020651abd-f258-434b-b2d0-f642fce7c9f4https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results-for-2021/default.aspxThu, 29 Apr 2021 06:59:00 -04008f9b0ccd-fa57-4d1f-96f6-cc5e6095be9ehttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-to-Take-Part-in-the-7th-Annual-Truist-Life-Sciences-Summit/default.aspxWed, 28 Apr 2021 06:59:00 -0400f7dadb5e-751c-44b9-bce5-e025d06fa639https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Presents-Positive-Data-from-Two-Pivotal-Phase-3-Psoriasis-Studies-Demonstrating-Superiority-of-Deucravacitinib-Compared-to-Placebo-and-Otezla-apremilast/default.aspxFri, 23 Apr 2021 10:00:00 -04000f58fd4b-c114-4999-bd41-3356f46ec41chttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Onureg-azacitidine-tablets-CC-486-as-Frontline-Oral-Maintenance-Therapy-for-Adults-with-Acute-Myeloid-Leukemia-in-First-Remission/default.aspxFri, 23 Apr 2021 06:51:00 -0400bbfe36b1-6454-4d60-8c5d-38537cd2e16chttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Approval-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-as-First-Line-Treatment-for-Unresectable-Malignant-Pleural-Mesothelioma/default.aspxFri, 23 Apr 2021 06:45:00 -0400590a669d-4d9a-4598-81d4-5b8648eecb7fhttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Invests-in-Europe-with-New-Cell-Therapy-Manufacturing-Site-Planned-in-the-Netherlands/default.aspxThu, 22 Apr 2021 06:59:00 -04003846076b-fe75-4514-9ba7-1d291c088037https://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-Approves-Opdivo-nivolumab-in-Combination-with-Chemotherapy-for-Patients-with-Advanced-or-Metastatic-Gastric-Cancer-Gastroesophageal-Junction-Cancer-and-Esophageal-Adenocarcinoma/default.aspxFri, 16 Apr 2021 13:10:00 -0400218d8eb4-5c99-4170-bb1e-a9fb3e4ecd6dhttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-in-Combination-with-Cabometyx-cabozantinib-as-First-Line-Treatment-for-Patients-with-Advanced-Renal-Cell-Carcinoma/default.aspxWed, 14 Apr 2021 16:16:00 -0400101c39eb-c31f-4ccf-985e-65f77558ca80https://news.bms.com/news/details/2021/Neoadjuvant-Opdivo-nivolumab-Plus-Chemotherapy-Significantly-Improves-Pathologic-Complete-Response-in-Patients-with-Resectable-Non-Small-Cell-Lung-Cancer-in-Phase-3-CheckMate--816-Trial/default.aspxSat, 10 Apr 2021 08:30:00 -04007de07954-e892-478c-9d85-fc1d5dca3579https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Announces-Opdivo-nivolumab-plus-Chemotherapy-and-Opdivo-plus-Yervoy-ipilimumab-Demonstrate-Superior-Survival-Benefit-Compared-to-Chemotherapy-in-Unresectable-Advanced-or-Metastatic-Esophageal-Squamous-Cell-Carcinoma/default.aspxThu, 08 Apr 2021 06:59:00 -040048551296-5a14-4dd2-a6fe-298c3bc97b8chttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-to-Host-Virtual-Investor-Event-to-Discuss-AAD-VMX-Highlights/default.aspxTue, 30 Mar 2021 06:59:00 -0400a4b49786-4d3a-4277-8d3a-b28c6591a8b0https://news.bms.com/news/details/2021/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-as-Adjuvant-Treatment-for-Patients-with-Muscle-Invasive-Urothelial-Carcinoma/default.aspxMon, 29 Mar 2021 06:59:00 -0400dc780661-f0ff-4933-b1c0-295c9b8d39a0https://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-Approves-Bristol-Myers-Squibbs-and-bluebird-bios-Abecma-idecabtagene-vicleucel-the-First-Anti-BCMA-CAR-T-Cell-Therapy-for-Relapsed-or-Refractory-Multiple-Myeloma/default.aspxFri, 26 Mar 2021 22:59:00 -04003358f823-d66d-4cf1-ace1-212c51681bddhttps://news.bms.com/news/details/2021/Japans-Ministry-of-Health-Labour-and-Welfare-Approves-Breyanzi-a-New-CAR-T-Cell-Therapy/default.aspxThu, 25 Mar 2021 18:00:00 -0400afed7833-f3f0-4ba3-b566-3c2d11336fd1https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Announces-RELATIVITY-047-a-Trial-Evaluating-Anti-LAG-3-Antibody-Relatlimab-and-Opdivo-nivolumab-in-Patients-with-Previously-Untreated-Metastatic-or-Unresectable-Melanoma-Meets-Primary-Endpoint-of-Progression-Free-Survival/default.aspxThu, 25 Mar 2021 06:59:00 -040009b4d98d-2149-4859-b30a-d3e2fb55f776https://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-FDA-Accepts-Bristol-Myers-Squibbs-Application-for-Mavacamten-in-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-oHCM/default.aspxFri, 19 Mar 2021 06:59:00 -04004d6946a6-aa1b-4b19-b097-dd679367dbcchttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Statement-on-Opdivo-nivolumab-Hepatocellular-Carcinoma--U.S.-Indication/default.aspxThu, 11 Mar 2021 18:30:00 -050042e0f1bb-da6e-40b4-ab35-cd1dd7ec788chttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-to-Report-Results-for-First-Quarter-2021-on-April-29-2021/default.aspxThu, 11 Mar 2021 06:59:00 -05002cef041a-6824-4e89-aaad-1723454d5fdahttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-to-Participate-in-Barclays-Virtual-Global-Healthcare-Conference/default.aspxTue, 02 Mar 2021 06:59:00 -0500845fe6b4-6b81-4f26-a97d-25be1775f836https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Announces-Dividend/default.aspxMon, 01 Mar 2021 16:16:00 -05004d6ddfeb-6d94-4fe9-9d58-591ec41b776dhttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Opdivo-nivolumab-in-Combination-with-Cabometyx-cabozantinib-as-First-Line-Treatment-for-Patients-with-Advanced-Renal-Cell-Carcinoma/default.aspxFri, 26 Feb 2021 06:25:00 -05009adec4d0-e919-4eea-920e-fd440ac53c1chttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-to-Take-Part-in-the-Cowen-Virtual-41st-Annual-Health-Care-Conference/default.aspxWed, 24 Feb 2021 07:10:00 -050049ccd82b-b74f-404b-8542-33a19ab72f87https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Donates-11-Million-to-Advance-Health-Equity/default.aspxWed, 24 Feb 2021 06:59:00 -0500df975ac3-9704-4f05-a442-271a9111491fhttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-and-the-American-Music-Therapy-Association-Team-Up-with-Ben-Platt-and-Sister-in-Law-Courtney-Platt-to-Launch-MS-in-Harmony-a-First-of-its-Kind-Music-Therapy-Offering-for-People-Living-with-Multiple-Sclerosis-MS/default.aspxTue, 23 Feb 2021 09:00:00 -050009b139a4-8f61-4334-bdb9-fb0b90632100https://news.bms.com/news/details/2021/New-State-of-the-Art-Cell-Therapy-Manufacturing-Facility-Under-Construction-to-Expand-Bristol-Myers-Squibb-Global-Footprint/default.aspxTue, 23 Feb 2021 09:00:00 -0500855de76d-2d2d-4d7c-87d5-79dba46d2183https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-to-Participate-in-Raymond-James-Virtual-42nd-Annual-Institutional-Investors-Conference/default.aspxTue, 23 Feb 2021 06:59:00 -0500f4f026ae-d2b5-4cb7-9eb1-cb65eed081b2https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-and-Celgene-Issue-Notices-of-Redemption-and-Partial-Redemption-of-Certain-of-Their-Senior-Notes-at-Make-Whole-Prices/default.aspxMon, 22 Feb 2021 18:15:00 -0500d9d34908-f032-4360-8d5b-18a8f0427ab2https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Announces-Accepted-Amounts-and-Pricing-Terms-of-Tender-Offers-for-an-Aggregate-Purchase-Price-of-Up-to-4.0-Billion/default.aspxFri, 19 Feb 2021 17:04:00 -05001e800278-1327-4762-9bae-34d99ae40bdahttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Announces-Early-Participation-Results-and-Early-Settlement-of-Tender-Offers-for-Up-to-an-Aggregate-Purchase-Price-of-Up-to-4.0-Billion/default.aspxThu, 18 Feb 2021 21:29:00 -0500e2bd0a42-d494-4ee4-925c-a5b9d5de6ac3https://news.bms.com/news/details/2021/OPDIVO-nivolumab-in-Combination-with-CABOMETYX-cabozantinib-Shows-Sustained-Survival-and-Response-Rate-Benefits-as-First-Line-Treatment-for-Patients-with-Advanced-Renal-Cell-Carcinoma-in-the-Phase-3-CheckMate--9ER-Trial/default.aspxMon, 08 Feb 2021 17:00:00 -050077af300d-9246-47e1-b9d4-aea130a03225https://news.bms.com/news/details/2021/Adjuvant-Treatment-with-Opdivo-nivolumab-Demonstrates-Statistically-Significant-and-Clinically-Meaningful-Improvement-in-Disease-Free-Survival-in-Patients-with-Muscle-Invasive-Urothelial-Carcinoma-in-Phase-3-CheckMate--274-Trial/default.aspxMon, 08 Feb 2021 17:00:00 -05006723a3de-e8a9-4707-87a6-6021a20d0469https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Inrebic-fedratinib-for-Adult-Patients-with-Newly-Diagnosed-and-Previously-Treated-Myelofibrosis/default.aspxMon, 08 Feb 2021 12:12:00 -05004b226d5c-d1b0-402c-bd2b-a3da92826ca9https://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-Approves-Bristol-Myers-Squibbs-Breyanzi-lisocabtagene-maraleucel-a-New-CAR-T-Cell-Therapy-for-Adults-with-Relapsed-or-Refractory-Large-B-cell-Lymphoma/default.aspxFri, 05 Feb 2021 16:39:00 -0500d85da296-de5f-4dad-9fbd-7523588c4c88https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-to-Participate-in-Guggenheims-Virtual-Healthcare-Talks--2021-Oncology-Day/default.aspxFri, 05 Feb 2021 06:59:00 -05003b14f1ee-b5c4-4ae0-bbf6-4366c572f2f4https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2020/default.aspxThu, 04 Feb 2021 06:59:00 -05004094036a-38cf-4f31-bb95-6e105c13a5eahttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Announces-Tender-Offers-for-an-Aggregate-Purchase-Price-of-Up-to-4.0-Billion/default.aspxThu, 04 Feb 2021 06:30:00 -0500281db386-80fc-4465-9e6b-763adac11479https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-and-The-Rockefeller-University-Announce-License-Agreement-for-SARS-CoV-2-Neutralizing-Monoclonal-Antibody-Combination-for-the-Treatment-of-COVID-19/default.aspxWed, 03 Feb 2021 06:59:00 -05002e4247e4-dbb1-4680-85fb-57fd660ee0bfhttps://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Second-Pivotal-Phase-3-Psoriasis-Study-Showing-Superiority-of-Deucravacitinib-Compared-to-Placebo-and-Otezla-apremilast/default.aspxTue, 02 Feb 2021 06:59:00 -050038fd96d2-401d-4ab1-adc5-722ddc3d87ebhttps://news.bms.com/news/details/2021/WuXi-STA-to-Purchase-Bristol-Myers-Squibb-Manufacturing-Facility-in-Couvet-Switzerland/default.aspxTue, 02 Feb 2021 06:59:00 -050028ffbf89-edf4-405f-8573-e1b117a75917https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Application-for-Zeposia-ozanimod-for-the-Treatment-of-Ulcerative-Colitis-Accepted-for-Filing-with-Priority-Review-by-U.S.-Food-and-Drug-Administration/default.aspxMon, 01 Feb 2021 06:59:00 -0500cb140ae8-a892-4754-8095-188d5644c887https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Donates-JPY-5.5-Billion-to-Kyoto-University--to-Support-Its-Cancer-Research/default.aspxTue, 26 Jan 2021 15:00:00 -05005337a8cf-663a-43d1-bcee-d9ca046fa713https://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-Approves-OPDIVO-nivolumab-in-Combination-with-CABOMETYX-cabozantinib-as-First-line-Treatment-for-Patients-with-Advanced-Renal-Cell-Carcinoma/default.aspxFri, 22 Jan 2021 13:18:00 -05002be3f5ff-1182-4b29-aded-50f1ab7758f5https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Announces-Earnings-Call-Time-Change-Fourth-Quarter-2020-Earnings-Call-to-Occur-on-February-4-2021-at-10-a.m.-Eastern-Time/default.aspxThu, 21 Jan 2021 06:59:00 -05002ce18501-bcee-4ee8-ae49-086f69037578https://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-Accepts-for-Priority-Review-Application-for-Opdivo-nivolumab-as-Adjuvant-Therapy-for-Patients-with-Resected-Esophageal-or-Gastroesophageal-Junction-Cancer/default.aspxWed, 20 Jan 2021 06:59:00 -0500a3dac21e-3d95-4447-bdf2-a9d731be9cdchttps://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-Accepts-for-Priority-Review-Application-for-Opdivo-nivolumab-Combined-with-Chemotherapy-as-First-Line-Treatment-in-Metastatic-Gastric-Cancer-Gastroesophageal-Junction-Cancer-and-Esophageal-Adenocarcinoma/default.aspxWed, 20 Jan 2021 06:59:00 -05009f66ac7a-709d-4008-8741-4a926f511af0https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Announces-2-Billion-Incremental-Share-Repurchase-Authorization/default.aspxMon, 11 Jan 2021 06:59:00 -050001835175-92b3-4068-963c-10f86f3c73b8https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-to-Present-at-J.P.-Morgans-39th-Annual-Virtual-Healthcare-Conference/default.aspxMon, 04 Jan 2021 06:59:00 -0500577f6fe6-5efd-4ad9-a83e-3b9da2777c49https://news.bms.com/news/details/2021/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-as-Adjuvant-Treatment-for-Resected-Esophageal-or-Gastroesophageal-Junction-Cancer-Following-Chemoradiotherapy/default.aspxMon, 04 Jan 2021 06:59:00 -05001e9b3435-748d-4ccc-97f9-8b7c1f7d0cb6https://news.bms.com/news/details/2021/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-Combined-with-Chemotherapy-as-First-Line-Treatment-in-Metastatic-Gastric-Cancer-Gastroesophageal-Junction-Cancer-and-Esophageal-Adenocarcinoma/default.aspxMon, 04 Jan 2021 06:59:00 -0500cd4c4438-35a5-42eb-b9f1-758ee3300077https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Provides-Update-on-Status-of-Contingent-Value-Rights/default.aspxFri, 01 Jan 2021 06:59:00 -050066dec970-5329-427c-9629-31f315f13647https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Statement-on-Status-of-Liso-cel-Application-and-Contingent-Value-Rights/default.aspxFri, 01 Jan 2021 06:58:00 -05001128f7e6-1696-4205-8955-e3deb397cf8bhttps://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Statement-on-Opdivo-nivolumab-Small-Cell-Lung-Cancer-US-Indication/default.aspxTue, 29 Dec 2020 18:00:00 -0500fcf269dd-4def-477f-828f-292b030eec11https://news.bms.com/news/details/2020/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Application-for-Zeposia-ozanimod-for-the-Treatment-of-Ulcerative-Colitis/default.aspxMon, 28 Dec 2020 06:59:00 -05005701cec9-1100-441c-9856-ea1b4ac645d9https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Announces-Update-on-Phase-3-CheckMate--548-Trial-Evaluating-Patients-with-Newly-Diagnosed-MGMT-Methylated-Glioblastoma-Multiforme/default.aspxWed, 23 Dec 2020 06:59:00 -0500f99c4e5a-3b78-4a95-8e38-dc3e0d80c796https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Announce-Results-for-Fourth-Quarter-2020-on-February-4-2021/default.aspxMon, 21 Dec 2020 06:59:00 -05007f13c036-97fb-4619-96ea-2eadfb34e1dahttps://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Strengthens-its-Commitment-to-the-Environment-with-New-Corporate-Goals/default.aspxWed, 16 Dec 2020 06:59:00 -05009d02690a-31c9-423a-8c1b-0830a4571d91https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Inrebic-fedratinib-for-Adult-Patients-with-Newly-Diagnosed-and-Previously-Treated-Myelofibrosis/default.aspxFri, 11 Dec 2020 07:15:00 -050026247290-c497-4492-adca-1580e330b682https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Announces-Settlement-of-U.S.-Patent-Litigation-for-REVLIMID-lenalidomide-with-Cipla/default.aspxFri, 11 Dec 2020 06:59:00 -0500b252f7bb-76ae-467a-88a0-0675b166ab70https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Announces-Dividend-Increase/default.aspxThu, 10 Dec 2020 16:16:00 -0500c1dafc2c-d4a9-4361-8495-0f5366f0b557https://news.bms.com/news/details/2020/Scripps-Research-Names-Jin-Quan-Yu-to-Newly-Endowed-Bristol-Myers-Squibb-Chair-in-Chemistry/default.aspxTue, 08 Dec 2020 06:59:00 -05006fa9e38c-9624-479a-8d27-0df2737e3330https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Presents-Analyses-from-Pivotal-QUAZAR-AML-001-Study-of-Onureg-azacitidine-tablets-CC-486-in-Adults-with-Acute-Myeloid-Leukemia-in-First-Remission/default.aspxMon, 07 Dec 2020 16:30:00 -050028069e9d-fcd8-43a6-8055-831dc1d5b206https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Presents-Data-Evaluating-Potential-of-Liso-cel-Across-Leukemia-and-Lymphomas-at-ASH-2020/default.aspxMon, 07 Dec 2020 10:00:00 -0500048164a8-c101-41c0-8912-1f3684890172https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-and-bluebird-bio-Present-Data-Highlighting-Anti-BCMA-CAR-T-Cell-Therapy-Ide-cel-in-Relapsed-and-Refractory-Multiple-Myeloma-at-ASH-2020/default.aspxSat, 05 Dec 2020 12:30:00 -0500715c95c6-4839-450d-8e15-9e1141aa9c5ehttps://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-as-Second-Line-Treatment-for-Unresectable-Advanced-Recurrent-or-Metastatic-Esophageal-Squamous-Cell-Carcinoma/default.aspxTue, 24 Nov 2020 06:59:00 -05000c7474ff-1153-4fb1-9335-8418da3a7e50https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Completes-Acquisition-of-MyoKardia-Strengthening-Companys-Leading-Cardiovascular-Franchise/default.aspxTue, 17 Nov 2020 08:30:00 -0500ab5c3383-c931-494f-8636-d91d3f293948https://news.bms.com/news/details/2020/The-Bristol-Myers-Squibb-Foundation-and-National-Medical-Fellowships-Launch-100-Million-Program-to-Help-Increase-Diversity-and-Inclusion-in-Clinical-Trials/default.aspxTue, 17 Nov 2020 06:59:00 -0500e83f092b-c066-4ab8-8893-5f6edf7745a1https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Provides-Regulatory-Update-on-Lisocabtagene-Maraleucel-liso-cel/default.aspxMon, 16 Nov 2020 16:21:00 -0500ca555b7b-872f-4756-be50-bb9bb8895b2chttps://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Participate-in-Wolfe-Researchs-2nd-Annual-Virtual-Healthcare-Conference/default.aspxWed, 11 Nov 2020 16:15:00 -05006787962a-8230-44ca-8e8b-39efcd3d3745https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Showcases-Research-Advancing-Outcomes-Addressing-Hard-to-Treat-Blood-Cancers-and-Diseases-Across-Small-Molecule-Biologic-and-Cell-Therapies-at-ASH-2020/default.aspxWed, 11 Nov 2020 06:59:00 -0500af73e659-0f4d-49ef-b6c3-0c2a410f530bhttps://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Prices-7-Billion-of-Senior-Unsecured-Notes/default.aspxMon, 09 Nov 2020 19:27:00 -0500e13f590e-4e83-4d0f-a7dc-143ccede2c1dhttps://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Presents-Late-Breaking-Phase-2-Data-Demonstrating-the-Safety-and-Efficacy-of-Deucravacitinib-BMS-986165-in-Patients-with-Psoriatic-Arthritis/default.aspxMon, 09 Nov 2020 06:59:00 -05006bc1f3ae-9c4d-4413-bb05-30f36a3525e0https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-plus-Yervoy-ipilimumab-with-Two-Cycles-of-Chemotherapy-for-First-Line-Treatment-of-Metastatic-Non-Small-Cell-Lung-Cancer/default.aspxFri, 06 Nov 2020 06:59:00 -0500b1cb6692-b5b3-47ad-9487-ab28e1d88784https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Data-at-ACR-Convergence-2020-Underscore-Commitment-to-Advancing-Science-for-Patients-with-Difficult-to-Treat-Immune-Mediated-Diseases/default.aspxThu, 05 Nov 2020 07:01:00 -0500b9267149-6e71-484d-b072-a0adbe5ef45ehttps://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Reports-Third-Quarter-2020-Financial-Results/default.aspxThu, 05 Nov 2020 06:59:00 -0500723a862f-d8ee-4e91-a4dd-f09b309e53b1https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-and-MyoKardia-Announce-Expiration-of-HSR-Act-Waiting-Period/default.aspxWed, 04 Nov 2020 06:59:00 -0500a3407824-2fe9-426f-8214-c13121480d60https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Announces-Deucravacitinib-BMS-986165-Demonstrated-Superiority-to-Placebo-and-Otezla-apremilast-in-Pivotal-Phase-3-Psoriasis-Study/default.aspxTue, 03 Nov 2020 06:59:00 -05005e41d964-ec65-460d-b011-d21f9771804ehttps://news.bms.com/news/details/2020/New-Report-Identifies-Need-for-More-Effective-Policy-Responses-and-Investment-to-Prevent-Strokes-in-Europe/default.aspxThu, 29 Oct 2020 08:00:00 -04002c87b402-b705-40ad-9e6f-e7efd6eb5989https://news.bms.com/news/details/2020/Decreases-in-Americans-Primary-Care-Visits-May-Lead-to-Late-Diagnoses-of-Potentially-Serious-Conditions/default.aspxMon, 26 Oct 2020 08:00:00 -0400aef0a72b-02e9-4c14-886f-babb4da6b23bhttps://news.bms.com/news/details/2020/U.S.-Food-and-Drug-Administration-Accepts-for-Priority-Review-Applications-for-OPDIVO-nivolumab-in-Combination-with-CABOMETYX-cabozantinib-in-Advanced-Renal-Cell-Carcinoma/default.aspxMon, 19 Oct 2020 06:59:00 -0400dbd403eb-d6ad-44df-8b2d-84b6fe459dcahttps://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Opdivo-nivolumab-as-Second-Line-Treatment-for-Unresectable-Advanced-Recurrent-or-Metastatic-Esophageal-Squamous-Cell-Carcinoma/default.aspxFri, 16 Oct 2020 07:45:00 -0400d273f08e-65b0-44c8-b377-e06df982be22https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Presents-Positive-Late-Breaking-Data-from-Phase-3-True-North-Trial-Evaluating-Zeposia-ozanimod-in-Adult-Patients-with-Moderate-to-Severe-Ulcerative-Colitis/default.aspxSat, 10 Oct 2020 18:06:00 -040001052e3c-401b-45fc-a95f-9c008ec1c7e5https://news.bms.com/news/details/2020/Opdivo-nivolumab-Plus-Chemotherapy-Shows-Statistically-Significant-Improvement-in-Pathologic-Complete-Response-as-Neoadjuvant-Treatment-of-Resectable-Non-Small-Cell-Lung-Cancer-in-Phase-3-CheckMate--816-Trial/default.aspxWed, 07 Oct 2020 06:59:00 -0400cada6430-3d28-4dd3-88b7-1ed6d4a368e8https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Acquire-MyoKardia-for-13.1-Billion-in-Cash/default.aspxMon, 05 Oct 2020 06:30:00 -04005717736a-133a-45e3-853d-2eb8af69673ahttps://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Announces-Update-on-CheckMate--915-Evaluating-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Versus-Opdivo-in-Resected-High-Risk-Melanoma-Patients/default.aspxFri, 02 Oct 2020 16:17:00 -04008e537494-1622-488e-bf27-c0147b1a2b39https://news.bms.com/news/details/2020/U.S.-Food-and-Drug-Administration-Approves-Opdivo-nivolumab--Yervoy-ipilimumab-as-the-First-and-Only-Immunotherapy-Treatment-for-Previously-Untreated-Unresectable-Malignant-Pleural-Mesothelioma/default.aspxFri, 02 Oct 2020 16:12:00 -04003eb79bd8-21a6-41d9-9ecc-ba88cc380e83https://news.bms.com/news/details/2020/UNCF-Bristol-Myers-Squibb-Announce-Second-Cohort-of-the-Ernest-E.-Just-Postgraduate-Fellowship-and-Extension-of-Partnership-Through-2026/default.aspxFri, 02 Oct 2020 06:59:00 -0400455bb53d-e183-449c-a337-c7c232b8b9e6https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Host-Virtual-Investor-Event-to-Discuss-Results-from-Phase-3-True-North-Trial-Evaluating-Zeposia-ozanimod-in-Ulcerative-Colitis-at-UEG-Week-2020/default.aspxFri, 02 Oct 2020 06:59:00 -040009e0f1ce-a740-463f-a27f-077fdb03835fhttps://news.bms.com/news/details/2020/19-Organizations-from-the-Healthcare-Community-Unite-to-Form-COVID-19-Testing-Industry-Consortium/default.aspxThu, 01 Oct 2020 08:00:00 -0400b4bb00c3-9c96-492b-874e-f4286c0c04e4https://news.bms.com/news/details/2020/Opdivo-nivolumab-Significantly-Improves-Disease-Free-Survival-vs.-Placebo-as-Adjuvant-Therapy-for-Patients-with-High-Risk-Muscle-Invasive-Urothelial-Carcinoma-in-Phase-3-CheckMate--274-Trial/default.aspxThu, 24 Sep 2020 16:15:00 -0400715d03d4-fac9-41cd-b238-c953cf6a42b5https://news.bms.com/news/details/2020/U.S.-Food-and-Drug-Administration-FDA-Accepts-for-Priority-Review-Bristol-Myers-Squibb-and-bluebird-bio-Application-for-Anti-BCMA-CAR-T-Cell-Therapy-Idecabtagene-Vicleucel-Ide-cel-bb2121/default.aspxTue, 22 Sep 2020 06:59:00 -0400d7e9330a-0642-4673-a93a-135c5ca32022https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Completes-Acquisition-of-Forbius/default.aspxMon, 21 Sep 2020 16:16:00 -04009ae57ea0-4c8b-4af4-ac3b-0da7d2b49448https://news.bms.com/news/details/2020/Opdivo-nivolumab-Demonstrated-Superior-Disease-Free-Survival-in-Patients-with-Resected-Esophageal-or-Gastroesophageal-Junction-Cancer-Compared-to-Placebo-in-the-Adjuvant-Setting/default.aspxMon, 21 Sep 2020 12:31:00 -04003aaebbd2-8f7f-4a26-8b11-3a95cb592d2dhttps://news.bms.com/news/details/2020/Opdivo-nivolumab-Plus-Chemotherapy-Demonstrated-Significant-Overall-and-Progression-Free-Survival-Benefits-Versus-Chemotherapy-in-First-Line-Treatment-of-Gastric-and-Esophageal-Cancers/default.aspxMon, 21 Sep 2020 12:30:00 -0400ae05c953-2df6-4eac-b352-e1fcfbc65d25https://news.bms.com/news/details/2020/Opdivo-nivolumab-in-Combination-with-CABOMETYX-cabozantinib-Demonstrates-Significant-Survival-Benefits-in-Patients-with-Advanced-Renal-Cell-Carcinoma-in-Pivotal-Phase-3-CheckMate--9ER-Trial/default.aspxSat, 19 Sep 2020 12:30:00 -04000cabac9c-87d2-48d6-8cf1-37f3bccfe7e5https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Approval-of-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Combined-with-Two-Cycles-of-Chemotherapy-as-First-Line-Treatment-of-Metastatic-Non-Small-Cell-Lung-Cancer/default.aspxFri, 18 Sep 2020 07:17:00 -04006201dc7c-c96f-4250-917d-9ae1a23d223chttps://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Announce-Results-for-Third-Quarter-2020-on-November-5-2020/default.aspxThu, 17 Sep 2020 16:16:00 -040071fbd3c3-3d9c-4b2b-bdce-54cac5180fedhttps://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Announces-Settlement-of-U.S.-Patent-Litigation-for-REVLIMID-lenalidomide-With-Dr.-Reddys/default.aspxThu, 17 Sep 2020 06:59:00 -04006f229c9d-8d2d-4846-8b8b-afc7d7fa928fhttps://news.bms.com/news/details/2020/Four-Year-Data-Continue-to-Show-Superior-Long-Term-Survival-Benefit-with-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-in-Patients-with-Previously-Untreated-Advanced-or-Metastatic-Renal-Cell-Carcinoma/default.aspxThu, 17 Sep 2020 06:15:00 -04001b534970-11ca-45dd-a815-7ed8e36aad00https://news.bms.com/news/details/2020/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Type-II-Variation-Application-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-for-First-line-Treatment-of-Malignant-Pleural-Mesothelioma/default.aspxTue, 15 Sep 2020 06:59:00 -040037454163-fae4-4d70-ab99-58f5d04b06a8https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Announces-Quarterly-Dividend-for-Third-Quarter-2020/default.aspxThu, 10 Sep 2020 16:15:00 -04009ba45ae3-95fa-473a-b9f5-c23e73cee5d0https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Participate-in-Morgan-Stanleys-18th-Annual-Global-Healthcare-Virtual-Conference/default.aspxThu, 10 Sep 2020 06:59:00 -0400a4595f90-b809-4223-9fcb-d17afdfdcfd7https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Research-at-ESMO-Virtual-Congress-2020-Highlights-Significant-Progress-in-Cancers-with-High-Unmet-Medical-Need/default.aspxTue, 08 Sep 2020 06:59:00 -04005e0990a1-7bf5-41e4-8c05-ddf31a495fa4https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Participate-in-Citis-15th-Annual-BioPharma-Virtual-Conference/default.aspxWed, 02 Sep 2020 06:59:00 -0400074665a6-400f-4b23-a89e-c946c60778behttps://news.bms.com/news/details/2020/U.S.-Food-and-Drug-Administration-Approves-Onureg-azacitidine-tablets-a-New-Oral-Therapy-as-Continued-Treatment-for-Adults-in-First-Remission-with-Acute-Myeloid-Leukemia/default.aspxTue, 01 Sep 2020 12:50:00 -04002afcce40-331d-47fb-82ba-a868fc71dd37https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Announces-Interim-Results-from-Long-Term-Study-Reinforcing-Efficacy-and-Safety-Profile-of-Zeposia-ozanimod-in-Patients-with-Relapsing-Forms-of-Multiple-Sclerosis/default.aspxTue, 01 Sep 2020 09:00:00 -040038f37942-9ff1-4db0-a5d5-b06c201900e1https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Provides-Update-on-Phase-3-IDHENTIFY-Trial-in-Patients-with-Relapsed-or-Refractory-Acute-Myeloid-Leukemia/default.aspxTue, 25 Aug 2020 06:59:00 -0400153439ed-b9b4-4872-aec4-c0a2475cd84bhttps://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Enters-Agreement-to-Acquire-Forbius-Adding-Lead-TGF-beta-Asset-to-Portfolio/default.aspxMon, 24 Aug 2020 06:59:00 -0400ca0e65f0-0045-43a7-9da8-7c70449401f2https://news.bms.com/news/details/2020/Dragonfly-Therapeutics-and-Bristol-Myers-Squibb-Announce-Exclusive-Global-License-for-Dragonflys-IL-12-Investigational-Immunotherapy-Program/default.aspxMon, 17 Aug 2020 06:59:00 -0400d1047fbc-6092-4dbb-95b1-0509d8ffb4b8https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-and-the-Bristol-Myers-Squibb-Foundation-Commit-300-Million-to-Accelerate-and-Expand-Health-Equity-and-Diversity-and-Inclusion-Efforts/default.aspxWed, 12 Aug 2020 06:59:00 -04004f91495f-968b-4ac0-b738-27bc65019df7https://news.bms.com/news/details/2020/CheckMate--577-a-Phase-3-Trial-Evaluating-Opdivo-nivolumab-as-Adjuvant-Therapy-for-Patients-with-Resected-Esophageal-or-Gastroesophageal-Junction-Cancer-Meets-Primary-Endpoint-of-Disease-Free-Survival/default.aspxTue, 11 Aug 2020 06:59:00 -04007b8d91d4-4cb3-4a49-bb49-ed0d5f48dab7https://news.bms.com/news/details/2020/CheckMate--649-a-Phase-3-Trial-Evaluating-Opdivo-nivolumab-Plus-Chemotherapy-vs.-Chemotherapy-Meets-Primary-Endpoints-Demonstrating-Superior-Overall-Survival-and-Progression-Free-Survival-in-First-Line-Treatment-of-Gastric-and-Esophageal-Cancers/default.aspxTue, 11 Aug 2020 06:59:00 -0400e5c42249-fdf5-44ea-ae1a-f4fedf4f5466https://news.bms.com/news/details/2020/Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Demonstrates-Durable-Survival-Benefit-vs.-Chemotherapy-in-Patients-with-Previously-Untreated-Malignant-Pleural-Mesothelioma/default.aspxSat, 08 Aug 2020 07:00:00 -04001e6c9c7f-bb99-4158-be3d-5922cb790f66https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Reports-Second-Quarter-2020-Financial-Results/default.aspxThu, 06 Aug 2020 06:59:00 -0400a51bcf0d-c540-4d84-9f65-307b7bcbdacdhttps://news.bms.com/news/details/2020/The-Bristol-Myers-Squibb-Pfizer-Alliance-is-pleased-with-the-U.S.-District-Court-decision-to-uphold-both-the-composition-of-matter-COM-patent-US-6967208-and-formulation-patent-US-9326945-covering-Eliquis/default.aspxWed, 05 Aug 2020 18:00:00 -0400f01be1d3-9a7b-4ca4-852a-0aaef3e2b257https://news.bms.com/news/details/2020/Updated-Statement-Bristol-Myers-Squibb-on-Coronavirus-COVID-19-1/default.aspxTue, 04 Aug 2020 14:00:00 -0400469645e5-1a73-4c6a-9320-607b5ee0482dhttps://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Board-Elects-Two-New-Independent-Directors/default.aspxThu, 30 Jul 2020 06:59:00 -04009654a4ca-34ae-4ed7-ab04-aa680b3b6139https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-and-bluebird-bio-Announce-Submission-of-Biologics-License-Application-BLA-to-FDA-for-Idecabtagene-Vicleucel-Ide-cel-bb2121-for-Adults-with-Relapsed-and-Refractory-Multiple-Myeloma/default.aspxWed, 29 Jul 2020 16:16:00 -04000d7101d7-32db-4b36-a907-11cf389f6c08https://news.bms.com/news/details/2020/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Application-for-CAR-T-Cell-Therapy-Lisocabtagene-Maraleucel-liso-cel/default.aspxFri, 17 Jul 2020 06:59:00 -040065fb8389-fa85-4e5b-ae9d-3251844f4a72https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Announces-Expiration-and-Final-Results-of-Registered-Exchange-Offers/default.aspxThu, 16 Jul 2020 06:59:00 -0400abf54f9d-cdab-4bf4-871c-2d72568574b5https://news.bms.com/news/details/2020/European-Commission-Approves-Reblozyl-luspatercept-for-the-Treatment-of-Transfusion-Dependent-Anemia-in-Adult-Patients-with-Myelodysplastic-Syndromes-or-Beta-Thalassemia/default.aspxFri, 26 Jun 2020 09:05:00 -0400a8417af2-d2a6-43dd-b3a7-23fc0846092chttps://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Announce-Results-for-Second-Quarter-2020-on-August-6-2020/default.aspxThu, 18 Jun 2020 06:59:00 -04003bc3c99f-12dc-40f1-b6ac-644c07eea725https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Announces-Commencement-of-Registered-Exchange-Offers/default.aspxTue, 16 Jun 2020 06:59:00 -040044934e2e-6df0-41b1-8624-8f0d0e0db711https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Announces-Dividend/default.aspxThu, 11 Jun 2020 16:15:00 -0400a254fe91-369a-45a8-be3d-2d0ccd7a1aedhttps://news.bms.com/news/details/2020/US-Food-and-Drug-Administration-Approves-Opdivo-nivolumab-for-the-Treatment-of-Patients-with-Advanced-Esophageal-Squamous-Cell-Carcinoma-ESCC-After-Prior-Fluoropyrimidine--and-Platinum-based-Chemotherapy/default.aspxWed, 10 Jun 2020 19:52:00 -04004a97c9b3-8f20-4dcb-ba77-c3c9328890d6https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Take-Part-in-41st-Annual-Goldman-Sachs-Global-Healthcare-Conference/default.aspxThu, 04 Jun 2020 06:59:00 -04002febbfe3-7ce1-473d-baef-38acc0f990fbhttps://news.bms.com/news/details/2020/New-Data-Reinforce-Improved-and-Durable-Clinical-Responses-of-Orencia-in-Moderate-to-Severe-Early-Rheumatoid-Arthritis-Patients-with-Autoantibodies-Linked-to-More-Severe-Disease/default.aspxWed, 03 Jun 2020 06:59:00 -04009c9e3246-7f96-4af7-b72d-f0e1d7d1e7b1https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Pivotal-Phase-3-True-North-Trial-Evaluating-Zeposia-ozanimod-in-Patients-with-Moderate-to-Severe-Ulcerative-Colitis/default.aspxTue, 02 Jun 2020 06:59:00 -04004ff2cbc6-4d40-4e71-9c46-ca2c8cf94881https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Announces-Commercial-Launch-and-Availability-of-ZEPOSIA-ozanimod-a-New-Oral-Treatment-for-Relapsing-Forms-of-Multiple-Sclerosis/default.aspxMon, 01 Jun 2020 06:59:00 -04000b790ec8-f6f0-4add-8809-47ef3de8e680https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Hold-Virtual-Three-Part-Investor-Series/default.aspxFri, 29 May 2020 06:59:00 -0400ceee00ea-3a34-467f-945b-550f045f3962https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Zeposia-ozanimod-for-the-Treatment-of-Adult-Patients-with-Relapsing-Remitting-Multiple-Sclerosis-with-Active-Disease/default.aspxWed, 27 May 2020 06:59:00 -0400eace9e0f-4be9-4461-8105-d2d27ccc5b77https://news.bms.com/news/details/2020/US-Food-and-Drug-Administration-Approves-Opdivo-nivolumab--Yervoy-ipilimumab-Combined-with-Limited-Chemotherapy-as-First-Line-Treatment-of-Metastatic-or-Recurrent-Non-Small-Cell-Lung-Cancer/default.aspxTue, 26 May 2020 17:48:00 -04007137fa64-31cb-46ac-9c1b-390ebb816b90https://news.bms.com/news/details/2020/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Applications-for-Idecabtagene-Vicleucel-Ide-cel-bb2121-and-CC-486/default.aspxFri, 22 May 2020 06:59:00 -04006b4a9d21-cc2f-4b20-8bbd-3fb44c89ce4bhttps://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Research-at-EHA-2020-Demonstrates-Continued-Advances-Across-Multiple-Blood-Diseases/default.aspxWed, 20 May 2020 06:59:00 -04000cae4e6d-b4fa-430a-b207-acbdcc936be5https://news.bms.com/news/details/2020/US-Food-and-Drug-Administration-Approves-Opdivo-nivolumab--Yervoy-ipilimumab-as-First-Line-Treatment-of-Patients-with-Metastatic-Non-Small-Cell-Lung-Cancer-Whose-Tumors-Express-PD-L11/default.aspxFri, 15 May 2020 15:56:00 -0400c6c806ae-a42a-4eba-be74-a5c8b69fbc77https://news.bms.com/news/details/2020/US-Food-and-Drug-Administration-Approves-Bristol-Myers-Squibbs-Pomalyst-pomalidomide-for-AIDS-Related-and-HIV-Negative-Kaposi-Sarcoma/default.aspxFri, 15 May 2020 08:53:00 -040037eedb92-b73b-402a-ac36-1158b1c3976ehttps://news.bms.com/news/details/2020/Bristol-Myers-Squibb-and-bluebird-bio-to-Present-Updated-Positive-Results-from-Pivotal-KarMMa-Study-of-Ide-cel-in-Relapsed-and-Refractory-Multiple-Myeloma-Patients-at-ASCO20/default.aspxWed, 13 May 2020 17:00:00 -0400b670e660-6ed5-4ced-b795-aef96a60174ehttps://news.bms.com/news/details/2020/Opdivo-nivolumab-Plus-Yervoy-ipilimumab-with-Limited-Chemotherapy-Significantly-Improves-Overall-Survival-vs-Chemotherapy-Alone-for-Patients-with-First-Line-Metastatic-Non-Small-Cell-Lung-Cancer-in-CheckMate--9LA-Study/default.aspxWed, 13 May 2020 17:00:00 -04001ea096fe-20e0-46af-a467-b8f6877417e7https://news.bms.com/news/details/2020/Three-Year-Data-from-CheckMate--227-Confirm-Durable-Long-Term-Survival-Benefit-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-vs-Chemotherapy-in-Metastatic-First-Line-Non-Small-Cell-Lung-Cancer-Patients-with-PD-L1-1/default.aspxWed, 13 May 2020 17:00:00 -0400a5e17bc7-9ada-4738-bca1-5bc7ae0046b8https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-and-bluebird-bio-Provide-Regulatory-Update-on-Idecabtagene-Vicleucel-ide-cel-bb2121-for-the-Treatment-of-Patients-with-Multiple-Myeloma/default.aspxWed, 13 May 2020 06:59:00 -0400a2a43090-c1fb-49a0-a0b5-236aaf3c9c91https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Take-Part-in-the-UBS-Virtual-Global-Healthcare-Conference/default.aspxTue, 12 May 2020 06:59:00 -04009452bbea-4fac-4d69-ad06-6dc3b0e3ec85https://news.bms.com/news/details/2020/GRYT-Health-and-Bristol-Myers-Squibb-Team-Up-to-Launch-COVID-Advocacy-Exchange-for-Patient-Advocates/default.aspxTue, 12 May 2020 06:58:00 -0400880adb95-729e-481b-b07f-18a4d29cb649https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Research-at-ASCO-Demonstrates-Diverse-Approaches-in-Treating-Cancer-to-Improve-Outcomes-for-Patients/default.aspxMon, 11 May 2020 06:59:00 -0400f83d5697-b0ec-4315-b26b-2c6e2702a4d1https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Reports-Strong-First-Quarter-2020-Financial-Results/default.aspxThu, 07 May 2020 06:59:00 -040046e8f08e-7f3b-4e40-8ff9-1842cc00b1ebhttps://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Provides-Update-on-Biologics-License-Application-BLA-for-Lisocabtagene-Maraleucel-liso-cel/default.aspxWed, 06 May 2020 06:59:00 -04002c9d1811-bd5b-4cf3-84c7-c15973112164https://news.bms.com/news/details/2020/Maintaining-Our-Focus-on-Patients-People-and-Science/default.aspxTue, 05 May 2020 07:00:00 -040099d03141-c4b3-4bff-89c3-89fbbd8bc22fhttps://news.bms.com/news/details/2020/US-Food-and-Drug-Administration-FDA-Accepts-for-Priority-Review-Bristol-Myers-Squibbs-Application-for-CC-486-for-Maintenance-Treatment-of-Adult-Patients-in-Remission-with-Acute-Myeloid-Leukemia/default.aspxFri, 01 May 2020 06:59:00 -040028e8a5c0-2e18-47f6-b476-b9f51aa6ebb6https://news.bms.com/news/details/2020/Reblozyl-luspatercept-Receives-Positive-CHMP-Opinion-for-the-Treatment-of-Adults-with-Anemia-in-Beta-Thalassemia-and-Myelodysplastic-Syndromes/default.aspxThu, 30 Apr 2020 16:16:00 -0400dcdfd690-a108-4edd-8e92-16603b9de457https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Announces-Positive-Topline-Result-from-Pivotal-Phase-3-Trial-Evaluating-Opdivo-nivolumab-plus-Yervoy-ipilimumab-vs-Chemotherapy-in-Previously-Untreated-Malignant-Pleural-Mesothelioma/default.aspxMon, 20 Apr 2020 06:59:00 -04000414ac4f-0622-4633-9b24-9ceb7b3e606chttps://news.bms.com/news/details/2020/Bristol-Myers-Squibb-and-Exelixis-Announce-Positive-Topline-Results-from-Pivotal-Phase-3-CheckMate--9ER-Trial-Evaluating-Opdivo-nivolumab-in-Combination-with-CABOMETYX-cabozantinib-in-Previously-Untreated-Advanced-Renal-Cell-Carcinoma/default.aspxMon, 20 Apr 2020 06:59:00 -0400239e3e43-c562-41d2-afaf-5256bd0eb63bhttps://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Announces-Virtual-2020-Annual-Meeting-of-Shareholders/default.aspxTue, 14 Apr 2020 16:16:00 -0400b7dceb15-b518-4602-be2a-6cced819e9a2https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Announces-Acceptance-of-US-and-EU-Regulatory-Filings-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Combined-with-Limited-Chemotherapy-in-First-Line-Lung-Cancer/default.aspxWed, 08 Apr 2020 06:59:00 -04002f160b6b-32a4-43ac-89b9-e0fa67ece157https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Expands-Patient-Support-Programs-to-Help-Newly-Uninsured-Patients-in-the-US/default.aspxTue, 07 Apr 2020 06:59:00 -0400e01e71c4-314f-45d2-b9dc-1ef63a29c7fbhttps://news.bms.com/news/details/2020/US-Food-and-Drug-Administration-FDA-Approves-Reblozyl-luspatercept-aamt-the-First-and-Only-Erythroid-Maturation-Agent-to-Treat-Anemia-in-Adults-with-Lower-Risk-Myelodysplastic-Syndromes-MDS/default.aspxFri, 03 Apr 2020 17:08:00 -04004bfc33b9-5815-4586-94ea-e28b91a3b450https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-and-bluebird-bio-Announce-Submission-of-Biologics-License-Application-BLA-for-Anti-BCMA-CAR-T-Cell-Therapy-Idecabtagene-Vicleucel-Ide-cel-bb2121-to-FDA/default.aspxTue, 31 Mar 2020 06:59:00 -0400faa370c0-d67a-4908-a155-ec7936ab4f4bhttps://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Approval-of-ZEPOSIA-ozanimod-for-the-Treatment-of-Adult-Patients-with-Relapsing-Remitting-Multiple-Sclerosis-with-Active-Disease/default.aspxFri, 27 Mar 2020 12:05:00 -04008cba2b44-7623-43b6-be35-04a2b2421c5ahttps://news.bms.com/news/details/2020/New-England-Journal-of-Medicine-Publishes-Results-from-Pivotal-Phase-3-BELIEVE-Trial-of-Reblozyl-luspatercept-aamt-in-Adult-Patients-With-Beta-Thalassemia/default.aspxThu, 26 Mar 2020 07:59:00 -04004a9b68cc-9061-4f19-97ac-3df66e258db5https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Announce-Results-for-First-Quarter-2020-on-May-7-2020/default.aspxThu, 26 Mar 2020 07:58:00 -040048e2559d-f9de-4308-a57a-3cfa2a959574https://news.bms.com/news/details/2020/US-Food-and-Drug-Administration-Approves-Bristol-Myers-Squibbs-ZEPOSIA-ozanimod-a-New-Oral-Treatment-for-Relapsing-Forms-of-Multiple-Sclerosis/default.aspxThu, 26 Mar 2020 07:30:00 -0400a07e5e6f-4e20-4404-965b-4c3bda8ec9f6https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Postpones-April-2-2020-Investor-Day/default.aspxMon, 23 Mar 2020 07:59:00 -040000b58cb2-84d9-4454-9543-e04a355a859bhttps://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Appoints-Elizabeth-Mily-as-Executive-Vice-President-Strategy--Business-Development/default.aspxWed, 18 Mar 2020 07:59:00 -0400d41f5309-0d18-4e5b-830e-c9a1c10b54a2https://news.bms.com/news/details/2020/US-Food-and-Drug-Administration-Approves-Opdivo-nivolumab--Yervoy-ipilimumab-for-Patients-with-Hepatocellular-Carcinoma-HCC-Previously-Treated-with-Sorafenib/default.aspxWed, 11 Mar 2020 07:59:00 -0400470e1ebd-83a3-40d0-932d-6f72fc225df9https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Reports-Primary-Results-of-ELOQUENT-1-Study-Evaluating-Empliciti-elotuzumab-Plus-Revlimid-lenalidomide-and-Dexamethasone-in-Patients-with-Newly-Diagnosed-Untreated-Multiple-Myeloma/default.aspxMon, 09 Mar 2020 07:59:00 -04009337aaa6-eaa3-43de-bfbc-f9dd005d2672https://news.bms.com/news/details/2020/Voluntis-and-Bristol-Myers-Squibb-to-Co-Develop-Digital-Therapeutics-For-Oncology/default.aspxTue, 03 Mar 2020 18:46:00 -050031838d96-edb0-44df-ac0c-b3ac7a07192ehttps://news.bms.com/news/details/2020/CORRECTING-and-REPLACING-BristolMyers-Squibb-Announces-Dividend/default.aspxMon, 02 Mar 2020 21:52:00 -050005a3dbe6-5d3e-4aa2-9bc6-12615314593chttps://news.bms.com/news/details/2020/Japan-Ministry-of-Health-Labor-and-Welfare-Approves-Opdivo-nivolumab-for-the-Treatment-of-Patients-with-Unresectable-Advanced-or-Recurrent-Esophageal-Cancer/default.aspxFri, 21 Feb 2020 07:59:00 -050057053825-d4c5-4ff6-9f86-89c8e2113582https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Hold-Investor-Day-on-April-2/default.aspxWed, 19 Feb 2020 07:59:00 -0500e0f8246d-e3ae-4e93-91ae-4f90b3111d6fhttps://news.bms.com/news/details/2020/Updated-CheckMate--025-Results-Show-26-of-Patients-Treated-with-Opdivo-are-Alive-at-Five-Years-in-Patients-with-Previously-Treated-Advanced-or-Metastatic-Renal-Cell-Carcinoma/default.aspxSat, 15 Feb 2020 15:30:00 -05009a5de8cf-661c-44c7-b520-354854ede823https://news.bms.com/news/details/2020/Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Demonstrates-Continued-Survival-Benefit-at-42-Month-Follow-up-in-Patients-with-Previously-Untreated-Advanced-or-Metastatic-Renal-Cell-Carcinoma/default.aspxSat, 15 Feb 2020 14:00:00 -0500b219752f-386f-4cf5-8f08-46f9e2101773https://news.bms.com/news/details/2020/Multinational-Inflammatory-Bowel-Disease-Survey-Uncovers-Striking-Differences-in-Patients-and-Physicians-Treatment-Goals-and-Disease-Management-Expectations/default.aspxFri, 14 Feb 2020 07:30:00 -050033e12ee5-eab3-4974-826a-b5e038b7830fhttps://news.bms.com/news/details/2020/US-Food-and-Drug-Administration-FDA-Accepts-for-Priority-Review-Bristol-Myers-Squibbs-Biologics-License-Application-BLA-for-Lisocabtagene-Maraleucel-liso-cel-for-Adult-Patients-with-Relapsed-or-Refractory-Large-B-Cell-Lymphoma/default.aspxThu, 13 Feb 2020 07:59:00 -0500e0327ac9-47b3-4466-9156-5ee6435ae520https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2019/default.aspxThu, 06 Feb 2020 08:05:00 -0500a065dc1f-3e94-4d7e-9bc0-6491956a749chttps://news.bms.com/news/details/2020/BioMotiv-and-Bristol-Myers-Squibb-announce-the-Launch-of-Anteros-Pharmaceuticals/default.aspxTue, 04 Feb 2020 09:01:00 -050034ea0f30-103a-4234-8a6b-4958ccac3a02https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Withdraws-European-Application-of-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-for-the-First-Line-Treatment-of-Advanced-Non-Small-Cell-Lung-Cancer/default.aspxFri, 31 Jan 2020 17:16:00 -0500fb798261-b6ca-4b98-96db-48bead8ee272https://news.bms.com/news/details/2020/US-Food-and-Drug-Administration-Accepts-for-Priority-Review-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-in-First-Line-Non-Small-Cell-Lung-Cancer/default.aspxWed, 15 Jan 2020 07:59:00 -05006bd53c76-24b4-4a8e-9bcc-c30ea5d2b655https://news.bms.com/news/details/2020/Nektar-Therapeutics-and-Bristol-Myers-Squibb-Amend-Strategic-Collaboration-Agreement-for-bempegaldesleukin-Plus-Opdivo-nivolumab/default.aspxFri, 10 Jan 2020 07:59:00 -0500c76c906a-78be-42a7-a609-9b2cc771566dhttps://news.bms.com/news/details/2020/New-England-Journal-of-Medicine-Publishes-Results-of-Pivotal-Phase-3-Reblozyl-luspatercept-aamt-MEDALIST-Trial/default.aspxThu, 09 Jan 2020 07:59:00 -05003f024d6f-be05-4d28-9310-139ab73fa8a6https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Completes-Divestment-of-Manufacturing-Facility-in-Anagni-Italy/default.aspxTue, 07 Jan 2020 04:00:00 -0500ddf65ddd-15ed-44aa-9a55-d91f76904083https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Present-at-the-38th-Annual-JP-Morgan-Healthcare-Conference/default.aspxMon, 06 Jan 2020 17:16:00 -050049f088c2-7f16-4358-aedf-664f34fe84e5https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Take-Part-at-the-Goldman-Sachs-12th-Annual-Healthcare-CEOs-Unscripted-Conference/default.aspxThu, 02 Jan 2020 07:59:00 -0500850edf15-066c-452d-b2eb-0bae308372c2https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Revlimid-lenalidomide-in-Combination-with-Rituximab-for-the-Treatment-of-Adult-Patients-with-Previously-Treated-Follicular-Lymphoma/default.aspxFri, 20 Dec 2019 07:59:00 -0500511e6439-3d06-4761-a41e-7f453834d369https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-to-Announce-Results-for-Fourth-Quarter-2019-on-February-6-2020/default.aspxThu, 19 Dec 2019 07:59:00 -05006cf95670-df0a-45e5-93d8-26908e1ddb29https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Announces-Submission-of-Biologics-License-Application-for-CAR-T-Cell-Therapy-Lisocabtagene-Maraleucel-liso-cel-to-FDA/default.aspxWed, 18 Dec 2019 17:16:00 -050032d4b7ed-e38e-4795-9a11-b87256f305dbhttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Announces-Leadership-Changes/default.aspxFri, 13 Dec 2019 08:00:00 -050096ffb6b8-b4a1-446f-a7f0-9fd72a579067https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Presents-Overall-Survival-and-Safety-Data-From-Pivotal-CC-486-Study-QUAZAR-AML-001/default.aspxTue, 10 Dec 2019 08:30:00 -050007fbe640-877b-45b7-a94c-41836f938e87https://news.bms.com/news/details/2019/bluebird-bio-and-Bristol-Myers-Squibb-Present-Updated-Data-from-Ongoing-Phase-1-Study-of-BCMA-Targeted-CAR-T-Cell-Therapy-bb21217-in-RelapsedRefractory-Multiple-Myeloma-at-61st-ASH-Annual-Meeting-and-Exposition/default.aspxMon, 09 Dec 2019 20:08:00 -050049edb7ba-5da9-4186-b450-4f8c0049ba84https://news.bms.com/news/details/2019/Reblozyl-luspatercept-aamt-Studies-Evaluating-Treatment-of-Anemia-in-Rare-Blood-Diseases-Presented-at-American-Society-of-Hematology-ASH-Annual-Meeting/default.aspxMon, 09 Dec 2019 17:30:00 -050061568890-1134-445d-8355-79972acbe2b4https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-AnnouncesStudies-Evaluating-liso-cel-in-Multiple-Additional-Patient-Populations-Site-of-Care-and-Disease-Areas-Presented-at-American-Society-of-Hematology-ASH-Annual-Meeting/default.aspxSun, 08 Dec 2019 17:30:00 -050071afb2f7-72b4-4295-8a09-744f7881ff93https://news.bms.com/news/details/2019/Findings-Released-from-Real-World-Data-Analysis-of-Eliquis-apixaban-for-the-Treatment-of-Venous-Thromboembolism-in-Patients-with-Active-Cancer/default.aspxSat, 07 Dec 2019 17:00:00 -0500cce593ce-b90d-44f4-89bd-9ae337d466c7https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Announces-Liso-Cel-Met-Primary-and-Secondary-Endpoints-in-TRANSCEND-NHL-001-Study/default.aspxSat, 07 Dec 2019 15:00:00 -0500006c4582-58bb-4f65-9aab-d8173d84815dhttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-and-bluebird-bio-Announce-Positive-Top-line-Results-from-the-Pivotal-Phase-2-KarMMa-Study-of-Ide-cel-in-Relapsed-and-Refractory-Multiple-Myeloma/default.aspxFri, 06 Dec 2019 17:16:00 -050073398ae9-2ab1-4233-913a-9a6c56e545a2https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-and-Acceleron-Pharma-Provide-Update-on-FDA-Advisory-Committee-for-Reblozyl-luspatercept-aamt/default.aspxFri, 06 Dec 2019 13:05:00 -05001eb925c2-e9c1-4394-888a-36b8b18abf1dhttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Announces-Dividend-Increase/default.aspxThu, 05 Dec 2019 17:16:00 -05007089959a-8de4-45d0-b043-d380aa1b25a5https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Announces-US-FDA-Breakthrough-Therapy-Designation-for-ORENCIA-abatacept-to-Help-Prevent-Acute-Graft/default.aspxWed, 04 Dec 2019 09:00:00 -0500a87e77cd-a267-4cea-85c9-d7ad349616echttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-and-Acceleron-Pharma-Announce-FDA-Advisory-Committee-Will-Review-Reblozyl-luspatercept-aamt-for-Use-in-Patients-With-Myelodysplastic-Syndromes/default.aspxTue, 03 Dec 2019 08:38:00 -05006c8856f2-5b0c-4ad7-9955-b2d3813598b0https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-to-Hold-Investor-Webcast-to-Discuss-ASH-Highlights/default.aspxTue, 26 Nov 2019 07:59:00 -05008eff02a9-d684-4bc2-a484-6daf8514e03bhttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Company-Announces-Final-Results-of-Exchange-Offers-for-Celgene-Corporation-Notes/default.aspxThu, 21 Nov 2019 07:59:00 -0500e5dea84c-f87f-466e-8891-233e9984bfb5https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Completes-Acquisition-of-Celgene-Creating-a-Leading-Biopharma-Company/default.aspxWed, 20 Nov 2019 17:16:00 -0500e64e9ce3-cc54-4896-8b34-deab2c4f76f6https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Announces-Update-on-CheckMate--915-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Versus-Opdivo-Alone-in-Patients-with-Resected-High-Risk-Melanoma-and-PD-L1-1/default.aspxWed, 20 Nov 2019 07:58:00 -0500b8f70453-5959-4b86-b363-b69e8f317776https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Company-Announces-It-Expects-No-Further-Extension-of-the-Expiration-Date-for-Exchange-Offers-for-Celgene-Corporation-Notes/default.aspxFri, 15 Nov 2019 19:39:00 -0500e6c676f8-a57a-4163-93c5-4289610a1dd7https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Receives-Clearance-from-US-Federal-Trade-Commission-for-Celgene-Acquisition/default.aspxFri, 15 Nov 2019 17:55:00 -050034392f30-290e-4ac3-92f3-edf8ccc2cd42https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-and-Pfizer-Announce-Randomized-Controlled-Trial-to-Evaluate-the-Effect-of-Atrial-Fibrillation-Screening-on-Health-Outcomes-in-Older-Individuals/default.aspxFri, 15 Nov 2019 10:00:00 -050030e80ce3-7ec0-4043-bb7c-9d0fe3f122fdhttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Company-Announces-Extension-of-the-Expiration-Date-for-Exchange-Offers-for-Celgene-Corporation-Notes11152019/default.aspxFri, 15 Nov 2019 07:59:00 -0500a7e2dad5-fc61-4566-bd02-7201d314c9fahttps://news.bms.com/news/details/2019/-Bristol-Myers-Squibb-Company-Announces-Extension-of-the-Expiration-Date-for-Exchange-Offers-for-Celgene-Corporation-Notes11-15-2019/default.aspxFri, 15 Nov 2019 06:59:00 -0500b0b59728-e710-4114-bf32-3edbdf68eb3chttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Company-Announces-Extension-of-the-Expiration-Date-for-Exchange-Offers-for-Celgene-Corporation-Notes11122019/default.aspxTue, 12 Nov 2019 07:59:00 -05008ff07e7f-2759-4ca0-b896-379acbfeeaf2https://news.bms.com/news/details/2019/US-Food-and-Drug-Administration-Accepts-for-Priority-Review-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Combination-for-Patients-with-Previously-Treated-Advanced-Hepatocellular-Carcinoma/default.aspxMon, 11 Nov 2019 07:59:00 -0500015d22bf-8d58-4802-b10a-3127ca682ab5https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Underscores-Precision-Focused-Immunology-Leadership-with-New-Data-on-ORENCIA-abatacept-in-Early-RA-ACPA-Positive-Patients-Presented-at-2019-ACRARP-Annual-Meeting1/default.aspxThu, 07 Nov 2019 07:59:00 -05007bbc6414-a53c-4027-b364-a4a5d24326cdhttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Company-Announces-Extension-of-the-Expiration-Date-for-Exchange-Offers-for-Celgene-Corporation-Notes/default.aspxThu, 07 Nov 2019 07:58:00 -0500a859c960-4d63-4b52-9e49-f1678cade526https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Company-Announces-Extension-of-the-Expiration-Date-for-Exchange-Offers-for-Celgene-Corporation-Notes-51d8a82a8/default.aspxTue, 05 Nov 2019 07:59:00 -05007871bad8-6f88-4b56-ac8d-0ce65746e51bhttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Company-Announces-Extension-of-the-Expiration-Date-for-Exchange-Offers-for-Celgene-Corporation-Notes-0/default.aspxFri, 01 Nov 2019 06:59:00 -0400cc9c25b9-8b0f-4e79-b8fe-9d4369226d88https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Reports-Third-Quarter-Financial-Results/default.aspxThu, 31 Oct 2019 07:59:00 -040028f7e094-7005-414e-a150-54e4ed6b4b36https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-to-Take-Part-at-the-Wolfe-Research-Healthcare-Conference/default.aspxWed, 30 Oct 2019 17:15:00 -0400e8631b3e-909a-40f4-9873-297d836e10e1https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Awards-Golden-Tickets-for-LabCentral-to-Carmine-Therapeutics-STIMIT/default.aspxWed, 30 Oct 2019 07:59:00 -04006df16c79-eed2-4a09-9abe-f45c586722c4https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Company-Announces-Extension-of-the-Expiration-Date-for-Exchange-Offers-for-Celgene-Corporation-Notes-1/default.aspxWed, 30 Oct 2019 06:59:00 -0400aa3cac2c-e0d2-4d80-a97e-21b25ce03e59https://news.bms.com/news/details/2019/European-Commission-Approves-Opdivo-nivolumab-Four-Week-Dosing-Schedule-for-the-Adjuvant-Treatment-of-Adult-Patients-with-Melanoma-with-Involvement-of-Lymph-Nodes-or-Metastatic-Disease-Who-Have-Undergone-Complete-Resection/default.aspxThu, 24 Oct 2019 06:59:00 -0400bd1b9264-e88c-455d-8a86-596f8e0e18f6https://news.bms.com/news/details/2019/CheckMate--9LA-a-Phase-3-Trial-Evaluating-Opdivo-nivolumab-Plus-Low-Dose-Yervoy-ipilimumab-Combined-with-Chemotherapy-Meets-Primary-Endpoint-Demonstrating-Superior-Overall-Survival-Compared-to-Chemotherapy-Alone-in-First-Line-Lung-Cancer/default.aspxTue, 22 Oct 2019 06:59:00 -0400ab54301c-4493-4c1a-94ca-e613fc49be6bhttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Company-Announces-Extension-of-the-Expiration-Date-for-Exchange-Offers-for-Celgene-Corporation-Notes-2/default.aspxFri, 18 Oct 2019 06:59:00 -04002ee69a8c-a550-41fa-8c77-432a17464b83https://news.bms.com/news/details/2019/The-Bristol-Myers-Squibb-Pfizer-Alliance-and-Fitbit-Collaborate-to-Address-Gaps-in-Atrial-Fibrillation-Detection-with-the-Aim-of-Accelerating-Diagnosis/default.aspxThu, 17 Oct 2019 09:00:00 -04004c64ede8-d2a2-4c76-9c75-7f4a437edebfhttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Company-Announces-Extension-of-the-Expiration-Date-for-Exchange-Offers-for-Celgene-Corporation-Notes-3/default.aspxTue, 08 Oct 2019 06:59:00 -0400af4eadb8-7d12-4115-9f34-20cea876dd9ehttps://news.bms.com/news/details/2019/Opdivo-nivolumab-Demonstrates-Statistically-Significant-Overall-Survival-Benefit-Versus-Chemotherapy-in-Patients-with-Advanced-Esophageal-Cancer/default.aspxMon, 30 Sep 2019 10:30:00 -0400c8935c67-f8dc-48bb-9640-6d8861e92227https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Announces-Final-Results-from-CheckMate--227-Part-1-Demonstrating-Superior-Overall-Survival-for-Opdivo-nivolumab-Plus-Low-Dose-Yervoy-ipilimumab-vs-Chemotherapy-in-Advanced-Non-Small-Cell-Lung-Cancer/default.aspxSat, 28 Sep 2019 10:30:00 -04004733caec-7471-48cb-a3ea-80b02cbd81echttps://news.bms.com/news/details/2019/Adjuvant-Treatment-with-Opdivo-nivolumab-Continues-to-Demonstrate-Extended-Recurrence-Free-Survival-at-Three-Years-in-Resected-High-Risk-Melanoma-Patients/default.aspxSat, 28 Sep 2019 02:30:00 -0400b8d0f6ed-6b7b-460b-bfce-9f2a1d079e00https://news.bms.com/news/details/2019/Five-Year-Outcomes-for-Opdivo-nivolumab-in-Combination-with-Yervoy-ipilimumab-Demonstrate-Durable-Long-Term-Survival-Benefits-in-Patients-with-Advanced-Melanoma/default.aspxSat, 28 Sep 2019 02:30:00 -0400e2f934b7-7fde-4cc2-8b3c-f464222a6abahttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Approval-of-Opdivo-nivolumab-Four-Week-Dosing-Schedule-for-the-Adjuvant-Treatment-of-Adult-Patients-with-Melanoma-with-Involvement-of-Lymph-Nodes-or-Metastatic-Disease-who-have/default.aspxTue, 24 Sep 2019 06:59:00 -04009cbe0954-fc25-4785-ac7b-1e95e4e8f4f2https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Company-Announces-Extension-of-the-Expiration-Date-for-Exchange-Offers-for-Celgene-Corporation-Notes-4/default.aspxMon, 23 Sep 2019 06:59:00 -040049614312-89de-4caf-b3bf-0880273acec4https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-to-Hold-Investor-Webcast-to-Discuss-ESMO-Highlights/default.aspxFri, 20 Sep 2019 06:59:00 -04005f2ea2f5-9cd0-493b-a019-c643906f7808https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Research-at-ESMO-Demonstrates-Breadth-of-Oncology-Development-Program-and-Focus-on-Improving-Overall-Survival-Across-Multiple-Cancers/default.aspxThu, 19 Sep 2019 06:59:00 -0400f88e9e5f-3ebd-4274-aab1-b6351773b9a3https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-to-Announce-Results-for-Third-Quarter-2019-on-October-31-2019/default.aspxThu, 12 Sep 2019 06:59:00 -0400250df5e4-83e9-4877-a3ad-efc9458f392chttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Board-Announces-Election-of-Three-New-Directors/default.aspxWed, 11 Sep 2019 17:39:00 -040006b71920-35db-470a-b837-ddb00bf5462ehttps://news.bms.com/news/details/2019/BristolMyers-Squibb-Announces-Dividend/default.aspxWed, 11 Sep 2019 16:16:00 -0400473c6a12-3ecc-4c27-8aa6-74b522bac716https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Announces-Pooled-Five-Year-Survival-Results-for-Opdivo-nivolumab-in-Previously-Treated-Advanced-Non-Small-Cell-Lung-Cancer-Patients/default.aspxTue, 10 Sep 2019 05:30:00 -0400f66a8461-e612-4fe5-a182-064f93eb7cc5https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Provides-Update-on-Phase-3-Opdivo-nivolumab-CheckMate--548-Trial-in-Patients-with-Newly-Diagnosed-MGMT-Methylated-Glioblastoma-Multiforme/default.aspxThu, 05 Sep 2019 06:59:00 -0400a5df2937-92b4-42d2-8bb1-29bd9e2e1380https://news.bms.com/news/details/2019/More-Than-100-Bristol-Myers-Squibb-Employees-Embark-on-Coast-2-Coast-4-Cancer-Ride-to-Help-Advance-Groundbreaking-Cancer-Research/default.aspxWed, 04 Sep 2019 07:00:00 -0400a4904961-6eb8-4db1-9249-29e5726dbed2https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-to-Take-Part-at-the-Morgan-Stanley-Conference/default.aspxTue, 03 Sep 2019 06:59:00 -0400835d3c7f-5d0b-4d48-b555-8ae46fec1628https://news.bms.com/news/details/2019/Findings-Released-from-NAXOS-a-French-Real-World-Data-Analysis-and-the-Largest-Real-World-Data-Analysis-on-Oral-Anticoagulant-Effectiveness-and-Safety-in-Europe-Among-Patients-with-Non-Valvular-Atrial-Fibrillation/default.aspxSun, 01 Sep 2019 05:00:00 -0400cde0a763-c40e-49e7-af9c-f51da0149e91https://news.bms.com/news/details/2019/European-Commission-Approves-Empliciti-elotuzumab-Plus-Pomalidomide-and-Low-Dose-Dexamethasone-EPd-for-the-Treatment-of-Patients-with-Relapsed-and-Refractory-Multiple-Myeloma/default.aspxTue, 27 Aug 2019 16:16:00 -04000b330e85-f7dd-4ca5-93b0-af149131aa69https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Announces-Agreement-Between-Celgene-and-Amgen-to-Divest-OTEZLA-for-134-Billion/default.aspxMon, 26 Aug 2019 06:30:00 -0400597fbe5e-2cfe-408e-8c64-7d628b1a5070https://news.bms.com/news/details/2019/Nektar-Therapeutics-and-Bristol-Myers-Squibb-Announce-US-FDA-Breakthrough-Therapy-Designation-for-Bempegaldesleukin-NKTR-214-in-Combination-with-Opdivo-nivolumab-for-the-Treatment-of-Patients-with-Untreated-Advanced-Melanoma/default.aspxThu, 01 Aug 2019 07:00:00 -0400ea4662e9-8b1a-4b62-822c-69652c61b016https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Announces-European-Commission-Approval-of-Pending-Acquisition-of-Celgene/default.aspxMon, 29 Jul 2019 10:10:00 -0400b4b64ef5-42ca-4c24-b9df-73a3bf0e639dhttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Approval-of-Empliciti-elotuzumab-Plus-Pomalidomide-and-Low-Dose-Dexamethasone-for-Treatment-of-Patients-with-Relapsed-and-Refractory-Multiple-Myeloma/default.aspxFri, 26 Jul 2019 06:59:00 -0400b938481d-bb2e-4270-8ee9-1d234549887chttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Reports-Second-Quarter-Financial-Results/default.aspxThu, 25 Jul 2019 06:59:00 -040010f0e32c-1013-4a6e-8d08-611566701b11https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Provides-Update-on-Part-2-of-CheckMate--227/default.aspxWed, 24 Jul 2019 16:16:00 -0400b1afca37-b708-442f-81d0-f92afe57df26https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Announces-CheckMate--227-Part-1a-Meets-Co-Primary-Endpoint-of-Overall-Survival/default.aspxWed, 24 Jul 2019 16:16:00 -0400eb1026de-b8d0-4f50-b407-d70269b365d6https://news.bms.com/news/details/2019/Bayer-Bristol-Myers-Squibb-and-Ono-Pharmaceutical-Enter-Into-a-Clinical-Collaboration-Agreement-to-Investigate-Stivarga-regorafenib-and-Opdivo-nivolumab-as-Combination-Therapy-in-Patients-With-Metastatic-Colorectal-Cancer/default.aspxThu, 18 Jul 2019 06:30:00 -040080dc41b0-c6ae-4b28-86a8-d6d2c5e03fa3https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Completes-Divestment-of-UPSA/default.aspxMon, 01 Jul 2019 05:17:00 -0400f5b3c430-b102-40c2-9d65-c933c9aa593bhttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Company-Announces-Extension-of-the-Expiration-Date-for-Exchange-Offers-for-Celgene-Corporation-Notes-5/default.aspxFri, 28 Jun 2019 06:59:00 -04009dd2c11c-daea-4c97-a188-63eaf7a60f55https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Provides-Update-on-Pending-Merger-with-Celgene/default.aspxMon, 24 Jun 2019 06:59:00 -0400c7c5b990-c51c-48fd-b118-9c1f2d8b7fd1https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Announces-Results-from-CheckMate--459-Study-Evaluating-Opdivo-nivolumab-as-a-First-Line-Treatment-for-Patients-with-Unresectable-Hepatocellular-Carcinoma/default.aspxMon, 24 Jun 2019 06:59:00 -0400b43fa65b-6e95-423d-be7a-70c87f060fb6https://news.bms.com/news/details/2019/Catalent-to-Purchase-Bristol-Myers-Squibb-Manufacturing-Facility-in-Anagni-Italy/default.aspxWed, 19 Jun 2019 06:59:00 -0400f8f0b698-0afd-4267-bb88-f3e95b05763ehttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Presents-Updated-Efficacy-Data-from-Phase-2-Trial-of-Empliciti-elotuzumab-Plus-Pomalidomide-and-Dexamethasone-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma-RRMM/default.aspxFri, 14 Jun 2019 06:59:00 -0400a8635362-97d6-4399-bac0-36c719899882https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Announces-Dividend/default.aspxThu, 13 Jun 2019 16:38:00 -04005dc9ee49-bed5-4bed-a154-944c014470c9https://news.bms.com/news/details/2019/New-Mechanistic-Study-Explores-the-Relationship-Between-a-Key-Genetic-Marker-and-Clinical-Efficacy-of-ORENCIA-abatacept-or-adalimumab-in-Moderate-to-Severe-Early-Rheumatoid-Arthritis-Patients/default.aspxThu, 13 Jun 2019 16:30:00 -04000e933c45-4d34-4e62-a9b0-d193cafd523ahttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-to-Announce-Results-for-Second-Quarter-2019-on-July-25-2019/default.aspxThu, 06 Jun 2019 06:59:00 -0400681230a0-62ad-43fa-a362-c77733f4f887https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Announces-Post-Closing-Leadership-Team/default.aspxWed, 05 Jun 2019 06:59:00 -0400a5eae6c9-8284-4f78-aaa1-a27ef13665cahttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-to-Take-Part-in-Goldman-Sachs-40th-Annual-Global-Healthcare-Conference/default.aspxTue, 04 Jun 2019 12:23:00 -0400e848fb1a-8391-4870-a191-9a9c5645711bhttps://news.bms.com/news/details/2019/Five-Year-Survival-Observed-in-Longest-Follow-up-to-Date-of-Advanced-Melanoma-Patients-Treated-with-the-Combination-of-Opdivo-nivolumab-and-Yervoy-ipilimumab/default.aspxMon, 03 Jun 2019 14:15:00 -0400a1bef523-bda0-4b7e-b208-2e98744eda1ahttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Announces-First-Presentation-of-Results-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Combination-in-Advanced-Hepatocellular-Carcinoma-at-ASCO-2019/default.aspxMon, 03 Jun 2019 06:59:00 -0400a5dcdce3-7e48-4001-ae6f-5cbc6c6ddfe0https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Company-Announces-Extension-of-the-Expiration-Date-for-Exchange-Offers-for-Celgene-Corporation-Notes-6/default.aspxFri, 24 May 2019 06:59:00 -0400e0440662-3cfc-4a9a-b45a-92851526210ahttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-to-Present-New-Data-on-20-Types-of-Cancer-from-Across-its-Oncology-Portfolio-at-ASCO-and-EHA-2019/default.aspxThu, 16 May 2019 16:15:00 -040041c1d71a-8073-45eb-8ebd-7ab7f30f8b20https://news.bms.com/news/details/2019/Award-Winning-Actor-and-Producer-Sterling-K-BrownJoins-Bristol-Myers-Squibb-in-Effort-to-Share-Stories-of-What-Its-Like-to-Live-with-Cancer-Today/default.aspxTue, 14 May 2019 07:15:00 -040054e61fec-3132-4c70-b506-753380e7e83chttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-to-Take-Part-in-the-UBS-Global-Healthcare-Conference/default.aspxTue, 14 May 2019 06:59:00 -04005b82dd74-5ab9-4c78-8e06-fb27afc61b5fhttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Announces-Phase-3-CheckMate--498-Study-Did-Not-Meet-Primary-Endpoint-of-Overall-Survival-with-Opdivo-nivolumab-Plus-Radiation-in-Patients-with-Newly-Diagnosed-MGMT-Unmethylated-Glioblastoma-Multiforme/default.aspxThu, 09 May 2019 06:59:00 -0400cba80738-785c-471b-969b-8bed742771dbhttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Company-Prices-19-Billion-of-Senior-Unsecured-Notes/default.aspxWed, 08 May 2019 06:59:00 -04004711e609-2c35-4ca4-81dd-093039c4c200https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Company-Announces-Results-of-Early-Participation-in-Exchange-Offers-and-Consent-Solicitations-for-Celgene-Corporation-Notes/default.aspxWed, 01 May 2019 21:06:00 -040023074958-dd04-451d-9bee-4970c550f1achttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Company-Announces-Launch-of-Private-Offering-of-Senior-Unsecured-Notes/default.aspxWed, 01 May 2019 17:46:00 -0400dd12ada2-a9c8-44d4-a66c-efc0c3bd189chttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results/default.aspxThu, 25 Apr 2019 06:59:00 -0400a374e63c-a800-4cd1-a9de-60bca487d276https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Company-Announces-Commencement-of-Exchange-Offers-and-Consent-Solicitations-for-Celgene-Notes/default.aspxWed, 17 Apr 2019 08:18:00 -0400be6fad08-2d74-4b82-b583-4f4269a1ffbahttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Shareholders-Approve-Celgene-Acquisition/default.aspxFri, 12 Apr 2019 10:48:00 -0400f2da52c3-468a-444c-94be-574c9c012940https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Receives-2019-ENERGY-STAR-Partner-of-the-Year--Sustained-Excellence-Award/default.aspxThu, 11 Apr 2019 06:59:00 -0400bbad3c71-30fb-4b95-8fdf-a99c67ec4b35https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Announces-Long-Term-Survival-Results-from-Pooled-Analyses-of-Opdivo-nivolumab-in-Previously-Treated-Non-Small-Cell-Lung-Cancer-Patients/default.aspxTue, 02 Apr 2019 13:00:00 -04000f5bc7dd-4701-430b-bdcd-f61de1f3567ehttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Issues-Statement-on-Celgenes-Settlement-with-Alvogen-on-Revlimid-Patent-Litigation/default.aspxFri, 29 Mar 2019 14:33:00 -04000f7eadd4-fd41-47c5-831a-9b03d7c0a76ehttps://news.bms.com/news/details/2019/Independent-Proxy-Advisory-Firms-ISS-and-Glass-Lewis-Recommend-Bristol-Myers-Squibb-Shareholders-Vote-FOR-Proposed-Merger-with-Celgene/default.aspxFri, 29 Mar 2019 12:13:00 -04004cd1b535-c51a-4521-b175-6d56ee0bb5c3https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Board-of-Directors-Sends-Letter-to-Shareholders-Highlighting-the-Compelling-Strategic-and-Financial-Rationale-of-the-Celgene-Transaction-Company-Provides-Additional-Investor-Materials/default.aspxMon, 25 Mar 2019 07:59:00 -0400268f2c98-fcde-438e-8f9a-c570c56cef0dhttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Files-Investor-Presentation-Highlighting-Significant-Benefits-of-Pending-Transaction-with-Celgene/default.aspxTue, 19 Mar 2019 07:59:00 -04004617eafe-65e4-450c-9fd3-3d70fbd0ed96https://news.bms.com/news/details/2019/AUGUSTUS-Demonstrates-Favorable-Safety-Results-of-Eliquis-Versus-Vitamin-K-Antagonists-in-Non-Valvular-Atrial-Fibrillation-Patients-with-Acute-Coronary-Syndrome-andor-Undergoing-Percutaneous-Coronary-Intervention/default.aspxSun, 17 Mar 2019 12:45:00 -0400471d1a06-1140-4320-9824-ab8701ae7521https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Announces-Dividend-a326d4faf/default.aspxThu, 07 Mar 2019 18:22:00 -0500803f1ddd-7b2a-4fb7-97c3-f54aaeac32e2https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-to-Announce-Results-for-First-Quarter-2019-on-April-25-2019/default.aspxThu, 07 Mar 2019 07:59:00 -050007422a72-ebae-4eca-9aaf-5db87ef80541https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-to-Take-Part-in-the-Barclays-2019-Global-Healthcare-Conference/default.aspxWed, 06 Mar 2019 17:58:00 -0500e73896aa-e062-4492-8505-04e80ca263b6https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Files-Investor-Presentation-and-Board-of-Directors-Sends-Letter-to-Shareholders-Regarding-Pending-Transaction-with-Celgene/default.aspxWed, 06 Mar 2019 07:59:00 -050023f1a2fb-03fb-41da-856a-ed30940db7ebhttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-to-Take-Part-in-the-Cowen-and-Company-39th-Annual-Health-Care-Conference/default.aspxTue, 05 Mar 2019 07:59:00 -0500634d26b8-9a5e-4030-8524-5008a6431d7bhttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Issues-Statement-in-Response-to-Starboards-Letter/default.aspxThu, 28 Feb 2019 12:59:00 -05008c1b5c07-deeb-4c28-a356-f94126e364cchttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Announces-Filing-of-Definitive-Proxy-Statement-in-Connection-with-Proposed-Merger-with-Celgene/default.aspxFri, 22 Feb 2019 17:49:00 -050016aa6f3f-93c6-453e-b9b2-1a6727a9fd06https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Provides-Update-on-Pending-Transaction-with-Celgene/default.aspxWed, 20 Feb 2019 10:00:00 -0500063ab17d-8448-4f80-ae94-a3fdc9e98e69https://news.bms.com/news/details/2019/Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Shows-Response-in-Pre-Treated-Patients-with-Metastatic-Castration-Resistant-Prostate-Cancer/default.aspxThu, 14 Feb 2019 17:00:00 -0500e0c04d8d-1e32-41a5-9f0d-35a175093b53https://news.bms.com/news/details/2019/Opdivo-nivolumab-Plus-Low-Dose-Yervoy-ipilimumab-Demonstrates-Continued-Survival-Benefit-at-30-Month-Follow-up-in-Patients-with-Previously-Untreated-Advanced-or-Metastatic-Renal-Cell-Carcinoma/default.aspxMon, 11 Feb 2019 18:00:00 -05002101b637-c7d9-490f-aa12-189c08a18373https://news.bms.com/news/details/2019/European-Commission-Approves-Bristol-Myers-Squibbs-Sprycel-dasatinib-in-Combination-with-Chemotherapy-for-Treatment-of-Pediatric-Patients-with-Newly-Diagnosed-Philadelphia-Chromosome-Positive-Acute-Lymphoblastic-Leukemia/default.aspxMon, 11 Feb 2019 07:59:00 -0500c2aab83e-e4b3-4da1-bade-97ddceaacb55https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-to-Take-Part-in-Guggenheim-Healthcare-Talks-Idea-Forum/default.aspxThu, 07 Feb 2019 07:59:00 -050033f5ff66-af62-4a62-8430-4c7f6c891c22https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Announces-Time-Change-for-Q4-Earnings-Results-Conference-Call/default.aspxThu, 24 Jan 2019 07:59:00 -05000170b2cc-7431-4486-a781-f62495decc33https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results/default.aspxThu, 24 Jan 2019 07:59:00 -0500bfaceab9-5ad2-4cd8-93f8-b9af71d60b0dhttps://news.bms.com/news/details/2019/European-Commission-Approves-Opdivo-nivolumab-Plus-Low-Dose-Yervoy-ipilimumab-for-First-Line-Treatment-of-Patients-with-Intermediate--and-Poor-Risk-Advanced-Renal-Cell-Carcinoma/default.aspxMon, 14 Jan 2019 17:15:00 -05005a182f76-ea39-46b0-bed5-685ed234d257https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-to-Participate-in-the-37th-Annual-JP-Morgan-Healthcare-Conference/default.aspxSat, 05 Jan 2019 12:07:00 -05005e003e28-4ffb-4097-a3f6-3beea4650a6bhttps://news.bms.com/news/details/2019/Bristol-Myers-Squibb-to-Acquire-Celgene-to-Create-a-Premier-Innovative-Biopharma-Company/default.aspxThu, 03 Jan 2019 07:58:00 -0500d04aecfd-5ca5-4814-afb3-d97092d90e13https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Provides-2019-EPS-Guidance/default.aspxThu, 03 Jan 2019 07:58:00 -05001d7ffd3a-747e-4493-9523-3f029f7b0851https://news.bms.com/news/details/2019/Bristol-Myers-Squibbs-Sprycel-dasatinib-Tablets-Now-Approved-in-Combination-with-Chemotherapy-in-Certain-Pediatric-Patients-with-Philadelphia-Chromosome-Positive-Acute-Lymphoblastic-Leukemia/default.aspxWed, 02 Jan 2019 17:25:00 -05001bc5e830-6724-4301-9131-b1ebb6f23f7bhttps://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Announces-Offer-from-Taisho-Pharmaceutical-Holdings-Co-Ltd-to-Purchase-UPSA/default.aspxWed, 19 Dec 2018 04:30:00 -0500b3a524fd-55bf-4642-8e22-e4c3fad9fb0dhttps://news.bms.com/news/details/2018/Bristol-Myers-Squibb-and-Boston-Medical-Center-Announce-Research-Collaboration-to-Investigate-Markers-of-Immuno-Oncology-Response-and-Resistance/default.aspxMon, 17 Dec 2018 17:30:00 -0500adf37ef8-5338-40ed-b918-75a4f5e68113https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Sprycel-dasatinib-for-Pediatric-Patients-with-Newly-Diagnosed-Philadelphia-Chromosome-Positive-Acute-Lymphoblastic-Leukemia/default.aspxMon, 17 Dec 2018 07:59:00 -05008d082f2d-4d5f-4095-a5a1-8b061ab44128https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-and-H3-Biomedicine-Announce-Research-Collaboration-to-Advance-Novel-Therapeutics-Leveraging-H3s-RNA-Splicing-Platform/default.aspxMon, 17 Dec 2018 07:59:00 -0500169745c0-fa23-49f9-ae62-d11f3e00bd8chttps://news.bms.com/news/details/2018/Bristol-Myers-Squibb-and-Vedanta-Biosciences-Announce-a-New-Clinical-Collaboration-to-Evaluate-OPDIVO-Nivolumab-and-VE800-in-Patients-with-Advanced-or-Metastatic-Cancers/default.aspxMon, 10 Dec 2018 03:00:00 -050006873df6-f8b6-42af-8294-da43db6d34c6https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Announces-Dividend-Increase/default.aspxThu, 06 Dec 2018 17:15:00 -0500ecb12759-ca36-41de-9a01-864960817351https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-to-Announce-Results-for-Fourth-Quarter-2018-on-January-24/default.aspxWed, 05 Dec 2018 07:59:00 -050077caf5a6-5140-43d3-bbe6-4bf571a32d9dhttps://news.bms.com/news/details/2018/Bristol-Myers-Squibb-to-Transfer-38-billion-in-US-Pension-Liabilities/default.aspxMon, 03 Dec 2018 18:00:00 -05004d16d88d-73b8-4678-b10b-d0dc7f100419https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-to-Highlight-New-Data-from-Broad-Oncology-Portfolio-at-the-60th-American-Society-of-Hematology-Annual-Meeting/default.aspxThu, 29 Nov 2018 17:30:00 -050056a1f31d-d49f-4e61-a3de-ef65fb3d20a4https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-to-Take-Part-in-Citi-2018-Global-Healthcare-Conference/default.aspxThu, 29 Nov 2018 07:59:00 -0500d29ecc4b-262f-4bec-b531-b803dcf96366https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Announces-CheckMate--451-Study-Did-Not-Meet-Primary-Endpoint-of-Overall-Survival-with-Opdivo-Plus-Yervoy-Vs-Placebo-as-A-Maintenance-Therapy-in-Patients-with-Extensive-Stage-Small-Cell-Lung-Cancer-After-Completion-of-First-Line/default.aspxMon, 26 Nov 2018 17:30:00 -0500dd28046c-a48a-4e71-a351-824435dddf3dhttps://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Awards-Golden-Tickets-for-LabCentral-to-ReviveMed-Strand-Therapeutics/default.aspxMon, 26 Nov 2018 07:59:00 -0500030f5b27-91ff-4fac-9100-d406ab3e5bc3https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-to-Take-Part-in-Evercore-ISI-HealthCONx-Conference/default.aspxTue, 20 Nov 2018 07:59:00 -0500298c12ad-403b-40ca-9132-239460ccffb9https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Approval-of-Opdivo-nivolumab-Plus-Low-Dose-Yervoy-ipilimumab-as-First-Line-Treatment-for-Patients-with-Intermediate--and-Poor-Risk-Advanced-Renal-Cell-Carcinoma/default.aspxThu, 15 Nov 2018 17:30:00 -0500945dcadd-003b-4130-9408-ddc960712dc0https://news.bms.com/news/details/2018/Real-World-Evidence-on-Patients-Aged-80-and-Older-Presented-From-ARISTOPHANES-the-Largest-Real-World-Data-Study-Evaluating-Oral-Anticoagulants-Among-Patients-with-Non-Valvular-Atrial-Fibrillation/default.aspxSun, 11 Nov 2018 13:45:00 -05006708cca3-44ee-469a-8c8e-b2cb844a451bhttps://news.bms.com/news/details/2018/Bristol-Myers-Squibb-to-Take-Part-in-Credit-Suisse-2018-Health-Care-Conference/default.aspxWed, 07 Nov 2018 07:59:00 -05009abaa2dd-da1e-4486-9bf4-436aa130bbd0https://news.bms.com/news/details/2018/US-Food-and-Drug-Administration-Approves-Empliciti-elotuzumab-Plus-Pomalidomide-and-Dexamethasone-a-New-Immunotherapy-Combination-for-Certain-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma/default.aspxTue, 06 Nov 2018 17:34:00 -0500ff7358d0-81b5-4ab9-9c7f-79d7743a1f48https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-and-Infinity-Pharmaceuticals-Announce-a-New-Clinical-Collaboration-to-Evaluate-Opdivo-Nivolumab-in-Combination-with-IPI-549-in-Urothelial-Cancer/default.aspxMon, 05 Nov 2018 07:59:00 -0500a00f2b63-aabe-4913-8b32-83fea3d2fdc8https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Reports-Third-Quarter-Financial-Results/default.aspxThu, 25 Oct 2018 06:59:00 -040033ac90d3-4421-4556-8ead-ca0515ad678chttps://news.bms.com/news/details/2018/Opdivo-nivolumab-in-Combination-with-Yervoy-ipilimumab-Results-in-Significantly-Longer-Treatment-Free-Survival-in-Patients-with-Previously-Untreated-Advanced-or-Metastatic-Renal-Cell-Carcinoma/default.aspxMon, 22 Oct 2018 06:45:00 -04004004a58f-d138-4941-a1fb-97e3392d6777https://news.bms.com/news/details/2018/Opdivo-nivolumab-in-Combination-with-Yervoy-ipilimumab-Demonstrates-Durable-Four-Year-Survival-Benefits-in-Patients-with-Advanced-Melanoma/default.aspxMon, 22 Oct 2018 03:20:00 -040099b1f53e-7c76-419b-9e06-a11ddf3b8c7chttps://news.bms.com/news/details/2018/Opdivo-nivolumab-Plus-Low-Dose-Yervoy-ipilimumab-Demonstrates-Durable-Clinical-Benefit-in-Previously-Untreated-Patients-with-MSI-H-or-dMMR-Metastatic-Colorectal-Cancer/default.aspxMon, 22 Oct 2018 03:15:00 -0400c9d1ddc6-cc2a-49ce-8e63-7b508ef77fe1https://news.bms.com/news/details/2018/Opdivo-nivolumab-in-Combination-with-Yervoy-ipilimumab-Shows-Promising-Results-in-Patients-with-Advanced-Form-of-Bladder-Cancer/default.aspxSat, 20 Oct 2018 03:15:00 -040025b46c47-de89-410f-8298-d7fd7f1e3ba3https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Provides-Update-on-the-Ongoing-Regulatory-Review-of-Opdivo-Plus-Low-Dose-Yervoy-in-First-Line-Lung-Cancer-Patients-with-Tumor-Mutational-Burden-10-mutMb/default.aspxFri, 19 Oct 2018 16:16:00 -0400744dd0f6-d447-44be-8294-765a408d7919https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-to-Showcase-Immunoscience-Research-and-Biomarker-Guided-Treatment-Approaches-at-the-2018-American-College-of-Rheumatology-and-Association-of-Rheumatology-Health-Professionals-Annual-Meeting/default.aspxWed, 17 Oct 2018 06:59:00 -0400e045de9b-1ebf-449c-b582-89ec16922654https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Announces-Phase-3-CheckMate--331-Study-Does-Not-Meet-Primary-Endpoint-of-Overall-Survival-with-Opdivo-Versus-Chemotherapy-in-Patients-with-Previously-Treated-Relapsed-Small-Cell-Lung-Cancer/default.aspxFri, 12 Oct 2018 06:59:00 -0400f18f8fee-9559-4811-9996-0077e1c83bdbhttps://news.bms.com/news/details/2018/Bristol-Myers-Squibb-and-Compugen-Announce-Clinical-Collaboration-to-Evaluate-Therapeutic-Regimen-in-Advanced-Solid-Tumors/default.aspxThu, 11 Oct 2018 06:59:00 -04009df1d899-7f3e-492b-b25c-48bf45a9d346https://news.bms.com/news/details/2018/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Application-for-Empliciti-elotuzumab-Plus-Pomalidomide-and-Low-Dose-Dexamethasone-in-Patients-with-Multiple-Myeloma/default.aspxTue, 18 Sep 2018 06:59:00 -04008d8e84bc-2981-44bb-845a-9f971b91bef5https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Statement-on-Resignation-of-Dr-Jos-Baselga/default.aspxFri, 14 Sep 2018 17:23:00 -040053f3e99c-bb33-4efc-b7bb-231f74d19b92https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Announces-Dividend/default.aspxWed, 12 Sep 2018 16:10:00 -0400b6a50e18-763c-4007-aa4b-4754b7a384f6https://news.bms.com/news/details/2018/Bristol-Myers-Squibbs-Novel-Oral-Selective-TYK2-Inhibitor-Delivered-Significant-Skin-Clearance-in-Patients-with-Moderate-to-Severe-Plaque-Psoriasis-in-Phase-2-Trial/default.aspxWed, 12 Sep 2018 02:01:00 -04007f2115b1-2b03-48c4-a047-66efdfaf6d20https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-to-Take-Part-in-Morgan-Stanley-Global-Health-Care-Conference/default.aspxThu, 06 Sep 2018 15:00:00 -04003956b331-297c-4b21-952e-918bb4a15fbahttps://news.bms.com/news/details/2018/Bristol-Myers-Squibb-to-Announce-Results-for-Third-Quarter-2018-on-October-25/default.aspxThu, 06 Sep 2018 06:59:00 -04006a96a39a-855d-447c-850f-eae74d5007a5https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Kicks-Off-Coast-2-Coast-4-Cancer-Ride-to-Fundraise-for-the-V-Foundation-for-Cancer-Research/default.aspxWed, 05 Sep 2018 06:59:00 -040023e7b00f-1c52-4c4f-9166-a32bbd6a0dbchttps://news.bms.com/news/details/2018/US-Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-Application-for-Sprycel-dasatinib-in-Pediatric-Patients-with-Newly-Diagnosed-Philadelphia-Chromosome-Positive-Acute-Lymphoblastic-Leukemia/default.aspxThu, 30 Aug 2018 06:59:00 -0400eb59de3e-9dab-4aa7-a623-030b4282eb28https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Appoints-Christopher-Boerner-Executive-Vice-President-and-Chief-Commercial-Officer/default.aspxTue, 28 Aug 2018 09:00:00 -0400f61d98ec-528c-4553-a181-a97b903bf7c6https://news.bms.com/news/details/2018/US-Food-and-Drug-Administration-Accepts-for-Priority-Review-Bristol-Myers-Squibbs-Application-for-Empliciti-elotuzumab-Plus-Pomalidomide-and-Low-Dose-Dexamethasone-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma/default.aspxThu, 23 Aug 2018 06:59:00 -04004cff06a1-ca98-41c1-aa3b-3bc258e44c51https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Pfizer-Alliance-ACROPOLIS-Real-World-Data-Program-Grows-to-Sample-Size-of-Nearly-One-Million-Lives-Worldwide/default.aspxMon, 20 Aug 2018 10:21:00 -0400279811ef-defa-45fe-8341-c37f23da9cc2https://news.bms.com/news/details/2018/US-Food-and-Drug-Administration-Approves-Opdivo-nivolumab-as-the-First-New-Medication-in-Nearly-20-Years-for-Certain-Patients-with-Previously-Treated-Small-Cell-Lung-Cancer/default.aspxFri, 17 Aug 2018 06:59:00 -0400e017f9c2-a1b0-4c5a-8abd-b15fb7654b0chttps://news.bms.com/news/details/2018/European-Commission-Approves-Bristol-Myers-Squibbs-Opdivo-nivolumab-for-the-Adjuvant-Treatment-of-Adult-Patients-with-Melanoma-with-Involvement-of-Lymph-Nodes-or-Metastatic-Disease-Who-Have-Undergone-Complete-Resection/default.aspxTue, 31 Jul 2018 06:59:00 -040012c02494-029a-4294-9d98-aa19ef860943https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Reports-Second-Quarter-Financial-Results/default.aspxThu, 26 Jul 2018 06:59:00 -0400536ede0c-08e1-4c7f-a1ae-29a511afc905https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-and-Tsinghua-University-Announce-Collaboration-to-Accelerate-Early-Research-into-Potential-Therapies-for-Autoimmune-Diseases-and-Cancer/default.aspxTue, 24 Jul 2018 07:00:00 -0400ca2ce6f3-491e-4103-87a9-2bb1ce119e70https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Announces-Departure-of-Chief-Commercial-Officer/default.aspxMon, 23 Jul 2018 08:30:00 -0400028be4a8-6b1e-4e5f-8481-f4e5cdc6fcc0https://news.bms.com/news/details/2018/Bristol-Myers-Squibbs-Opdivo-nivolumab--Low-Dose-Yervoy-ipilimumab-is-the-First-Immuno-Oncology-Combination-Approved-for-MSI-HdMMR-mCRC-Patients-Who-Progressed-Following-Treatment-with-a-Fluoropyrimidine-Oxaliplatin-and/default.aspxWed, 11 Jul 2018 06:59:00 -040051b6f37e-70f0-4a67-9d23-be9ba9059467https://news.bms.com/news/details/2018/European-Commission-Approves-Expanded-Indication-for-Sprycel-dasatinib-to-Include-Treatment-of-Children-with-Philadelphia-Chromosome-Positive-Chronic-Myeloid-Leukemia-in-Chronic-Phase/default.aspxThu, 05 Jul 2018 06:59:00 -040038af64d3-3e6a-423e-899d-65904a72c1a4https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Approval-of-Opdivo-nivolumab-for-the-Adjuvant-Treatment-of-Adult-Patients-with-Melanoma/default.aspxFri, 29 Jun 2018 07:54:00 -04007e7bb7f2-7e32-4c57-aadf-64591994ddbdhttps://news.bms.com/news/details/2018/US-Food-and-Drug-Administration-FDA-Accepts-Application-for-Opdivo-Plus-Low-Dose-Yervoy-for-Treatment-of-First-Line-Non-Small-Cell-Lung-Cancer-in-Patients-with-Tumor-Mutational-Burden-10-mutMb/default.aspxThu, 21 Jun 2018 16:15:00 -0400ad0142ca-9216-488a-a0bf-a31147fda19bhttps://news.bms.com/news/details/2018/Dallas-Cowboys-Quarterback-Dak-Prescott-Modern-Family-Star-Eric-Stonestreet-and-Actress-Tia-Mowry-Call-on-Americans-to-Rise-Up-Against-Cancer-Through-Ready-Raise-Rise/default.aspxWed, 20 Jun 2018 06:59:00 -040064423c38-5752-4dea-b16e-e5e646f8a88fhttps://news.bms.com/news/details/2018/Empliciti-elotuzumab-Plus-Pomalidomide-and-Low-Dose-Dexamethasone-Reduces-the-Risk-of-Disease-Progression-by-46-Versus-PomalidomideDexamethasone-Alone-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma/default.aspxSun, 17 Jun 2018 06:30:00 -0400dcfae9f9-12cd-419c-8951-35544e0ad49chttps://news.bms.com/news/details/2018/China-National-Drug-Administration-Approves-Countrys-First-Immuno-Oncology-Agent-Opdivo-nivolumab-injection-for-Previously-Treated-Non-Small-Cell-Lung-Cancer-NSCLC/default.aspxFri, 15 Jun 2018 08:32:00 -04000e3f6008-5daa-48cf-bddf-33a491bcd12fhttps://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Announces-Dividend-c42865541/default.aspxThu, 14 Jun 2018 16:30:00 -04003d0ea5f5-4686-4048-b029-3695cfe51835https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-to-Present-New-Research-Findings-on-the-Treatment-of-Patients-with-Early-Rheumatoid-Arthritis-at-the-Annual-European-Congress-of-Rheumatology-EULAR-2018/default.aspxWed, 13 Jun 2018 06:00:00 -0400ba770ea1-3849-457f-8ba8-16e63e1ab08bhttps://news.bms.com/news/details/2018/Bristol-Myers-Squibb-to-Take-Part-in-Goldman-Sachs-39th-Annual-Global-Healthcare-Conference/default.aspxMon, 11 Jun 2018 16:45:00 -04009d606c49-7aae-4e54-be68-b2d6386dca87https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-to-Announce-Results-for-Second-Quarter-2018-on-July-26/default.aspxThu, 07 Jun 2018 06:59:00 -04004e88cd44-bc83-4121-8c76-079d4db2fa89https://news.bms.com/news/details/2018/Opdivo-nivolumab-3-mgkg-Demonstrates-Sustained-Superior-Recurrence-Free-Survival-Versus-Yervoy-ipilimumab-10-mgkg-for-Broad-Range-of-Patients-with-Resected-Stage-III-or-IV-Melanoma/default.aspxMon, 04 Jun 2018 09:00:00 -040023354aa6-cca5-49b0-96c6-24136736972dhttps://news.bms.com/news/details/2018/Opdivo-Plus-Chemotherapy-Showed-Improved-Progression-Free-Survival-Versus-Chemotherapy-in-First-Line-Lung-Cancer-Patients-with-PD-L1-1-in-CheckMate--227-Study-to-Be-Presented-at-ASCO-2018/default.aspxMon, 04 Jun 2018 06:59:00 -04005c37ae75-7275-4c20-a16d-b928cd4f44b3https://news.bms.com/news/details/2018/Preliminary-Data-for-NKTR-214-in-Combination-with-Opdivo-nivolumab-for-Patients-with-Stage-IV-Metastatic-Melanoma-Renal-Cell-Carcinoma-and-Urothelial-Cancers-Presented-at-ASCO-2018/default.aspxSat, 02 Jun 2018 18:16:00 -04006e7eaba3-9805-4965-bfc5-5d09578995edhttps://news.bms.com/news/details/2018/US-Food-and-Drug-Administration-Lifts-Partial-Clinical-Hold-on-Opdivo-nivolumab-based-Combination-Study-in-Multiple-Myeloma/default.aspxFri, 01 Jun 2018 18:50:00 -0400a90a0a54-b95d-43f4-8ef6-d3454971c70chttps://news.bms.com/news/details/2018/Opdivo-nivolumab-Plus-Low-Dose-1mgkg-Yervoy-ipilimumab-Provided-Significant-and-Sustained-Health-Related-Quality-of-Life-Improvements-in-Intermediate--and-Poor-Risk-Patients-with-Advanced-Renal-Cell-Carcinoma-in-CheckMate--214-Study/default.aspxFri, 01 Jun 2018 06:59:00 -0400317f499f-9370-4a6e-b5a2-d49b895d7971https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-to-Hold-Investor-Event-to-Discuss-ASCO-Highlights/default.aspxThu, 24 May 2018 06:59:00 -0400b31881d2-cfe8-4ff2-8ce5-77329af7d90ehttps://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Highlights-Breadth-of-Immuno-OncologyBased-Combination-Research-and-Commitment-to-Advancing-Precision-Medicine-at-ASCO-2018/default.aspxWed, 16 May 2018 17:07:00 -040093e774e0-9f33-44d0-af40-997ecdb233a7https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-to-Take-Part-in-UBS-2018-Global-Healthcare-Conference/default.aspxTue, 15 May 2018 06:59:00 -0400d48d0ab8-3c34-4f9d-a53d-17dd541ba221https://news.bms.com/news/details/2018/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Type-II-Variation-Application-for-Opdivo-Plus-Yervoy-Combination-for-Treatment-of-First-Line-Metastatic-Non-Small-Cell-Lung-Cancer-NSCLC/default.aspxThu, 03 May 2018 08:38:00 -0400af66ccb1-cc26-4ffe-b847-0cad7745100chttps://news.bms.com/news/details/2018/Bristol-Myers-Squibb-and-Flatiron-Health-Expand-Collaboration-with-a-Three-Year-Agreement/default.aspxWed, 02 May 2018 08:30:00 -04005a642970-f279-4204-a1af-82303c101169https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results/default.aspxThu, 26 Apr 2018 11:15:00 -0400330e37a6-215a-44d3-847a-2a32c551437ehttps://news.bms.com/news/details/2018/European-Commission-Approves-Bristol-Myers-Squibbs-Opdivo-nivolumab-Four-Week-Dosing-Schedule-for-Advanced-Melanoma-and-Previously-Treated-Renal-Cell-Carcinoma/default.aspxWed, 25 Apr 2018 16:20:00 -04009a0f0ace-63b4-46b7-a765-25e777c424e0https://news.bms.com/news/details/2018/US-Food-and-Drug-Administration-Accepts-Supplemental-Biologics-License-Application-for-Opdivo-nivolumab-in-Previously-Treated-Patients-with-Small-Cell-Lung-Cancer-and-Grants-Priority-Review/default.aspxWed, 18 Apr 2018 16:15:00 -04006bed7372-ef38-4281-90b8-05abe1c19fbchttps://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Announces-Worldwide-Collaboration-with-Janssen-to-Develop-and-Commercialize-Next-Generation-Cardiovascular-Therapy/default.aspxMon, 16 Apr 2018 16:15:00 -040083056080-82fb-4052-a748-7a33e6cc2f07https://news.bms.com/news/details/2018/In-CheckMate--141-Opdivo-nivolumab-Demonstrated-Sustained-Overall-Survival-OS-Advantage-over-Standard-of-Care-in-Patients-with-Recurrent-or-Metastatic-Squamous-Cell-Carcinoma-of-the-Head-and-Neck-SCCHN/default.aspxMon, 16 Apr 2018 16:03:00 -0400d7a67b9c-77e6-41c8-8b22-1c64d50de9b9https://news.bms.com/news/details/2018/US-Food-and-Drug-Administration-Approves-Opdivo-nivolumab--Yervoy-ipilimumab-Combination-as-First-Line-Treatment-for-Patients-with-Intermediate--and-Poor-Risk-Advanced-Renal-Cell-Carcinoma/default.aspxMon, 16 Apr 2018 12:52:00 -040021ed2eaa-bb49-40ed-ac65-2760d9e267aehttps://news.bms.com/news/details/2018/Opdivo-Plus-Low-Dose-Yervoy-Combination-Reduces-the-Risk-of-Progression-or-Death-by-42-Versus-Chemotherapy-in-First-Line-Lung-Cancer-Patients-with-High-Tumor-Mutational-Burden-TMB/default.aspxMon, 16 Apr 2018 09:05:00 -0400f4a6c5c4-61c2-40f3-ab23-b492a99d6942https://news.bms.com/news/details/2018/Opdivo-nivolumab-First-PD-1-Inhibitor-to-Demonstrate-Superior-Survival-Benefit-Compared-with-Chemotherapy-in-a-Predominantly-Chinese-Population-with-Previously-Treated-Non-Small-Cell-Lung-Cancer-NSCLC/default.aspxFri, 13 Apr 2018 16:34:00 -0400de4129bf-abbe-492a-bb9b-64dd4403e09ehttps://news.bms.com/news/details/2018/Bristol-Myers-Squibb-and-Illumina-Announce-Strategic-Collaboration-to-Develop-and-Commercialize-Companion-Diagnostics-for-Bristol-Myers-Squibbs-Oncology-Immunotherapies/default.aspxFri, 13 Apr 2018 16:15:00 -04001540f9a5-6eb3-4d8d-b548-1f400a7abba4https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-and-Harvard-Announce-New-Fibrosis-Research-Collaboration/default.aspxThu, 12 Apr 2018 06:59:00 -040001bd249e-3b6d-4826-9d55-70b2fbc8300chttps://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Receives-2018-ENERGY-STAR-Partner-of-the-Year-Sustained-Excellence-Award/default.aspxMon, 02 Apr 2018 17:05:00 -0400560e3f63-cc3d-4089-ade8-c1d678577b51https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-to-Hold-Investor-Event-to-Discuss-AACR-Highlights/default.aspxMon, 02 Apr 2018 16:30:00 -040070eaaf19-42df-4677-ba5d-ab0b3952b067https://news.bms.com/news/details/2018/US-Food-and-Drug-Administration-FDA-Accepts-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-for-Previously-Treated-Patients-with-MSI-H-or-dMMR-Metastatic-Colorectal-Cancer-for-Priority-Review/default.aspxTue, 27 Mar 2018 06:59:00 -04007a4b4c8f-8a40-4e7b-9093-18020779de2ahttps://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Approval-of-Opdivo-Four-Week-Dosing-Schedule-for-Advanced-Melanoma-and-Previously-Treated-Renal-Cell-Carcinoma/default.aspxMon, 26 Mar 2018 06:59:00 -0400c454523d-9951-4565-9069-a1197e4f1469https://news.bms.com/news/details/2018/Research-from-Bristol-Myers-Squibbs-Innovative-Oncology-Development-Program-to-Be-Presented-at-AACR-2018-Demonstrates-Commitment-to-Advancing-Precision-Medicine-Research-for-Patients-with-Cancer/default.aspxWed, 14 Mar 2018 18:49:00 -04003abc69a7-6c5a-4c41-958b-c5ef57ee3238https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-to-Announce-Results-for-First-Quarter-2018-on-April-26/default.aspxWed, 14 Mar 2018 07:59:00 -04009780aacc-b7a6-4fce-be55-0206d78011c8https://news.bms.com/news/details/2018/Findings-Released-from-Largest-Real-World-Data-Analysis-of-Non-Valvular-Atrial-Fibrillation-Patients-Receiving-Direct-Oral-Anticoagulants/default.aspxSun, 11 Mar 2018 09:00:00 -04003efc1c11-62b5-4c59-ab80-b584ba039103https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-to-Take-Part-in-Barclays-Global-Healthcare-Conference/default.aspxWed, 07 Mar 2018 17:15:00 -0500b3aefa06-73ab-4480-8507-ec49eb9fdbedhttps://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Named-One-of-the-2018-Top-70-Companies-for-Executive-Women/default.aspxTue, 06 Mar 2018 10:00:00 -0500e1b53ee1-1f13-4eeb-bc1c-08eab09a6c2bhttps://news.bms.com/news/details/2018/Bristol-Myers-Squibbs-Opdivo-nivolumab-Now-the-First-and-Only-FDA-Approved-PD-1-Inhibitor-to-Offer-Every-Four-Week-Dosing/default.aspxTue, 06 Mar 2018 07:59:00 -0500d389f23c-2bc1-4ecd-8d93-e85f08fc725ahttps://news.bms.com/news/details/2018/Bristol-Myers-Squibb-to-Take-Part-in-Cowen-and-Company-38th-Annual-Global-Health-Care-Conference/default.aspxMon, 05 Mar 2018 07:59:00 -0500ee0f529c-a9bf-4bd8-b356-34e4dc59e914https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Announces-Dividend-7dbd280d9/default.aspxThu, 01 Mar 2018 17:20:00 -05005004abba-6cf3-4f43-954d-5b8d958e601bhttps://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Names-Jos-Baselga-MD-PhD-to-Board-of-Directors/default.aspxThu, 01 Mar 2018 17:15:00 -0500156c8933-3db8-445d-bf15-7d10bad93b2fhttps://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Announces-Expansion-of-the-International-Immuno-Oncology-Network-II-ON-with-Addition-of-Yale-Cancer-Center/default.aspxMon, 26 Feb 2018 08:00:00 -0500ec53ee21-f696-4053-a33a-4ae45c776c00https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-and-Nektar-Therapeutics-Announce-Global-Development--Commercialization-Collaboration-for-Nektars-CD122-biased-Agonist-NKTR-214/default.aspxWed, 14 Feb 2018 07:59:00 -0500411f4922-7f33-4526-b11b-9c8ac4db1104https://news.bms.com/news/details/2018/Bristol-Myers-Squibb-to-Take-Part-in-Leerink-7th-Annual-Global-Healthcare-Conference/default.aspxThu, 08 Feb 2018 07:59:00 -0500a3278910-b945-4386-a44a-4d33e84b26e0https://news.bms.com/news/details/2018/Statement-Bristol-Myers-Squibb-Validates-Predictive-Role-of-Tumor-Mutation-Burden-in-Phase-3-CheckMate--227-Program-in-First-Line-Non-Small-Cell-Lung-Cancer/default.aspxMon, 05 Feb 2018 08:12:00 -0500f57644c9-6960-4c47-b201-216e49d59fdchttps://news.bms.com/news/details/2018/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results/default.aspxMon, 05 Feb 2018 07:59:00 -0500a8602f9a-e6d9-4173-a392-9a6cc4cb7b4fhttps://news.bms.com/news/details/2018/Pivotal-Phase-3-CheckMate--227-Study-Demonstrates-Superior-Progression-Free-Survival-PFS-with-the-Opdivo-Plus-Yervoy-Combination-Versus-Chemotherapy-in-First-Line-Non-Small-Cell-Lung-Cancer-NSCLC-Patients-with-High-Tumor-Mutation-Burden-TMB/default.aspxMon, 05 Feb 2018 07:59:00 -05000b80595a-7928-40c2-bb84-9fec7bc89af6https://news.bms.com/news/details/2018/European-Commission-Approves-Bristol-Myers-Squibbs-Yervoy-ipilimumab-for-Treatment-of-Pediatric-Patients-12-Years-and-Older-with-Unresectable-or-Metastatic-Melanoma/default.aspxMon, 22 Jan 2018 07:59:00 -0500704aa44f-3601-4ff2-89be-23f7c1d037c7https://news.bms.com/news/details/2018/Opdivo-nivolumab-in-Combination-with-Yervoy-ipilimumab-Demonstrates-Clinical-Activity-in-Previously-Treated-Patients-with-dMMR-or-MSI-H-Metastatic-Colorectal-Cancer/default.aspxSat, 20 Jan 2018 15:03:00 -0500015c9c14-11f6-46af-a9d2-58a3d223c2bdhttps://news.bms.com/news/details/2018/Bristol-Myers-Squibb-to-Present-at-JP-Morgan-Healthcare-Conference/default.aspxWed, 03 Jan 2018 10:00:00 -05008e73b446-da73-4b3f-97fa-cb3f4a0ec195https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Receives-FDA-Approval-for-Opdivo-nivolumab-as-Adjuvant-Therapy-in-Patients-with-Completely-Resected-Melanoma-with-Lymph-Node-Involvement-or-Metastatic-Disease/default.aspxWed, 20 Dec 2017 16:28:00 -0500a1d72109-38c6-450c-ab34-366f2fe04248https://news.bms.com/news/details/2017/TARIS-and-Bristol-Myers-Squibb-Announce-Clinical-Trial-Collaboration/default.aspxWed, 20 Dec 2017 07:59:00 -0500adc12528-4249-45be-9ac7-ec5b794ba449https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Announce-Results-for-Fourth-Quarter-2017-on-February-5th/default.aspxTue, 19 Dec 2017 10:00:00 -0500ea7d88b2-a7fa-4fa6-8cfb-db07803c16dehttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Approval-of-Yervoy-ipilimumab-for-the-Treatment-of-Pediatric-Patients-12-Years-and-Older-with-Unresectable-or-Metastatic-Melanoma/default.aspxMon, 18 Dec 2017 07:59:00 -050035ba2994-e680-4385-b820-e2b23cd74b8fhttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Named-One-of-Americas-Most-JUST-Companies-in-2017-By-Forbes-and-JUST-Capital/default.aspxThu, 14 Dec 2017 15:20:00 -05002e75cc61-f73f-45f0-9883-6118ab4b4696https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Granted-Exclusive-License-by-Ono-Pharmaceutical-for-Multiple-Programs-Targeting-Immuno-Suppressive-Factors-in-the-Tumor-Microenvironment/default.aspxWed, 13 Dec 2017 19:30:00 -050029fb8394-da2d-417d-9dae-df6f53a9800dhttps://news.bms.com/news/details/2017/US-Food-and-Drug-Administration-FDA-Accepts-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-in-Intermediate--and-Poor-Risk-Patients-with-Advanced-Renal-Cell-Carcinoma-and-Grants-Priority-Review/default.aspxWed, 13 Dec 2017 18:28:00 -05000276ad6e-21c5-4572-8201-bc8c76b6d052https://news.bms.com/news/details/2017/Seattle-Genetics-and-Bristol-Myers-Squibb-Highlight-Interim-Results-from-Phase-12-Study-Evaluating-the-Combination-of-ADCETRIS-Brentuximab-Vedotin-and-Opdivo-Nivolumab-in-Relapsed-or-Refractory-Hodgkin-Lymphoma/default.aspxMon, 11 Dec 2017 11:30:00 -050040f24416-7cbe-43fe-bb1e-63cfe850c754https://news.bms.com/news/details/2017/Sprycel-dasatinib-Added-to-Standard-Chemotherapy-Demonstrates-Three-Year-Survival-Benefit-in-Pediatric-Patients-with-Newly-Diagnosed-Philadelphia-Chromosome-Positive-Acute-Lymphoblastic-Leukemia/default.aspxSat, 09 Dec 2017 10:30:00 -050096391f45-c5eb-4ba7-8483-7f26e0b655a0https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Announces-Dividend-Increase/default.aspxThu, 07 Dec 2017 17:15:00 -0500d3c9f643-97d8-4d8d-b749-f45785b3137ehttps://news.bms.com/news/details/2017/US-Food-and-Drug-Administration-Lifts-Partial-Clinical-Holds-on-Two-Opdivo-based-Combination-Studies-in-Multiple-Myeloma/default.aspxTue, 05 Dec 2017 19:24:00 -0500f5b7084c-6afc-4e20-af37-12e8ab6a6161https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-and-Pfizer-Alliance-Urge-People-to-Tune-in-to-AFib-Take-Note-of-Stroke-Risk/default.aspxTue, 05 Dec 2017 09:00:00 -0500d3dc9497-3733-4bf3-b003-37acd54b4e79https://news.bms.com/news/details/2017/CheckMate--078-a-Pivotal-Multinational-Phase-3-Opdivo-nivolumab-Lung-Cancer-Trial-with-Predominantly-Chinese-Patients-Stopped-Early-for-Demonstrating-Superior-Overall-Survival/default.aspxThu, 30 Nov 2017 20:00:00 -0500fd1eac8b-fcf1-4f37-b029-76f67a7a561bhttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Take-Part-at-the-Citi-2017-Global-Healthcare-Conference/default.aspxThu, 30 Nov 2017 17:59:00 -0500b1be348c-5aae-47cb-a620-3fe73971c681https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Present-New-Data-Across-a-Broad-Range-of-Blood-Cancers-at-the-59th-Annual-Meeting--Exposition-of-the-American-Society-of-Hematology/default.aspxWed, 29 Nov 2017 17:15:00 -050056acdbda-1650-45e9-ba8d-065ce68cee90https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Awards-Golden-Tickets-for-LabCentral-to-Neutrolis-Remora-Therapeutics/default.aspxTue, 28 Nov 2017 07:59:00 -0500b6032a28-2412-4594-ac42-b1f5d794a388https://news.bms.com/news/details/2017/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Type-II-Variation-Application-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-in-Intermediate--and-Poor-Risk-Patients-with-Advanced-Renal-Cell-Carcinoma/default.aspxTue, 28 Nov 2017 07:40:00 -050027b107f4-7370-46c4-a818-8e02fda9ea18https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Take-Part-in-Evercore-ISI-Biopharma-Conference/default.aspxWed, 22 Nov 2017 07:59:00 -050041afd57b-d7aa-4428-b8b3-5ebd20eac906https://news.bms.com/news/details/2017/BMS-Pfizer-Alliance-to-Unveil-Real-World-Data-Analyses---Cost-Safety-and-Comparative-Effectiveness-Findings-Associated-with-Oral-Anticoagulants-in-Non-Valvular-Atrial-Fibrillation/default.aspxFri, 10 Nov 2017 17:13:00 -05008213b236-dfc7-448f-ade2-41997d84e78bhttps://news.bms.com/news/details/2017/Encouraging-Response-Observed-with-Opdivo-nivolumab-Plus-Investigational-IDO1-Inhibitor-BMS-986205-in-Heavily-Pre-Treated-Patients-with-Advanced-Cancers-in-Phase-12a-Study-CA017-003/default.aspxFri, 10 Nov 2017 08:00:00 -05003ef96385-8e45-4b5e-91a1-bc97afb45b7fhttps://news.bms.com/news/details/2017/US-Food-and-Drug-Administration-Expands-Approval-of-Sprycel-dasatinib-to-Include-Treatment-of-Children-with-Philadelphia-Chromosome-Positive-Chronic-Myeloid-Leukemia-in-Chronic-Phase/default.aspxFri, 10 Nov 2017 07:30:00 -050009a6bdbd-aaea-401a-afb6-5069a985cc22https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-and-Five-Prime-Present-Phase-1a1b-Data-Evaluating-Cabiralizumab-anti-CSF-1-receptor-antibody-with-Opdivo-nivolumab-in-Patients-with-Advanced-Solid-Tumors/default.aspxThu, 09 Nov 2017 09:00:00 -0500958f43cd-1812-49b3-b06d-67b2ed03bac6https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Take-Part-in-Jefferies-London-Healthcare-Conference/default.aspxWed, 08 Nov 2017 07:59:00 -0500ac59b5dc-55da-404d-ad34-55a18140a9f7https://news.bms.com/news/details/2017/Opdivo-Plus-Yervoy-Combination-Delivered-Overall-Survival-Benefit-Across-PD-L1-Expression-Levels-in-Intermediate--and-Poor-Risk-Patients-with-Previously-Untreated-Advanced-or-Metastatic-Renal-Cell-Carcinoma/default.aspxTue, 07 Nov 2017 09:35:00 -0500c6174d4d-89db-4c4e-aafb-2380d144e17bhttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Highlight-Clinical-and-Translational-Research-at-the-Society-for-Immunotherapy-of-Cancer-SITC-32nd-Annual-Meeting/default.aspxTue, 07 Nov 2017 09:00:00 -05001d5eb403-27d0-4dc8-a67d-4ee38b8e424ahttps://news.bms.com/news/details/2017/Opdivo-nivolumab-Demonstrates-Superior-Three-Year-Survival-Benefit-for-Patients-with-Previously-Treated-Advanced-Renal-Cell-Carcinoma-RCC/default.aspxMon, 06 Nov 2017 07:59:00 -050005cf84fa-a28c-4088-9096-5cec0c3f3758https://news.bms.com/news/details/2017/PHOTO-ADVISORY-Eric-Stonestreet-Visits-Lung-Cancer-Alliances-Lung-Love-Walk-Houston-to-Raise-Awareness-of-Cancer-Research/default.aspxSun, 05 Nov 2017 11:00:00 -05008b6cbda3-cdb5-4c8e-a5df-06320057a86bhttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Opens-New-Child-Development-Center-in-Lawrence-NJ/default.aspxFri, 03 Nov 2017 17:09:00 -0400862c9b6a-8f73-4720-a8ac-de18bca10f67https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Showcase-Companys-Progress-in-Researching-Personalized-Medicine-for-the-Potential-Treatment-of-Autoimmune-Diseases-at-2017-American-College-of-Rheumatology-and-Association-of-Rheumatology-Health-Professionals-Annual-Meeting/default.aspxThu, 02 Nov 2017 07:59:00 -04002868e5d6-7d79-4727-a073-4b119e99007fhttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-BioLabs-Announce-Founding-Sponsorship-in-Support-of-Promising-Biotech-Companies-in-New-York/default.aspxWed, 01 Nov 2017 07:59:00 -04004f9f6ba6-320e-4f06-817b-7ff17db4c698https://news.bms.com/news/details/2017/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Type-II-Variation-Application-for-Opdivo-nivolumab-for-Treatment-of-Patients-with-Resected-High-Risk-Advanced-Melanoma/default.aspxMon, 30 Oct 2017 07:59:00 -0400df42627e-5e50-48b5-8655-14ef43be4f99https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Reports-Third-Quarter-Financial-Results/default.aspxThu, 26 Oct 2017 06:59:00 -0400f212ad77-e82b-42df-a7f5-8220aa35df35https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Present-New-Data-Advancing-Research-Across-Serious-Liver-Diseases-at-The-Liver-Meeting-2017/default.aspxFri, 20 Oct 2017 06:59:00 -0400c0cd4538-f4cc-4516-82be-832a9b72567ahttps://news.bms.com/news/details/2017/US-Food-and-Drug-Administration-FDA-Accepts-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-in-Patients-with-Resected-High-Risk-Advanced-Melanoma-and-Grants-Priority-Review/default.aspxMon, 16 Oct 2017 16:15:00 -040014eb7549-b4c2-4c3c-af56-0820d3e426fehttps://news.bms.com/news/details/2017/Opdivo-Alone-or-Combined-with-Yervoy-Shows-Encouraging-Response-and-Survival-Rates-in-Recurrent-Small-Cell-Lung-Cancer-Patients-with-High-Tumor-Mutation-Burden-in-Exploratory-Analysis-from-Phase-12-Study-CheckMate--032/default.aspxMon, 16 Oct 2017 03:15:00 -040063d963ce-5496-4ab8-970d-ba7f4a871659https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Appoints-Saurabh-Saha-MD-PhD-as-Senior-Vice-President-Global-Head-of-Translational-Medicine/default.aspxMon, 09 Oct 2017 06:59:00 -04002fcb5d2c-a7b9-40f5-89b7-0e6640bf916chttps://news.bms.com/news/details/2017/Caregivers-Wish-Liver-Cancer-Received-Greater-Public-Awareness-in-the-US-New-Survey-Reveals/default.aspxWed, 04 Oct 2017 06:59:00 -04004a933dae-0153-4308-8178-681fd04eb580https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Advancing-Research-Across-Thoracic-Cancers-with-New-Data-at-IASLC-18th-World-Conference-on-Lung-Cancer/default.aspxWed, 27 Sep 2017 17:00:00 -040082b4f65a-531b-4d79-b3e8-fe64aabea0e5https://news.bms.com/news/details/2017/Bristol-Myers-Squibbs-Opdivo-nivolumab-Receives-FDA-Approval-for-the-Treatment-of-Hepatocellular-Carcinoma-Patients-Previously-Treated-with-Sorafenib/default.aspxFri, 22 Sep 2017 18:10:00 -04007b896a0f-0ade-4380-ae0e-6a16ab6d3772https://news.bms.com/news/details/2017/AbbVie-and-Bristol-Myers-Squibb-Announce-Clinical-Research-Collaboration-to-Evaluate-a-Therapeutic-Regimen-in-Advanced-Solid-Tumors/default.aspxFri, 22 Sep 2017 06:59:00 -040012635098-b515-46b8-a1fd-2b6670c8a3fbhttps://news.bms.com/news/details/2017/Japan-Ministry-of-Health-Labor-and-Welfare-Approves-Opdivo-nivolumab-for-the-Treatment-of-Patients-with-Unresectable-Advanced-or-Recurrent-Gastric-Cancer-Which-Has-Progressed-After-Chemotherapy/default.aspxFri, 22 Sep 2017 05:00:00 -0400ee07ab63-1c0a-4deb-9bee-44c98c7c62cehttps://news.bms.com/news/details/2017/New-Global-Report-Finds-Majority-of-People-at-High-Risk-of-Stroke-Not-Being-Screened-for-Common-Risk-Factors/default.aspxThu, 21 Sep 2017 06:59:00 -040084fa2e9a-98e9-40c5-9aaa-aeda40b4f449https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Take-Part-in-Leerink-Partners-Rare-Disease--Immuno-Oncology-Roundtable-Conference/default.aspxThu, 21 Sep 2017 06:59:00 -0400028d9733-e2f6-42f5-81ff-3295ddaf57e4https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-and-Halozyme-Enter-Global-Collaboration-and-License-Agreement-for-ENHANZE-Technology/default.aspxThu, 14 Sep 2017 06:59:00 -040057a44df5-726f-4ddf-b25a-2587fbfa47dchttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Announces-Dividend/default.aspxWed, 13 Sep 2017 16:30:00 -040071f0e2f7-a392-4edb-bbe2-883b4df60fbfhttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Names-Karen-Vousden-PhD-to-Board-of-Directors/default.aspxWed, 13 Sep 2017 16:15:00 -0400ea47b6b2-0126-4488-bf94-5fa2049619d2https://news.bms.com/news/details/2017/Opdivo-nivolumab-Demonstrates-Superior-Recurrence-Free-Survival-Versus-Yervoy-ipilimumab-for-Patients-with-Resected-High-Risk-Melanoma-in-Phase-3-CheckMate--238-Study/default.aspxSun, 10 Sep 2017 18:11:00 -040032081ee1-75d4-46f9-aa04-236485bf3af4https://news.bms.com/news/details/2017/Opdivo-Plus-Yervoy-Combination-Demonstrated-Superior-Overall-Survival-and-Showed-Durable-Responses-in-Patients-with-Previously-Untreated-Advanced-or-Metastatic-Renal-Cell-Carcinoma-in-Phase-3-CheckMate--214-Trial/default.aspxSun, 10 Sep 2017 11:55:00 -0400caeafead-0ba5-418d-84f3-236fd8a32c67https://news.bms.com/news/details/2017/Two-Pivotal-Opdivo-nivolumab-Trials-Show-Three-Year-Survival-Benefit-in-Patients-with-Previously-Treated-Advanced-Non-Small-Cell-Lung-Cancer/default.aspxFri, 08 Sep 2017 05:30:00 -0400ee00f3de-011b-46c0-86e7-43ee2ef52218https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Completes-Previously-Announced-Acquisition-of-IFM-Therapeutics/default.aspxThu, 07 Sep 2017 16:30:00 -0400b508a308-f954-4066-a69a-5cd1879de67chttps://news.bms.com/news/details/2017/CheckMate--214-Study-Evaluating-Opdivo-in-Combination-with-Yervoy-Stopped-Early-for-Demonstrating-Overall-Survival-Benefit-in-Patients-with-Previously-Untreated-Advanced-or-Metastatic-Renal-Cell-Carcinoma/default.aspxThu, 07 Sep 2017 06:59:00 -0400f1d25c85-4356-46e9-b10e-8fcedc924d71https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Announce-Results-for-Third-Quarter-2017-on-October-26/default.aspxThu, 07 Sep 2017 06:59:00 -0400a13af281-4a94-4447-8c26-7e76d16550b7https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Provides-an-Update-on-Three-Opdivo-based-Combination-Clinical-Studies-in-Multiple-Myeloma/default.aspxWed, 06 Sep 2017 17:19:00 -04006e36ca37-16dc-4bb4-b0bd-055c62463b32https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Employees-Ride-Across-the-US-to-Raise-Money-to-Support-Cancer-Research-by-Stand-Up-To-Cancer/default.aspxWed, 06 Sep 2017 07:00:00 -04003eefa32c-0ff9-4a5e-9ec0-860662107ea1https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Take-Part-in-Morgan-Stanley-Global-Health-Care-Conference/default.aspxTue, 05 Sep 2017 06:59:00 -0400222b013d-bd5a-4ba4-a9d0-4d79558f4434https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Data-at-ESMO-2017-Demonstrate-Companys-Innovative-Research-Approach-to-Treating-Cancer-from-All-Angles/default.aspxWed, 30 Aug 2017 18:05:00 -040067c189e1-f038-48a2-b29d-8b3bb38ea6cdhttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-and-Pfizer-Alliance-Announce-Real-World-Observational-Analysis-of-the-Effectiveness-and-Safety-of-Direct-Oral-Anticoagulants-Compared-to-Warfarin-in-Elderly-Patients-with-Non-Valvular-Atrial-Fibrillation/default.aspxTue, 29 Aug 2017 08:35:00 -0400bf969e29-2afb-4091-a7dc-ec7f560731c9https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-and-Daiichi-Sankyo-Announce-Research-Collaboration-to-Evaluate-Opdivo-nivolumab-and-DS-8201-in-HER2-Expressing-Breast-and-Bladder-Cancers/default.aspxMon, 28 Aug 2017 16:01:00 -040043d52f88-b750-4dab-bcc0-448f277b8e40https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-and-Pfizer-Present-Investigational-Eliquis-apixaban-Data-for-Patients-with-Non-Valvular-Atrial-Fibrillation-NVAF-Undergoing-Cardioversion/default.aspxMon, 28 Aug 2017 05:00:00 -0400647f0e1c-8bd1-4891-abb8-8082ade378cdhttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-and-Pfizer-Present-Observational-Real-World-Data-Analysis-on-the-Effectiveness-and-Safety-of-Eliquis-apixaban-Compared-to-Warfarin-in-Select-High-Risk-Patients-with-Non-Valvular-Atrial-Fibrillation/default.aspxMon, 28 Aug 2017 02:30:00 -040044a3cadb-f371-4ed1-8681-99e69a71ff65https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-and-Pfizer-to-Highlight-Commitment-to-Reducing-the-Risk-of-Stroke-Caused-by-Non-Valvular-Atrial-Fibrillation-NVAF-and-Treating-Deep-Vein-ThrombosisPulmonary-Embolism-DVTPE-at-ESC-Congress-2017/default.aspxFri, 18 Aug 2017 06:59:00 -0400dc8182a8-b8d4-4806-89d0-992ab4584a25https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Announces-Topline-Results-from-CheckMate--214-a-Phase-3-Study-of-Opdivo-in-Combination-with-Yervoy-in-Intermediate-and-Poor-Risk-Patients-with-Previously-Untreated-Advanced-or-Metastatic-Renal-Cell-Carcinoma/default.aspxTue, 15 Aug 2017 16:30:00 -0400f8d61847-78a2-436d-95f0-9179e70b483bhttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Acquire-IFM-Therapeutics-to-Strengthen-Oncology-Pipeline-Focus-on-Innate-Immunity/default.aspxThu, 03 Aug 2017 16:00:00 -0400bcb56e4e-b832-47cc-90cb-ef12f3eee9d0https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Receives-FDA-Approval-for-Opdivo-nivolumab-in-MSI-H-or-dMMR-Metastatic-Colorectal-Cancer-That-Has-Progressed-Following-Treatment-with-a-Fluoropyrimidine-Oxaliplatin-and-Irinotecan/default.aspxTue, 01 Aug 2017 06:59:00 -0400167b0e24-4f30-4a95-9d49-ee455e6dbf8ahttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-and-Clovis-Oncology-Announce-a-Broad-Clinical-Collaboration-to-Evaluate-Combination-of-Opdivo-Nivolumab-and-Rubraca-Rucaparib-in-Phase-2-and-Pivotal-Phase-3-Clinical-Trials-in-Multiple-Tumor-Types/default.aspxMon, 31 Jul 2017 06:59:00 -04009714fe1f-9c0d-4370-8967-704a8ebc72ffhttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Reports-Second-Quarter-Financial-Results/default.aspxThu, 27 Jul 2017 06:59:00 -04003f896d61-71dd-4b9c-a8f3-337c21051cd9https://news.bms.com/news/details/2017/Bristol-Myers-Squibbs-ORENCIA-abatacept-Receives-Second-European-Commission-Approval-in-Less-than-a-Year--New-Approval-for-Treatment-of-Active-Psoriatic-Arthritis-PsA1/default.aspxWed, 26 Jul 2017 06:59:00 -040067e210f9-dcfb-416b-976c-3f958f292ab5https://news.bms.com/news/details/2017/US-Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-Applications-for-Opdivo-nivolumab-Four-Week-Dosing-Schedule-Across-All-Approved-Indications/default.aspxMon, 24 Jul 2017 16:15:00 -040054df6e8f-cae8-4e56-91e6-87cb2a21bd27https://news.bms.com/news/details/2017/US-Food-and-Drug-Administration-Expands-Approval-of-Yervoy-ipilimumab-to-Include-Pediatric-Patients-12-Years-and-Older-with-Unresectable-or-Metastatic-Melanoma/default.aspxMon, 24 Jul 2017 06:59:00 -0400f180aba3-227a-438b-87bb-1344faa9c559https://news.bms.com/news/details/2017/Exelixis-and-Bristol-Myers-Squibb-Initiate-Phase-3-Trial-of-Opdivo-in-Combination-with-CABOMETYX-or-Opdivo-and-Yervoy-in-Combination-with-CABOMETYX-Versus-Sunitinib-in-Previously-Untreated-Advanced-or-Metastatic-Renal-Cell-Carcinoma/default.aspxMon, 10 Jul 2017 08:00:00 -0400ce028976-a15e-4aee-8219-efbd4f2ede6ehttps://news.bms.com/news/details/2017/US-Food-and-Drug-Administration-Accepts-for-Priority-Review-Bristol-Myers-Squibbs-Application-for-Sprycel-dasatinib-in-Children-with-Philadelphia-Chromosome-Positive-Chronic-Phase-Chronic-Myeloid-Leukemia/default.aspxMon, 10 Jul 2017 06:58:00 -04005bc46450-768a-44fa-a937-66e0d12e6a04https://news.bms.com/news/details/2017/Bristol-Myers-Squibbs-ORENCIA-abatacept-Receives-FDA-Approval-for-Treatment-of-Active-Psoriatic-Arthritis-PsA-in-Adults/default.aspxThu, 06 Jul 2017 07:30:00 -0400d79b4639-fd81-4755-8c4e-42031c0d29d1https://news.bms.com/news/details/2017/Phase-3-Study-Evaluatingthe-Safety-and-Efficacy-of-Adjuvant-Opdivoin-Resected-High-Risk-Melanoma-Patients-Meets-Primary-Endpoint/default.aspxWed, 05 Jul 2017 06:15:00 -0400596e1a76-f780-4097-9104-379a4ff5a428https://news.bms.com/news/details/2017/Modern-Family-Star-Eric-Stonestreet-Challenges-Americans-to-Support-the-Cancer-Community-and-Learn-about-Immuno-Oncology-Research-Through-Ready-Raise-Rise/default.aspxWed, 28 Jun 2017 06:59:00 -04007f190096-1beb-4145-8e11-73b41f5906fehttps://news.bms.com/news/details/2017/Four-Year-Follow-up-with-Empliciti-elotuzumab-Plus-LenalidomideDexamethasone-ELd-in-Patients-with-Advanced-Multiple-Myeloma-Shows-Long-term-Efficacy-in-ELOQUENT-2-Trial/default.aspxSat, 24 Jun 2017 10:00:00 -040076a0b10c-deec-482c-a331-ff82334826f7https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Announces-the-Expiration-of-its-Cash-Tender-Offer/default.aspxWed, 21 Jun 2017 06:59:00 -04004cc7a836-9694-4ec8-8a83-5cf1600b31a7https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Announces-the-Pricing-Terms-of-its-Cash-Tender-Offer-For-Any-and-All-of-Certain-of-its-Outstanding-Debt-Securities/default.aspxTue, 20 Jun 2017 15:40:00 -04000f27b9d3-2856-4377-85f8-074c7d8f6968https://news.bms.com/news/details/2017/Extended-Follow-UpData-EvaluatingOpdivonivolumab-Shows-Durable-Response-in-Adult-Patients-with-Relapsed-or-Progressed-Classical-Hodgkin-Lymphoma/default.aspxFri, 16 Jun 2017 06:58:00 -04000d95b561-5421-4c60-9909-51bfa7201560https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Sell-Manufacturing-Facility-in-Swords-Ireland-to-SK-Biotek-Co-Ltd/default.aspxFri, 16 Jun 2017 04:35:00 -0400e44f42a4-d668-4e2e-b245-79c4807a8c3fhttps://news.bms.com/news/details/2017/Seattle-Genetics-and-Bristol-Myers-Squibb-Highlight-Interim-Phase-12-Data-Evaluating-Combination-of-ADCETRIS-Brentuximab-Vedotin-and-Opdivo-Nivolumab-in-Relapsed-Hodgkin-Lymphoma-at-the-International-Conference-on-Malignant-Lymphoma/default.aspxThu, 15 Jun 2017 06:58:00 -04006f4628cd-e3bf-427d-93f5-a4881d9a395dhttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Announces-Cash-Tender-Offer-For-Any-and-All-of-Certain-of-Its-Outstanding-Debt-Securities/default.aspxWed, 14 Jun 2017 08:40:00 -040017b0d898-b31e-4910-823e-0b397fa29c04https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-To-Present-New-Research-Related-to-the-Treatment-of-Rheumatoid-Arthritis-Patients-With-Highly-Active-Progressive-Disease-at-the-Annual-European-Congress-of-RheumatologyEULAR-2017/default.aspxWed, 14 Jun 2017 06:59:00 -0400b849ff23-76c1-46af-b3f5-7e09d109cf4ahttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Announces-Dividend-c5a6c5dab/default.aspxTue, 13 Jun 2017 16:05:00 -0400ff499678-f40b-403c-b16f-03099d50ad7ehttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Announce-Results-for-Second-Quarter-2017-on-July-27/default.aspxMon, 12 Jun 2017 10:00:00 -04002f7cbe00-97a3-4563-931b-f5a9cf77a990https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Announces-Availability-of-New-ORENCIA-abatacept-Subcutaneous-Administration-Option-for-Patients-2-Years-of-Age-and-Older-with-Moderately-to-Severely-Active-Polyarticular-Juvenile-Idiopathic-Arthritis-JIA/default.aspxThu, 08 Jun 2017 07:30:00 -0400b569a6e1-03bb-4c59-b713-75cfda1664fchttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Take-Part-in-Goldman-Sachs-38th-Annual-Global-Healthcare-Conference/default.aspxWed, 07 Jun 2017 06:59:00 -04000ffa6244-4e89-4b2d-8361-63a64c481201https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Announces-New-Collaboration-to-Evaluate-Combination-Therapy-in-Colorectal-Cancer/default.aspxMon, 05 Jun 2017 16:05:00 -0400d49fddd5-f764-4968-8dd1-27d3f3afb4cfhttps://news.bms.com/news/details/2017/Encouraging-Disease-Control-Rates-Observed-with-Nivolumab-Alone-or-in-Combination-with-Ipilimumab-in-Refractory-or-Relapsing-Malignant-Pleural-Mesothelioma-Patients-Results-from-IFCT-1501-MAPS-2-Trial/default.aspxMon, 05 Jun 2017 07:30:00 -0400f849a064-2e46-49b4-a004-317df25e2dfahttps://news.bms.com/news/details/2017/Clinical-Trial-Data-for-Combination-of-Epacadostat-and-Opdivo-nivolumab-Demonstrate-Durable-Clinical-Responses-in-Patients-with-Melanoma-and-Head-and-Neck-Cancer/default.aspxMon, 05 Jun 2017 07:30:00 -0400b9eeb02c-2dcb-4594-b0ed-14dd653c4853https://news.bms.com/news/details/2017/Early-Durable-Responses-Seen-with-Sprycel-dasatinib-in-First--and-Second-Line-Treatment-of-Pediatric-Patients-with-Chronic-Myeloid-Leukemia-in-Chronic-Phase-CP-CML/default.aspxMon, 05 Jun 2017 07:15:00 -040030ef1da9-e1a6-41d7-be2a-83da25a3698ahttps://news.bms.com/news/details/2017/NewData-Evaluatingthe-Safety-and-Preliminary-Relapse-Free-Survival-of-Adjuvant-Yervoyipilimumab-3-mgkg-and-10-mgkg-in-Resected-High-Risk-Melanoma-Patients-Presented-at-ASCO/default.aspxSun, 04 Jun 2017 08:30:00 -04005f6c235b-70aa-4b1f-8a99-af1f6849196chttps://news.bms.com/news/details/2017/First-Presentation-of-Efficacy-Data-from-CheckMate--204-Evaluating-the-Combination-of-Opdivonivolumab-and-Yervoyipilimumab-Demonstrates-Anti-tumor-Activity-in-Advanced-Melanoma-Patients-with-Brain-Metastases/default.aspxSun, 04 Jun 2017 08:00:00 -0400fa3c184d-9ce7-498a-bb32-e5df66121ab6https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-and-QIAGEN-Sign-Agreement-for-Use-of-NGS-Technology-to-Develop-Gene-Expression-Profiles-for-Immuno-Oncology-Therapies/default.aspxSat, 03 Jun 2017 13:00:00 -0400ff5a2327-058b-458c-851b-6de5c5598f52https://news.bms.com/news/details/2017/Opdivo-nivolumab-in-Combination-with-Yervoy-ipilimumab-Demonstrated-Promising-Activity-in-Previously-Treated-Patients-with-dMMR-or-MSI-H-Metastatic-Colorectal-Cancer-in-Phase-2-CheckMate--142-Study/default.aspxSat, 03 Jun 2017 09:00:00 -0400b4f559c2-b506-4c73-8139-e2ce029cd7eehttps://news.bms.com/news/details/2017/Anti-LAG-3-BMS-986016-in-Combination-with-Opdivo-nivolumab-Showed-Activity-in-Patients-with-Melanoma-Who-Were-Relapsed-or-Refractory-to-Anti-PD-1PD-L1-Therapy/default.aspxSat, 03 Jun 2017 08:00:00 -040031776fd9-728d-46a7-b2d6-bffb4b434877https://news.bms.com/news/details/2017/European-Commission-Approves-Bristol-Myers-Squibbs-Opdivo-nivolumab-for-Previously-Treated-Locally-Advanced-Unresectable-or-Metastatic-Urothelial-Carcinoma-in-Adults-After-Failure-of-Prior-Platinum-Containing-Therapy/default.aspxFri, 02 Jun 2017 17:00:00 -0400edf6ae3c-e884-4c9f-b472-661ae1e15679https://news.bms.com/news/details/2017/Opdivo-nivolumab-Data-in-Patients-with-Advanced-Cervical-Vaginal-and-Vulvar-Cancers-from-Phase-12-CheckMate--358-Presented-at-ASCO/default.aspxFri, 02 Jun 2017 06:59:00 -0400d4255dcb-61cb-4ed1-ba13-732d2a281b0ahttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-and-Seattle-Genetics-Expand-Clinical-Collaboration-to-Evaluate-Combination-of-Opdivo-Nivolumab-and-ADCETRIS-Brentuximab-Vedotin-in-Pivotal-Phase-3-Clinical-Trial-in-Relapsed-Hodgkin-Lymphoma/default.aspxFri, 02 Jun 2017 06:00:00 -0400c6df9c99-36da-47e7-a100-c5a14f9ac7aahttps://news.bms.com/news/details/2017/Array-BioPharma-and-Bristol-Myers-Squibb-Announce-Strategic-Collaboration/default.aspxTue, 30 May 2017 06:59:00 -0400b2afe788-4c46-42b2-8c27-cfeba90a58c2https://news.bms.com/news/details/2017/Advaxis-and-Bristol-Myers-Squibb-Announce-Clinical-Collaboration-to-Evaluate-ADXS-DUAL-and-Opdivo-nivolumab-in-Metastatic-Cervical-Cancer/default.aspxTue, 30 May 2017 06:59:00 -0400cf91666b-86bb-4791-a94a-6889e4073740https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Hold-Investor-Teleconference-to-Discuss-ASCO-Highlights/default.aspxFri, 26 May 2017 09:47:00 -0400f5346e3d-02c4-4504-81f2-5a9baa49a361https://news.bms.com/news/details/2017/US-Food-and-Drug-Administration-Accepts-for-Priority-Review-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-in-Previously-Treated-Hepatocellular-Carcinoma/default.aspxWed, 24 May 2017 11:15:00 -04009e77f362-8a08-4be9-bb8a-d797e787f3f9https://news.bms.com/news/details/2017/European-Medicines-Agency-Validates-Application-for-Bristol-Myers-Squibbs-Sprycel-dasatinib-in-Children-with-Chronic-Myelogenous-Leukemia/default.aspxFri, 19 May 2017 08:13:00 -04006b3403d7-eac2-49c6-b737-32b9414f3250https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Research-Showcases-Expansive-Oncology-Clinical-Development-Program-and-Commitment-to-Exploring-Novel-Combinations-at-ASCO-2017/default.aspxWed, 17 May 2017 17:00:00 -04007003d960-2dd7-4aad-a533-60ba068e019dhttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Take-Part-in-UBS-Global-Healthcare-Conference/default.aspxTue, 16 May 2017 06:59:00 -0400f1e4dce5-a56d-48b1-a2d3-54e1b7b16049https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-and-Calithera-Biosciences-Expand-Collaboration-Evaluating-Opdivo-nivolumab-in-Combination-with-CB-839-into-Non-Small-Cell-Lung-Cancer-and-Melanoma/default.aspxWed, 10 May 2017 06:59:00 -040053c2650b-9e67-4c95-ac54-0448ff0aba19https://news.bms.com/news/details/2017/European-Commission-Approves-Bristol-Myers-Squibbs-Opdivo-nivolumab-for-Squamous-Cell-Cancer-of-the-Head-and-Neck-in-Adults-Progressing-On-or-After-Platinum-based-Therapy/default.aspxFri, 28 Apr 2017 14:38:00 -0400c69111f8-c12c-4a99-980d-6f10a5cc6f4fhttps://news.bms.com/news/details/2017/China-FDA-Approves-Countrys-First-All-Oral-Regimen-for-Chronic-Hepatitis-C-Daklinza-daclatasvir-in-Combination-with-Sunvepra-asunaprevir/default.aspxFri, 28 Apr 2017 07:19:00 -0400498ded25-e7e3-4f80-9b85-4e018c0f7dbfhttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Take-Part-in-Deutsche-Bank-Annual-Health-Care-Conference/default.aspxThu, 27 Apr 2017 08:00:00 -040064867f81-5d8e-48af-b7ba-72013b375ab9https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results/default.aspxThu, 27 Apr 2017 06:59:00 -0400be3a9999-56ca-42ea-abf5-bcb3dff1cab8https://news.bms.com/news/details/2017/Transgene-and-Bristol-Myers-Squibb-Announce-Clinical-Research-Collaboration-to-Evaluate-TG4010-in-Combination-with-Opdivo-and-Standard-Chemotherapy-in-First-Line-Non-Small-Cell-Lung-Cancer/default.aspxTue, 25 Apr 2017 01:30:00 -0400bea1c333-ee7e-465c-8996-3e204dccacc3https://news.bms.com/news/details/2017/Bristol-Myers-Squibbs-BMS-986036-Pegylated-FGF21-Shows-Consistent-Improvement-in-Liver-Fat-Liver-Injury-and-Fibrosis-in-Patients-with-Nonalcoholic-Steatohepatitis-NASH-in-Phase-2-Trial/default.aspxSat, 22 Apr 2017 01:01:00 -0400fc20735a-a834-4c7b-9029-db6687d8e94ehttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Approval-of-Opdivo-nivolumab-for-the-Treatment-of-Patients-with-Previously-Treated-Locally-Advanced-or-Metastatic-Urothelial-Carcinoma-a-Type-of-Bladder-Cancer/default.aspxFri, 21 Apr 2017 14:06:00 -0400d95f081c-311a-49b1-8094-aaf4709cffbchttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-and-Nordic-Bioscience-Announce-Collaboration-for-Fibrosis-Biomarker-Technology/default.aspxMon, 17 Apr 2017 06:59:00 -04002576d94d-3527-4724-abe7-4e7a5a239d5fhttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Enters-into-Separate-Agreements-with-Biogen-and-Roche-to-License-Anti-eTau-and-Anti-Myostatin-Compounds-Respectively/default.aspxThu, 13 Apr 2017 06:59:00 -0400fb7ccf8d-9306-46cf-8c18-8d4e40afddb7https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-and-Apexigen-Inc-Announce-Clinical-Collaboration-to-Evaluate-Opdivo-nivolumab-in-Combination-with-APX005M-in-Advanced-Solid-Tumors/default.aspxTue, 11 Apr 2017 06:59:00 -040012539dbd-a5c0-4491-a5ba-0ba23eaf027dhttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Earns-ENERGY-STAR-Partner-of-the-Year-Award-for-Third-Consecutive-Year/default.aspxFri, 07 Apr 2017 18:00:00 -04005394b7c2-a415-4dd0-b9e1-965add2622fdhttps://news.bms.com/news/details/2017/US-Food-and-Drug-Administration-Accepts-for-Priority-Review-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-in-Previously-Treated-dMMR-or-MSI-H-Metastatic-Colorectal-Cancer/default.aspxTue, 04 Apr 2017 16:15:00 -040006832ec0-ebb0-493a-b6a0-70ad50e1a3cehttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Announces-Results-from-CheckMate--143-a-Phase-3-Study-of-Opdivo-nivolumab-in-Patients-with-Glioblastoma-Multiforme/default.aspxMon, 03 Apr 2017 10:47:00 -04009676dd89-0102-480b-ba76-19d9a53246b3https://news.bms.com/news/details/2017/Five-Year-Survival-Observed-With-Opdivo-nivolumab-in-Patients-With-Previously-Treated-Advanced-Non-Small-Cell-Lung-Cancer-NSCLC-in-Phase-1-Study-CA209-003/default.aspxMon, 03 Apr 2017 08:30:00 -0400a0de1d9b-e5b5-47bc-aa37-8bff1f1715f6https://news.bms.com/news/details/2017/Opdivo-nivolumab-in-Combination-with-Yervoy-ipilimumab-and-Opdivo-Monotherapy-Significantly-Improved-Overall-Survival-Versus-Yervoy-Alone-in-Patients-with-Previously-Untreated-Advanced-Melanoma/default.aspxMon, 03 Apr 2017 08:30:00 -04008e9d15f5-6c1c-4ec9-add6-bafdc78bfbc1https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-and-Incyte-to-Advance-the-Combination-of-Opdivo-nivolumab-and-Epacadostat-into-First-line-Registrational-Trials/default.aspxSun, 02 Apr 2017 06:59:00 -040086e98f99-490e-41f7-9d57-c0e70e2ee97ahttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Enters-Collaboration-to-Leverage-Foundation-Medicines-Molecular-Information-Platform-to-Identify-Predictive-Biomarkers-Across-Multiple-Tumor-Types-and-Immunotherapy-Agents/default.aspxThu, 30 Mar 2017 06:59:00 -0400e1aacc31-4d56-417d-b858-d9abc35799d2https://news.bms.com/news/details/2017/Parker-Institute-for-Cancer-Immunotherapy-Bristol-Myers-Squibb-and-the-Cancer-Research-Institute-Announce-Collaboration-to-Accelerate-Immuno-Oncology-Research/default.aspxTue, 28 Mar 2017 06:59:00 -04004812b367-69bb-4fdc-a341-fce7ebda20e7https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Opdivo-nivolumab-for-the-Treatment-of-Squamous-Cell-Cancer-of-the-Head-and-Neck-in-Adults-Progressing-on-or-After-Platinum-based-Therapy/default.aspxFri, 24 Mar 2017 09:31:00 -04004258e04f-a555-4756-aae2-4eb5df07e0cahttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-and-CytomX-Therapeutics-Extend-Worldwide-Collaboration-to-Discover-Probody-Therapeutics-for-the-Treatment-of-Cancer-and-Other-Diseases/default.aspxMon, 20 Mar 2017 07:59:00 -0400accf6585-7105-4cb9-b7d2-70d8f139c680https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-and-Pfizer-Present-Large-Real-World-Observational-Analysis-of-the-Effectiveness-and-Safety-of-Direct-Oral-Anticoagulants-Compared-to-Warfarin-in-Patients-with-Non-Valvular-Atrial-Fibrillation/default.aspxFri, 17 Mar 2017 12:15:00 -04004acbb6b5-b33f-4057-ab46-6118a4540bebhttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Announce-Results-for-First-Quarter-2017-on-April-27/default.aspxFri, 10 Mar 2017 11:20:00 -050000a643cf-9430-4812-a51d-ed0c4d2d95b4https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Appoints-Dr-Thomas-J-Lynch-Jr-Executive-Vice-President-and-Chief-Scientific-Officer/default.aspxWed, 08 Mar 2017 13:24:00 -05007ef4cdc2-ba7b-411e-b940-7a1c9bd3f881https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Take-Part-in-Barclays-Global-Health-Care-Conference/default.aspxWed, 08 Mar 2017 10:00:00 -05004ab73ab2-40e7-4bb0-9a37-40d5183911cfhttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-and-Pfizer-to-Present-New-Analyses-of-Eliquis-apixaban--Clinical-and-Real-World-Data-at-the-American-College-of-Cardiology-2017-Scientific-Session/default.aspxMon, 06 Mar 2017 12:21:00 -050089bfe16c-2f26-42a2-a278-300c23ace5ffhttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Announces-Dividend-aecd057d7/default.aspxThu, 02 Mar 2017 17:34:00 -05006be25a62-29a0-4e4d-9e3e-f2cad79db6a5https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Present-Data-That-Advances-Understanding-of-Effects-of-Immuno-Oncology-Therapies-on-Cancer-Biology-and-Patient-Outcomes-at-AACR-2017/default.aspxWed, 01 Mar 2017 19:20:00 -0500dd803fd1-c12a-4e94-8662-e69c1ff89979https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Expands-Focus-on-Precision-Medicine-with-Investment-and-Planned-Collaboration-with-GRAIL-on-Blood-Based-Cancer-Screening/default.aspxWed, 01 Mar 2017 09:10:00 -05009c5328d6-e1bb-4688-8fe9-8a7536e3e708https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Take-Part-in-Cowen-and-Company-37th-Annual-Global-Health-Care-Conference/default.aspxMon, 27 Feb 2017 10:30:00 -05005e2bf37c-b39a-4ddf-ae58-4bb62df13877https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Expands-International-Immuno-Oncology-Network-II-ON-With-Addition-of-Columbia-University-Medical-Center-and-Peter-MacCallum-Cancer-Centre/default.aspxMon, 27 Feb 2017 07:59:00 -05009ca014bd-3877-4c78-b840-6aa1e84641e3https://news.bms.com/news/details/2017/Exelixis-and-Bristol-Myers-Squibb-Enter-Clinical-Collaboration-for-Late-Stage-Combination-Trial-in-First-Line-Renal-Cell-Carcinoma/default.aspxMon, 27 Feb 2017 07:59:00 -050083e324ff-c7a2-4168-93a8-c90076900758https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Prices-15-Billion-of-Senior-Notes/default.aspxThu, 23 Feb 2017 00:00:00 -05007a46337d-8228-4db6-a5e9-b41b7bef34fdhttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Appoints-Three-New-Independent-Directors/default.aspxTue, 21 Feb 2017 07:59:00 -0500a632c0fd-03cc-4b3e-8ecd-2a9ea98093e9https://news.bms.com/news/details/2017/First-Comprehensive-Pediatric-Hematology-Oncology-Initiative-Launched-in-Africa/default.aspxTue, 21 Feb 2017 04:00:00 -0500a25573bc-a8c4-4b90-9639-46095646525chttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Take-Part-in-Leerink-6th-Annual-Global-Health-Care-Conference/default.aspxWed, 08 Feb 2017 11:54:00 -050082336dca-a258-4019-9df8-ebf43894d75chttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Receives-FDA-Approval-for-Opdivo-nivolumab-in-Previously-Treated-Locally-Advanced-or-Metastatic-Urothelial-Carcinoma-a-Type-of-Bladder-Cancer/default.aspxThu, 02 Feb 2017 17:15:00 -0500f5442995-a273-4cd6-98b3-d8ff0e2fdf6chttps://news.bms.com/news/details/2017/Cancer-Survivors-Need-More-Efficient-Integrated-Long-Term-Care-and-Stronger-Policies-Across-Healthcare-Advocacy-and-the-Workplace-New-Research-Concludes/default.aspxThu, 02 Feb 2017 10:21:00 -0500932cd13b-d86c-4304-96f9-6d62684c388fhttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Announces-European-Patent-Office-Decision-on-Sprycel/default.aspxWed, 01 Feb 2017 13:19:00 -05003d179d48-f989-4c29-98b9-f07cd7a6aee8https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-2016-Financial-Results/default.aspxThu, 26 Jan 2017 07:59:00 -050025d93fe6-f78f-4763-940e-05b61dc0e84ahttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-and-Ono-Pharmaceutical-Company-Enter-Settlement-and-License-Agreement-with-Merck-to-Resolve-PD-1-Antibody-Patent-Litigation/default.aspxFri, 20 Jan 2017 17:01:00 -0500ffeb45cb-0309-442a-89af-38ca8d832786https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Provides-Regulatory-Update-in-First-line-Lung-Cancer/default.aspxThu, 19 Jan 2017 19:30:00 -050017bd92bd-470e-4da2-a845-933562670febhttps://news.bms.com/news/details/2017/Opdivo-nivolumab-Demonstrated-Efficacy-and-Improved-Survival-in-Patients-with-Previously-Treated-Advanced-Gastric-Cancer-in-a-Randomized-Phase-3-Study/default.aspxThu, 19 Jan 2017 10:00:00 -050003e5ac95-f2ea-4b74-9791-ba6ce86d21e4https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-and-GeneCentric-Diagnostics-Announce-Exploratory-Biomarker-Research-Collaboration/default.aspxFri, 06 Jan 2017 07:59:00 -0500b212e923-3805-415d-acb8-4e5bbf44249ahttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Announces-Immunotherapy-Clinical-Collaboration-with-Janssen-to-Evaluate-Opdivo-nivolumab-in-Combination-with-Darzalex-daratumumab/default.aspxThu, 05 Jan 2017 07:59:00 -05005e7aa953-9de2-43de-af8b-18c334e4824ahttps://news.bms.com/news/details/2017/Bristol-Myers-Squibb-to-Present-at-JP-Morgan-Healthcare-Conference/default.aspxTue, 03 Jan 2017 10:18:00 -0500254360cd-56bb-4c65-9cd7-685bb78796f0https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Take-Part-at-the-Goldman-Sachs-Healthcare-CEOs-Unscripted-A-View-from-the-Top/default.aspxThu, 29 Dec 2016 10:00:00 -05002cdff6cc-ea8f-4493-a106-d1e0d2902188https://news.bms.com/news/details/2016/Giovanni-Caforio-Named-Chairman-of-Bristol-Myers-Squibbs-Board-of-Directors/default.aspxWed, 21 Dec 2016 09:30:00 -050057098d18-7f51-4dde-ae24-663058c75c0chttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-and-Calithera-Biosciences-Announce-Clinical-Collaboration-to-Evaluate-Opdivo-nivolumab-in-Combination-with-CB-839-in-Clear-Cell-Renal-Cell-Carcinoma/default.aspxWed, 21 Dec 2016 07:59:00 -0500f5fe0d7c-add3-4e73-b1b4-524f8c075deehttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Signs-Exclusive-Worldwide-License-Agreement-with-PsiOxus-Therapeutics-for-NG-348-an-Armed-Oncolytic-Virus-to-Address-Solid-Tumors/default.aspxTue, 20 Dec 2016 07:59:00 -0500ec141592-9f72-4a20-8520-ff3ce91e86e4https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Strengthens-Capabilities-with-Evolution-of-its-US-Geographic-Footprint/default.aspxTue, 13 Dec 2016 10:30:00 -0500439f103c-a0bd-4a15-b299-b5a57bc77fcbhttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Announce-Results-for-Fourth-Quarter-2016-on-January-26-2017/default.aspxFri, 09 Dec 2016 17:00:00 -050051539157-e3e0-4cfd-a26a-a7feea965ea4https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Announces-Dividend-Increase/default.aspxThu, 08 Dec 2016 17:15:00 -050067a82bdf-b9a6-4ca6-bea7-7d5ed1eebafbhttps://news.bms.com/news/details/2016/Opdivo-nivolumab-Alone-or-Combined-With-Yervoy-ipilimumab-Shows-Encouraging-Response-and-Survival-Rates-in-Recurrent-Small-Cell-Lung-Cancer-From-Phase-12-Study-CheckMate--032/default.aspxTue, 06 Dec 2016 09:45:00 -05003a732e66-cf1c-468f-8219-b1675148b911https://news.bms.com/news/details/2016/Seattle-Genetics-and-Bristol-Myers-Squibb-Highlight-First-Data-from-Phase-12-Study-Evaluating-ADCETRIS-Brentuximab-Vedotin-in-Combination-with-Opdivo-nivolumab-in-Relapsed-or-Refractory-Hodgkin-Lymphoma-at-ASH-Annual-Meeting/default.aspxMon, 05 Dec 2016 20:30:00 -0500a5ea1182-8ad2-45fe-b3d6-aed800f632d6https://news.bms.com/news/details/2016/Encouraging-Survival-Observed-With-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-With-Longer-Follow-up-in-First-line-Advanced-Non-small-Cell-Lung-Cancer-in-Updated-Phase-1b-CheckMate--012-Study/default.aspxMon, 05 Dec 2016 06:00:00 -05006f1ac349-b4af-4854-a902-55f6e4ea8255https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Take-Part-at-the-Citi-2016-Global-Healthcare-Conference/default.aspxWed, 30 Nov 2016 10:54:00 -0500a52e6902-2c2f-4931-9062-ddac5f24b736https://news.bms.com/news/details/2016/European-Commission-Approves-Bristol-Myers-Squibbs-Opdivo-nivolumab-for-the-Treatment-of-Adult-Patients-With-Relapsed-or-Refractory-Classical-Hodgkin-Lymphoma-After-Autologous-Stem-Cell-Transplant-and-Treatment-With-Brentuximab-Vedotin/default.aspxTue, 22 Nov 2016 16:00:00 -050053502c41-efbc-4e40-a59e-5ca4c9e3beafhttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Presents-New-Data-at-IASLC-17th-World-Conference-on-Lung-Cancer-Underscoring-Progress-and-Leadership-in-Broad-Lung-Development-Program/default.aspxWed, 16 Nov 2016 18:13:00 -0500a7672ef8-4bea-4acb-94e1-2ca1d8af0bd1https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-and-Enterome-Announce-Immuno-Oncology-Collaboration-Focused-on-Microbiome-Derived-Biomarkers-Drug-Targets-and-Bioactive-Molecules/default.aspxWed, 16 Nov 2016 04:00:00 -0500500a0ef4-e8e4-4e73-a74f-bb9eadec861bhttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Showcases-Rheumatoid-Arthritis-and-Immunoscience-Commitment-with-Depth-of-Research-at-2016-American-College-of-Rheumatology-and-Association-of-Rheumatology-Health-Professionals-Annual-Meeting/default.aspxMon, 14 Nov 2016 07:59:00 -0500d5b1e9dd-dca5-4af6-b48c-38dbccf84884https://news.bms.com/news/details/2016/Opdivo-nivolumab-and-Yervoy-ipilimumab-Regimen-Shows-Promising-Efficacy-and-Safety-in-Previously-Treated-Patients-With-Advanced-Form-of-Bladder-Cancer/default.aspxSat, 12 Nov 2016 12:30:00 -050050f90f44-a0f3-42de-a2ad-a162f4e0cf20https://news.bms.com/news/details/2016/Interim-Phase-12-Data-Show-Encouraging-Clinical-Benefit-for-Lirilumab-in-Combination-With-Opdivo-nivolumab-in-Patients-With-Advanced-Platinum-Refractory-Squamous-Cell-Carcinoma-of-the-Head-and-Neck/default.aspxSat, 12 Nov 2016 12:15:00 -0500d2b815c7-e75f-444d-950a-25ed488dd885https://news.bms.com/news/details/2016/Phase-12-Data-Combining-Urelumab-with-Opdivo-nivolumab-in-Hematologic-and-Solid-Tumors-Suggest-Increased-Antitumor-Effect-in-Patients-with-Melanoma/default.aspxSat, 12 Nov 2016 11:40:00 -0500d0f086b1-ee22-48e5-bb93-68baaaab1798https://news.bms.com/news/details/2016/Bristol-Myers-Squibbs-Opdivo-nivolumab-is-the-First-Immuno-Oncology-Treatment-to-Receive-FDA-Approval-Based-on-Overall-Survival-in-Head-and-Neck-Cancer/default.aspxThu, 10 Nov 2016 18:00:00 -0500bb291cf7-1d45-4ff5-b5c7-ff0479f38546https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Showcase-New-Data-Spanning-Rheumatoid-Arthritis-and-Other-Autoimmune-Diseases-at-2016-American-College-of-Rheumatology-and-Association-of-Rheumatology-Health-Professionals-Annual-Meeting/default.aspxThu, 10 Nov 2016 17:15:00 -0500b6397503-d562-4355-9866-4a458ee2eaf8https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Enters-into-New-Collaboration-with-Johns-Hopkins-Focused-on-Immuno-Oncology-Research/default.aspxThu, 10 Nov 2016 12:19:00 -0500bae640a6-f0bc-4646-8096-9a5cb54ac2a3https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-and-Pfizer-to-Deliver-12-New-Eliquis-apixaban-Presentations-at-American-Heart-Association-AHAScientific-Sessions-2016/default.aspxThu, 10 Nov 2016 08:59:00 -05000ccad787-1055-4fff-9fcf-2513b692e623https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Signs-Exclusive-Worldwide-License-Agreement-with-Nitto-Denko-for-Targeted-siRNA-Therapy-in-Advanced-Non-alcoholic-Steatohepatitis-NASH-and-Cirrhosis-Due-to-NASH/default.aspxThu, 10 Nov 2016 07:59:00 -05004de7682d-b2b8-4454-8a89-98984d2b6943https://news.bms.com/news/details/2016/Opdivo-nivolumab-Demonstrates-Overall-Survival-Benefit-in-Patients-With-Unresectable-Advanced-or-Recurrent-Gastric-Cancer-in-Phase-3-Study/default.aspxThu, 10 Nov 2016 07:55:00 -0500d081a74d-a947-4f6b-8d67-8111e4023c42https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Take-Part-in-Stifel-2016-Health-Care-Conference/default.aspxWed, 09 Nov 2016 09:31:00 -05003ceee7f4-28ca-4d4c-98ec-4ca64ae4cac6https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-and-Infinity-Pharmaceuticals-Announce-Clinical-Collaboration-to-Evaluate-Opdivo-nivolumab-in-Combination-with-IPI-549-in-Advanced-Solid-Tumors/default.aspxWed, 09 Nov 2016 07:59:00 -05008961af84-c117-4464-a5aa-6ec1e0a6d9behttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Present-New-Data-at-the-58th-Annual-Meeting--Exposition-of-the-American-Society-of-Hematology-Demonstrating-Research-Advancements-in-Immuno-Oncology-and-Across-Multiple-Blood-Cancers/default.aspxThu, 03 Nov 2016 10:10:00 -040008c11952-a343-49ad-baba-e95f47d5b380https://news.bms.com/news/details/2016/New-Data-Presentations-at-SITC-2016-Annual-Meeting-Highlight-Bristol-Myers-Squibbs-Leadership-in-Advancing-the-Science-of-Immuno-Oncology-Combinations/default.aspxWed, 02 Nov 2016 07:59:00 -0400183d1c6f-7a6a-447b-a7b2-fbc8d7d5dfb8https://news.bms.com/news/details/2016/New-US-Survey-Sheds-Light-on-the-Experiences-of-People-Caring-for-Someone-Living-with-Lung-Cancer/default.aspxWed, 02 Nov 2016 07:00:00 -0400367bb875-63c6-4320-a079-87aad8f6cf86https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Take-Part-in-Credit-Suisse-2016-Health-Care-Conference/default.aspxTue, 01 Nov 2016 12:12:00 -040093eb54a2-316b-4ae8-8652-3fe6a942e20ehttps://news.bms.com/news/details/2016/New-Bristol-Myers-Squibb-Research-on-Opdivo-nivolumab-Monotherapy-and-in-Combination-With-Yervoy-ipilimumab-at-SMR-2016-Congress-Reinforces-Immuno-Oncology-Leadership-and-Scientific-Expertise-in-Melanoma/default.aspxMon, 31 Oct 2016 09:04:00 -0400d0563050-8151-402a-bd8f-b4c45ed8646ahttps://news.bms.com/news/details/2016/Bristol-Myers-Squibbs-Yervoy-ipilimumab-Awarded-Prix-Galien-USA-Discovery-of-the-Decade/default.aspxFri, 28 Oct 2016 10:11:00 -0400db4f26f2-59ec-4e13-a0e2-bc6ea78cdc61https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Reports-Third-Quarter-Financial-Results/default.aspxThu, 27 Oct 2016 06:59:00 -0400770dc622-769f-48d1-9628-70e4a8c3895fhttps://news.bms.com/news/details/2016/New-Results-Presented-for-Opdivo-nivolumab-Demonstrate-Encouraging-Response-Rate-in-an-Expanded-Population-of-Heavily-Pre-Treated-Classical-Hodgkin-Lymphoma-Patients/default.aspxTue, 25 Oct 2016 08:00:00 -04004b52af9a-dd09-4212-945b-75370d50528ehttps://news.bms.com/news/details/2016/Bristol-Myers-Squibbs-Coast-2-Coast-4-Cancer-Ride-Raises-Over-1-Million-for-Cancer-Research/default.aspxMon, 24 Oct 2016 06:59:00 -040086b58c69-35d4-4b88-a805-5e0b28ae5b88https://news.bms.com/news/details/2016/US-Food-and-Drug-Administration-Accepts-for-Priority-Review-the-Supplemental-Biologics-License-Application-for-Opdivo-nivolumab-in-Previously-Treated-Patients-With-Advanced-Form-of-Bladder-Cancer/default.aspxFri, 21 Oct 2016 14:19:00 -040073a76a89-35ea-46a1-8c2f-3ebe55ea562dhttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Updates-Conference-Call-Dial-inID-for-Third-Quarter-2016-Results-on-October-27/default.aspxFri, 21 Oct 2016 11:03:00 -040025ba973f-dd69-4687-bfa5-7cf8a32a9003https://news.bms.com/news/details/2016/Defining-the-True-Value-of-Innovation-in-Cancer-Treatment/default.aspxThu, 20 Oct 2016 10:59:00 -04006822a3b7-ae85-434c-bf55-9cf7599759fehttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Foundation-Joins-White-House-Cancer-Moonshot/default.aspxMon, 17 Oct 2016 12:15:00 -04008bb0421f-c80b-4653-8cec-cb49e968f96fhttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Opdivo-nivolumab-for-the-Treatment-of-Adult-Patients-With-Relapsed-or-Refractory-Classical-Hodgkin-Lymphoma-After-Autologous-Stem-Cell-Transplant-and-Treatment-With-Brentuximab-Vedotin/default.aspxFri, 14 Oct 2016 06:59:00 -04005e57561d-b9d2-4d83-9ba5-a62aa09fed47https://news.bms.com/news/details/2016/Opdivo-nivolumab-Shows-Durable-Response-in-Longest-Follow-up-for-a-PD-1-Inhibitor-in-Previously-Treated-Advanced-Non-Small-Cell-Lung-Cancer/default.aspxSun, 09 Oct 2016 08:45:00 -040061a37717-b6e3-43ac-a107-2ab8b21caff6https://news.bms.com/news/details/2016/Updated-Results-Presented-for-the-Opdivo-nivolumab-and-Yervoy-ipilimumab-Combination-in-Metastatic-Renal-Cell-Carcinoma-From-Phase-1-Study/default.aspxSun, 09 Oct 2016 07:30:00 -0400e159b598-6025-4969-979b-941f7effe222https://news.bms.com/news/details/2016/Safety-Data-for-Lirilumab-in-Combination-with-Nivolumab-or-Ipilimumab-Announced-at-ESMO-2016-Congress/default.aspxSun, 09 Oct 2016 07:00:00 -040076621ac2-9580-4ad0-9a35-2618c43ea72chttps://news.bms.com/news/details/2016/Opdivo-nivolumab-Stabilized-Patient-reported-Outcomes-in-Patients-With-Previously-Treated-Recurrent-or-Metastatic-Squamous-Cell-Carcinoma-of-the-Head-and-Neck-in-Pivotal-Phase-3-CheckMate--141-Study/default.aspxSun, 09 Oct 2016 02:15:00 -040056a0bc90-785b-4fdf-9144-87a90b31622chttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Presents-Results-From-CheckMate--026-a-Phase-3-Study-of-Opdivo-nivolumab-Monotherapy-Versus-Chemotherapy-as-First-Line-Therapy-in-a-Broad-PD-L1-Positive-Population-With-Advanced-Lung-Cancer/default.aspxSun, 09 Oct 2016 02:15:00 -0400601c6aa7-8dd5-4614-8c5f-355c51a95bb5https://news.bms.com/news/details/2016/Results-From-CheckMate-275-Validate-Further-Study-of-Opdivo-nivolumab-in-Patients-With-Advanced-Form-of-Bladder-Cancer/default.aspxSat, 08 Oct 2016 03:09:00 -0400563a6b83-237a-4ce4-a362-c047b68b6c45https://news.bms.com/news/details/2016/Yervoy-ipilimumab-Improves-Overall-Survival-in-Fully-Resected-Stage-III-Melanoma-Patients-From-Phase-3-Study/default.aspxSat, 08 Oct 2016 02:15:00 -040084d91780-1187-4ec8-8c32-8d9526f45545https://news.bms.com/news/details/2016/New-Research-From-Bristol-Myers-Squibb-at-ESMO-2016-Congress-Reinforces-Leadership-in-Immuno-Oncology-and-Differentiated-Research-Approach/default.aspxMon, 03 Oct 2016 17:13:00 -0400881cbb51-6c78-4fc6-b706-fa906917ad9ehttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-and-Nektar-Therapeutics-Announce-Oncology-Clinical-Collaboration-to-Evaluate-the-Combination-of-Opdivo-nivolumab-and-NKTR-214/default.aspxTue, 27 Sep 2016 06:59:00 -04008abf630e-fd84-4351-8f87-95ddebc34fbehttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Take-Part-in-Leerink-Partners-Immuno-Oncology-Roundtable-Conference/default.aspxThu, 22 Sep 2016 09:38:00 -0400515966a7-d3c7-4173-a28b-1b85873a6b93https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Awards-First-Golden-Tickets-for-LabCentral-to-PanTher-Suono-Bio/default.aspxTue, 20 Sep 2016 06:59:00 -04002b75c477-b604-4a9e-8cc6-643f80572d8fhttps://news.bms.com/news/details/2016/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Type-II-Variation-Application-for-Opdivo-nivolumab-in-Advanced-Form-of-Bladder-Cancer/default.aspxTue, 20 Sep 2016 06:59:00 -04002c9b6009-c62d-48c8-af2a-f41faf8ead38https://news.bms.com/news/details/2016/Bristol-Myers-Squibbs-Response-to-ICERs-Call-for-Improvements-to-its-Value-Assessment-Framework/default.aspxMon, 12 Sep 2016 15:35:00 -04009498bd60-7fe9-4264-9bc8-222daa65a10bhttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Announce-Results-for-Third-Quarter-2016-on-October-27/default.aspxWed, 07 Sep 2016 11:17:00 -0400ba664cc2-a7a1-40f7-a2aa-f7b29ba987d4https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Present-at-Bank-of-America-Merrill-Lynch-Global-Health-Care-Conference/default.aspxWed, 07 Sep 2016 10:41:00 -0400c76d1cec-f664-4a3d-ab06-64756f5c503ehttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Employees-Cycle-Coast-to-Coast-to-Raise-Money-and-Awareness-for-Cancer-Research/default.aspxWed, 07 Sep 2016 06:59:00 -0400de0999b4-ecb3-4483-a0ec-221e0975e585https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Take-Part-in-Morgan-Stanley-Global-Health-Care-Conference/default.aspxTue, 06 Sep 2016 12:14:00 -0400b814caba-238c-47d3-9c60-cdbf7b4f798bhttps://news.bms.com/news/details/2016/European-Commission-Approves-Bristol-Myers-Squibbs-ORENCIA-abatacept-for-the-Treatment-of-Highly-Active-and-Progressive-Disease-in-Adult-Patients-with-Rheumatoid-Arthritis-Not-Previously-Treated-with-Methotrexate/default.aspxTue, 06 Sep 2016 06:59:00 -0400574e2c9c-244d-4953-bb3b-fe822f637e42https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Hold-Investor-Teleconference-to-Discuss-ESMO-2016-Congress-Highlights/default.aspxWed, 31 Aug 2016 19:05:00 -04001b576eef-8f70-4711-897e-b410ef68597bhttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-and-Pfizer-to-Present-New-Eliquis-apixaban-Analyses-at-ESC-Congress-2016/default.aspxTue, 23 Aug 2016 06:59:00 -04006d3c1138-3c1f-4f79-83dc-4131cd9bfb8dhttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Statement-on-Top-Line-Results-from-CheckMate--026/default.aspxFri, 05 Aug 2016 08:22:00 -0400b7e5eba8-e260-4f78-882f-d7a910e94456https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Announces-Top-Line-Results-from-CheckMate--026-a-Phase-3-Study-of-Opdivo-nivolumab-in-Treatment-Nave-Patients-with-Advanced-Non-Small-Cell-Lung-Cancer/default.aspxFri, 05 Aug 2016 08:20:00 -04008b0ea726-54f2-4c9e-b619-ab1e71fc701fhttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Announces-Dividend/default.aspxWed, 03 Aug 2016 16:15:00 -0400de4d6f4a-d112-49c4-8cce-cc189247275ehttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Reports-Second-Quarter-Financial-Results/default.aspxThu, 28 Jul 2016 06:59:00 -0400b65c0ec5-1ee5-45ca-afed-c77847822420https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Announces-New-Research-Collaboration-with-Janssen-in-Immuno-Oncology-Focused-on-Lung-Cancer/default.aspxTue, 26 Jul 2016 06:59:00 -0400ac9f03f3-afdd-42cf-89c2-9dba42b7788chttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Appoints-Fouad-Namouni-MD-Oncology-Development-Head/default.aspxMon, 25 Jul 2016 11:00:00 -040033792795-30cf-4f22-8c22-4e644b857990https://news.bms.com/news/details/2016/CHMP-Issues-Positive-Opinion-for-ORENCIA-abatacept-in-the-Treatment-of-Highly-Active-and-Progressive-Disease-in-Adult-Patients-with-Rheumatoid-Arthritis-not-Previously-Treated-with-Methotrexate-in-the-EU/default.aspxMon, 25 Jul 2016 06:59:00 -0400e5cbde56-8d7d-49b9-a258-6aec36f87935https://news.bms.com/news/details/2016/AbbVie-and-Bristol-Myers-Squibb-Announce-Oncology-Clinical-Collaboration-to-Evaluate-the-Combination-of-Rova-T-plus-Opdivo-and-Opdivo--Yervoy-Regimen/default.aspxMon, 25 Jul 2016 06:59:00 -04008293a583-9210-48f3-91fe-2f0cb6aa0bfchttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Announces-Availability-of-FDA-Approved-ORENCIA-abatacept-ClickJect-a-Self-Administered-Subcutaneous-Autoinjector-for-Adults-with-Moderate-to-Severe-Rheumatoid-Arthritis/default.aspxWed, 20 Jul 2016 06:59:00 -0400ab98eddf-6352-4f29-bef8-62e6ef43e63bhttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Announces-Regulatory-Updates-for-Opdivo-nivolumab-in-Previously-Treated-Recurrent-or-Metastatic-Squamous-Cell-Carcinoma-of-the-Head-and-Neck/default.aspxMon, 18 Jul 2016 06:59:00 -040038ba5023-3ac4-4db8-a985-c317286863dbhttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Acquires-Cormorant-Pharmaceuticals/default.aspxTue, 05 Jul 2016 06:59:00 -0400a0754927-cf21-45d8-b6b8-accd37e95cc7https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-and-PsiOxus-Therapeutics-Announce-Immuno-Oncology-Clinical-Collaboration-to-Evaluate-the-Combination-of-Opdivo-and-Enadenotucirev/default.aspxThu, 30 Jun 2016 06:59:00 -0400e4750c5d-0e42-47e2-be8d-a2f70c5c4009https://news.bms.com/news/details/2016/Bristol-Myers-Squibbs-Response-to-ICERs-Draft-Scoping-Document-Treatment-Options-for-Advanced-Non-Small-Cell-Lung-Cancer/default.aspxWed, 29 Jun 2016 09:31:00 -040028c33d4c-089f-443b-bc15-9b0d05bad09dhttps://news.bms.com/news/details/2016/Bristol-Myers-Squibbs-Opdivo-nivolumab-Receives-Breakthrough-Therapy-Designation-from-US-Food-and-Drug-Administration-for-Advanced-Form-of-Bladder-Cancer/default.aspxMon, 27 Jun 2016 06:59:00 -0400f53edbfe-b047-4cc8-b71e-616031181ac4https://news.bms.com/news/details/2016/Sickle-Cell-Partnership-Creates-Demonstration-Project-to-Treat-Children-in-Angola/default.aspxFri, 24 Jun 2016 16:10:00 -0400c9ed8bf6-a5b3-43cc-b6d1-b06615dda2abhttps://news.bms.com/news/details/2016/Murdo-Gordon-Appointed-Executive-Vice-President-and-Chief-Commercial-Officer/default.aspxMon, 20 Jun 2016 16:15:00 -0400b7d2b5d7-234f-4a4b-8ca8-60a9157f6c3ehttps://news.bms.com/news/details/2016/New-Data-on-Bristol-Myers-Squibbs-Opdivo-nivolumab-Indicate-Benefit-in-Heavily-Pre-Treated-Classical-Hodgkin-Lymphoma-Patients-in-Phase-2-Single-Arm-Pivotal-Trial/default.aspxFri, 10 Jun 2016 02:30:00 -04006224c1f4-b315-4c2f-bf30-078f5fa3129ehttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Announce-Results-for-Second-Quarter-2016-on-July-28/default.aspxThu, 09 Jun 2016 10:00:00 -04007a537321-7689-4588-bbdd-097c2f5f6189https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Present-New-Data-Demonstrating-Continued-Research-Expansion-and-Immuno-Oncology-Advancements-Across-Multiple-Blood-Cancers-at-the-21st-Congress-of-the-European-Hematology-Association/default.aspxThu, 09 Jun 2016 06:59:00 -040030308ab6-fbcb-463b-8596-4a6d54f95ea2https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Announces-New-Rheumatoid-Arthritis-Research-and-Real-World-Data-at-the-Annual-European-Congress-of-RheumatologyEULAR-2016/default.aspxWed, 08 Jun 2016 07:48:00 -0400ccdcf8ee-9c6a-4b2b-9148-ca955afa497fhttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Announces-Dividend-94eb719f3/default.aspxTue, 07 Jun 2016 16:15:00 -04005e8b1a07-1a08-495e-9991-7500edc026c6https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-and-MD-Anderson-Announce-New-Research-Collaboration-in-Immuno-Oncology-Focused-on-Lung-Cancer/default.aspxTue, 07 Jun 2016 06:59:00 -04008a9a492d-8d0d-4a02-85da-fbea609bfd71https://news.bms.com/news/details/2016/Long-Term-Data-from-Two-Trials-Evaluating-the-Opdivo-nivolumab-and-Yervoy-ipilimumab-Regimen-in-Advanced-Melanoma-Continues-to-Validate-Bristol-Myers-Squibbs-Immuno-Oncology-Combination-Approach/default.aspxMon, 06 Jun 2016 06:59:00 -0400669cb5a5-0d70-4db7-b8cc-f73cf237cb16https://news.bms.com/news/details/2016/Long-Term-Survival-and-Improvement-in-Quality-of-Life-Observed-with-Opdivo-nivolumab-in-Advanced-Renal-Cell-Carcinoma-Patients-Based-on-New-Data-Presented-at-the-2016-ASCO-Annual-Meeting/default.aspxSun, 05 Jun 2016 11:24:00 -04001f12b1df-83d5-460e-a5f6-b81b2459372dhttps://news.bms.com/news/details/2016/First-Presentation-of-Phase-2-CheckMate--142-Study-Evaluating-Opdivo-nivolumab-Alone-or-in-Combination-with-Yervoy-ipilimumab-Demonstrates-Encouraging-Clinical-Activity-in-MSI-High-Metastatic-Colorectal-Cancer/default.aspxSun, 05 Jun 2016 09:00:00 -04000e66544c-261a-486d-844b-e0bcd536f43fhttps://news.bms.com/news/details/2016/Promising-Response-Rates-with-Opdivo-nivolumab-Observed-in-Advanced-Form-of-Bladder-Cancer-from-Phase-12-Study-CheckMate--032/default.aspxSun, 05 Jun 2016 08:06:00 -040091473d93-3d9d-425a-a852-736f42a47275https://news.bms.com/news/details/2016/Opdivo-nivolumab-and-Yervoy-ipilimumab-Combination-Regimen-Shows-Clinically-Meaningful-Responses-in-First-Line-Advanced-Non-Small-Cell-Lung-Cancer-In-Updated-Phase-1b-Study-CheckMate--012/default.aspxSat, 04 Jun 2016 14:27:00 -04000df9cdd7-8816-4761-b2ed-676901a56047https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Take-Part-in-Goldman-Sachs-37th-Annual-Global-Health-Care-Conference/default.aspxTue, 31 May 2016 10:30:00 -04006eb32774-12bb-4a13-b81d-2ac07b17f28chttps://news.bms.com/news/details/2016/How-to-Define-Value-Patient-Outcomes-or-Modeling/default.aspxThu, 26 May 2016 10:55:00 -0400154f02ac-1c80-4650-8478-290c70520f60https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Hold-Investor-Teleconference-to-Discuss-ASCO-Highlights/default.aspxMon, 23 May 2016 11:15:00 -0400075703eb-0cae-421c-a4bc-78e0a09e1410https://news.bms.com/news/details/2016/Two-Year-Overall-Survival-Data-from-Two-Pivotal-Opdivo-nivolumab-Trials-Demonstrate-Sustained-Benefit-In-Patients-with-Advanced-Non-Small-Cell-Lung-Cancer/default.aspxWed, 18 May 2016 17:40:00 -04000ae01d71-6ddc-464b-8900-88c4adfecf5ahttps://news.bms.com/news/details/2016/Breadth-and-Depth-of-Bristol-Myers-Squibbs-Immuno-Oncology-Clinical-Development-Program-to-be-Showcased-at-2016-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting/default.aspxWed, 18 May 2016 06:59:00 -04009f300876-7245-4056-8cd5-39b11c52ad91https://news.bms.com/news/details/2016/Opdivo-nivolumab-Granted-First-Approval-of-a-PD-1-Inhibitor-in-Hematology-for-the-Treatment-of-Classical-Hodgkin-Lymphoma-Patients-Who-Have-Relapsed-or-Progressed-After-Auto-HSCT-and-Post-transplantation-Brentuximab-Vedotin-by-the-FDA1/default.aspxTue, 17 May 2016 19:04:00 -04001f6ea0fd-3be8-4bce-91e3-b5549c2c535ahttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Opens-Expanded-Biologics-Facility/default.aspxTue, 17 May 2016 13:00:00 -0400d84b5c08-dab6-4c8e-9aaf-757fac6b5fcfhttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-and-AbbVie-Announce-European-Commission-Approval-of-Empliciti-elotuzumab-for-the-Treatment-of-Multiple-Myeloma-in-Adult-Patients-Who-Have-Received-at-Least-One-Prior-Therapy/default.aspxWed, 11 May 2016 14:25:00 -04001a02cb04-9901-414f-a020-40cf44b60a63https://news.bms.com/news/details/2016/European-Commission-Approves-the-First-and-Only-Immuno-Oncology-Combination-Bristol-Myers-Squibbs-Opdivo-nivolumab--Yervoy-ipilimumab-Regimen-for-Treatment-of-Advanced-Melanoma/default.aspxWed, 11 May 2016 11:31:00 -040079cee9b1-b148-4f1b-b6c5-a3713a15b311https://news.bms.com/news/details/2016/Modern-Family-Star-Eric-Stonestreet-and-His-Mom-a-Two-Time-Cancer-Survivor-Join-Forces-to-Raise-Awareness-of-Immuno-Oncology-Research-through-Ready-Raise-Rise-Campaign/default.aspxThu, 05 May 2016 07:30:00 -040024d77594-acc2-4510-aab8-edac1233f410https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results/default.aspxThu, 28 Apr 2016 06:59:00 -040079fc0e89-5b65-4d8b-a9f2-be5c40b26fbahttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Take-Part-in-Deutsche-Bank-Annual-Health-Care-Conference/default.aspxWed, 27 Apr 2016 10:00:00 -040023505e06-d36b-4f5b-8548-c536e2bdaee7https://news.bms.com/news/details/2016/Bristol-Myers-Squibbs-Opdivo-nivolumab-Receives-Breakthrough-Therapy-Designation-from-US-Food-and-Drug-Administration-for-Previously-Treated-Recurrent-or-Metastatic-Squamous-Cell-Carcinoma-of-the-Head-and-Neck/default.aspxMon, 25 Apr 2016 06:59:00 -04004a9707e5-b49f-499a-8297-93a0084e6b27https://news.bms.com/news/details/2016/First-Presentation-of-Overall-Survival-Data-for-Opdivo-nivolumab-Shows-Significant-Survival-Benefit-at-One-Year-Versus-Investigators-Choice-in-Recurrent-or-Metastatic-Squamous-Cell-Carcinoma-of-the-Head-and-Neck/default.aspxTue, 19 Apr 2016 09:30:00 -04007e43a2b5-3f95-4018-a273-8bfc99e50370https://news.bms.com/news/details/2016/First-Presentation-of-Two-Year-Overall-Survival-Data-for-Opdivo-nivolumab-in-Combination-with-Yervoy-ipilimumab-Showed-Superior-Efficacy-Versus-Yervoy-Alone-in-Advanced-Melanoma/default.aspxSun, 17 Apr 2016 15:15:00 -04003886162d-ff55-4ae9-b250-3a00d27f2203https://news.bms.com/news/details/2016/US-Food-and-Drug-Administration-Accepts-for-Priority-Review-Bristol-Myers-Squibbs-Supplemental-Biologics-License-Application-for-Opdivo-nivolumab-for-the-Treatment-of-Classical-Hodgkin-Lymphoma-Patients/default.aspxThu, 14 Apr 2016 06:59:00 -0400d1803905-b4f0-4aed-a95f-1c466b91d009https://news.bms.com/news/details/2016/European-Commission-Approves-Bristol-Myers-Squibbs-Opdivo-nivolumab-for-Previously-Treated-Advanced-Renal-Cell-Carcinoma/default.aspxWed, 06 Apr 2016 11:45:00 -040034f76d47-b0a3-4a67-9454-4f7ee337ec6chttps://news.bms.com/news/details/2016/European-Commission-Approves-Expanded-Use-of-Opdivo-nivolumab-to-Include-Previously-Treated-Metastatic-Non-Squamous-Non-Small-Cell-Lung-Cancer/default.aspxWed, 06 Apr 2016 11:12:00 -04003ff612e7-d9e7-4413-a37b-612be2a4b8c8https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Completes-Previously-Announced-Acquisition-of-Padlock-Therapeutics-Inc/default.aspxFri, 01 Apr 2016 16:15:00 -0400ec67176d-31d7-400e-a876-19072a463b51https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Opdivo-nivolumab-in-Combination-with-Yervoy-ipilimumab-for-Treatment-of-Advanced-Melanoma/default.aspxFri, 01 Apr 2016 11:52:00 -0400bc7ce9d8-31f3-4c1a-9442-4a15d9a4b122https://news.bms.com/news/details/2016/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-for-the-Treatment-of-Classical-Hodgkin-Lymphoma-Patients/default.aspxWed, 30 Mar 2016 16:15:00 -04006a162b72-7a07-4945-874a-cca123f95b04https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-and-Pfizer-Announce-Global-Real-World-Data-Program-and-Present-New-Analyses-of-Eliquis-apixaban-at-the-American-College-of-Cardiologys-65th-Annual-Scientific-Session/default.aspxWed, 30 Mar 2016 07:45:00 -0400c4181301-fdf6-4f82-b458-fdc740333017https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Present-at-William-Blair-Conference-Cancer-Immunotherapy-A-Long-Awaited-Reality/default.aspxThu, 24 Mar 2016 15:00:00 -04002d8eccc7-3f4c-4aa6-acaf-43deb18f2aa6https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Acquire-Padlock-Therapeutics-Inc/default.aspxWed, 23 Mar 2016 07:59:00 -0400beaceb59-34d8-41e7-8ebe-f4e0c31b4c83https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Present-New-Overall-Survival-Data-for-Opdivo-nivolumab-as-Monotherapy-and-in-Combination-with-Yervoy-ipilimumab-at-the-AACR-2016-Annual-Meeting/default.aspxWed, 16 Mar 2016 17:30:00 -040073fe7e59-f3e0-4a5d-9a35-e7fda681471ehttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Announce-Results-for-First-Quarter-2016-on-April-28/default.aspxTue, 15 Mar 2016 12:00:00 -04002ba06b0f-40fe-41d3-b90b-2be067dab851https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Present-at-Barclays-Global-Health-Care-Conference/default.aspxWed, 09 Mar 2016 11:30:00 -0500f164bc8a-fdca-4afa-b96e-223174faa6c6https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-and-LabCentral-Team-Up-in-Cambridge-Massachusetts-to-Support-Promising-Biotech-Startup-Companies/default.aspxMon, 07 Mar 2016 07:59:00 -0500d727d9ad-621a-4c26-a5bc-fb36c7d0d65fhttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Announces-Dividend-b70d16f40/default.aspxThu, 03 Mar 2016 17:15:00 -05009389cff7-e4b0-43fe-937b-c1e5c778d27bhttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Names-Peter-J-Arduini-to-Board-of-Directors/default.aspxThu, 03 Mar 2016 14:15:00 -05002c31fa5d-1b36-4148-a4a5-0558210b40e7https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Present-at-Cowen-and-Company-Annual-Global-Health-Care-Conference/default.aspxMon, 29 Feb 2016 11:00:00 -05000f3edaf9-859f-4b3b-aca7-f23cdf2c2345https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Receives-Two-Positive-CHMP-Opinions-for-Opdivo-nivolumab-for-Patients-with-Previously-Treated-Advanced-Non-Squamous-Non-Small-Cell-Lung-Cancer-and-Renal-Cell-Carcinoma/default.aspxFri, 26 Feb 2016 08:13:00 -050067eab577-7837-4cd4-b22d-a7e1bc1933ddhttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Completes-Previously-Announced-Sale-of-its-HIV-RD-Portfolio-to-ViiV-Healthcare/default.aspxMon, 22 Feb 2016 11:45:00 -0500fb5a45eb-b4b2-4ca1-bde6-dd62b7346b61https://news.bms.com/news/details/2016/Data-Presented-at-APASL-from-First-Completed-Phase-3-Trial-of-All-oral-Chronic-Hepatitis-C-Regimen-in-Chinese-Patient-Population-Shows-Daclatasvir-and-Asunaprevir-DUAL-Therapy-Demonstrated-High-Cure-Rates-Among-HCV-Genotype-1b-Patients/default.aspxMon, 22 Feb 2016 07:59:00 -050044ccecd3-bf47-4f59-a126-155f6ca4deb3https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-and-Dana-Farber-Cancer-Institute-Enter-Into-a-Collaboration-Agreement-as-Part-of-US-Immuno-Oncology-Rare-Population-Malignancy-Research-Program/default.aspxTue, 16 Feb 2016 07:59:00 -050023389e34-445e-4fc2-bf65-7688f5730d96https://news.bms.com/news/details/2016/US-FDA-Approves-Expanded-Use-of-Bristol-Myers-Squibbs-Daklinza-daclatasvir-for-Additional-Challenging-to-treat-Patients-with-Genotype-1-or-Genotype-3-Chronic-Hepatitis-C/default.aspxFri, 05 Feb 2016 13:47:00 -050003f5958c-9984-4415-8ac9-9b30459b376dhttps://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Take-Part-in-Leerink-Swann-Global-Healthcare-Conference/default.aspxWed, 03 Feb 2016 11:00:00 -0500fead9db6-a874-4ab7-ad02-d9d87586b5f3https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Foundation-Awards-Eight-Grants-Totaling-Nearly-115M-to-Make-Lung-and-Skin-Cancer-Screening-Care-More-Accessible-in-High-Risk-US-Communities/default.aspxMon, 01 Feb 2016 10:00:00 -050007de9060-26f7-4ebc-ab76-ae2b275cb486https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-and-Pfizer-Sign-Collaboration-with-Portola-Pharmaceuticals-to-Develop-and-Commercialize-Investigational-Andexanet-Alfa-in-Japan/default.aspxMon, 01 Feb 2016 07:55:00 -050024f1f0ba-7452-48da-b0b0-363a1ffb2e38https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-and-AbbVie-Receive-Positive-CHMP-Opinion-for-Investigational-Antibody-Empliciti-elotuzumab-for-the-Treatment-of-Multiple-Myeloma-in-Patients-Who-Have-Received-at-Least-One-Prior-Therapy/default.aspxFri, 29 Jan 2016 08:48:00 -0500cbc4cf16-53bd-4a4d-902c-65edc1f447cbhttps://news.bms.com/news/details/2016/European-Commission-Approves-Daklinza-daclatasvir-for-the-Treatment-of-Genotype-1-3-and-4-Chronic-Hepatitis-C-Patients-with-HIV-Coinfection-Advanced-Cirrhosis-and-Post-liver-Transplant-Recurrence-of-HCV/default.aspxThu, 28 Jan 2016 13:41:00 -05007197b382-6554-4e92-bbc5-a30127650db9https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-2015-Financial-Results/default.aspxThu, 28 Jan 2016 07:59:00 -050032d39d0c-34d2-4b07-afdf-c92268b7c5dehttps://news.bms.com/news/details/2016/CheckMate--141-a-Pivotal-Phase-3-Opdivo-nivolumab-Head-and-Neck-Cancer-Trial-Stopped-Early/default.aspxThu, 28 Jan 2016 07:59:00 -0500ac8b141b-d84f-4db0-b514-eb78365d289bhttps://news.bms.com/news/details/2016/Bristol-Myers-Squibbs-Opdivo-nivolumab--Yervoy-ipilimumab-Regimen-Receives-Expanded-FDA-Approval-in-Unresectable-or-Metastatic-Melanoma-Across-BRAF-Status1/default.aspxSat, 23 Jan 2016 19:36:00 -0500e80785d3-f816-4a0f-8bfd-1f63c0ac5a41https://news.bms.com/news/details/2016/Bristol-Myers-Squibb-to-Present-at-JP-Morgan-Healthcare-Conference/default.aspxTue, 05 Jan 2016 11:00:00 -050074465082-c0ec-40cc-bcba-4fd236ed0a30https://news.bms.com/news/details/2015/Seattle-Genetics-and-Bristol-Myers-Squibb-Announce-Initiation-of-Phase-12-Clinical-Trial-of-ADCETRIS-Brentuximab-Vedotin-in-Combination-with-Opdivo-Nivolumab-in-Relapsed-or-Refractory-Non-Hodgkin-Lymphoma/default.aspxWed, 23 Dec 2015 09:00:00 -05003da0c04c-cc9b-4888-bab1-42a26b007618https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Sell-its-HIV-RD-Portfolio-to-ViiV-Healthcare/default.aspxFri, 18 Dec 2015 03:01:00 -0500e7ab251c-fb62-4d08-8962-c3eee0fa6fefhttps://news.bms.com/news/details/2015/BMS-and-The-Ohio-State-University-Comprehensive-Cancer-Center--Arthur-G-James-Cancer-Hospital-and-Richard-J-Solove-Research-Institute-Enter-Into-a-Collaboration-Agreement-as-Part-of-US-Immuno-Oncology-Rare-Population-Malignancy-Program/default.aspxThu, 17 Dec 2015 17:30:00 -0500bb549fa8-3120-42ab-80cb-089d51e4d82ehttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-and-UCLA-Enter-into-a-Collaboration-Agreement-as-Part-of-US-Immuno-Oncology-Rare-Population-Malignancy-Research-Program/default.aspxMon, 14 Dec 2015 07:59:00 -050039b35ecd-e0dd-45a7-bd2a-81548d6b3c92https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Announce-Results-for-Fourth-Quarter-Full-Year-2015-on-January-28/default.aspxFri, 11 Dec 2015 12:40:00 -050046bd9def-dba0-4f05-8496-0ce6f5cc36b3https://news.bms.com/news/details/2015/AMPLIFY-Post-Hoc-Early-Time-Course-Analysis-Evaluated-Recurrent-Venous-Thromboembolism-VTE-VTE-Related-Death-and-Major-Bleeding-in-Deep-Vein-Thrombosis-and-Pulmonary-Embolism-Patients-Treated-with-Eliquis-apixaban-or-Conventional-Therapy/default.aspxThu, 10 Dec 2015 17:15:00 -050092b16869-37fb-4bec-87a9-4583526c5d22https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Completes-Previously-Announced-Acquisition-of-Cardioxyl-Pharmaceuticals-Inc/default.aspxTue, 08 Dec 2015 17:15:00 -050063ad9a7b-8de6-4d39-bb2f-a38a5671f69ehttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Establishes-Center-for-Molecular-Synthesis-in-New-Collaboration-with-Princeton-University/default.aspxTue, 08 Dec 2015 17:10:00 -0500abc8ad99-5143-4088-8f83-404e10eee89bhttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Announces-Dividend-Increase/default.aspxTue, 08 Dec 2015 17:05:00 -050012d0659f-9f03-4c72-9db1-93d55dd2869ehttps://news.bms.com/news/details/2015/New-Longer-Term-Data-for-Empliciti-elotuzumab-Showed-a-Continued-Progression-Free-Survival-Benefit-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma/default.aspxSat, 05 Dec 2015 09:15:00 -0500ba5094ec-892c-4b23-8e18-9f695cad7b6bhttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Receives-Multiple-Myeloma-Research-Foundations-2015-Collaborator-Award/default.aspxFri, 04 Dec 2015 09:00:00 -05002808b561-445b-45a6-baef-08afc1bc93c2https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Foundation-Marks-World-AIDS-Day-with-Grants-Totaling-More-than-35M-for-HIV-and-Cervical-and-Breast-Cancer-Programs-in-Africa/default.aspxTue, 01 Dec 2015 10:00:00 -0500a8fe0af3-4fdd-46dc-ad3c-b9bbd2d6ed7fhttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-and-AbbVie-Receive-FDA-Approval-of-Empliciti-elotuzumab-for-the-Treatment-of-Patients-with-Multiple-Myeloma-Who-Have-Received-One-to-Three-Prior-Therapies/default.aspxMon, 30 Nov 2015 16:14:00 -05008edf5825-0661-4500-8f0b-85262e1e3462https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Present-New-Data-across-Multiple-Blood-Cancers-at-the-57th-Annual-Meeting--Exposition-of-the-American-Society-of-Hematology/default.aspxMon, 30 Nov 2015 07:59:00 -05005798a128-236e-46cf-b026-45a71499054dhttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Announces-Regulatory-Update-for-Opdivo-nivolumab-in-Advanced-Melanoma/default.aspxFri, 27 Nov 2015 16:29:00 -05002ee9709b-a3a9-46dc-8e42-ab5373bc582dhttps://news.bms.com/news/details/2015/European-Commission-Approves-Reconciliation-of-Indications-for-nivolumab-Under-the-Opdivo-European-Marketing-Authorization-Application/default.aspxTue, 24 Nov 2015 07:59:00 -0500d42ba0bd-3464-4bb8-bf16-e6713f75845ahttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Announces-US-Food-and-Drug-Administration-Approval-for-Opdivo-nivolumab-as-a-Single-Agent-for-the-Treatment-of-Patients-with-Previously-Untreated-BRAF-Wild-Type-Advanced-Melanoma/default.aspxTue, 24 Nov 2015 07:55:00 -0500691be7d0-275e-49c7-ba17-b0b5226f26aahttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Receives-FDA-Approval-for-Opdivo-nivolumab-the-Only-Treatment-to-Deliver-Significant-Overall-Survival-in-Advanced-Renal-Cell-Carcinoma-vs-a-Standard-of-Care-in-Patients-Who-Have-Received-Prior-Anti-Angiogenic-Therapy1/default.aspxMon, 23 Nov 2015 20:23:00 -0500ed1ad0e0-1292-4de2-82c4-ec6c989e4983https://news.bms.com/news/details/2015/New-Long-Term-Data-on-Opdivo-and-the-Opdivo--Yervoy-Regimen-Shows-Survival-Benefit-Across-Lines-of-Therapy-in-Advanced-Melanoma/default.aspxWed, 18 Nov 2015 13:00:00 -050064a90bb5-f84a-4703-9919-4a382d8d397dhttps://news.bms.com/news/details/2015/US-Food-and-Drug-Administration-Accepts-for-Priority-Review-the-Supplemental-Biologics-License-Application-for-Opdivo-nivolumab-in-Patients-with-Advanced-Renal-Cell-Carcinoma/default.aspxMon, 16 Nov 2015 18:03:00 -05004e1486ba-41b9-402d-8819-a14d7984215fhttps://news.bms.com/news/details/2015/Data-from-ALLY-3-Trial-Investigating-Daklinza-daclatasvir-in-Combination-with-Sofosbuvir-and-Ribavirin-in-Chronic-Hepatitis-C-Genotype-3-Patients-with-Advanced-Fibrosis-or-Cirrhosis-Presented-at-AASLD/default.aspxMon, 16 Nov 2015 07:59:00 -0500cafd178e-a174-4550-ac84-ed7e1b6f2f6ahttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Present-New-Data-for-Opdivo-nivolumab-in-Advanced-Melanoma-as-Monotherapy-and-in-Combination-with-Yervoy-ipilimumab-at-the-Society-for-Melanoma-Research-2015-International-Congress/default.aspxThu, 12 Nov 2015 07:59:00 -0500a54e8474-8aac-414a-9a45-fd95a9f2114ahttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Foundation-Awards-Five-Grants-Totaling-More-than-277M-to-Programs-Supporting-Post-911-Military-Veterans-their-Families-and-Caregivers/default.aspxWed, 11 Nov 2015 12:00:00 -0500936bcf2f-63ae-463f-929b-1f0a230eabeehttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-and-Pfizer-to-Present-New-Data-on-Eliquis-apixaban-at-the-American-Heart-Association-AHA-Scientific-Sessions-2015/default.aspxFri, 06 Nov 2015 17:15:00 -0500f7d4685a-da96-4500-be37-6acdc0edf808https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Present-Data-from-24-Abstracts-in-Immunoscience-at-the-American-College-of-Rheumatology-ACR-2015-Congress/default.aspxThu, 05 Nov 2015 07:59:00 -05009dc4ed26-a855-4b80-a254-a8b1da329c0ehttps://news.bms.com/news/details/2015/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Type-II-Variation-Application-for-Opdivo-nivolumab-in-Previously-Treated-Advanced-Renal-Cell-Carcinoma/default.aspxThu, 05 Nov 2015 07:59:00 -050097a6f77b-f006-41cb-a335-c13cf778a32dhttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-and-the-Johns-Hopkins-Kimmel-Cancer-Center-Enter-Into-a-Collaboration-Agreement-as-Part-of-US-Immuno-Oncology-Rare-Population-Malignancy-Research-Program/default.aspxTue, 03 Nov 2015 11:19:00 -050045d7a395-7512-40aa-aa7c-be98851a9634https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Present-at-Credit-Suisse-2015-Health-Care-Conference/default.aspxTue, 03 Nov 2015 11:00:00 -0500dcfca295-3736-4801-b4d0-bc05529e4600https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Acquire-Cardioxyl-Pharmaceuticals-Inc/default.aspxMon, 02 Nov 2015 07:59:00 -0500e3de7de5-8f62-48b4-82e4-055382d23c22https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Receives-Approval-from-the-US-Food-and-Drug-Administration-for-Yervoy-ipilimumab-as-Adjuvant-Treatment-for-Fully-Resected-Stage-III-Melanoma/default.aspxWed, 28 Oct 2015 20:35:00 -04004a70158a-5b9d-4f56-9f2c-0195456392fdhttps://news.bms.com/news/details/2015/Bristol-Myers-Squibbs-Opdivo-nivolumab-Recipient-of-Prix-Galien-USA-2015-Award-for-Best-Biotechnology-Product/default.aspxWed, 28 Oct 2015 09:36:00 -0400445ca581-6a26-4bc3-b4d1-1fa80aff54bchttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Reports-Third-Quarter-Financial-Results/default.aspxTue, 27 Oct 2015 07:59:00 -0400fad2cdbc-106d-4d85-8d4a-e8c298023b6dhttps://news.bms.com/news/details/2015/Complete-Phase-2a-Study-of-HIV-1-Investigational-Maturation-Inhibitor-Demonstrates-Positive-Results-for-Therapy-Designed-to-Attack-Virus-Differently-Than-Existing-Treatments/default.aspxFri, 23 Oct 2015 09:30:00 -0400cec7647f-5efa-436d-b2f0-8cffe54a589fhttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Present-Data-from-Multiple-Studies-of-Difficult-to-Treat-Chronic-Hepatitis-C-Patients-at-AASLD/default.aspxWed, 21 Oct 2015 07:09:00 -04002e97fe62-f4ad-4a82-a1a4-76d8ae823628https://news.bms.com/news/details/2015/NICE-Recommends-Daklinza-daclatasvir-for-Treatment-of-Certain-Patients-with-Chronic-Hepatitis-C-Genotypes-1-3-and-4/default.aspxThu, 15 Oct 2015 19:01:00 -0400c36b6666-7bb9-4e6b-98ae-ab795385e445https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Appoints-Paul-Biondi-Senior-Vice-President-Head-of-Business-Development/default.aspxThu, 15 Oct 2015 14:12:00 -040038aba606-d9bd-43a7-b194-ed5885d3af1ahttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Enters-into-Exclusive-Worldwide-License-and-Collaboration-Agreement-with-Five-Prime-Therapeutics-for-Colony-Stimulating-Factor-1-Receptor-CSF1R-Antibody-Program/default.aspxThu, 15 Oct 2015 04:00:00 -04005a6ae9fd-6632-42c3-846f-ea8a2af38bbehttps://news.bms.com/news/details/2015/Bristol-Myers-Squibbs-Ready-Raise-Rise-Recognizes-23-Cancer-Advocacy-Groups-in-Immuno-Oncology-Research-Awareness-Campaign/default.aspxTue, 13 Oct 2015 06:59:00 -0400c2205b5f-e709-4a4e-85f7-95e5fd45e8ddhttps://news.bms.com/news/details/2015/Bristol-Myers-Squibbs-Opdivo-nivolumab-Receives-Expanded-FDA-Approval-in-Previously-Treated-Metastatic-Non-Small-Cell-Lung-Cancer-NSCLC-Offering-Improved-Survival-to-More-Patients/default.aspxFri, 09 Oct 2015 15:02:00 -04009ac41308-f6e3-4556-b88e-5301202d3db3https://news.bms.com/news/details/2015/US-FDA-Grants-Priority-Review-For-Daklinza-daclatasvir-sNDAs/default.aspxTue, 06 Oct 2015 07:00:00 -040003545320-3b9a-4410-8b1c-4e94cad01459https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Receives-Approval-from-the-US-Food-and-Drug-Administration-for-the-Opdivo-nivolumab--Yervoy-ipilimumab-Regimen-in-BRAF-V600-Wild-Type-Unresectable-or-Metastatic-Melanoma/default.aspxThu, 01 Oct 2015 06:59:00 -04003e0ee748-a315-4cd2-8193-2eed8d1a4971https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Launches-Working-Together-for-Patients-a-Program-Highlighting-the-Companys-Commitment-to-Patients/default.aspxMon, 28 Sep 2015 09:00:00 -04006a9a30ce-def0-4c8b-864c-00101499e659https://news.bms.com/news/details/2015/REPEATActor-Jack-Huston-Challenges-Europeans-to-Take-ACTion-Against-Lung-Cancer/default.aspxMon, 28 Sep 2015 03:30:00 -0400ab390acc-3347-496a-b8ff-9bfe7b673cbchttps://news.bms.com/news/details/2015/Opdivo-nivolumab-Demonstrates-Long-Term-Survival-Benefit-in-Patients-with-Previously-Treated-Non-Squamous-Non-Small-Cell-Lung-Cancer-in-CheckMate--057/default.aspxSun, 27 Sep 2015 18:01:00 -04005e2608ec-1698-464a-9029-aded777a6de9https://news.bms.com/news/details/2015/Actor-Jack-Huston-Challenges-Europeans-to-Take-ACTion-Against-Lung-Cancer/default.aspxSat, 26 Sep 2015 05:24:00 -04000974de04-9fa5-472d-bfa9-840d693bd03dhttps://news.bms.com/news/details/2015/Opdivo-nivolumab-Demonstrates-Superior-Overall-Survival-in-a-Phase-3-Trial-Compared-to-Standard-of-Care-in-Patients-with-Previously-Treated-Advanced-Renal-Cell-Carcinoma/default.aspxFri, 25 Sep 2015 18:01:00 -0400d91fdd9e-8dd6-40a6-a538-c84ca17b8388https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Announces-US-Food-and-Drug-Administration-Regulatory-Filing-Update-for-the-OpdivoYervoy-Regimen-in-Patients-with-Previously-Untreated-Advanced-Melanoma/default.aspxFri, 25 Sep 2015 16:15:00 -04008a2d0737-03d0-4d65-a254-5e7bee0c64cchttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-and-Moffitt-Cancer-Center-Enter-Into-a-Collaboration-Agreement-as-Part-of-US-Immuno-Oncology-Rare-Population-Malignancy-Program/default.aspxFri, 25 Sep 2015 08:00:00 -04005bd672fd-10bf-4bd7-94d7-71036eff67a0https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Take-Part-in-Leerink-Partners-Inaugural-Immuno-Oncology-Roundtable-Conference/default.aspxThu, 24 Sep 2015 15:17:00 -04004e255c82-219a-431f-838d-b6ce1df37dabhttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Announce-Results-for-Third-Quarter-2015-on-October-27/default.aspxThu, 24 Sep 2015 09:00:00 -040078b7d9e4-f800-49b8-acb1-6b978196129fhttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Foundation-Awards-Additional-Grants-to-Promote-Cervical-Cancer-Screenings-and-Services-for-Women-Living-with-HIV-in-Tanzania/default.aspxFri, 18 Sep 2015 08:00:00 -04009b702a48-541a-4a84-839a-312d1da6c3b6https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Announces-Dividend/default.aspxThu, 17 Sep 2015 16:32:00 -04000f476ef2-f3ae-4906-88e9-2e766f35e15fhttps://news.bms.com/news/details/2015/Bristol-Myers-Squibbs-Opdivo-nivolumab-Receives-Breakthrough-Therapy-Designation-from-US-Food-and-Drug-Administration-for-Advanced-Renal-Cell-Carcinoma/default.aspxWed, 16 Sep 2015 08:00:00 -0400792a76fe-dc48-41a4-912c-ea6a87059953https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Take-Part-in-Morgan-Stanley-Global-Health-Care-Conference/default.aspxThu, 10 Sep 2015 10:00:00 -04008f5c1607-68ec-4687-b9b3-63fd802f56e2https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Employees-Cycle-Nearly-2900-Miles-Across-the-Country-to-Raise-Money-for-Cancer-Research/default.aspxThu, 10 Sep 2015 08:00:00 -0400bddb528b-5786-4f8a-a9aa-94fb6e410154https://news.bms.com/news/details/2015/Updated-Label-for-Daklinza-daclatasvir-for-the-12-week-Treatment-of-Non-cirrhotic-Patients-with-Chronic-Hepatitis-C-Genotype-3-Approved-by-the-European-Commission/default.aspxThu, 10 Sep 2015 07:00:00 -0400b3e56bb2-a87d-4646-b741-900132de6122https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-and-Pfizer-Enroll-First-Patient-in-Phase-4-AUGUSTUS-Trial-to-Evaluate-Safety-of-Eliquis-apixaban-in-Nonvalvular-Atrial-Fibrillation-Patients-with-a-Recent-Acute-Coronary-Syndrome-or-Undergoing-Percutaneous-Coronary-Intervention/default.aspxWed, 09 Sep 2015 08:00:00 -0400c3fac1c2-fd99-4eff-b976-c83ec723de42https://news.bms.com/news/details/2015/Follow-up-Data-from-Two-Pivotal-Opdivo-nivolumab-Trials-Demonstrates-Sustained-Survival-Results-in-Patients-with-Previously-Treated-Squamous-Non-Small-Cell-Lung-Cancer/default.aspxMon, 07 Sep 2015 12:45:00 -040063a1aa51-95ad-4c3e-924e-d4ceefec4bbdhttps://news.bms.com/news/details/2015/New-Cohorts-from-CheckMate--012-Assess-Optimal-Dosing-of-OpdivoYervoy-in-the-First-Line-Treatment-of-Patients-with-Advanced-Non-Small-Cell-Lung-Cancer/default.aspxMon, 07 Sep 2015 12:45:00 -0400c3d24227-8bb7-4710-a60e-530512566368https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Host-Investor-Teleconference-to-Discuss-World-Conference-on-Lung-Cancer-WCLC-Highlights/default.aspxWed, 02 Sep 2015 16:15:00 -04000ff99cf7-2988-4a6c-b54f-3c03d54151d1https://news.bms.com/news/details/2015/US-Food-and-Drug-Administration-Accepts-Supplemental-Biologics-License-Application-for-Opdivo-nivolumab-in-Previously-Treated-Non-Squamous-Non-Small-Cell-Lung-Cancer-Patients/default.aspxWed, 02 Sep 2015 08:00:00 -0400cb6df456-103d-4861-8dde-d8c34faa66d8https://news.bms.com/news/details/2015/US-Food-and-Drug-Administration-Accepts-for-Priority-Review-the-Biologics-License-Application-for-Empliciti-elotuzumab-for-the-Treatment-of-Multiple-Myeloma-in-Patients-Who-Have-Received-One-or-More-Prior-Therapies/default.aspxTue, 01 Sep 2015 07:30:00 -0400deb805f2-9877-4b0d-ae8a-82ccc0478336https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Enters-Agreement-Providing-Exclusive-Right-to-Acquire-Promedior-Inc-and-its-Novel-PRM-151-in-Development-for-Fibrotic-Diseases/default.aspxMon, 31 Aug 2015 08:30:00 -0400c535aa0d-0655-41bf-933e-a021f4be310fhttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-and-QIMR-Berghofer-Medical-Research-Institute-Announce-Worldwide-Collaboration-to-Discover-Novel-Immuno-Oncology-Antibodies/default.aspxSun, 30 Aug 2015 19:00:00 -0400f1aa6357-502d-4079-830a-e384871fd19ehttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-and-Pfizer-to-Present-New-Data-on-Eliquis-apixaban-at-the-ESC-Congress-2015/default.aspxMon, 24 Aug 2015 08:15:00 -0400aedbf8a3-9b65-46f0-94d9-2b9656c23936https://news.bms.com/news/details/2015/FDA-Approves-US-Product-Labeling-Update-for-Sprycel-dasatinib-to-Include-Five-Year-First-Line-and-Seven-Year-Second-Line-Efficacy-and-Safety-Data-in-Chronic-Myeloid-Leukemia-in-Chronic-Phase/default.aspxThu, 13 Aug 2015 08:00:00 -0400fae1e84f-3f87-4a08-add9-cc5d8438bcbahttps://news.bms.com/news/details/2015/US-Food-and-Drug-Administration-Extends-Action-Date-for-Supplemental-Biologics-License-Application-for-Opdivo-nivolumab-in-Previously-Untreated-Advanced-Melanoma/default.aspxWed, 12 Aug 2015 16:15:00 -0400f21da891-bf3f-4279-98fa-cd7c5af4a0a3https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-and-The-Leukemia--Lymphoma-Society-Announce-Charitable-Donation-to-Support-Critical-Routine-Testing-and-Awareness-for-Chronic-Myeloid-Leukemia-Patients/default.aspxTue, 04 Aug 2015 08:00:00 -0400659a98aa-42e0-44bf-8d6e-11c19cfcb9fehttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Establishes-Collaborative-Immuno-Oncology-Rare-Population-Malignancy-I-O-RPM-Program-in-the-US/default.aspxMon, 03 Aug 2015 09:00:00 -0400479dc558-45d2-400a-810e-1f7c5d6adeedhttps://news.bms.com/news/details/2015/Kyowa-Hakko-Kirin-and-Bristol-Myers-Squibb-Announce-Immuno-Oncology-Clinical-Collaboration-Studying-Mogamulizumab-and-Opdivo-nivolumab-in-Advanced-Solid-Tumors-in-the-US/default.aspxWed, 29 Jul 2015 19:00:00 -04001174f1e2-30c4-4bea-99dc-40a49444369ehttps://news.bms.com/news/details/2015/European-Medicines-Agency-Validates-and-Grants-Accelerated-Assessment-of-Marketing-Authorization-Application-for-Empliciti-elotuzumab-For-the-Treatment-of-Multiple-Myeloma-in-Patients-Who-Have-Received-One-or-More-Prior-Therapies/default.aspxMon, 27 Jul 2015 07:00:00 -0400e59b6f9d-b5de-4fcc-9430-d0ccae72a052https://news.bms.com/news/details/2015/FDA-Approves-Daklinza-daclatasvir-for-the-Treatment-of-Patients-with-Chronic-Hepatitis-C-Genotype-3/default.aspxFri, 24 Jul 2015 14:06:00 -0400ec581d08-2ea8-4069-83cd-58b31864ae56https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Reports-Second-Quarter-Financial-Results/default.aspxThu, 23 Jul 2015 07:30:00 -040068ced1e4-119b-4241-a11f-4efcfc7e5de6https://news.bms.com/news/details/2015/European-Medicines-Agency-Validates-Two-Parallel-Type-II-Variation-Applications-to-Extend-the-Opdivo-nivolumab-Indication-in-Europe/default.aspxThu, 23 Jul 2015 06:30:00 -04008c970abe-24ec-43f7-9dd8-7221a6078465https://news.bms.com/news/details/2015/Second-Generation-Investigational-HIV-1-Maturation-Inhibitor-Demonstrates-Positive-New-Phase-IIa-Results-Supporting-Continued-Development/default.aspxTue, 21 Jul 2015 14:00:00 -040012778ffd-45f4-43be-9f46-28dca269b860https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Receives-US-FDA-Breakthrough-Therapy-Designation-for-Investigational-HIV-1-Attachment-Inhibitor-for-Heavily-Treatment-Experienced-Patients/default.aspxTue, 21 Jul 2015 09:00:00 -0400f41a974e-e377-4135-aa79-5ece34cf14f2https://news.bms.com/news/details/2015/European-Commission-Approves-Nivolumab-BMS-the-First-PD-1-Immune-Checkpoint-Inhibitor-in-Europe-Proven-to-Extend-Survival-for-Patients-with-Previously-Treated-Advanced-Squamous-Non-Small-Cell-Lung-Cancer/default.aspxMon, 20 Jul 2015 12:07:00 -04007ad761c5-f208-4edf-9032-9aed89f543b6https://news.bms.com/news/details/2015/CheckMate--025-a-Pivotal-Phase-III-Opdivo-nivolumab-Renal-Cell-Cancer-Trial-Stopped-Early/default.aspxMon, 20 Jul 2015 08:00:00 -0400fb4d3878-4d9c-43b8-a1b9-f9ef5f1bf972https://news.bms.com/news/details/2015/European-Commission-Approves-Bristol-Myers-Squibbs-Evotaz-atazanavir-and-cobicistat-fixed-dose-combination-for-the-Treatment-of-HIV-1-Infection-in-Adults/default.aspxThu, 16 Jul 2015 09:21:00 -0400ffa60a6b-2476-482b-832c-8e7cbd8ac4adhttps://news.bms.com/news/details/2015/MUSC-and-Bristol-Myers-Squibb-Announce-Translational-Research-Collaboration-Focused-on-Fibrotic-Diseases/default.aspxWed, 15 Jul 2015 08:30:00 -0400e2cb0307-06ad-44fa-811e-51a7ec931ca6https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Expands-RD-Presence-Within-Hubs-of-World-Class-Science-and-Innovation/default.aspxThu, 25 Jun 2015 09:30:00 -040049114ffa-fa0e-47af-a302-bb1181c11d29https://news.bms.com/news/details/2015/Portola-Bristol-Myers-Squibb-and-Pfizer-Announce-Full-Results-of-Second-Part-of--Phase-3-ANNEXA-A-Study-Demonstrating-that-Investigational-Andexanet-Alfa-Sustained-Reversal-of-Anticoagulant-Effect-of-Factor-Xa-Inhibitor-Eliquis-apixaban/default.aspxMon, 22 Jun 2015 08:49:00 -04005a8ce3fb-70b2-455e-869a-753c7741771ahttps://news.bms.com/news/details/2015/European-Commission-Approves-Bristol-Myers-Squibbs-Opdivo-nivolumab-the-First-and-Only-PD-1-Checkpoint-Inhibitor-Approved-in-Europe-for-Both-First-Line-and-Previously-Treated-Advanced-Melanoma-Patients/default.aspxFri, 19 Jun 2015 11:37:00 -0400a60b4349-0955-472e-aa2e-4ebe46b19df3https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Announce-Results-for-Second-Quarter-2015-on-July-23/default.aspxThu, 18 Jun 2015 09:00:00 -04007cde5500-7c42-48b6-ba49-7c66b3d23136https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Announces-Dividend-320e73e45/default.aspxTue, 16 Jun 2015 16:30:00 -0400808d00b7-a2b7-4b84-9182-f7b52ec7edc7https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Demonstrates-Commitment-to-Hematology-and-Advancing-Research-and-Development-Across-Multiple-Blood-Cancers-Through-Immuno-Oncology-Leadership-at-the-20th-Congress-of-the-European-Hematology-Association/default.aspxThu, 11 Jun 2015 00:00:00 -040000da6220-49d7-4d93-b2d1-7d43fe2b062bhttps://news.bms.com/news/details/2015/New-Post-Hoc-Analyses-of-Phase-3b-Data-Examine-Treatment-with-Orencia-abatacept-Plus-Methotrexate-MTX-in-Patients-with-Early-Moderate-to-Severe-Rheumatoid-Arthritis-RA-and-Markers-of-Poor-Prognosis/default.aspxTue, 09 Jun 2015 18:02:00 -0400f6965cae-76fa-43bc-899e-cfcb488bfcf4https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Present-Data-from-14-Abstracts-on-Orencia-abatacept-at-the-European-League-Against-Rheumatism-EULAR-2015-Annual-Meeting/default.aspxWed, 03 Jun 2015 08:00:00 -0400937e7b63-3c2c-4ab2-9aa2-1575c8b23e1fhttps://news.bms.com/news/details/2015/Adding-Investigational-Agent-Elotuzumab-to-Standard-Treatment-for-Multiple-Myeloma-Significantly-Reduced-the-Risk-of-Disease-Progression-According-to-New-Phase-III-Data-from-ELOQUENT-2-Trial-Published-in-New-England-Journal-of-Medicine/default.aspxTue, 02 Jun 2015 10:45:00 -0400f41c55d5-4ea0-4983-8d00-a47799b427d9https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Take-Part-in-Goldman-Sachs-36th-Annual-Global-Health-Care-Conference/default.aspxTue, 02 Jun 2015 10:00:00 -040073d25014-299b-496e-81ac-fdfcd644464ahttps://news.bms.com/news/details/2015/US-Food-and-Drug-Administration-Accepts-Supplemental-Biologics-License-Application-for-OpdivoYervoy-Regimen-in-Patients-with-Previously-Untreated-Advanced-Melanoma/default.aspxMon, 01 Jun 2015 07:44:00 -0400fea089ef-1cd1-44f0-af58-5dcc8a9a1e60https://news.bms.com/news/details/2015/Opdivo-nivolumab-Demonstrates-Superior-Survival-Compared-to-Standard-of-Care-docetaxel-for-Previously-Treated-Squamous-Non-Small-Cell-Lung-Cancer-in-Phase-III-Trial/default.aspxSun, 31 May 2015 17:35:00 -0400bec7b710-dee5-47f7-993a-00a0f432ab76https://news.bms.com/news/details/2015/Phase-III-CheckMate--067-Trial-Demonstrates-Superior-Progression-Free-Survival-of-OpdivoYervoy-Regimen-or-Opdivo-Monotherapy-vs-Yervoy-Monotherapy-in-Previously-Untreated-Patients-with-Advanced-Melanoma/default.aspxSun, 31 May 2015 14:35:00 -040091d3c7af-440a-40b9-be4f-40f44ecdb7cahttps://news.bms.com/news/details/2015/Phase-III-Opdivo-nivolumab-Trial-Shows-Bristol-Myers-Squibbs-PD-1-Immune-Checkpoint-Inhibitor-is-First-to-Demonstrate-Anti-Tumor-Activity-In-Patients-With-Hepatocellular-Carcinoma/default.aspxFri, 29 May 2015 14:02:00 -0400f1f8c52b-039e-43f5-8ef5-dec96698ec62https://news.bms.com/news/details/2015/Opdivo-nivolumab-First-PD-1-Inhibitor-to-Demonstrate-Superior-Overall-Survival-Versus-Standard-of-Care-docetaxel-in-Previously-Treated-Non-Squamous-Non-Small-Cell-Lung-Cancer-in-Pivotal-Phase-III-Trial/default.aspxFri, 29 May 2015 14:02:00 -04002e424a0f-6469-4f58-9a0c-75b2a4e4a45chttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Hold-Investor-Teleconference-to-Discuss-ASCO-Highlights/default.aspxThu, 28 May 2015 14:04:00 -040030883a56-4026-4a48-aa95-a87c27ef196ahttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Announces-the-Expiration-of-its-Cash-Tender-Offer/default.aspxWed, 27 May 2015 08:00:00 -04008fa7a9b8-50f8-4a18-8b96-76d57d81b90chttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-in-the-European-Union-for-Nivolumab-Opdivo-Nivolumab-BMS-for-the-Treatment-of-Advanced-Squamous-Non-Small-Cell-Lung-Cancer-in-Previously-Treated-Patients/default.aspxFri, 22 May 2015 07:31:00 -040095560a87-e6ae-41af-a504-eb3764a26b10https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Receives-Amended-US-FDA-Breakthrough-Therapy-Designation-for-Investigational-Daclatasvir-based-Hepatitis-C-Regimen/default.aspxWed, 20 May 2015 09:00:00 -0400f44c88e3-7f43-49ff-9b18-98d9f2dc514bhttps://news.bms.com/news/details/2015/Eric-Stonestreet-of-Televisions-Hit-Comedy-Modern-Family-Joins-Forces-with-Bristol-Myers-Squibb-to-Launch-Ready-Raise-Rise-to-Honor-Those-Affected-by-Cancer-and-Increase-Awareness-of-Innovative-Immuno-Oncology-Research/default.aspxTue, 19 May 2015 08:00:00 -04002f767d9f-653b-442b-9077-80aa1bf5f136https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Present-Data-at-2015-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting-that-Demonstrate-the-Promise-of-its-Broad-Immuno-Oncology-Portfolio-Across-Solid-Tumors-and-Blood-Cancers-Including-Multiple-Myeloma/default.aspxWed, 13 May 2015 08:02:00 -04000ee408d3-bdcf-446b-bc7e-e37ab070a003https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Announces-the-Pricing-Terms-of-its-Cash-Tender-Offer-For-Up-to-500-Million-Aggregate-Principal-Amount-of-its-Outstanding-Debt-Securities/default.aspxTue, 12 May 2015 18:15:00 -040028d921dc-df7d-4777-ac76-8c3817fbd35fhttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Announces-the-Early-Results-of-its-Cash-Tender-Offer-For-Up-to-400-Million-Aggregate-Principal-Amount-of-its-Outstanding-Debt-Securities-Increases-the-Maximum-Amount-of-the-Tender-Offer/default.aspxTue, 12 May 2015 08:00:00 -04008c87a6a0-4725-476a-b035-f39c1a3c6a54https://news.bms.com/news/details/2015/Long-Term-7-Year-Study-of-Nulojix-belatacept-Regimen-Demonstrates-Statistically-Significant-Relative-Risk-Reduction-of-Death-or-Graft-Loss-over-Cyclosporine-Regimen-in-Kidney-Transplant/default.aspxWed, 06 May 2015 10:00:00 -0400494689a9-1825-49fe-a0be-2ffe8d21256ehttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Present-at-Bank-of-America-Merrill-Lynch-2015-Health-Care-Conference/default.aspxMon, 04 May 2015 15:38:00 -0400026347c0-1a6a-440e-b75b-eb0165d64b50https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Prices-115-Billion-of-Senior-Notes/default.aspxWed, 29 Apr 2015 18:30:00 -0400bb013e1c-2f4b-4b86-896b-ed642f97eed3https://news.bms.com/news/details/2015/US-Food-and-Drug-Administration-Accepts-Supplemental-Biologics-License-Application-for-Opdivo-nivolumab-in-Patients-with-Previously-Untreated-Advanced-Melanoma/default.aspxWed, 29 Apr 2015 17:00:00 -0400678883b6-9bf0-46c4-bceb-f14a797045dchttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Take-Part-in-Deutsche-Bank-Global-Health-Care-Conference/default.aspxWed, 29 Apr 2015 10:00:00 -040096142e08-a0a8-40e9-b6f9-89de548494fchttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Announces-Cash-Tender-Offer-For-Up-to-400-Million-Aggregate-Principal-Amount-of-its-Outstanding-Debt-Securities/default.aspxTue, 28 Apr 2015 07:48:00 -040063bbf570-e6ae-4b79-9fda-88d554cff1cahttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results/default.aspxTue, 28 Apr 2015 07:30:00 -0400f6c7dbe5-7f9c-4de2-b165-a43ace5c5140https://news.bms.com/news/details/2015/ALLY-1-Trial-Results-Show-Investigational-Daclatasvir-Based-Regimen-Cures-94-of-Post-Liver-Transplant-Patients-with-Hepatitis-C-and-Up-to-94-of-Hepatitis-C-Patients-with-Cirrhosis-Child-Pugh-Class-A-or-B/default.aspxSat, 25 Apr 2015 10:00:00 -0400fef22435-0306-482c-bf64-4cf5b44ebac6https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-in-the-European-Union-for-Opdivo-nivolumab-for-the-Treatment-of-Advanced-Melanoma-in-Both-First-Line-and-Previously-Treated-Patients/default.aspxFri, 24 Apr 2015 07:46:00 -0400236ea56e-c7c6-4d44-ab15-bcafed3944cdhttps://news.bms.com/news/details/2015/First-Randomized-Study-Evaluating-Opdivo-nivolumabYervoy-ipilimumab-Regimen-Demonstrates-Superior-Efficacy-Versus-Yervoy-Alone-in-Patients-with-Previously-Untreated-Advanced-Melanoma/default.aspxMon, 20 Apr 2015 08:30:00 -0400e9850f27-5267-40c4-849d-cc2b5727441ehttps://news.bms.com/news/details/2015/CheckMate--057-a-Pivotal-Phase-III-Opdivo-nivolumab-Lung-Cancer-Trial-Stopped-Early/default.aspxFri, 17 Apr 2015 08:55:00 -0400e12e5413-4670-4b64-b7af-44c7fe05aadbhttps://news.bms.com/news/details/2015/Lilly-Bristol-Myers-Squibb-Restructure-Erbitux-cetuximab-Collaboration-in-North-America/default.aspxThu, 16 Apr 2015 12:15:00 -040083b12d94-b5ff-434a-a708-3c2d1dce8209https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Completes-Previously-Announced-Acquisition-of-Flexus-Biosciences-Inc/default.aspxWed, 08 Apr 2015 08:00:00 -04003a85a964-d768-4941-a3fc-e2c763524de3https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-and-uniQure-Enter-into-Exclusive-Strategic-Collaboration-to-Develop-Gene-Therapies-for-Cardiovascular-Diseases/default.aspxMon, 06 Apr 2015 07:32:00 -0400f2c7cde4-3a25-4e51-a49d-2445dc4017abhttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Announce-Results-for-First-Quarter-2015-on-April-28/default.aspxFri, 27 Mar 2015 11:08:00 -04009bc3ab17-4458-4357-8e15-5c2323205ef2https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Acquires-Exclusive-License-from-Novo-Nordisk-for-a-Discovery-Research-Program-Focused-on-Autoimmune-Diseases/default.aspxTue, 24 Mar 2015 09:00:00 -0400c63c606f-25ca-438a-ad15-f75c7929b374https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Announces-Acceptance-of-New-Drug-Application-for-Investigational-Daclatasvir-for-FDA-Review-for-the-Treatment-of-Hepatitis-C-Genotype-3/default.aspxThu, 12 Mar 2015 16:00:00 -0400161db706-1c77-408b-9600-506aeafce282https://news.bms.com/news/details/2015/FDA-Approves-Opdivo-nivolumab-for-the-Treatment-of-Patients-with-Previously-Treated-Metastatic-Squamous-Non-Small-Cell-Lung-Cancer/default.aspxWed, 04 Mar 2015 17:13:00 -0500fb84c380-2231-4173-b699-ccede4db95d2https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Announces-US-FDA-Approval-of-an-Additional-Indication-for-Opdivo-nivolumab/default.aspxWed, 04 Mar 2015 15:21:00 -0500a8436e20-1beb-4c1a-b309-45f93ade417ehttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Signs-Exclusive-Agreement-with-Bavarian-Nordic-for-PROSTVAC-a-Prostate-Specific-Antigen-Targeting-Cancer-Immunotherapy/default.aspxWed, 04 Mar 2015 02:30:00 -05004a42668a-b3c9-472f-9e4a-7bb6f399b5e6https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Announces-Dividend-1a292849b/default.aspxMon, 02 Mar 2015 17:30:00 -0500249709d7-f0b5-4682-b60a-0a965f655346https://news.bms.com/news/details/2015/US-Food-and-Drug-Administration-Accepts-Supplemental-Biologics-License-Application-for-Yervoy-ipilimumab-as-Adjuvant-Treatment-for-Patients-with-Stage-3-Melanoma-Who-Are-at-High-Risk-of-Recurrence/default.aspxMon, 02 Mar 2015 10:25:00 -05008d2adff5-d1b6-4fa7-81e9-5a12bcad4935https://news.bms.com/news/details/2015/US-Food-and-Drug-Administration-Accepts-Biologics-Licensing-Application-for-Opdivo-nivolumab-for-the-Treatment-of-Advanced-Squamous-Non-Small-Cell-Lung-Cancer/default.aspxFri, 27 Feb 2015 14:34:00 -0500db301831-2544-44d5-8d7d-77caf362dc0bhttps://news.bms.com/news/details/2015/ALLY-Trial-Demonstrates-97-Hepatitis-C-Cure-Rates-Among-Patients-Coinfected-with-HIV-After-Ribavirin-Free-Investigational-12-Week-Regimen-of-Daclatasvir-and-Sofosbuvir/default.aspxThu, 26 Feb 2015 16:15:00 -05008c509e08-a3ff-4649-881f-40fb4d7292behttps://news.bms.com/news/details/2015/Study-of-Next-Generation-Investigational-HIV-1-Maturation-Inhibitor-Shows-Positive-Results-in-Preventing-Viral-Replication-via-Different-Mechanism-of-Action-Than-Current-Therapies/default.aspxThu, 26 Feb 2015 09:30:00 -05000c17b905-fd9e-47b9-87ae-1429a054863bhttps://news.bms.com/news/details/2015/48-Week-Analysis-of-Investigational-HIV-1-Attachment-Inhibitor-Paves-Way-for-Phase-III-Trial-Initiation/default.aspxWed, 25 Feb 2015 09:30:00 -0500d8672545-ca55-436c-ad23-2e44e932317ehttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Present-at-Cowen-and-Company-Annual-Global-Health-Care-Conference/default.aspxTue, 24 Feb 2015 11:00:00 -0500b845a855-9dd8-490c-9aec-dbeaec071e1ahttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Foundation-Awards-GRU-Cancer-Center-Three-Year-174M-Grant-to-Address-Lung-Cancer-Among-Neediest-Communities-in-Central-Savannah-River-Area/default.aspxMon, 23 Feb 2015 11:30:00 -0500ff27f6ec-e98d-41b4-a4fa-5f8c31685713https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-To-Expand-Its-Immuno-Oncology-Pipeline-with-Agreement-to-Acquire-Flexus-Biosciences-Inc/default.aspxMon, 23 Feb 2015 09:00:00 -0500c2f44a14-6715-4ecb-aca1-d9211cbabb53https://news.bms.com/news/details/2015/Rigel-and-Bristol-Myers-Squibb-Announce-Research-and-Development-Collaboration-for-TGF-Beta-Receptor-Kinase-Inhibitors-for-Use-in-Immuno-Oncology-Related-Indications/default.aspxMon, 23 Feb 2015 09:00:00 -050075f58667-ad16-441e-8bbb-b30c53c93d74https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Take-Part-in-Leerink-Swann-Global-Health-Care-Conference/default.aspxThu, 05 Feb 2015 10:30:00 -0500f54cfb25-8f06-4918-ab15-64cd3be295d9https://news.bms.com/news/details/2015/US-Food-and-Drug-Administration-Approves-Bristol-Myers-Squibbs-Evotaz-atazanavir-and-cobicistat-for-the-Treatment-of-HIV-1-Infection-in-Adults/default.aspxThu, 29 Jan 2015 18:19:00 -0500ead5a413-0cf7-4e73-b82a-c663d0a8f41ehttps://news.bms.com/news/details/2015/Celldex-Therapeutics-and-Bristol-Myers-Squibb-Announce-Initiation-of-Phase-12-Combination-Study-of-Varlilumab-and-Opdivo-in-Advanced-Refractory-Solid-Tumors/default.aspxThu, 29 Jan 2015 09:06:00 -0500e678e9b3-59c0-48eb-be32-cc72cd3cce88https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-2014-Financial-Results/default.aspxTue, 27 Jan 2015 08:30:00 -0500e52354d4-f41b-4c95-89c2-e7e23d699cc8https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Appoints-Giovanni-Caforio-MD-Chief-Executive-Officer-Effective-May-5-Lamberto-Andreotti-to-Become-Chairman/default.aspxTue, 20 Jan 2015 17:30:00 -05004c7712fe-3da8-4c5b-990a-e3999fed3375https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-and-Lilly-Enter-Clinical-Collaboration-Agreement-to-Evaluate-Opdivo-nivolumab-in-Combination-with-Galunisertib-in-Advanced-Solid-Tumors/default.aspxTue, 13 Jan 2015 09:00:00 -0500d5efb6ec-dd8b-481a-804a-6025342dbed7https://news.bms.com/news/details/2015/Seattle-Genetics-and-Bristol-Myers-Squibb-Announce-Clinical-Collaboration-to-Evaluate-Combination-of-Adcetris-Brentuximab-Vedotin-and-Opdivo-Nivolumab-in-Hematologic-Malignancies/default.aspxMon, 12 Jan 2015 09:00:00 -0500309ac681-fb3b-420a-b9c1-a9b3bfcf5893https://news.bms.com/news/details/2015/CheckMate--017-A-Phase-3-Study-of-Opdivo-Nivolumab-Compared-to-Docetaxel-in-Patients-with-Second-Line-Squamous-Cell-Non-small-Cell-Lung-Cancer-Stopped-Early/default.aspxSun, 11 Jan 2015 22:06:00 -0500cd1c3a8d-460d-4cea-aba8-005fcd8062fdhttps://news.bms.com/news/details/2015/Bristol-Myers-Squibb-to-Present-at-JP-Morgan-Healthcare-Conference/default.aspxTue, 06 Jan 2015 10:30:00 -0500b7bc29b2-2610-413c-a4b3-140100720769https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-and-California-Institute-for-Biomedical-Research-Calibr-Sign-Worldwide-Research-Collaboration-and-License-Agreement-Focused-on-New-Treatment-Approaches-for-Fibrotic-Diseases/default.aspxMon, 05 Jan 2015 09:00:00 -0500fd1eb667-4c28-4a4a-ab4e-1d3b4c6f6134https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Receives-Accelerated-Approval-of-Opdivo-nivolumab-from-the-US-Food-and-Drug-Administration/default.aspxMon, 22 Dec 2014 18:21:00 -05006ad158a8-acd9-4d60-82d4-8897b4dffbf9https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Announces-US-FDA-Approval-of-Opdivo-nivolumab/default.aspxMon, 22 Dec 2014 16:11:00 -0500441e020d-09e6-4170-bfbd-819b48781582https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Announce-Results-for-Fourth-Quarter-Full-Year-2014-on-January-27/default.aspxWed, 17 Dec 2014 11:00:00 -0500fcd97304-fe93-43f6-925f-484fa322887bhttps://news.bms.com/news/details/2014/Ono-Pharmaceutical-Bristol-Myers-Squibb-and-Kyowa-Hakko-Kirin-Announce-Immuno-Oncology-Clinical-Collaboration-Studying-Opdivo-nivolumab-and-Mogamulizumab-in-Advanced-Solid-Tumors/default.aspxWed, 10 Dec 2014 07:00:00 -0500c2b6b1c8-a549-4def-8ac0-255f0d7003a7https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Announces-Dividend/default.aspxTue, 09 Dec 2014 17:30:00 -050062520663-39e4-48b0-b7e0-5c94ea1dc4cfhttps://news.bms.com/news/details/2014/Anticoagulant-Effect-of-Eliquis-apixaban-Reversed-by-Two-Separate-4-Factor-Prothrombin-Complex-Concentrates-in-Healthy-Subjects/default.aspxMon, 08 Dec 2014 14:30:00 -050055b21c43-5fde-4394-ba81-acc406765376https://news.bms.com/news/details/2014/Opdivo-nivolumab-Demonstrates-High-Overall-Response-Rate-of-87-for-Treatment-of-Relapsed-or-Refractory-Hodgkin-Lymphoma/default.aspxSat, 06 Dec 2014 14:00:00 -0500104aaf43-f240-4c1c-a31d-0f6a97e1166ehttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Foundation-Awards-Nine-Grants-Totaling-More-than-35-Million-to-Support-Care-for-High-Risk-Patients-with-Hepatitis-B-and-C-in-China-and-India/default.aspxWed, 03 Dec 2014 10:00:00 -0500bacd0bfe-a520-471f-b6e2-406f26616befhttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Foundation-Marks-World-AIDS-Day-by-Awarding-147-Million-in-New-Grants-to-Strengthen-HIV-Related-Services-in-Five-Sub-Saharan-Countries/default.aspxMon, 01 Dec 2014 10:00:00 -050072d3f244-d1a7-43dd-bc82-b4be71aaf694https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Receives-Complete-Response-Letter-from-US-Food-and-Drug-Administration-for-Daclatasvir-an-Investigational-Treatment-for-Hepatitis-C/default.aspxWed, 26 Nov 2014 12:34:00 -050085f07270-1d85-4175-9832-5c77ddd7cb94https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-and-Five-Prime-Therapeutics-Announce-Exclusive-Clinical-Collaboration-to-Evaluate-the-Combination-of-Investigational-Immunotherapies-Opdivo-nivolumab-and-FPA008-in-Six-Tumor-Types/default.aspxMon, 24 Nov 2014 09:59:00 -0500bf04a926-c7dc-4350-a4ef-6f900dba0c1dhttps://news.bms.com/news/details/2014/Analyses-from-Phase-IIIb-Study-Provide-Additional-Data-in-Earlier-Use-of-Orencia-abatacept-Plus-Methotrexate-MTX-in-Citrullinated-Protein-CCP-Positive-Adult-Patients-with-Early-Rheumatoid-Arthritis-RA/default.aspxMon, 17 Nov 2014 09:00:00 -05003ae9423a-c0b5-4f34-86db-d64f63eede8fhttps://news.bms.com/news/details/2014/Portola-Bristol-Myers-Squibb-and-Pfizer-Announce-Statistically-Significant-Results-from-the-First-Part-of-the-Phase-3-ANNEXA-A-Studies-of-Investigational-Andexanet-Alfa-with-Eliquis-apixaban/default.aspxMon, 17 Nov 2014 09:00:00 -0500dc12a6d6-59ac-4485-ba9c-7571cb59fac2https://news.bms.com/news/details/2014/Study-Comparing-Opdivo-nivolumab-to-Chemotherapy-in-Treatment-Nave-Advanced-Melanoma-Patients-Marks-First-PD-1-Immune-Checkpoint-Inhibitor-to-Demonstrate-a-Survival-Benefit-in-a-Phase-3-Trial/default.aspxSun, 16 Nov 2014 04:45:00 -0500beac9c97-8b58-4000-b7c2-04b4d08e5159https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Construct-a-New-Large-Scale-Biologics-Manufacturing-Facility-in-Cruiserath-Ireland/default.aspxFri, 14 Nov 2014 07:00:00 -0500495fbf63-5407-49f0-88df-57e42b69eacdhttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Present-Sixteen-Orencia-abatacept-Data-Abstracts-at-The-American-College-of-Rheumatology-ACR-2014-Annual-Meeting/default.aspxWed, 12 Nov 2014 09:36:00 -05004f7b6a8f-37fa-451a-abe7-27ec3c52e300https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Foundation-Awards-2-Million-in-New-Grants-to-Help-Veterans-and-their-Families-Transition-from-Military-to-Civilian-Life/default.aspxMon, 10 Nov 2014 10:00:00 -05003b876dcf-243b-4fab-a3e6-a172b14fa544https://news.bms.com/news/details/2014/Phase-3-UNITY-Trials-Demonstrate-High-Cure-Rates-for-Investigational-All-Oral-Daclatasvir-TRIO-Fixed-Dose-Combination-in-Genotype-1-Hepatitis-C-Patients-Including-Those-with-Cirrhosis/default.aspxSat, 08 Nov 2014 10:00:00 -0500d547e30b-2206-4641-b497-c1a77007c1c6https://news.bms.com/news/details/2014/ALLY-Trial-Demonstrates-High-Cure-Rates-for-Investigational-Daclatasvir-and-Sofosbuvir-Combination-among-Genotype-3-Hepatitis-C-Patients/default.aspxSat, 08 Nov 2014 10:00:00 -05008b6cff12-ce1c-4f09-b555-ca4a9a14868ahttps://news.bms.com/news/details/2014/Multiple-Bristol-Myers-Squibb-Oncology-Compounds-to-be-Featured-in-Oral-Presentations-at-56th-Annual-American-Society-for-Hematology-ASH-Meeting/default.aspxFri, 07 Nov 2014 14:44:00 -0500bc6cbcad-08ad-400a-bf65-ad804dc7b13fhttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Present-at-Credit-Suisse-2014-Health-Care-Conference/default.aspxTue, 04 Nov 2014 11:00:00 -0500f8d579e8-0a2d-400d-9def-6454aedd91a1https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Signs-Exclusive-Option-Agreement-to-Acquire-Galecto-Biotech-AB-and-Its-Novel-Galectin-3-Inhibitor-in-Development-for-Idiopathic-Pulmonary-Fibrosis/default.aspxMon, 03 Nov 2014 09:30:00 -05000819a79e-89a8-40e3-acac-1f6239cee8d0https://news.bms.com/news/details/2014/Bristol-Myers-Squibbs-ZymoGenetics-RD-Facility-Earns-LEED-Silver-Certification-from-US-Green-Building-Council/default.aspxFri, 31 Oct 2014 10:23:00 -04003f1894ea-7ed4-490f-8dd1-3f54772d24dahttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-and-Lonza-Expand-Manufacturing-Agreement/default.aspxThu, 30 Oct 2014 14:00:00 -04000ad8aa76-dbf6-4373-918a-d7a9bbe5aa2ahttps://news.bms.com/news/details/2014/Phase-2-Objective-Response-Rate-and-Survival-Data-for-Opdivo-nivolumab-in-Heavily-Pre-treated-Advanced-Squamous-Cell-Non-Small-Cell-Lung-Cancer-to-be-Presented-at-the-2014-Chicago-Multidisciplinary-Symposium-on-Thoracic-Oncology/default.aspxThu, 30 Oct 2014 10:00:00 -0400deb1fab8-07e0-4689-b104-cb77d1935fd2https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Enters-into-Agreement-that-Provides-an-Exclusive-Option-to-Acquire-F-star-Alpha-Ltd-and-its-Novel-HER2-Targeted-Therapy/default.aspxTue, 28 Oct 2014 08:00:00 -0400decf7c50-874c-46b2-b33a-5555aa663543https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Reports-Third-Quarter-2014-Financial-Results/default.aspxFri, 24 Oct 2014 07:30:00 -040041a21d19-5f44-4558-8e39-512c0f2e776dhttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Hold-Investor-Teleconference-to-Discuss-CMSTO-Highlights/default.aspxMon, 13 Oct 2014 09:00:00 -0400f08e36ab-4914-40ca-8d7b-79aa11318b5ehttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Pharmacyclics-and-Janssen-Announce-Clinical-Collaboration-to-Evaluate-OPDIVO-nivolumab-and-IMBRUVICAibrutinib-in-Non-Hodgkin-Lymphoma/default.aspxMon, 13 Oct 2014 08:00:00 -040058f32ee5-98bb-4fd8-bf14-641a0d320d6chttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Statement-on-Sustiva-efavirenz-in-the-US/default.aspxWed, 08 Oct 2014 08:00:00 -0400c70d9798-37ae-462f-9d8c-dc1975b17043https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Statement-about-Asunaprevir-in-the-US/default.aspxTue, 07 Oct 2014 08:30:00 -0400c2a6713a-a939-4ff8-9292-5ed13e4cf377https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Announces-Collaboration-to-Evaluate-Opdivo-nivolumab-in-Combination-with-Targeted-Therapies-from-Novartis-to-Treat-Non-Small-Cell-Lung-Cancer-NSCLC/default.aspxMon, 06 Oct 2014 08:00:00 -04009741bd36-2d37-4453-a65c-f2a416ad587ehttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-and-MD-Anderson-Cancer-Center-Announce-Novel-Research-Collaboration-in-Immuno-Oncology-Focused-on-Leukemia-and-Hematologic-Malignancies/default.aspxMon, 06 Oct 2014 08:00:00 -0400b699b50a-238e-416c-9a9c-ba5487486a85https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Presents-Data-from-Multiple-New-Studies-at-IDWeek-2014-Showcasing-Continued-Innovation-in-Virology/default.aspxFri, 03 Oct 2014 08:00:00 -04008d321b08-0e0b-465b-a6e9-44313d9246e0https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Announce-Results-for-Third-Quarter-on-October-24/default.aspxWed, 01 Oct 2014 10:00:00 -04007c5d26cd-a476-40c3-b96b-890d93ee86bfhttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Transfer-14-Billion-in-US-Pension-Obligations-to-Prudential/default.aspxTue, 30 Sep 2014 17:00:00 -0400ce0a23f4-5eb7-421b-88f3-a9f593e69e46https://news.bms.com/news/details/2014/European-Medicines-Agency-Validates-the-Marketing-Authorization-Application-for-Nivolumab-in-Non-Small-Cell-Lung-Cancer/default.aspxMon, 29 Sep 2014 08:21:00 -0400d7ef0b9f-95e6-4ed9-9a0e-683f05b183b3https://news.bms.com/news/details/2014/Positive-Phase-3-Data-for-Opdivo-nivolumab-in-Advanced-Melanoma-Patients-Previously-Treated-with-Yervoy-ipilimumab-Presented-at-the-ESMO-2014-Congress-First-Phase-3-Results-Presented-for-a-PD-1-Immune-Checkpoint-Inhibitor/default.aspxMon, 29 Sep 2014 03:00:00 -040013505bec-ffab-467d-8e88-00347103be4dhttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Announces-Multiple-Regulatory-Milestones-for-Opdivo-nivolumab-in-the-US-and-European-Union/default.aspxFri, 26 Sep 2014 16:18:00 -040017274175-61ee-4fe9-aff4-60b53ca9590ahttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Build-State-of-the-Art-Campus-in-Lawrenceville-NJ/default.aspxTue, 23 Sep 2014 12:00:00 -0400f6155710-bbc9-4e03-8043-4f42dbac4608https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-and-Pfizer-Announce-Charitable-Donations-of-More-Than-1-Million-to-Support-Cardiovascular-Education-for-Patients-and-Caregivers/default.aspxMon, 22 Sep 2014 08:00:00 -0400d3235dbf-541a-40de-b214-d909e1dedf20https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Announces-Dividend-c7a4631d9/default.aspxTue, 16 Sep 2014 16:30:00 -04007adb6b55-c2b3-43ef-9baa-bf2dbf6552eahttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Present-at-Bank-of-America-Merrill-Lynch-Global-Health-Care-Conference/default.aspxThu, 11 Sep 2014 10:00:00 -040034736181-244c-450a-9163-695d789755eehttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Take-Part-in-Morgan-Stanley-Global-Health-Care-Conference/default.aspxTue, 02 Sep 2014 10:58:00 -04009f4d79e1-9ad8-491f-b29d-07172de54c7chttps://news.bms.com/news/details/2014/Secondary-Analysis-of-AMPLIFY-EXT-Examining-Predictors-of-Hospitalization-Presented-at-ESC-Congress-Eliquis-apixaban-Significantly-Reduced-the-Risk-of-All-Cause-Hospitalization-Versus-Placebo-in-Patients-with-Venous-Thromboembolism-VTE/default.aspxSat, 30 Aug 2014 05:15:00 -0400471ba869-021f-49db-9462-cc04f6666600https://news.bms.com/news/details/2014/European-Commission-Approves-Bristol-Myers-Squibbs-Daklinza-daclatasvir-Across-Multiple-Genotypes-for-the-Treatment-of-Chronic-Hepatitis-C-Infection/default.aspxWed, 27 Aug 2014 05:00:00 -04009b9290e6-54e2-4a05-a184-1114147ed1d7https://news.bms.com/news/details/2014/US-FDA-Approves-Eliquis-apixaban-for-the-Treatment-of-Deep-Vein-Thrombosis-DVT-and-Pulmonary-Embolism-PE-and-for-the-Reduction-in-the-Risk-of-Recurrent-DVT-and-PE-Following-Initial-Therapy/default.aspxThu, 21 Aug 2014 13:31:00 -040076868c8c-82b5-4233-986c-5e0546e2105ahttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-and-Celgene-Enter-Clinical-Collaboration-Agreement-to-Evaluate-Immunotherapy-and-Chemotherapy-Combination-Regimen/default.aspxWed, 20 Aug 2014 08:00:00 -04009456835f-64ef-4a63-8a42-99ad4f139514https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-and-Pfizer-to-Present-New-Data-on-Eliquis-apixaban-at-the-ESC-Congress-2014/default.aspxWed, 20 Aug 2014 08:00:00 -0400f925a3de-22bc-41cc-b7c5-f504415cab9ahttps://news.bms.com/news/details/2014/Allied-Minds-and-Bristol-Myers-Squibb-Form-New-Enterprise-to-Advance-Discoveries-of-Biopharmaceutical-Innovations-at-Leading-US-Academic-Research-Institutions/default.aspxMon, 04 Aug 2014 02:00:00 -040075a57f91-bb0c-4c22-aa6c-825c674a9e4fhttps://news.bms.com/news/details/2014/European-Commission-Approves-Eliquis-apixaban-for-the-Treatment-of-Deep-Vein-Thrombosis-DVT-and-Pulmonary-Embolism-PE-and-Prevention-of-Recurrent-DVT-and-PE/default.aspxTue, 29 Jul 2014 07:00:00 -0400a16f3919-c487-40d8-954f-c58bf97ca9b6https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Reports-Second-Quarter-2014-Financial-Results/default.aspxThu, 24 Jul 2014 07:30:00 -04000911b962-b8e4-4a18-932f-5199d9bea1fdhttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-and-Ono-Pharmaceutical-Co-Ltd-Announce-Strategic-Immuno-Oncology-Collaboration-in-Japan-South-Korea-and-Taiwan/default.aspxWed, 23 Jul 2014 21:00:00 -040022c1ee62-7632-4a81-86e0-24cd4fba114ahttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-and-Pfizer-Announce-Enrollment-of-First-Patient-in-Phase-IV-EMANATE-Trial-to-Assess-Effectiveness-and-Safety-of-Eliquis-apixaban-in-Patients-with-NVAF-Undergoing-Cardioversion/default.aspxThu, 17 Jul 2014 08:06:00 -0400fc95743d-67a3-497e-9283-77f03baf9d28https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Announces-Plans-for-Third-Quarter-Submission-of-a-Biologics-License-Application-for-Opdivo-nivolumab-an-Investigational-PD-1-Immune-Checkpoint-Inhibitor-for-Previously-Treated-Advanced-Melanoma/default.aspxThu, 10 Jul 2014 07:30:00 -040054c13075-1c76-470c-978b-ec6392e8f4c7https://news.bms.com/news/details/2014/Japan-Approves-First-All-Oral-Interferon--and-Ribavirin-Free-Hepatitis-C-Treatment-Daklinza-daclatasvir-and-Sunvepra-asunaprevir-Dual-Regimen/default.aspxMon, 07 Jul 2014 07:00:00 -0400171201a3-0d2c-4eeb-87b1-c429ef8b1053https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Announce-Results-for-Second-Quarter-on-July-24/default.aspxTue, 01 Jul 2014 10:11:00 -0400867cacff-b80d-48b5-8772-fd41c0521f21https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Issues-Voluntary-Nationwide-Recall-of-COUMADIN-warfarin-sodium-FOR-INJECTION-Due-to-Presence-of-Particulate-Matter/default.aspxMon, 30 Jun 2014 13:18:00 -0400179273c1-541b-446f-9437-178116b11ea3https://news.bms.com/news/details/2014/Eliquis-apixaban-Receives-CHMP-Positive-Opinion-for-the-Treatment-of-Deep-Vein-Thrombosis-DVT-and-Pulmonary-Embolism-PE-and-Prevention-of-Recurrent-DVT-and-PE/default.aspxFri, 27 Jun 2014 07:00:00 -040036549755-04f0-4b19-b7b7-54df066ce773https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Daklinza-daclatasvir-for-Treatment-of-Chronic-Hepatitis-C-in-the-European-Union/default.aspxFri, 27 Jun 2014 07:00:00 -0400d71833bc-eca9-4017-bcd1-e4e803480cbdhttps://news.bms.com/news/details/2014/Phase-3-First-Line-Melanoma-Study-of-Nivolumab-an-Investigational-PD-1-Checkpoint-Inhibitor-Demonstrates-Superior-Overall-Survival-Compared-to-Dacarbazine-Study-Stopped-Early/default.aspxTue, 24 Jun 2014 16:45:00 -04005779c20b-2809-48df-8e5a-1948bafaad4fhttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Expands-Access-to-Clinical-Trial-Data-Through-Collaboration-with-Academic-Research-Institute/default.aspxTue, 24 Jun 2014 08:00:00 -0400e7aa6fc0-b4f9-4bf1-bf57-69b94ffdf4eehttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Announces-Dividend-20e740e8e/default.aspxTue, 17 Jun 2014 16:30:00 -04009bd9a9f0-b0d2-4356-93da-73b6b7741cb2https://news.bms.com/news/details/2014/US-Court-of-Appeals-Denies-Appeal-in-Baraclude-Patent-Case/default.aspxThu, 12 Jun 2014 15:41:00 -04004aa9e0b2-5240-4171-94b8-73e5429f1be5https://news.bms.com/news/details/2014/AVERT-Trial-Demonstrates-High-Rates-of-DAS-defined-Remission-with-Orencia-abatacept-in-Combination-with-Methotrexate-MTX-in-Adult-Patients-with-Early-Rheumatoid-Arthritis-RA/default.aspxTue, 10 Jun 2014 18:40:00 -0400faed0ef6-c11f-4c3b-896b-72e36ffd3800https://news.bms.com/news/details/2014/Giovanni-Caforio-MD-Appointed-Chief-Operating-Officer-and-Elected-to-Board-of-Directors/default.aspxMon, 09 Jun 2014 08:00:00 -04007b096ea8-bf14-4efa-9efa-b388a9c41536https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Take-Part-in-Goldman-Sachs-35th-Annual-Global-Health-Care-Conference/default.aspxTue, 03 Jun 2014 12:34:00 -04009c9ccad6-c745-4ef4-a9aa-e9a146907801https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-and-Syngene-International-Extend-Research-Collaboration/default.aspxTue, 03 Jun 2014 07:00:00 -04004fd0865a-b1fb-49c5-9f01-8a1a335b591ahttps://news.bms.com/news/details/2014/One---Two-Year-Survival-Rates-of-94-and-88-Announced-from-Phase-1b-Trial-of-Investigational-PD-1-Checkpoint-Inhibitor-Nivolumab-and-Yervoy-ipilimumab-in-Advanced-Melanoma-Ongoing-Phase-23-Trials-to-Confirm-Results/default.aspxMon, 02 Jun 2014 07:30:00 -04003ef31ba0-f25c-4de0-83ff-a987090f9106https://news.bms.com/news/details/2014/Phase-3-Study-Evaluating-Yervoy-Ipilimumab-for-Melanoma-in-an-Adjuvant-Setting-Meets-Primary-Endpoint-of-Recurrence-Free-Survival/default.aspxMon, 02 Jun 2014 07:30:00 -040096cb37ff-5966-48f5-bb3e-59169a3ef681https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-and-Incyte-Enter-Clinical-Collaboration-Agreement-to-Evaluate-Combination-Regimen-of-Two-Novel-Immunotherapies/default.aspxTue, 27 May 2014 07:00:00 -040034de64a5-1f9a-41b9-b26b-f7107899df3ahttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-and-CytomX-Therapeutics-Announce-Worldwide-Collaboration-to-Develop-Probody-Therapeutics-Against-Multiple-Immuno-Oncology-Targets/default.aspxTue, 27 May 2014 07:00:00 -0400800a37cb-65ae-421c-b103-fa86956c096chttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Present-New-Remission-Data-on-ORENCIA-abatacept-and-Clazakizumab-at-The-European-League-Against-Rheumatism-EULAR-2014-Annual-Meeting/default.aspxWed, 21 May 2014 08:00:00 -04000b4afc09-7f3e-426e-9f7a-2d7d6ff5fd1chttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-and-AbbVie-Receive-US-FDA-Breakthrough-Therapy-Designation-for-Elotuzumab-an-Investigational-Humanized-Monoclonal-Antibody-for-Multiple-Myeloma/default.aspxMon, 19 May 2014 08:00:00 -0400c83a7daf-2fd2-4afe-9731-c9c9c42af155https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Hold-Investor-Teleconference-to-Discuss-ASCO-Highlights/default.aspxFri, 16 May 2014 08:00:00 -04005e1790b6-0958-4adc-b493-c8c800cbdde7https://news.bms.com/news/details/2014/In-Phase-2-and-1b-Renal-Cell-Carcinoma-Trials-Investigational-PD-1-Immune-Checkpoint-Inhibitor-Nivolumab-Showed-Antitumor-Activity-as-a-Single-Agent-and-in-Combination-Regimen-with-Yervoy-ipilimumab/default.aspxWed, 14 May 2014 17:09:00 -0400226747d2-1786-448f-b4f0-e3f56f086fb5https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Announces-Two--and-Three-Year-Survival-Data-for-Nivolumab-an-Investigational-PD-1-Immune-Checkpoint-Inhibitor-from-Advanced-Melanoma-Cohort-of-a-Phase-1b-Study/default.aspxWed, 14 May 2014 17:01:00 -04005d0bcd82-ed6b-4602-bee1-4ac1e359e2a6https://news.bms.com/news/details/2014/Investigational-PD-1-Immune-Checkpoint-Inhibitor-Nivolumab-Showed-Antitumor-Activity-in-Previously-Treated-and-Chemotherapy-Nave-Patients-in-Phase-1b-Non-Small-Cell-Lung-Cancer-Trials/default.aspxWed, 14 May 2014 17:00:00 -040066fd6af7-29cb-4d5c-b11e-8966e8643302https://news.bms.com/news/details/2014/Investigational-PD-1-Immune-Checkpoint-Inhibitor-Nivolumab-Receives-US-FDA-Breakthrough-Therapy-Designation-for-Hodgkin-Lymphoma/default.aspxWed, 14 May 2014 17:00:00 -04004de0e3b6-74ac-46f8-b1e4-188557dcaecdhttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-and-Celldex-Therapeutics-Announce-Clinical-Trial-Collaboration-to-Evaluate-the-Combination-of-Investigational-Immunotherapies-Nivolumab-and-Varlilumab/default.aspxWed, 14 May 2014 08:00:00 -0400267a6438-2747-4555-825e-4d5bbb437915https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Present-at-UBS-Global-Healthcare-Conference/default.aspxMon, 12 May 2014 10:12:00 -0400f14b024d-c94a-4788-a364-41a082fbeff8https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Announces-Retirement-of-Brian-Daniels/default.aspxTue, 06 May 2014 09:00:00 -0400b276900b-c274-42e9-a47a-4c9afbc94964https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Continues-to-Lead-the-Advancement-of-Immuno-Oncology-with-Broad-Set-of-New-Data-at-2014-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting/default.aspxMon, 05 May 2014 07:30:00 -0400a45e49f4-71cf-4a51-aefc-8194ceeac18chttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Reports-First-Quarter-2014-Financial-Results/default.aspxTue, 29 Apr 2014 07:30:00 -040008950423-4498-4d82-a22b-72d6ba3a316fhttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Acquires-iPierian-Inc/default.aspxTue, 29 Apr 2014 07:00:00 -040078120942-7bc4-4b5d-b50e-b264d366869chttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Ranks-First-on-2014-Best-Corporate-Citizens-List/default.aspxThu, 24 Apr 2014 13:01:00 -0400bb32ff4e-3a1b-4815-a354-420c50c3dd39https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-and-Samsung-BioLogics-Expand-Manufacturing-Agreement/default.aspxTue, 22 Apr 2014 19:00:00 -0400fc961c09-7f44-4f81-a3a1-720352f70836https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Submits-New-Drug-Application-to-US-FDA-for-a-Fixed-Dose-Combination-Tablet-of-Atazanavir-Sulfate-with-Cobicistat-for-People-Living-with-HIV-1/default.aspxMon, 14 Apr 2014 08:00:00 -040056c57f72-d880-4d74-ad48-22d202ede010https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Presents-Phase-III-Data-Demonstrating-that-Investigational-All-oral-Daclatasvir-and-Asunaprevir-Therapy-Achieved-SVR12-Rates-of-up-to-90-Among-Broad-Range-of-Genotype-1b-Hepatitis-C-Patients/default.aspxThu, 10 Apr 2014 07:00:00 -0400a046e7ef-8a98-4015-b4d4-a34da4408caahttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Submits-NDAs-for-Daclatasvir-and-Asunaprevir-to-US-FDA-for-the-Treatment-of-Hepatitis-C/default.aspxMon, 07 Apr 2014 08:00:00 -04005ae53d56-f976-4211-b944-3756f293dd77https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Announce-Results-for-First-Quarter-2014-on-April-29/default.aspxTue, 01 Apr 2014 09:00:00 -04001f125921-313d-42af-8fbc-6c101308213bhttps://news.bms.com/news/details/2014/In-A-Subanalysis-The-Benefits-Of-Eliquis-apixaban-Vs-Warfarin-In-Reducing-The-Risk-Of-Stroke-In-Patients-With-Nonvalvular-Atrial-Fibrillation-Were-Consistent-Regardless-Of-Blood-Pressure-Control-1/default.aspxThu, 27 Mar 2014 09:14:00 -04008c7b48e1-b49e-4be8-adba-1087faa7d8f9https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Present-Data-for-Daclatasvir-in-Multiple-Investigational-All-oral-Combinations-across-Hepatitis-C-Genotypes-at-The-International-Liver-CongressTM/default.aspxMon, 24 Mar 2014 06:39:00 -04005394af6b-a832-46b4-8015-e3cae2db4d60https://news.bms.com/news/details/2014/Five-Prime-Therapeutics-and-Bristol-Myers-Squibb-Sign-Collaboration-Agreement-to-Discover-Novel-Immuno-Oncology-Therapies-for-Two-Immune-Checkpoint-Pathways/default.aspxMon, 17 Mar 2014 07:59:00 -0400a48f90f4-33ca-4d28-a4d1-c327b51a9919https://news.bms.com/news/details/2014/US-FDA-Approves-Eliquis-apixaban-To-Reduce-The-Risk-Of-Blood-Clots-Following-Hip-Or-Knee-Replacement-Surgery/default.aspxFri, 14 Mar 2014 14:00:00 -0400bf29355c-5304-455e-96c0-bbbe9a46f8a4https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Presents-Promising-Phase-IIb-Data-for-Novel-Investigational-Attachment-Inhibitor-for-HIV-1-Infected-Treatment-Experienced-Patients/default.aspxWed, 05 Mar 2014 13:30:00 -0500e535a73b-0212-4bb2-9ced-cd3ca1622c59https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Announces-Dividend-68864ca96/default.aspxMon, 03 Mar 2014 17:30:00 -0500f887669a-58f0-467a-8b0d-25a4dcc72bdchttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Announces-Charitable-Donation-of-1-Million-to-Support-Immuno-Oncology-Education-for-Patients-and-Caregivers/default.aspxMon, 03 Mar 2014 08:30:00 -0500962f79d2-e890-4780-a9bd-801a4aeb63ebhttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Receives-US-FDA-Breakthrough-Therapy-Designation-for-All-Oral-Daclatasvir-Dual-Investigational-Regimen-for-Chronic-Hepatitis-C/default.aspxMon, 24 Feb 2014 09:30:00 -05003f35a40c-a7cd-4951-abbe-a9ea6d6aff7ehttps://news.bms.com/news/details/2014/In-a-Subanalysis-Eliquis-apixaban-Reduced-the-Risk-of-Stroke-and-Demonstrated-Fewer-Major-Bleeding-Events-versus-Warfarin-Consistently-across-Age-Groups-Including-Older-Patients-with-Nonvalvular-Atrial-Fibrillation/default.aspxFri, 21 Feb 2014 12:06:00 -05009322a276-9712-4343-b9de-4caea73ecb6dhttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Present-at-Cowen-and-Company-34th-Annual-Global-Health-Care-Conference/default.aspxThu, 20 Feb 2014 15:00:00 -0500ba0b97e0-5174-4292-a7ea-08b81a3330fbhttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Present-at-Citi-2014-Global-Health-Care-Conference/default.aspxFri, 14 Feb 2014 16:30:00 -0500005fbbac-a577-4e3b-b903-02f41542b524https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Take-Part-in-Leerink-Swann-Global-Health-Care-Conference/default.aspxWed, 05 Feb 2014 12:00:00 -0500c2e3e8f5-ce23-4325-9879-674288ab5afehttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Completes-Previously-Announced-Sale-of-Global-Diabetes-Business-to-AstraZeneca/default.aspxMon, 03 Feb 2014 03:00:00 -050015bc021e-cb3b-4c81-9d29-a5adb55ca373https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-2013-Financial-Results/default.aspxFri, 24 Jan 2014 08:30:00 -05000221f778-6cc5-432e-a9a6-55cdbdf8bed4https://news.bms.com/news/details/2014/AstraZeneca-and-Bristol-Myers-Squibb-Diabetes-Alliance-Provides-5-Million-Grant-for-American-Diabetes-Associations-Pathway-to-Stop-Diabetes-Research-Initiative/default.aspxThu, 16 Jan 2014 09:30:00 -050077f3b545-b486-453c-bfdd-192f9bafef38https://news.bms.com/news/details/2014/US-FDA-Approves-Farxiga-Dapagliflozin-Tablets-for-the-Treatment-of-Adult-Patients-with-Type-2-Diabetes/default.aspxMon, 13 Jan 2014 03:02:00 -0500289f8c1c-fff6-4cbb-9092-340e9434fdcahttps://news.bms.com/news/details/2014/AstraZeneca-and-Bristol-Myers-Squibb-Announce-US-FDA-Approval-of-Farxiga-dapagliflozin/default.aspxWed, 08 Jan 2014 18:06:00 -05009796246c-30de-4a00-b184-f562335d21c7https://news.bms.com/news/details/2014/Daclatasvir-Marketing-Authorization-Application-for-Treatment-of-Chronic-Hepatitis-C-Validated-for-Accelerated-Regulatory-Review-by-the-European-Medicines-Agency/default.aspxWed, 08 Jan 2014 08:00:00 -0500a160ccbb-123a-482b-a60e-0e4b8a59c75fhttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Announce-Results-for-Fourth-Quarter-Full-Year-2013-on-January-24/default.aspxMon, 06 Jan 2014 16:16:00 -050090bff34f-1104-4dd1-9ee4-f091277fc6bdhttps://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Present-at-JP-Morgan-Healthcare-Conference/default.aspxMon, 06 Jan 2014 12:03:00 -0500fdec7f13-b576-4514-846e-745a6ab7fe54https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-to-Take-Part-in-Goldman-Sachs-Healthcare-CEOs-Unscripted-Conference/default.aspxFri, 03 Jan 2014 15:30:00 -050065af6312-4539-421b-902d-f0a18b3a5ea8https://news.bms.com/news/details/2013/FDA-Accepts-For-Review-ELIQUIS-apixaban-Supplemental-New-Drug-Application-for-the-Treatment-of-Deep-Vein-Thrombosis-DVT-and-Pulmonary-Embolism-PE-and-for-the-Reduction-in-the-Risk-of-Recurrent-DVT-and-PE/default.aspxThu, 19 Dec 2013 18:01:00 -05005361b324-51ff-43a8-87cf-e917498387ffhttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Announces-Dividend-Increase/default.aspxThu, 19 Dec 2013 04:34:00 -0500d7207263-e027-4980-8c58-8a22d8f3ce6fhttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Continues-Evolution-to-Specialty-BioPharma-Through-Sale-of-Its-Diabetes-Business/default.aspxThu, 19 Dec 2013 03:56:00 -05001fefb969-c0f9-4a25-b04f-e2f40a9ca77fhttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Foundation-Awards-328-Million-in-Grants-to-Support-Mental-Health-Needs-of-US-Military-Service-Members-Returning-from-Afghanistan-and-Iraq/default.aspxTue, 17 Dec 2013 10:00:00 -0500f69dc13d-fc6d-4618-a848-2e020428487ehttps://news.bms.com/news/details/2013/FDA-Advisory-Committee-Recommends-the-Investigational-SGLT2-Inhibitor-Dapagliflozin-for-the-Treatment-of-Type-2-Diabetes-in-Adults/default.aspxThu, 12 Dec 2013 19:59:00 -05006418aaa8-5f7b-449c-a57a-ae29569c5f9ahttps://news.bms.com/news/details/2013/FDA-Advisory-Committee-Votes-on-Investigational-Medicine-Metreleptin/default.aspxWed, 11 Dec 2013 22:49:00 -05003ce6f660-73e5-4f7d-b46e-18c700d23f3ehttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Names-Thomas-J-Lynch-Jr-MD-to-Board-of-Directors/default.aspxTue, 10 Dec 2013 17:35:00 -0500a1fc9250-4bbc-44d5-9287-bd0f6bc5ebd9https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Foundation-Announces-Two-Grants-to-Fund-Cancer-Nursing-Centers-of-Excellence-in-Russia-and-the-Czech-Republic/default.aspxTue, 10 Dec 2013 10:00:00 -0500756a0080-5ee0-4ab3-8740-6088c6c8b7dahttps://news.bms.com/news/details/2013/Four-Year-Data-from-Phase-3-DASISION-Trial-Comparing-Sprycel-dasatinib-to-Imatinib-in-First-Line-Treatment-of-Adults-with-Ph-CP-CML-Presented-at-Annual-Meeting-of-the-American-Society-of-Hematology/default.aspxMon, 09 Dec 2013 19:30:00 -0500ba8b8f16-0c43-4755-9060-39ed51bae12dhttps://news.bms.com/news/details/2013/Xigduo-dapagliflozin-and-metformin-hydrochloride-Receives-Positive-CHMP-Opinion-in-the-European-Union-for-the-Treatment-of-Type-2-Diabetes/default.aspxFri, 22 Nov 2013 09:45:00 -05004cc1d276-c49f-4f95-9e62-8dbcd009bc08https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Foundation-Marks-World-Diabetes-Day-with-Four-Grants-Addressing-Link-Between-Diabetes-Depression-and-Distress/default.aspxThu, 14 Nov 2013 10:00:00 -05005b5ce307-879b-4711-961d-2e6f73bac794https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Announces-Changes-in-Senior-Management-Team/default.aspxWed, 13 Nov 2013 16:00:00 -0500deaef56b-6e47-406b-bf65-c6b726ad84c8https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Submits-First-All-Oral-Interferon-Free-and-Ribavirin-Free-Treatment-Regimen-for-Regulatory-Review-in-Japan-for-Patients-with-Chronic-Hepatitis-C-Infection/default.aspxSat, 02 Nov 2013 10:00:00 -040029744f4e-d7e4-4502-b8ab-28381d72b564https://news.bms.com/news/details/2013/Promising-Phase-IIb-Data-On-Clazakizumab-In-Patients-With-Moderate-To-Severe-Rheumatoid-Arthritis-To-Be-Presented-At-The-2013-Annual-Meeting-Of-The-American-College-Of-Rheumatology/default.aspxMon, 28 Oct 2013 08:30:00 -0400ac3eba85-7efe-4cce-902e-cf3597bcb9f2https://news.bms.com/news/details/2013/Additional-Survival-Data-on-Nivolumab-an-Investigational-PD-1-Immune-Checkpoint-Inhibitor-from-Lung-Cancer-Cohort-of-a-Phase-1-Study-Presented-at-15th-World-Conference-on-Lung-Cancer/default.aspxFri, 25 Oct 2013 23:00:00 -04008ec69cdb-d59f-4542-962b-9fff2f8a9e7ehttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Prices-15-Billion-of-Senior-Notes/default.aspxThu, 24 Oct 2013 17:19:00 -040004f73e9e-d0f7-483f-a6b5-0c9cbd4c47cchttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Reports-Third-Quarter-2013-Financial-Results/default.aspxWed, 23 Oct 2013 07:30:00 -0400012772dc-36f6-4eec-b971-620c6a8fbac8https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-to-Present-Data-on-Rheumatoid-Arthritis-Assets-at-American-College-of-Rheumatology-ACR-2013-Annual-Meeting/default.aspxTue, 22 Oct 2013 16:19:00 -040057b40c12-aab8-4ed9-820a-fc86dde59f2dhttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-to-Announce-Results-for-Third-Quarter-2013-on-October-23/default.aspxMon, 07 Oct 2013 10:07:00 -0400fe0ffecb-cdfc-4d2f-aeaf-14e23b64827dhttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-to-Present-Range-of-New-Hepatitis-C-Data-at-the-2013-American-Association-for-the-Study-of-Liver-Diseases-AASLD-Annual-Meeting/default.aspxTue, 01 Oct 2013 11:46:00 -0400a7fca4f5-5d12-44cc-bfb2-91cbf3d03ac0https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Announces-Long-Term-Survival-Results-from-Pooled-Analysis-of-Yervoy-ipilimumab-Treatment-in-More-Than-1800-Patients-with-Metastatic-or-Locally-Advanced-or-Unresectable-Melanoma/default.aspxFri, 27 Sep 2013 16:09:00 -04007f6186a4-18aa-4cab-b420-8a7d765738d4https://news.bms.com/news/details/2013/New-Hypoglycemia-and-Pancreatitis-Subanalyses-from-the-Onglyza-saxagliptin-SAVOR-Cardiovascular-Outcomes-Trial-Presented-at-the-49th-Annual-Meeting-of-the-European-Association-for-the-Study-of-Diabetes-EASD/default.aspxThu, 26 Sep 2013 03:01:00 -0400c589d009-aaf5-4516-84b1-31a4e1c22703https://news.bms.com/news/details/2013/New-Phase-III-Data-Showed-Dapagliflozin-Significantly-Reduced-HbA1c-Compared-to-Placebo-at-24-Weeks-in-Patients-with-Type-2-Diabetes-Inadequately-Controlled-with-the-Combination-of-Metformin-Plus-Sulfonylurea/default.aspxTue, 24 Sep 2013 05:59:00 -040068b2a7dd-e69d-4791-b5fc-6933da7f5cf6https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Announces-Dividend/default.aspxTue, 17 Sep 2013 16:30:00 -040015b1c3b6-425f-43b3-9f65-59cb417a207ehttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Reports-Results-for-Phase-3-Trial-of-Yervoy-Ipilimumab-in-Previously-Treated-Castration-Resistant-Prostate-Cancer/default.aspxThu, 12 Sep 2013 04:01:00 -04008d3b9b81-3bc7-4cc1-a1a0-50fa0efeba47https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-to-Present-at-Bank-of-America-Merrill-Lynch-Global-Health-Care-Conference/default.aspxWed, 04 Sep 2013 11:00:00 -0400ff85da86-5fe6-4b72-93d7-1f350244911chttps://news.bms.com/news/details/2013/Subanalysis-of-Phase-III-ARISTOTLE-Trial-of-Eliquis-apixaban-Demonstrated-Consistent-Results-Versus-Warfarin-in-Patients-with-Nonvalvular-Atrial-Fibrillation-with-or-without-Valvular-Heart-Disease/default.aspxTue, 03 Sep 2013 02:30:00 -04005435ece5-8014-43bb-96a0-5358a7917bd5https://news.bms.com/news/details/2013/Onglyza-saxagliptin-Achieves-Primary-Safety-Endpoint-Demonstrating-No-Increased-Risk-for-Cardiovascular-Death-Heart-Attack-or-Stroke-in-SAVOR-Cardiovascular-Outcomes-Trial/default.aspxMon, 02 Sep 2013 02:00:00 -0400f743c467-e55f-4eaa-bcf7-e23ea27644a0https://news.bms.com/news/details/2013/New-Eliquis-apixaban-Post-hoc-Subanalysis-of-the-Phase-III-ARISTOTLE-trial-Demonstrated-that-within-30-Days-of-a-Procedure-Stroke-or-Systemic-Embolism-and-Major-Bleeding-were-Uncommon/default.aspxSat, 31 Aug 2013 08:00:00 -0400e0df2be5-17cf-4183-be02-6f21876682a0https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-to-Take-Part-in-Morgan-Stanley-Global-Health-Care-Conference/default.aspxThu, 29 Aug 2013 09:30:00 -0400f8413f17-9cc8-44a1-8c7d-e352ea3c22behttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-and-Samsung-BioLogics-Announce-Biopharmaceutical-Manufacturing-Relationship/default.aspxMon, 29 Jul 2013 07:30:00 -04004ddb7ad2-e476-4235-84d6-1f6dcfec90d9https://news.bms.com/news/details/2013/US-FDA-Acknowledges-Receipt-of-Resubmission-of-the-New-Drug-Application-for-Investigational-Compound-Dapagliflozin-for-the-Treatment-of-Type-2-Diabetes/default.aspxThu, 25 Jul 2013 17:00:00 -0400d1d84785-8937-40e0-8605-16aacc8912echttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Reports-Second-Quarter-2013-Financial-Results/default.aspxThu, 25 Jul 2013 07:30:00 -04003e3ae1a1-4c1a-4020-96de-4e76631d70achttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Partners-with-the-Centers-for-Disease-Control-Foundation-to-Increase-Awareness-of-Chronic-Hepatitis-B-on-World-Hepatitis-Day/default.aspxTue, 23 Jul 2013 11:00:00 -04004c7e8d71-17f5-450e-a88e-968040d77a18https://news.bms.com/news/details/2013/FDA-Accepts-Eliquis-apixaban-Supplemental-New-Drug-Application-for-Review-for-Prophylaxis-of-Deep-Vein-Thrombosis-Following-Hip-Or-Knee-Replacement-Surgery/default.aspxThu, 11 Jul 2013 07:30:00 -0400bce9f54d-9c78-41fc-bb8c-c2d7af99e3eahttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-to-Announce-Results-for-Second-Quarter-2013-on-July-25/default.aspxMon, 01 Jul 2013 10:00:00 -04001547c6dd-4700-4b07-ac50-2c405755053chttps://news.bms.com/news/details/2013/Eliquis-apixaban-Demonstrated-Comparable-Efficacy-and-Significantly-Lower-Rates-of-Major-Bleeding-in-Patients-Compared-to-Current-Standard-of-Care-for-the-Treatment-of-Acute-Venous-Thromboembolism/default.aspxSun, 30 Jun 2013 15:48:00 -04002b47a043-7e8f-48d7-9373-e9cd40936a5ahttps://news.bms.com/news/details/2013/Phase-IIa-Study-Assessing-Safety-and-Tolerability-of-Dapagliflozin-after-14-Days-as-Add-on-to-Insulin-in-Adult-Patients-with-Type-1-Diabetes-Presented-at-the-2013-American-Diabetes-Association-Scientific-Sessions/default.aspxSat, 22 Jun 2013 11:00:00 -0400dfb97988-c470-46a7-95a9-c383062a1593https://news.bms.com/news/details/2013/FDA-Approves-US-Product-Labeling-Update-for-Sprycel-dasatinib-to-Include-Three-Year-First-Line-and-Five-Year-Second-Line-Efficacy-and-Safety-Data-in-Chronic-Myeloid-Leukemia-in-Chronic-Phase/default.aspxThu, 20 Jun 2013 14:10:00 -0400e9aba4d5-942f-4bc7-b1d0-b393e1224f4chttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Names-Dinesh-C-Paliwal-to-Board-of-Directors/default.aspxWed, 19 Jun 2013 16:31:00 -04005c1a16a7-73e4-4d5e-888b-6a948319cc02https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Announces-Dividend-bade8a55b/default.aspxWed, 19 Jun 2013 16:30:00 -0400cf291405-61aa-4963-9be4-0803e70af890https://news.bms.com/news/details/2013/AstraZeneca-and-Bristol-Myers-Squibb-Announce-Top-Line-Results-for-SAVOR-TIMI-53-Cardiovascular-Outcomes-Trial-of-Onglyza-saxagliptin/default.aspxWed, 19 Jun 2013 02:02:00 -0400840ee84c-ee21-454c-bc3a-55a05a11a744https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Grants-Help-K-12-Educators-Bring-Science-to-Life-and-Help-Students-Explore-Their-Interests-in-the-Sciences-and-Science-Based-Careers/default.aspxTue, 18 Jun 2013 09:00:00 -0400e1e757a9-2a84-4c3f-88b6-1005213dedafhttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-and-AbbVie-Announce-Progression-Free-Survival-Data-from-Phase-2-Open-Label-Study-of-Investigational-Agent-Elotuzumab-in-Combination-with-Lenalidimide-and-Dexamethasone-in-Previously-Treated-Multiple-Myeloma/default.aspxSat, 15 Jun 2013 11:45:00 -0400a737a624-dbd2-4a44-b0f3-ea0db084e0bahttps://news.bms.com/news/details/2013/AstraZeneca-and-Bristol-Myers-Squibb-to-Present-New-Data-at-American-Diabetes-Association-73rd-Scientific-Sessions/default.aspxFri, 14 Jun 2013 09:00:00 -04007fb52a07-59de-4b3f-8433-53096f39eee7https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-and-Simcere-Enter-Partnership-to-Co-Develop-and-Co-Commercialize-Orencia-SC-abatacept-in-China/default.aspxFri, 14 Jun 2013 08:00:00 -0400c229f9ac-da63-4897-b49d-f6cd1fa5460dhttps://news.bms.com/news/details/2013/AstraZeneca-and-Bristol-Myers-Squibb-Statement-on-Proposal-by-the-American-Diabetes-Association-for-Independent-Review-of-Incretin-Based-Therapies/default.aspxWed, 12 Jun 2013 13:11:00 -0400a52a0390-da98-4973-959e-559597594999https://news.bms.com/news/details/2013/ORENCIA-abatacept-Shows-Comparable-Efficacy-to-Humira-adalimumab-in-Year-Two-Data-from-Head-to-Head-Study-in-Patients-with-Moderate-to-Severe-Rheumatoid-Arthritis/default.aspxTue, 11 Jun 2013 18:05:00 -0400d0e6a5d1-956d-4483-939a-0d65579853d2https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-to-Take-Part-in-Goldman-Sachs-Global-Healthcare-Conference/default.aspxWed, 05 Jun 2013 14:30:00 -04009ddcdffc-b931-4537-9d45-116d70cab8d6https://news.bms.com/news/details/2013/US-FDA-Grants-Priority-Review-to-Bristol-Myers-Squibb-and-AstraZenecas-Metreleptin-an-Investigational-Agent-for-Treatment-of-Metabolic-Disorders-Associated-with-Rare-Forms-of-Lipodystrophy/default.aspxTue, 04 Jun 2013 09:03:00 -0400d7f5f6a6-c2ec-499d-9e7f-59a49264fd0chttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Announces-Phase-1-Results-from-First-Trial-Combining-Immune-Checkpoint-Inhibitors-Investigational-Agent-Nivolumab-and-Yervoy-ipilimumab-in-Patients-with-Advanced-Melanoma/default.aspxSun, 02 Jun 2013 12:06:00 -040096712f62-8401-47bd-8716-f76f16b503d0https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Announces-Intention-to-Voluntarily-Delist-Preferred-Stock/default.aspxThu, 16 May 2013 16:30:00 -040000390023-a398-403a-8790-0c6c2cb6c759https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-to-Hold-Investor-Teleconference-to-Discuss-ASCO-Highlights/default.aspxWed, 15 May 2013 18:10:00 -0400b0cd67cd-a834-4fea-b247-e417bc3d9bc5https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Advances-Leadership-Position-in-Immuno-Oncology-with-Data-to-be-Presented-at-2013-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting/default.aspxWed, 15 May 2013 18:00:00 -0400a4878925-a77a-4b18-9d34-3f5a17764822https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-to-Present-at-UBS-Global-Health-Care-Conference/default.aspxTue, 14 May 2013 15:18:00 -04009a09dc36-85ce-4d18-bf99-2248dedcb6cchttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-to-Present-at-Bank-of-America-Merrill-Lynch-Health-Care-Conference/default.aspxWed, 08 May 2013 10:30:00 -0400e98bb89d-d8ae-4710-b22a-77953c7fc6f5https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-and-Pfizer-Announce-Publication-of-ARISTOTLE-Subanalysis-in-Circulation/default.aspxMon, 06 May 2013 17:00:00 -04008067f40a-80df-4856-b38d-74d4f4c3f405https://news.bms.com/news/details/2013/Sub-Group-Analysis-Shows-Investigational-Metreleptin-Treatment-Demonstrated-Reductions-in-HbA1c-Triglycerides-and-Liver-Function-Tests-in-Pediatric-Patients-with-Lipodystrophy-During-a-12-Month-Period/default.aspxMon, 06 May 2013 07:00:00 -040094298eb6-9df4-4ae5-a032-fb14f5213708https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Receives-US-FDA-sNDA-Approval-for-Use-of-SUSTIVA-efavirenz-in-HIV-1-Infected-Pediatric-Patients/default.aspxFri, 03 May 2013 08:00:00 -04002cfd39dd-dcfe-4180-a1e4-6a7a0bbf9123https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Reports-First-Quarter-2013-Financial-Results/default.aspxThu, 25 Apr 2013 07:30:00 -0400ce7864aa-cf1d-468d-8acf-f4a369107639https://news.bms.com/news/details/2013/Former-Pro-Football-Coach-Bill-Cowher-Tells-Men-No-Excuses-When-It-Comes-to-Getting-Screened-for-Melanoma/default.aspxTue, 23 Apr 2013 08:00:00 -0400e3e6a7d3-e194-4abf-abe2-d6c90acde9f9https://news.bms.com/news/details/2013/High-Rates-of-SVR-Demonstrated-in-Phase-II-Study-with-Investigational-Triple-DAA-Regimen-of-Daclatasvir-Asunaprevir-and-BMS-791325-in-Treatment-Nave-Patients-with-Genotype-1-Chronic-Hepatitis-C-Infection/default.aspxTue, 23 Apr 2013 06:01:00 -040028ca572c-5dcd-4660-a825-45042d5d9d53https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Funds-Green-Schools-Fellowship-to-Help-New-Jersey-School-Districts-Create-Healthier-More-Sustainable-Learning-Environments/default.aspxMon, 22 Apr 2013 09:30:00 -04003d20674f-2e04-4cd2-9a1b-3bdfca39a3a6https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Foundation-Morehouse-School-of-Medicine-Partner-to-Spread-Lessons-from-Together-on-Diabetes-Initiative/default.aspxWed, 10 Apr 2013 09:00:00 -04003f5eb46f-84a6-4370-a628-1c5f01210ad6https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-to-Present-New-Data-on-Hepatitis-C-and-Hepatitis-B-Compounds-at-The-International-Liver-Congress-ILC-2013/default.aspxMon, 08 Apr 2013 04:50:00 -04009f9ab4fb-1a0a-4868-bfb3-f18cb76e6760https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Announces-Appointment-of-Francis-Cuss-as-Executive-Vice-President-and-Chief-Scientific-Officer-Effective-July-1-Elliott-Sigal-Plans-to-Retire/default.aspxSun, 07 Apr 2013 15:00:00 -0400ba182e89-6e8d-404f-a3a2-3598b5805c56https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-to-Announce-Results-for-First-Quarter-2013-on-April-25/default.aspxMon, 01 Apr 2013 09:30:00 -0400bd8cc2df-a361-4a4a-9001-3d03fa59249ahttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Awards-Two-Grants-to-Support-Comprehensive-Cancer-Community-Collaboration-at-Several-Hospitals-in-New-Jersey/default.aspxWed, 13 Mar 2013 10:30:00 -04003838dd9b-04d7-4118-a997-8968769111fdhttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Announces-Dividend-4fe432c52/default.aspxThu, 07 Mar 2013 18:49:00 -050085a36902-e19d-405c-827f-61d5f244167fhttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-to-Present-at-Barclays-Global-Health-Care-Conference/default.aspxTue, 05 Mar 2013 17:20:00 -05000f2605a4-3529-4594-951d-7484a9063f4bhttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-to-Present-at-Cowen-and-Company-Health-Care-Conference/default.aspxWed, 27 Feb 2013 17:22:00 -05008ff8fff0-18a1-4db7-b788-e0cfe2146a7fhttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-to-Take-Part-in-Citi-2013-Global-Health-Care-Conference/default.aspxTue, 19 Feb 2013 17:33:00 -0500311ccca0-1a1d-4072-8a0a-17c9e17b37cahttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Appoints-Ann-Powell-Judge-Senior-Vice-President-Human-Resources/default.aspxThu, 14 Feb 2013 09:00:00 -050071c3478a-200d-460e-8ed6-4c49cc9bfac5https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Enters-a-Collaboration-Agreement-for-Several-Over-the-Counter-Medicines-with-Reckitt-Benckiser-Group-plc/default.aspxTue, 12 Feb 2013 08:00:00 -05002ca30185-524d-47b7-ad4c-af8556a93ab4https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-to-Take-Part-in-Leerink-Swann-Global-Health-Care-Conference/default.aspxWed, 06 Feb 2013 15:02:00 -0500c40cd2b3-448b-4426-9e29-f349d72653cehttps://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-2012-Financial-Results/default.aspxThu, 24 Jan 2013 08:30:00 -05003aa6bea8-5c17-48fc-b94a-28f3f6302a74https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-Appoints-Mike-Burgess-MD-PhD-Senior-Vice-President-Discovery-Medicine-and-Clinical-Pharmacology/default.aspxThu, 17 Jan 2013 15:00:00 -05008e043c4c-46c3-4373-9d5c-d6e371592108https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-to-Announce-Results-for-Fourth-Quarter-Full-Year-2012-on-January-24/default.aspxFri, 04 Jan 2013 12:00:00 -0500a21d6dfc-ae37-4f78-ae74-2c16e769eaf8https://news.bms.com/news/details/2013/Bristol-Myers-Squibb-to-Present-at-JP-Morgan-Healthcare-Conference/default.aspxThu, 03 Jan 2013 16:08:00 -0500f1fb2981-b802-4fea-a19d-9d76832bf209https://news.bms.com/news/details/2013/US-FDA-Approves-ELIQUIS-apixaban-to-Reduce-the-Risk-of-Stroke-and-Systemic-Embolism-in-Patients-with-Nonvalvular-Atrial-Fibrillation/default.aspxWed, 02 Jan 2013 09:00:00 -05009c299673-7cd2-4e67-89ee-861301c25344https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-and-Pfizer-Announce-US-FDA-Approval-of-ELIQUIS-apixaban/default.aspxFri, 28 Dec 2012 18:46:00 -050003192abc-2aa6-4036-bd68-36c596104199https://news.bms.com/news/details/2012/ELIQUIS-apixaban-Approved-In-Japan-For-The-Prevention-Of-Stroke-And-Systemic-Embolism-In-Patients-With-Nonvalvular-Atrial-Fibrillation/default.aspxWed, 26 Dec 2012 08:30:00 -0500607c7a98-b958-4ad5-8255-f5e2be4fddfehttps://news.bms.com/news/details/2012/The-Medicines-Company-and-Bristol-Myers-Squibb-Agree-to-Global-Alliance-For-Recothrom/default.aspxWed, 12 Dec 2012 08:07:00 -0500389d2978-8d7b-44ef-82b1-60baf09fd51ahttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Foundation-Awards-Mental-Health-Grants-of-Nearly-3-Million-to-Support-Returning-Veterans/default.aspxTue, 11 Dec 2012 10:00:00 -050013da0380-b91d-4926-9fac-a965b06f6bcehttps://news.bms.com/news/details/2012/Elotuzumab-Progression-Free-Survival-Data-from-Phase-2-Study-of-Patients-with-Previously-Treated-Multiple-Myeloma-Presented-at-54th-American-Society-of-Hematology-ASH-Annual-Meeting/default.aspxSun, 09 Dec 2012 17:30:00 -0500a3b47913-1b41-4ef9-9c02-4f9e5a64d6bfhttps://news.bms.com/news/details/2012/ELIQUIS-apixaban-Demonstrated-Superiority-In-Reducing-A-Composite-Of-Recurrent-Venous-Thromboembolism-And-All-Cause-Death-Without-Increasing-The-Rate-Of-Major-Bleeding-Versus-Placebo-During-One-Year-Of-Extended-Treatment/default.aspxSat, 08 Dec 2012 15:00:00 -0500da56c059-2c99-4159-bdb4-ee89cf6d1a0bhttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Announces-Dividend-Increase/default.aspxTue, 04 Dec 2012 17:30:00 -0500b5c4d5eb-d2da-4247-bdf4-a9386c98f02ehttps://news.bms.com/news/details/2012/ELIQUISapixaban-Approved-in-Europe-for-Prevention-of-Stroke-and-Systemic-Embolism-in-Patients-with-Nonvalvular-Atrial-Fibrillation/default.aspxTue, 20 Nov 2012 15:20:00 -0500e3309d8f-d639-4970-9445-13dcae71c98ehttps://news.bms.com/news/details/2012/Forxiga-dapagliflozin-First-In-Class-SGLT2-That-Works-Independently-of-Insulin-Now-Approved-in-European-Union-for-Treatment-of-Type-2-Diabetes/default.aspxWed, 14 Nov 2012 12:54:00 -05001a7ec2bc-615d-4477-af74-1474c85ec88fhttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Foundations-Together-on-Diabetes-Marks-World-Diabetes-Day-with-Second-Annual-Report-and-Two-New-Grants-in-India/default.aspxWed, 14 Nov 2012 10:00:00 -050009096375-2920-4e69-b608-58e0b441802chttps://news.bms.com/news/details/2012/Investigational-Triple-DAA-Regimen-of-Daclatasvir-Asunaprevir-and-BMS-791325-Achieved-SVR12-of-94-in-Treatment-Nave-Patients-with-Genotype-1-Chronic-Hepatitis-C-Infection-in-Phase-II-Trial/default.aspxMon, 12 Nov 2012 16:30:00 -0500e5eecbcf-a414-4370-88e9-5bcd760ae28fhttps://news.bms.com/news/details/2012/Bristol-Myers-Squibbs-Investigational-Hepatitis-C-Compounds-Lambda-and-Daclatasvir-Plus-Ribavirin-Achieved-SVR12-in-93-of-Genotype-1b-Treatment-Naive-Patients-In-Phase-IIb-Study/default.aspxMon, 12 Nov 2012 16:30:00 -0500372de931-605f-40ab-a1b7-aa6c88d21b08https://news.bms.com/news/details/2012/New-Head-to-Head-Patient-Reported-Outcomes-Data-for-Orencia--SC-abatacept-vs-Humira-adalimumab-Presented-at-the-2012-American-College-of-Rheumatology-Annual-Scientific-Meeting/default.aspxMon, 12 Nov 2012 10:00:00 -0500b4b1b92d-65ee-4630-846c-550fe38f28d7https://news.bms.com/news/details/2012/Investigational-Hepatitis-C-Quad-Therapy-Regimen-of-Daclatasvir-and-Asunaprevir-Plus-Interferon-Alfa-and-Ribavirin-Achieved-SVR24-in-93-of-Difficult-to-Treat-Genotype-1ab-Prior-Null-Responders-in-Expanded-Phase-II-Study/default.aspxSun, 11 Nov 2012 17:45:00 -05009890a184-58c8-40e2-89d3-77d852001ef8https://news.bms.com/news/details/2012/Investigational-Hepatitis-C-Dual-DAA-Regimen-of-Daclatasvir-and-Asunaprevir-Achieved-SVR12-in-78-of-Difficult-to-Treat-Genotype-1b-Prior-Null-Responders-In-Expanded-Phase-II-Study/default.aspxSun, 11 Nov 2012 17:45:00 -05002dcc4759-da17-412d-83a0-dddb99b470efhttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-to-Present-New-Investigational-Data-on-Orencia-abatacept-at-the-2012-American-College-of-Rheumatology-Annual-Scientific-Meeting/default.aspxThu, 08 Nov 2012 10:00:00 -0500e3cb6078-b9df-4cd7-b280-6b1e4fe6146ahttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-to-Present-at-Credit-Suisse-Healthcare-Conference/default.aspxWed, 07 Nov 2012 12:30:00 -05004fe4cbbc-6fc4-429e-b9b4-5ec09eb41b72https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Foundation-Announces-Centers-of-Excellence-Conference-to-Share-Insights-from-Asian-Pacific-Community-Groups-on-Viral-Hepatitis-Management-in-Honor-of-the-10-Year-Anniversary-of-Delivering-Hope/default.aspxWed, 07 Nov 2012 10:00:00 -05000af406d7-690b-45fb-b2d4-84cfe4350d79https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-and-Pfizer-Announce-New-Data-on-Stroke-Prevention-in-Atrial-Fibrillation-to-be-Presented-at-American-Heart-Association-2012-Scientific-Sessions/default.aspxFri, 02 Nov 2012 08:30:00 -0400b1771cb0-19d1-4545-92bc-a623359c6382https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Receives-Positive-Decision-from-National-Institute-of-Health-and-Clinical-Excellence-NICE-for-YERVOY-ipilimumab/default.aspxThu, 01 Nov 2012 21:01:00 -040012a3f5f6-06fc-4e3d-a526-c5b5039adce2https://news.bms.com/news/details/2012/Portola-Bristol-Myers-Squibb-and-Pfizer-Sign-Clinical-Collaboration-Agreement-to-Study-ELIQUIS-and-Portolas-Universal-Factor-Xa-Inhibitor-Antidote-PRT4445/default.aspxThu, 01 Nov 2012 19:45:00 -04005b317ff6-ee48-46ed-98ae-6acd7f003a5fhttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Reports-Third-Quarter-2012-Financial-Results/default.aspxWed, 24 Oct 2012 07:30:00 -04009c65c7dc-4a79-4fd5-9bea-5ae5dceb2fe2https://news.bms.com/news/details/2012/Bristol-Myers-Squibbs-YERVOY-ipilimumab-Awarded-Prestigious-Prix-Galien-USA-Prize-for-Best-Biotechnology-Product/default.aspxWed, 17 Oct 2012 08:00:00 -040001a9998b-ca4e-48e3-9f8d-a28b2f34ea70https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-to-Present-New-Data-Demonstrating-Companys-Continuing-Commitment-to-Research-and-Development-in-Liver-Disease-at-The-American-Association-for-the-Study-of-Liver-Diseases-AASLD-Annual-Meeting/default.aspxTue, 16 Oct 2012 11:28:00 -0400059d47d3-4363-4560-902d-263c19916dc5https://news.bms.com/news/details/2012/US-Food-and-Drug-Administration-Approves-Labeling-Update-for-BARACLUDE-entecavir-05-mg1-mg-Tablets-to-Include-Data-on-African-Americans-and-Liver-Transplant-Recipients-with-Chronic-Hepatitis-B-in-Adult-Patients/default.aspxMon, 15 Oct 2012 15:47:00 -0400e6d4546e-264f-4b5e-859c-d82023ff2557https://news.bms.com/news/details/2012/Sanofi-and-Bristol-Myers-Squibb-Announce-Restructuring-of-Alliance-Agreement/default.aspxWed, 03 Oct 2012 00:00:00 -0400d594bb69-1f8d-4cc4-be05-b54e4d990670https://news.bms.com/news/details/2012/ELIQUIS-apixaban-Demonstrates-Consistent-Reductions-in-Stroke-and-Systemic-Embolism-Major-Bleeding-and-Mortality-Compared-to-Warfarin-in-Patients-with-Nonvalvular-Atrial-Fibrillation-at-Varying-Risk-for-Stroke-and-Bleeding/default.aspxMon, 01 Oct 2012 18:30:00 -0400da620ba4-bcbf-4650-9bad-68c139b32e8fhttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-to-Announce-Results-for-Third-Quarter-on-October-24/default.aspxMon, 01 Oct 2012 16:56:00 -04003e20bd53-8435-44c3-a3e0-849f303fdc68https://news.bms.com/news/details/2012/New-Four--and-Five-Year-Survival-Data-for-YERVOY-ipilimumab-in-Treatment-Nave-and-Previously-Treated-Metastatic-Melanoma-Presented-at-the-ESMO-2012-Congress-European-Society-for-Medical-Oncology/default.aspxSat, 29 Sep 2012 07:00:00 -040005c44bb2-8d33-4bdd-bf05-008dd9a5bc1ahttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Appoints-Frances-Heller-Senior-Vice-President-Business-Development/default.aspxFri, 28 Sep 2012 16:32:00 -04009ac96fd3-3488-4927-aa44-1ac5f394b591https://news.bms.com/news/details/2012/FDA-Acknowledges-Receipt-of-Resubmission-of-the-ELIQUIS-apixaban-New-Drug-Application-to-Reduce-the-Risk-of-Stroke-and-Systemic-Embolism-in-Patients-with-Nonvalvular-Atrial-Fibrillation/default.aspxWed, 26 Sep 2012 17:01:00 -040080ba0ade-0361-4a65-83c3-7e1393ff7c84https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Foundation-Celebrates-Hispanic-Heritage-Month/default.aspxTue, 25 Sep 2012 15:38:00 -04005ac69a55-56e1-4b9c-81c9-5aa184b5b06ehttps://news.bms.com/news/details/2012/Vanderbilt-University-and-Bristol-Myers-Squibb-Sign-Collaboration-Agreement-to-Develop-Novel-Treatments-for-Parkinsons-Disease/default.aspxFri, 21 Sep 2012 08:30:00 -04008e5705bd-ebfd-49f7-9006-3156cd6718e0https://news.bms.com/news/details/2012/ELIQUIS-apixaban-Receives-CHMP-Positive-Opinion-For-The-Prevention-Of-Stroke-And-Systemic-Embolism-In-Patients-With-Nonvalvular-Atrial-Fibrillation/default.aspxFri, 21 Sep 2012 07:46:00 -0400ddc7a9fc-2f19-43fd-8697-3a71f9e2b477https://news.bms.com/news/details/2012/Ten-Pharmaceutical-Companies-Unite-to-Accelerate-Development-of-New-Medicines/default.aspxWed, 19 Sep 2012 10:54:00 -04005e5bdf38-cdd5-4c51-a2f0-51e8fbb4f401https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Announces-Dividend/default.aspxTue, 18 Sep 2012 16:30:00 -04006bd091c4-0632-4970-a155-4fc203f71607https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-to-Present-at-UBS-Global-Life-Sciences-Conference/default.aspxThu, 13 Sep 2012 10:36:00 -04007ddfc6c4-355d-4a91-9241-d025beb97756https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Foundation-Announces-Five-New-Grants-to-Advance-Cancer-Nursing-Skills-in-Central-and-Eastern-Europe/default.aspxTue, 11 Sep 2012 09:00:00 -04003c561029-37bc-4462-8701-b5feae111437https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-to-Present-at-Bank-of-America-Merrill-Lynch-Global-Health-Care-Conference/default.aspxThu, 06 Sep 2012 12:28:00 -04008d27e010-0756-42bc-95e3-884e2d9374a2https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-to-Take-Part-in-Morgan-Stanley-Global-Health-Care-Conference/default.aspxFri, 31 Aug 2012 09:30:00 -0400288d50ed-1387-4e6e-9a39-5fd24931bb1dhttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Initiates-Voluntary-Recall-of-10-Lots-of-BiCNR-carmustine-for-injection-Due-to-the-Potential-for-Overfill/default.aspxThu, 30 Aug 2012 18:04:00 -040043443624-2e18-4704-ae2c-09c4d61ea225https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Discontinues-Development-of-BMS-986094-an-Investigational-NS5B-Nucleotide-for-the-Treatment-of-Hepatitis-C/default.aspxThu, 23 Aug 2012 18:20:00 -0400d00cd049-fc0d-4b26-8615-0b61e090ddddhttps://news.bms.com/news/details/2012/ELIQUIS-apixaban-Data-Analyses-To-Be-Presented-At-European-Society-of-Cardiology-Congress-2012/default.aspxMon, 20 Aug 2012 07:30:00 -04001262254f-8861-4d05-b112-a58e26944da4https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Announces-Specialty-Pharmacy-Patient-Management-Programs-For-Sprycel-dasatinib-Patients/default.aspxWed, 15 Aug 2012 08:00:00 -04005670eb14-f89a-46dc-8f6c-be52d8dc178dhttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-and-AstraZeneca-Complete-Expansion-of-Diabetes-Alliance-Through-Bristol-Myers-Squibbs-Acquisition-of-Amylin/default.aspxThu, 09 Aug 2012 07:45:00 -040004d8b3b9-4f8b-4bd9-bde8-e62ac544fb0ehttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Completes-Acquisition-of-Amylin-Pharmaceuticals-Inc/default.aspxThu, 09 Aug 2012 07:30:00 -04003e842861-272b-487f-af5f-31162ad2e2fehttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Announces-Successful-Completion-of-Cash-Tender-Offer-for-Shares-of-Amylin-Pharmaceuticals-Inc/default.aspxWed, 08 Aug 2012 07:30:00 -0400a55e835b-5d12-4323-925d-51ba585b26d2https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Foundation-Awards-16-Million-in-Grants-to-Help-Communities-in-India-Address-Type-2-Diabetes/default.aspxMon, 06 Aug 2012 17:00:00 -04005f56c327-57d0-4a87-ac8a-ce8a08fb2663https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Suspends-Administration-of-Study-Drug-in-Clinical-Trial-of-Investigational-NS5B-Nucleotide-for-the-Treatment-of-Hepatitis-C/default.aspxWed, 01 Aug 2012 20:37:00 -04004325eac3-fb8d-4062-a625-f199a519d355https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Announces-Expiration-of-the-Hart-Scott-Rodino-Waiting-Period-for-Acquisition-of-Amylin-Pharmaceuticals-Inc/default.aspxWed, 01 Aug 2012 07:30:00 -04002c7e7f29-6a08-4292-b0ff-889174288075https://news.bms.com/news/details/2012/Pooled-Analysis-Showed-Onglyza-saxagliptin-Provided-Improvements-in-Key-Measures-of-Blood-Sugar-Control-in-Adults-with-Type-2-Diabetes-at-High-Risk-for-CV-Disease/default.aspxMon, 30 Jul 2012 14:00:00 -04006e5062cf-06d0-4e14-8067-e7e3e745679bhttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Prices-20-Billion-of-Senior-Notes/default.aspxThu, 26 Jul 2012 17:47:00 -0400589f481c-af87-4641-8bcf-8ab959806eb3https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Foundation-Marks-World-Hepatitis-Day-2012-with-New-Grants-Focused-on-Hepatitis-B-and-Hepatitis-C-Patient-Empowerment-in-China-and-India/default.aspxThu, 26 Jul 2012 16:45:00 -0400e5c7c55a-ca65-4370-8fdd-e567270f67a2https://news.bms.com/news/details/2012/Bristol-Myers-Squibbs-Second-Quarter-Highlighted-by-the-Planned-Strategic-Acquisition-of-Amylin-Pharmaceuticals-and-Important-Clinical-Data-in-Immuno-Oncology/default.aspxWed, 25 Jul 2012 07:30:00 -04008fcda5ae-b799-4dc9-a121-43edffc93e7fhttps://news.bms.com/news/details/2012/BRISK-FL-Study-with-Investigational-Compound-Brivanib-in-Hepatocellular-Carcinoma-Does-Not-Meet-Overall-Survival-Primary-Endpoint/default.aspxThu, 19 Jul 2012 16:30:00 -04004527a6dc-50e9-4a9d-8f8e-2ba39572c72chttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Announces-Humacao-Site-Expansion/default.aspxTue, 10 Jul 2012 10:00:00 -040066965f0e-4c0a-4ba1-b85d-9c786f2c0c97https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Begins-Tender-Offer-to-Acquire-Amylin-Pharmaceuticals-Inc/default.aspxTue, 10 Jul 2012 07:30:00 -0400c1efb753-5cb5-43fb-9ec6-17c262c09e6ahttps://news.bms.com/news/details/2012/FDA-Approves-ERBITUXR-cetuximab-as-First-Line-Treatment-in-KRAS-Mutation-Negative-Wild-Type-Epidermal-Growth-Factor-Receptor-EGFR-Expressing-Metastatic-Colorectal-Cancer-in-Combination-with-FOLFIRI-Irinotecan-5-Fluorouracil-Leucovorin/default.aspxFri, 06 Jul 2012 19:08:00 -040005cd5552-ce74-42a3-9289-ccb7c994e5e8https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-to-Announce-Results-for-Second-Quarter-2012-on-July-25/default.aspxMon, 02 Jul 2012 14:27:00 -0400142b4591-d63c-4316-b359-7b499e089558https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-and-AstraZeneca-Expand-Diabetes-Alliance-Through-Bristol-Myers-Squibbs-Acquisition-of-Amylin-Pharmaceuticals/default.aspxFri, 29 Jun 2012 21:28:00 -040033001a51-250c-4377-b52c-c0617f5ab009https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Announces-Dividend-3898e8bd4/default.aspxTue, 26 Jun 2012 16:30:00 -04001d4dfc62-0d23-4f12-a221-ec54ef4943dchttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Announces-the-Authorization-of-an-Additional-3-billion-for-Share-Repurchase-Program/default.aspxTue, 26 Jun 2012 16:30:00 -0400bbee0827-852e-4568-8054-05eb20df72behttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-and-Pfizer-Receive-Complete-Response-Letter-from-US-Food-and-Drug-Administration-for-ELIQUIS-apixaban/default.aspxMon, 25 Jun 2012 07:31:00 -0400c7019237-229e-4bc7-84fe-65349d1e1a84https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-and-Emory-University-Announce-Partnership-to-Advance-Clinical-Development-of-Investigational-Compounds/default.aspxWed, 20 Jun 2012 08:30:00 -0400246d6700-ac85-4207-a1dd-68063496a3d7https://news.bms.com/news/details/2012/New-Data-Show-Investigational-Compound-Dapagliflozin-Demonstrated-Significant-Reductions-in-Blood-Sugar-Levels-When-Added-to-Sitagliptin-in-Adults-with-Type-2-Diabetes-at-24-Weeks-with-Results-Maintained-Over-48-Weeks/default.aspxSat, 09 Jun 2012 10:00:00 -040049eb216f-4f5c-48b4-a1d5-018ed3f1b3d5https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Foundation-Announces-6-Million-in-Grants-to-Develop-Comprehensive-Solutions-for-US-Adults-with-Diabetes-and-Announces-15-Million-Expansion-to-China-and-India/default.aspxFri, 08 Jun 2012 09:00:00 -04001244449a-8bc2-4b83-b224-0ef983a06e1ehttps://news.bms.com/news/details/2012/ORENCIA-abatacept-Demonstrates-Comparable-Efficacy-to-Humira-adalimumab-in-Patients-with-Moderate-to-Severe-Rheumatoid-Arthritis-in-First-Head-to-Head-Study-of-These-Agents/default.aspxWed, 06 Jun 2012 00:01:00 -0400db662672-98cf-493d-916a-972ff685baffhttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Presents-New-4-Year-Data-from-the-Long-Term-Extensions-of-the-BENEFIT-and-BENEFIT-EXT-Clinical-Trials-of-NULOJIX-belatacept/default.aspxMon, 04 Jun 2012 14:30:00 -04005c0c8eaa-c020-4b55-b5a7-a175f684a3ffhttps://news.bms.com/news/details/2012/Investigational-Anti-PD-1-Immunotherapy-BMS-936558-Showed-Clinical-Activity-in-Phase-1-Trial-of-Patients-with-Previously-Treated-Non-Small-Cell-Lung-Cancer-Metastatic-Melanoma-and-Renal-Cell-Cancer/default.aspxSat, 02 Jun 2012 00:01:00 -04003fe8f877-572c-48af-afe3-550e74990aa4https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-to-Take-Part-in-the-Goldman-Sachs-33rd-Annual-Global-Healthcare-Conference/default.aspxThu, 31 May 2012 16:19:00 -04002cf6b78f-40a3-4b5c-b6e8-10656bb213fchttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Announces-Global-Collaboration-with-Leading-Academic-Institutions-to-Advance-Science-of-Immuno-Oncology/default.aspxTue, 29 May 2012 08:00:00 -04003c0d652c-ffb4-4aeb-b37b-a25e00ce9b7ahttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-to-Take-Part-in-Sanford-Bernsteins-28th-Annual-Strategic-Decisions-Conference/default.aspxThu, 24 May 2012 10:12:00 -0400e6c9eddb-4a54-4a9d-95c9-138dfb169af2https://news.bms.com/news/details/2012/New-Data-from-Bristol-Myers-Squibb-Oncology-Portfolio-to-be-Presented-at-2012-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting/default.aspxWed, 16 May 2012 18:00:00 -040005b99772-f09f-4049-933f-7e8ce107ef89https://news.bms.com/news/details/2012/US-FDA-Approves-Bristol-Myers-Squibb-Devens-Biologics-Manufacturing-Facility-for-Production-of-ORENCIA-abatacept/default.aspxTue, 15 May 2012 11:00:00 -040011fbbabf-80d4-4330-8671-85f694fbb21chttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Foundation-Announces-15-Million-Expansion-of-Together-on-Diabetes-to-China-and-India/default.aspxTue, 15 May 2012 10:00:00 -04009aa17fbd-1576-4e43-87d8-c0048be4f2fchttps://news.bms.com/news/details/2012/Former-Pro-Football-Coach-Bill-Cowher-Teams-Up-With-Leading-Advocacy-Groups-to-Launch-Melanoma-Exposed-an-Educational-Campaign-to-Raise-Awareness-of-the-Most-Deadly-Form-of-Skin-Cancer/default.aspxTue, 15 May 2012 08:00:00 -04004ce174d5-58a2-466f-a65a-8882a9338c9ehttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-and-Tsinghua-University-Enter-Strategic-Partnership/default.aspxMon, 14 May 2012 22:00:00 -0400b1549c13-e447-4562-8506-dd1db12f59c8https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-to-Present-New-Data-on-ORENCIA-abatacept-at-the-European-League-Against-Rheumatism-EULAR-2012-Congress/default.aspxMon, 14 May 2012 08:00:00 -040057556f7c-41aa-4d18-b4f1-d8118ef84e6bhttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-to-Present-at-Bank-of-America-Merrill-Lynch-Health-Care-Conference/default.aspxThu, 10 May 2012 11:00:00 -0400ddaee2d7-35bf-42b2-b319-63f6d5e4c975https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-to-Present-at-Deutsche-Bank-Health-Care-Conference/default.aspxMon, 30 Apr 2012 13:20:00 -040025933b1e-2e3e-442a-a1a0-a4de9e860628https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Delivers-a-Solid-First-Quarter-with-Strong-Operating-Results-and-Key-RD-Milestones/default.aspxThu, 26 Apr 2012 07:30:00 -040095cda02c-e2e9-46c1-89f7-0dd72beb8f44https://news.bms.com/news/details/2012/All-Oral-Hepatitis-C-Virus-Treatment-with-Bristol-Myers-Squibbs-Investigational-Compounds-Daclatasvir-and-Asunaprevir-Achieved-Sustained-Virologic-Response-in-77-of-Difficult-to-Treat-Patients/default.aspxThu, 19 Apr 2012 12:00:00 -04007a7d864c-4dd9-4983-8f00-bded5a9420cehttps://news.bms.com/news/details/2012/Investigational-Compound-Peginterferon-Lambda-Achieved-SVR24-Rates-Comparable-to-Peginterferon-Alfa-with-Fewer-Flu-Like-and-Musculoskeletal-Symptoms-in-Phase-IIb-Study-in-Treatment-Nave-Genotype-2-or-3-Hepatitis-C-Patients/default.aspxThu, 19 Apr 2012 12:00:00 -0400ec2c5986-506f-4e6a-b9af-1d2c60d35e23https://news.bms.com/news/details/2012/All-Oral-Combination-of-Investigational-Hepatitis-C-HCV-Compounds-Daclatasvir-and-GS-7977-Achieved-Sustained-Virologic-Response-SVR4-in-100-of-Genotype-1-and-91-of-Genotype-2-and-3-Treatment-Nave-Patients-in-Phase-II-Study/default.aspxThu, 19 Apr 2012 05:00:00 -0400b6bc8d7d-2dba-4675-8a0e-aba165bde65ehttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Ranks-First-on-2012-Best-Corporate-Citizens-List/default.aspxTue, 17 Apr 2012 16:00:00 -040023b0f32e-0702-4d89-aa75-8ab4d4857cf1https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-to-Present-New-Data-Demonstrating-Companys-Commitment-to-Research-and-Development-in-Liver-Disease-at-The-International-Liver-CongressTM--European-Association-for-the-Study-of-the-Liver-EASL-Annual-Meeting/default.aspxWed, 04 Apr 2012 10:44:00 -04002f4a3dcc-950d-4dbe-bbf9-fdd43f7c13b0https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-to-Announce-Results-for-First-Quarter-2012-on-April-26/default.aspxMon, 02 Apr 2012 11:42:00 -04000e32a18d-b407-49d1-b9a9-a40a999e36e7https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-and-Meso-Scale-Discovery-Enter-Agreement-to-Develop-Diagnostic-Assays-for-Alzheimers-Disease/default.aspxWed, 28 Mar 2012 08:00:00 -040042b75a53-c6dc-464c-b82e-25ece07679abhttps://news.bms.com/news/details/2012/Data-on-ELIQUIS-apixaban-for-the-Prevention-of-Stroke-in-Atrial-Fibrillation-to-Be-Presented-at-American-College-of-Cardiologys-61st-Annual-Scientific-Session/default.aspxWed, 21 Mar 2012 10:35:00 -0400c58f0453-3eb3-4c0e-9a76-2d605a828b32https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Posts-Data-Update-on-Daclatasvir-an-NS5A-Inhibitor-in-Phase-III-Development-for-the-Treatment-of-Hepatitis-C/default.aspxThu, 08 Mar 2012 20:33:00 -05002e0e47ed-f379-4858-895d-0e32d13362b1https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Announces-Dividend-a347111f9/default.aspxTue, 06 Mar 2012 17:45:00 -0500b6a10cde-ced1-4684-86ff-a75d70dfab9ahttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-to-Present-at-Barclays-Capital-2012-Global-Health-Care-Conference/default.aspxTue, 06 Mar 2012 11:00:00 -050031848174-0686-41f4-9087-d59a9325a108https://news.bms.com/news/details/2012/US-Food-and-Drug-Administration-Extends-Action-Date-for-ELIQUIS-apixaban-by-Three-Months/default.aspxWed, 29 Feb 2012 23:01:00 -0500984027ab-dbff-43bf-9575-49725d077ff8https://news.bms.com/news/details/2012/Public-Health-Experts-Address-Bristol-Myers-Squibb-Foundation-Together-on-Diabetes-Grantees-and-Applaud-Collaborations-between-Clinicians-and-Communities-to-Reduce-Diabetes-Disparities/default.aspxWed, 29 Feb 2012 17:41:00 -0500cb96f15c-9ef0-4566-bb6c-e2725b773f0bhttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-to-Present-at-Cowen-and-Company-Health-Care-Conference/default.aspxTue, 28 Feb 2012 12:48:00 -050063c790e6-e898-4f88-bf1a-43618e43cf56https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-and-Duke-Translational-Medicine-Institute-Form-Strategic-Relationship-to-Broaden-Interactions/default.aspxTue, 28 Feb 2012 08:30:00 -0500aa76699f-09ee-41c8-a4ba-27bd694c71e5https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-to-Take-Part-in-Citi-2012-Global-Health-Care-Conference/default.aspxTue, 21 Feb 2012 15:31:00 -0500455fe5f2-c636-4fec-bd5f-9edae7bbbe70https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Foundation-Announces-Grants-Focused-on-Prevention-Diagnosis-and-Care-of-Hepatitis-B-and-Hepatitis-C-in-Asia/default.aspxSat, 18 Feb 2012 10:00:00 -050037fa3bbd-ce25-44b4-9b21-22247bf1922ehttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Completes-Acquisition-of-Inhibitex-Inc/default.aspxMon, 13 Feb 2012 18:03:00 -0500ecb61090-04ad-470d-bb1e-2c9b8ee32deehttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Announces-Successful-Completion-of-Cash-Tender-Offer-for-Shares-of-Inhibitex-Inc/default.aspxMon, 13 Feb 2012 08:30:00 -0500d1f61c48-ddf9-4881-9312-3d3a761937b6https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-to-Present-at-Leerink-Swann-2012-Global-Healthcare-Conference/default.aspxWed, 08 Feb 2012 16:19:00 -0500a71182d4-1b36-44e4-a6a4-0dede2e94b99https://news.bms.com/news/details/2012/Sanofi-and-Bristol-Myers-Squibb-Collect-Damages-in-Plavix-Patent-Litigation-with-Apotex/default.aspxWed, 08 Feb 2012 02:30:00 -05002a11d3cb-5341-49ce-ab09-07472abd2eb9https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Announces-Expiration-of-the-Hart-Scott-Rodino-Waiting-Period-for-Acquisition-of-Inhibitex-Inc/default.aspxFri, 03 Feb 2012 08:30:00 -05004e7a07e6-e5d8-44a3-aa2e-ddbceff7984ehttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Delivers-Solid-Fourth-Quarter-Capping-a-Year-Highlighted-by-New-Product-Approvals-Continued-Execution-of-Strategic-Transactions-and-Good-Operating-Performance/default.aspxThu, 26 Jan 2012 08:30:00 -0500e85333a2-bef9-4263-b469-db2b5621924chttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Names-Gerald-L-Storch-to-Board-of-Directors/default.aspxTue, 24 Jan 2012 11:07:00 -050064a446eb-dde6-40c3-ae78-3b62891c45e8https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Announces-Charitable-Donation-of-69-Million-to-Support-Cancer-Patients/default.aspxThu, 19 Jan 2012 09:30:00 -0500a2316a3c-ffa5-48a8-a6a8-ffb3e25b3991https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-and-AstraZeneca-Receive-Complete-Response-Letter-from-US-Food-and-Drug-Administration-for-Dapagliflozin/default.aspxThu, 19 Jan 2012 03:00:00 -0500a0371764-438d-4356-b02d-d2a5bd9436afhttps://news.bms.com/news/details/2012/First-Hepatitis-C-Treatment-Data-Demonstrating-Proof-of-Principle-with-Direct-Acting-Antiviral-only-Therapy-Published/default.aspxWed, 18 Jan 2012 18:01:00 -0500108caa9b-8301-43e9-9246-68556bbaee36https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-Begins-Tender-Offer-to-Acquire-Inhibitex-Inc/default.aspxFri, 13 Jan 2012 08:30:00 -0500f7f11798-fcac-4b5a-a280-b63187fc7baahttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-to-Acquire-Inhibitex/default.aspxSat, 07 Jan 2012 22:13:00 -050096cad75c-09c5-46af-abad-c512a9b8571bhttps://news.bms.com/news/details/2012/Bristol-Myers-Squibb-to-Announce-Results-for-Fourth-Quarter-Full-Year-2011-on-January-26/default.aspxThu, 05 Jan 2012 15:00:00 -0500a19d5b46-da7c-45ee-890b-21e2a14d10c5https://news.bms.com/news/details/2012/Bristol-Myers-Squibb-to-Present-at-JP-Morgan-Healthcare-Conference/default.aspxWed, 04 Jan 2012 11:30:00 -0500fd1f4906-739a-4e39-ac79-e274595ddbe0https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-to-Present-at-Goldman-Sachs-Healthcare-CEOs-Unscripted-Conference/default.aspxThu, 29 Dec 2011 15:13:00 -0500db240b58-8af9-449b-911b-8497510938b2https://news.bms.com/news/details/2011/BRISK-PS-Study-with-Investigational-Compound-Brivanib-in-Hepatocellular-Carcinoma-Completed/default.aspxThu, 22 Dec 2011 17:30:00 -0500db6a5a23-d0d6-4902-a076-c120bb5a3dd0https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-and-the-Gladstone-Institutes-Enter-Three-Year-Discovery-Partnership-in-Alzheimers-Disease/default.aspxThu, 22 Dec 2011 14:00:00 -05002182b2ec-2e4a-4eda-ab52-165c8dcdf14dhttps://news.bms.com/news/details/2011/Simcere-and-Bristol-Myers-Squibb-Enter-Innovative-Partnership-to-Develop-Cardiovascular-Compound/default.aspxTue, 13 Dec 2011 20:00:00 -0500643165f6-86ff-4556-b9a2-d018c13a4140https://news.bms.com/news/details/2011/New-Data-Show-Investigational-Compound-Dapagliflozin-When-Added-to-Glimepiride-Maintained-Reductions-in-Blood-Sugar-Levels-in-Adults-with-Type-2-Diabetes-Over-48-Weeks-of-Treatment/default.aspxThu, 08 Dec 2011 04:30:00 -0500a1ce30d6-fc96-45f5-b7ab-6ab554309372https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Announces-Dividend-Increase/default.aspxTue, 06 Dec 2011 18:05:00 -05007c4ba981-7e05-4e89-acdc-5550b28c353chttps://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Enters-Clinical-Collaboration-Agreement-with-Tibotec-Pharmaceuticals-for-Phase-II-Combination-Study-in-Patients-Chronically-Infected-with-Hepatitis-C/default.aspxFri, 02 Dec 2011 08:30:00 -05005c2c803b-361e-45f2-b930-f73ad313ebf0https://news.bms.com/news/details/2011/Alvin-Ailey-American-Dance-Theater-Premieres-Home-A-New-Work-Inspired-by-the-Winning-Photos-and-Essays-from-the-2011-REYATAZ-atazanavir-sulfate-Fight-HIV-Your-Way-Contest-an-Initiative-of-Bristol-Myers-Squibb/default.aspxWed, 30 Nov 2011 11:00:00 -0500e65f64f5-fca2-40f6-8b0b-451ee512e6a0https://news.bms.com/news/details/2011/FDA-Accepts-ELIQUIS-apixaban-New-Drug-Application-for-Review-for-the-Prevention-of-Stroke-and-Systemic-Embolism-in-Patients-with-Atrial-Fibrillation/default.aspxTue, 29 Nov 2011 08:30:00 -050098b5f9a2-bb21-4cc6-99d9-ca43328fb7c4https://news.bms.com/news/details/2011/ONGLYZA-saxagliptin-Approved-for-Use-in-Europe-as-Combination-Therapy-With-Insulin-With-or-Without-Metformin-in-Adults-With-Type-2-Diabetes/default.aspxMon, 28 Nov 2011 09:00:00 -0500d4e671f1-31fd-4f74-b16f-c189ee30d7d0https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Foundation-Awards-234-Million-in-Grants-to-Help-Prisoners-with-Mental-Illness-Return-to-Community/default.aspxThu, 17 Nov 2011 11:00:00 -05009ae1c86f-68a4-42d2-8266-d44a1d3f1e68https://news.bms.com/news/details/2011/Meta-Analysis-of-Clinical-Data-on-Cardiovascular-Safety-Presented-for-Investigational-Compound-Dapagliflozin-in-Adult-Patients-with-Type-2-Diabetes/default.aspxWed, 16 Nov 2011 17:00:00 -05004005cf5c-3a17-4b91-ad30-d05069b85f26https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Foundations-Together-on-Diabetes-Initiative-Marks-First-Anniversary-by-Awarding-184-Million-in-Grants-to-Help-Communities-Hardest-Hit-by-Diabetes-Issuing-Annual-Report/default.aspxMon, 14 Nov 2011 12:58:00 -05001b3c63ef-0153-4e88-9c00-8f39677e45dbhttps://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Signs-New-Agreement-to-Expand-Access-to-Reyataz-atazanavir-sulfate-in-Brazil/default.aspxFri, 11 Nov 2011 10:05:00 -050065a3fa52-72c2-4fff-a080-ef5e8626d977https://news.bms.com/news/details/2011/12-Week-On-Treatment-Results-from-Large-Phase-IIb-Study-COMMAND-1-of-Bristol-Myers-Squibbs-NS5A-Inhibitor-Daclatasvir-Support-Anti-HCV-Activity-and-Safety-Profile-Observed-in-Earlier-Studies/default.aspxTue, 08 Nov 2011 13:00:00 -0500c7013cd0-9f81-46c2-9fd2-7e314d6a08d0https://news.bms.com/news/details/2011/Phase-IIIb-Comparison-of-BARACLUDE-entecavir-Monotherapy-Versus-BARACLUDE-Plus-Tenofovir-Combination-Shows-No-Statistical-Difference-Between-Study-Arms/default.aspxTue, 08 Nov 2011 12:00:00 -05008afe3eed-429e-4579-b3d0-375388fff761https://news.bms.com/news/details/2011/FDA-Approves-ERBITUX-cetuximab-for-First-Line-Recurrent-Locoregional-or-Metastatic-Head-and-Neck-Cancer-in-Combination-with-Platinum-based-Chemotherapy-with-5-Fluorouracil/default.aspxTue, 08 Nov 2011 00:09:00 -0500e08ba62f-c077-4cc0-99c9-bf4fbf76cd43https://news.bms.com/news/details/2011/All-Oral-Treatment-Regimen-of-Bristol-Myers-Squibbs-Investigational-NS5A-and-NS3-Inhibitors-Achieved-90-Sustained-Virologic-Response-SVR12-in-Phase-II-Study-Sentinel-Cohort-of-Genotype-1b-Null-Responders/default.aspxMon, 07 Nov 2011 19:30:00 -05006a23d88f-081a-417b-a017-3c54e49fad33https://news.bms.com/news/details/2011/New-12-Week-Interferon-Free-Treatment-Arms-Added-to-All-Oral-Combination-Study-of-PSI-7977-and-Daclatasvir-BMS-790052-for-HCV-Genotype-1/default.aspxFri, 04 Nov 2011 08:00:00 -0400997305b1-b42c-4c92-8259-637b631c86achttps://news.bms.com/news/details/2011/New-Investigational-Data-on-ORENCIA-abatacept-to-be-Presented-at-the-American-College-of-Rheumatology-Annual-Scientific-Meeting/default.aspxThu, 03 Nov 2011 10:00:00 -04006b29e9dd-d0c6-460b-bcbf-ae57101797dehttps://news.bms.com/news/details/2011/ASLAN-Pharmaceuticals-and-Bristol-Myers-Squibb-Enter-Innovative-Partnership-to-License-and-Develop-Investigational-Oncology-Compound/default.aspxThu, 03 Nov 2011 08:30:00 -040029fa9f2e-c972-4b59-a022-d3c3a2ca0dedhttps://news.bms.com/news/details/2011/Bristol-Myers-Squibb-to-Present-at-Credit-Suisse-Health-Care-Conference/default.aspxWed, 02 Nov 2011 11:00:00 -0400e971314b-a541-45ab-ab21-c55c407bcf6dhttps://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Delivers-Strong-Third-Quarter-with-Important-Clinical-Data-Solid-Operating-Results-and-Continued-Focus-on-Business-Development/default.aspxThu, 27 Oct 2011 07:30:00 -040022823ea2-8fb1-46fa-b464-03721ec03236https://news.bms.com/news/details/2011/US-Food-and-Drug-Administration-Extends-Action-Date-for-Dapagliflozin-by-Three-Months/default.aspxWed, 26 Oct 2011 16:05:00 -040006ab2b29-b589-40b8-a26b-5ddef1624f8chttps://news.bms.com/news/details/2011/Bristol-Myers-Squibb-and-Gilead-Sciences-Announce-Licensing-Agreement-for-Development-and-Commercialization-of-New-Fixed-Dose-Combination-Pill-for-People-Living-with-HIV/default.aspxWed, 26 Oct 2011 08:30:00 -0400a54100ad-71e0-4bde-ab53-92a11e51d174https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Announces-Changes-in-Senior-Management-Team/default.aspxWed, 19 Oct 2011 10:15:00 -0400bb7c2851-5fad-46e7-9063-2cf97dfef0aehttps://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Foundation-Awards-212-Million-in-Grants-to-Help-Returning-Soldiers-Heal-Emotional-Wounds-of-War/default.aspxWed, 19 Oct 2011 09:07:00 -0400e17a485b-5a1c-49a8-9db8-bfab3e89e324https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Foundation-Announces-Six-New-Grants-to-Bridge-Gaps-in-Cancer-Awareness-Prevention-and-Care-in-Central-and-Eastern-Europe/default.aspxFri, 14 Oct 2011 09:30:00 -04007b705d27-d8d1-4238-ab9a-fd6de0513860https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Foundation-Announces-Collaboration-with-World-Health-Organizations-Stop-TB-Department-to-Strengthen-Community-Based-Care-of-Tuberculosis-Including-HIV-Co-Infection-in-Five-African-Countries/default.aspxTue, 11 Oct 2011 09:00:00 -0400a7ae32c2-7493-4808-85e5-ba44ea886eadhttps://news.bms.com/news/details/2011/Bristol-Myers-Squibb-to-Announce-Financial-Results-for-Third-Quarter-2011-on-October-27/default.aspxTue, 04 Oct 2011 15:12:00 -04005c964912-273d-41f3-b452-49fc59b41b25https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-to-Present-New-Data-Demonstrating-Companys-Leadership-in-Liver-Disease-at-The-Liver-Meeting--AASLD-Annual-Meeting/default.aspxFri, 30 Sep 2011 17:23:00 -04005897273b-fa75-4193-abda-72cf704acc53https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-and-Ambrx-Announce-Collaboration-for-Novel-Biologics-Programs-in-Diabetes-and-Heart-Failure/default.aspxThu, 22 Sep 2011 08:00:00 -0400d707ca3d-37d0-4f2a-a7b7-057d2d7af0afhttps://news.bms.com/news/details/2011/Bristol-Myers-Squibb-and-Ono-Enter-into-Strategic-Agreement-for-Anti-PD-1-Antibody-BMS-936558ONO-4538-and-ORENCIA-abatacept/default.aspxTue, 20 Sep 2011 21:00:00 -0400c1a82788-c964-40de-a024-b7432ace457fhttps://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Announces-Dividend/default.aspxTue, 20 Sep 2011 16:30:00 -040028fc0169-84db-4bec-8dc7-df89dc6e00b0https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-and-Saladax-Biomedical-Expand-Collaboration-for-Diagnostic-Assays-for-Alzheimers-Disease/default.aspxTue, 20 Sep 2011 11:00:00 -0400c3de34f5-80ec-4efe-816e-e88c8541822chttps://news.bms.com/news/details/2011/BMS-790052-Plus-Peginterferon-Alfa-and-Ribavirin-Demonstrated-up-to-83-Sustained-Virologic-Response-24-Weeks-Post-Treatment-SVR24-in-Phase-II-Study-of-Genotype-1-Hepatitis-C-Patients/default.aspxSat, 17 Sep 2011 17:00:00 -040060674013-adab-42b0-b090-bd4e6539eac2https://news.bms.com/news/details/2011/ONGLYZA-saxagliptin-When-Added-to-Insulin-in-Adults-with-Type-2-Diabetes-Maintained-Reductions-in-Blood-Sugar-Levels-HbA1c-Over-52-Weeks-in-Investigational-Study-Extension/default.aspxFri, 16 Sep 2011 07:01:00 -0400e082aa58-6ac7-42eb-bc3e-8f16b00e5311https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-to-Present-at-Bank-of-America-Merrill-Lynch-Health-Care-Conference/default.aspxTue, 13 Sep 2011 11:28:00 -0400b6671da1-9260-41de-abf3-4cfcbb2ab73fhttps://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Completes-Acquisition-of-Amira-Pharmaceuticals/default.aspxThu, 08 Sep 2011 09:04:00 -0400ca5989e7-be52-4197-a9da-3ef8fe378d65https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-to-Present-at-the-Morgan-Stanley-Global-Healthcare-Conference/default.aspxWed, 07 Sep 2011 16:47:00 -040089f03466-506c-4ff9-bd64-fd561ec0ac94https://news.bms.com/news/details/2011/New-Data-from-Bristol-Myers-Squibb-on-NULOJIX-belatacept-to-be-Presented-at-the-2011-European-Society-for-Organ-Transplantation-Congress/default.aspxThu, 01 Sep 2011 09:00:00 -0400c2cddad8-8e6b-41cc-ba61-54ba04e854a6https://news.bms.com/news/details/2011/ELIQUIS-apixaban-was-Superior-to-Warfarin-for-the-Reduction-of-Stroke-or-Systemic-Embolism-with-Significantly-Less-Major-Bleeding-in-Patients-with-Atrial-Fibrillation-in-Phase-3-ARISTOTLE-Trial/default.aspxSun, 28 Aug 2011 02:01:00 -040047bae416-a287-4042-adda-f574fdbb2396https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-to-Hold-Investor-Teleconference-to-Discuss-ESC-Highlights/default.aspxMon, 15 Aug 2011 13:00:00 -0400408a1206-ca65-46b4-ae79-c52d9d320a2fhttps://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Announces-the-Winners-of-the-2011-REYATAZ-atazanavir-sulfate-Fight-HIV-Your-Way-Contest/default.aspxMon, 15 Aug 2011 10:00:00 -040030064832-b331-488b-81f8-75e155973a83https://news.bms.com/news/details/2011/US-Food-and-Drug-Administration-Approves-Subcutaneous-Formulation-of-ORENCIA-abatacept-a-Proven-Non-Anti-TNF-Biologic-for-Adults-with-Moderate-to-Severe-Rheumatoid-Arthritis/default.aspxFri, 29 Jul 2011 20:12:00 -040034e7dd9e-936a-4d58-8e8a-d03211e45acfhttps://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Delivers-Excellent-Second-Quarter-with-Global-New-Product-Approvals-Important-Clinical-Data-and-Strong-Financial-Results/default.aspxThu, 28 Jul 2011 07:30:00 -040037f6a795-3976-45f6-8604-a2e663525b0ehttps://news.bms.com/news/details/2011/Bristol-Myers-Squibb-to-Acquire-Amira-Pharmaceuticals/default.aspxThu, 21 Jul 2011 20:41:00 -0400a69425a4-ac66-4ee1-8c7e-a99e3d2bbc93https://news.bms.com/news/details/2011/Data-on-Bristol-Myers-Squibbs-Investigational-Treatment-for-Alzheimers-Disease-Demonstrate-Potential-Therapeutic-Window-at-Doses-Below-100-mg-in-Phase-II-Safety-and-Tolerability-Study/default.aspxWed, 20 Jul 2011 10:45:00 -04004ba0e99e-ae49-4964-a341-2914a114dfa4https://news.bms.com/news/details/2011/FDA-Advisory-Committee-Makes-Recommendation-on-Investigational-Compound-Dapagliflozin/default.aspxTue, 19 Jul 2011 19:34:00 -0400d7c1f407-765a-4955-a4a0-f4aea4bf0f49https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-to-Announce-Results-for-Second-Quarter-2011-on-July-28/default.aspxThu, 07 Jul 2011 12:04:00 -040022146d6a-c1dd-4cb9-b286-9169596ac701https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-and-Innate-Pharma-Announce-Breakthrough-Global-License-Agreement-for-an-Investigational-Immuno-Oncology-Biologic/default.aspxWed, 06 Jul 2011 14:30:00 -040015904935-38b1-4d5b-90b0-08e5dbcc26d5https://news.bms.com/news/details/2011/Innovative-Curriculum-Helps-Teachers-Meet-NJ-Standards-for-21st-Century-Essential-Work-Force-Skills/default.aspxTue, 05 Jul 2011 09:00:00 -040040cceaee-834e-4ce6-bf25-45ece084e573https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Signs-New-Agreement-to-Expand-Access-to-Reyataz-atazanavir-sulfate-in-sub-Saharan-Africa-and-India/default.aspxTue, 28 Jun 2011 10:00:00 -0400509538da-379d-40a5-9fb8-5a2fbd21d57ehttps://news.bms.com/news/details/2011/Investigational-Compound-Dapagliflozin-with-Metformin-Extended-Release-XR-as-Initial-Combination-Therapy-Significantly-Improved-Blood-Sugar-Control-in-Previously-Untreated-Adult-Type-2-Diabetes-Patients-with-High-Blood-Sugar-Levels/default.aspxMon, 27 Jun 2011 08:00:00 -040007e5c534-91bd-46c5-8029-874520d976f3https://news.bms.com/news/details/2011/Investigational-Compound-Dapagliflozin-Added-to-Metformin-Sustained-Reductions-in-Blood-Sugar-Levels-in-Adult-Patients-with-Type-2-Diabetes-in-Two-Year-Study/default.aspxSun, 26 Jun 2011 08:00:00 -04008fcf4f20-d3cb-4194-8d34-0328de0ea736https://news.bms.com/news/details/2011/Investigational-Compound-Dapagliflozin-Sustained-Glycemic-Control-and-Weight-Reduction-in-Study-of-Type-2-Diabetes-Patients-Inadequately-Controlled-with-Metformin/default.aspxSat, 25 Jun 2011 14:30:00 -0400a76902b7-d891-4138-b45d-c820058519c5https://news.bms.com/news/details/2011/Investigational-Study-Reported-ONGLYZA-saxagliptin-Added-to-Insulin-Significantly-Improved-Blood-Sugar-Levels-in-Adults-with-Type-2-Diabetes-Compared-to-Placebo-Added-to-Insulin/default.aspxSat, 25 Jun 2011 08:00:00 -04004e081d5a-8f87-4beb-b473-58cdb81288c1https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Foundation-Awards-15-Million-in-Grants-to-Help-African-American-Women-Fight-Type-2-Diabetes/default.aspxFri, 24 Jun 2011 08:00:00 -0400209f33ae-0d3f-41d7-8589-6262e6c9d79ahttps://news.bms.com/news/details/2011/ELIQUIS-apixaban-Meets-Primary-and-Key-Secondary-Endpoints-in-Phase-3-ARISTOTLE-Study/default.aspxWed, 22 Jun 2011 17:12:00 -0400949fc8b8-97b0-4263-8a5f-c038de1cd229https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Announces-Dividend-539e59d78/default.aspxWed, 22 Jun 2011 16:30:00 -040032a57684-19e2-4517-a9dd-0b91c3c5452ehttps://news.bms.com/news/details/2011/FDA-Approves-NULOJIX-belatacept/default.aspxThu, 16 Jun 2011 14:49:00 -04004ff0c8eb-fc78-408c-8935-ada74707e232https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-to-Take-Part-in-2011-Wells-Fargo-Securities-Healthcare-Conference/default.aspxThu, 16 Jun 2011 11:00:00 -04003561fcf6-9943-4ca1-acf7-49e723ba1ea6https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-and-Roche-Enter-into-a-Clinical-Collaboration-Agreement-to-Conduct-Combination-Studies-with-YERVOY-ipilimumab-and-Vemurafenib/default.aspxThu, 02 Jun 2011 07:00:00 -040056f0de20-67bb-48ba-9be6-195283d5f13fhttps://news.bms.com/news/details/2011/Bristol-Myers-Squibb-to-Take-Part-in-Goldman-Sachs-Health-Care-Conference-June-8/default.aspxWed, 01 Jun 2011 15:30:00 -0400ba0fafde-655a-44a7-be7b-7e114caba509https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-to-Hold-Investor-Teleconference-to-Discuss-ASCO-Highlights/default.aspxMon, 23 May 2011 14:00:00 -04009bf71e9b-d7e1-499a-aff2-b265290976b2https://news.bms.com/news/details/2011/ELIQUIS-apixaban-Approved-In-Europe-For-Preventing-Venous-Thromboembolism-After-Elective-Hip-Or-Knee-Replacement/default.aspxFri, 20 May 2011 10:41:00 -0400d41713f2-c971-4d37-93f1-14af530a4265https://news.bms.com/news/details/2011/New-Data-from-Bristol-Myers-Squibb-Oncology-Portfolio-to-be-Presented-at-2011-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting/default.aspxFri, 20 May 2011 08:10:00 -0400142df095-fb7c-4f20-890f-42936baf6b8fhttps://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Invites-Public-to-Listen-to-Webcast-of-2011-Annual-Meeting/default.aspxFri, 29 Apr 2011 09:00:00 -040002f947da-968e-482c-bba4-6a61635ddaf6https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Delivers-Excellent-First-Quarter-with-YERVOY-ipilimumab-Approval-Key-RD-Milestones-and-Strong-Financials/default.aspxThu, 28 Apr 2011 07:30:00 -040061319b6a-eef4-4492-83c8-bf3b61dc1a93https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-to-Present-at-Deutsche-Bank-Health-Care-Conference/default.aspxTue, 26 Apr 2011 10:00:00 -040025b2a2bf-36c7-42fe-b994-8660c79d6dc5https://news.bms.com/news/details/2011/New-Data-on-Investigational-Agent-Belatacept-in-Kidney-Transplant-Recipients-to-be-Presented-at-2011-American-Transplant-Congress/default.aspxMon, 25 Apr 2011 10:00:00 -0400c1e66cba-2c08-4a44-9104-83ec37946fcbhttps://news.bms.com/news/details/2011/Bristol-Myers-Squibb-to-Announce-Results-for-First-Quarter-2011-on-April-28/default.aspxThu, 07 Apr 2011 10:00:00 -0400c3da11b1-32a0-4a0f-b12e-84b8cec1d634https://news.bms.com/news/details/2011/Investigational-Compound-PEG-Interferon-Lambda-Achieved-Higher-Response-Rates-with-Fewer-Flu-Like-and-Musculoskeletal-Symptoms-and-Cytopenias-Than-PEG-Interferon-Alfa-in-Phase-IIb-Study-of-526-Treatment-Naive-Hepatitis-C-Patients/default.aspxSat, 02 Apr 2011 11:31:00 -0400b0bcaf76-1272-4a04-8194-444657eb498dhttps://news.bms.com/news/details/2011/Investigational-Direct-Acting-Antiviral-BMS-790052-Plus-PEG-Interferon-Alfa-and-Ribavirin-Achieved-Up-to-92-Sustained-Virologic-Response-in-Phase-II-Dose-Ranging-Study-of-Treatment-Nave-Hepatitis-C-Patients/default.aspxThu, 31 Mar 2011 10:31:00 -040067ce98dc-f31e-42be-9b70-efa61b18107ehttps://news.bms.com/news/details/2011/FDA-Approves-YERVOY-ipilimumab-for-the-Treatment-of-Patients-with-Newly-Diagnosed-or-Previously-Treated-Unresectable-or-Metastatic-Melanoma-the-Deadliest-Form-of-Skin-Cancer/default.aspxFri, 25 Mar 2011 23:43:00 -04008c38d3c9-b112-4fd5-9e0d-8d0241c36654https://news.bms.com/news/details/2011/Phase-III-Study-of-Investigational-Compound-Ipilimumab-Achieves-Primary-Endpoint-of-Improvement-in-Overall-Survival-in-Previously-Untreated-Patients-with-Metastatic-Melanoma/default.aspxMon, 21 Mar 2011 18:00:00 -0400febe3105-11db-49ef-b418-a407fa737bbchttps://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Awards-Grant-to-the-American-College-of-Physicians-Foundation-to-Address-US-HIV-Medical-Workforce-Shortage/default.aspxMon, 14 Mar 2011 11:07:00 -04003c37d811-c57f-4456-9a47-1fd26617fdfdhttps://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Foundation-Announces-Funding-of-Nearly-1-Million-to-Address-Needs-in-Hepatitis-B-and-C-Awareness-Prevention-and-Care-in-China-and-India/default.aspxFri, 11 Mar 2011 11:43:00 -05005b4346dd-4a08-4825-a1fb-8adfac9e7ea7https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-to-Present-at-Barclays-Capital-Global-Healthcare-Conference/default.aspxWed, 09 Mar 2011 11:00:00 -0500a25c0777-3cd3-4d73-b236-4a28f8a0898bhttps://news.bms.com/news/details/2011/FDA-Accepts-New-Drug-Application-for-Investigational-Compound-Dapagliflozin-for-the-Treatment-of-Type-2-Diabetes/default.aspxTue, 08 Mar 2011 09:00:00 -0500ca903d63-fce2-4b7b-a082-6e4fe6276cfchttps://news.bms.com/news/details/2011/New-Data-on-Multiple-Bristol-Myers-Squibb-Investigational-Hepatitis-C-Compounds-to-be-Presented-at-The-International-Liver-Congress-2011/default.aspxMon, 07 Mar 2011 14:51:00 -050045bc049b-99c8-43bf-bd9d-c77170fd20e0https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-and-WuXi-PharmaTech-Announce-Collaboration-for-a-New-Analytical-and-Stability-Testing-Facility/default.aspxMon, 07 Mar 2011 09:00:00 -05001df88f4f-f260-48e1-8e93-29f2f30fc0echttps://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Announces-Dividend-898edc55e/default.aspxTue, 01 Mar 2011 17:30:00 -0500571afb07-62c1-4a87-8e7b-6735646bd6dehttps://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Names-Elliott-Sigal-MD-PhD-to-Board-of-Directors/default.aspxTue, 01 Mar 2011 12:42:00 -0500819067bd-020f-4999-9b0d-b146ed31558ehttps://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Posts-New-Data-on-Pharmacodynamics-Safety-and-Pharmacokinetics-of-Investigational-Compound-BMS-663068-for-the-Treatment-of-HIV-1-Infection/default.aspxMon, 28 Feb 2011 13:10:00 -05005ff6cc08-e134-4ac5-882c-70b1e00d4741https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-to-Present-at-Cowen-and-Company-Health-Care-Conference/default.aspxMon, 28 Feb 2011 11:30:00 -050064601b34-4005-4851-8667-f0bd304beb31https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-to-Present-at-Citi-2011-Global-Health-Care-Conference/default.aspxWed, 23 Feb 2011 11:30:00 -050035e5e0ce-0ebc-4389-91e6-84bc9902f0cahttps://news.bms.com/news/details/2011/ONGLYZA-saxagliptin-US-Label-Update-Provides-Further-Evidence-Regarding-Use-in-Renally-Impaired-Adults-with-Type-2-Diabetes/default.aspxWed, 23 Feb 2011 09:00:00 -0500c21ff452-8189-47fe-a6c6-11ac7848eb41https://news.bms.com/news/details/2011/ABILIFY-aripiprazole-Approved-for-Maintenance-Treatment-of-Bipolar-I-Disorder-as-an-Adjunct-to-Either-Lithium-or-Valproate/default.aspxThu, 17 Feb 2011 12:02:00 -0500530fb22e-67a9-4646-86cb-695c2afd8d70https://news.bms.com/news/details/2011/New-AVERROES-Data-Demonstrate-Investigational-Apixaban-Superior-to-Aspirin-in-Reducing-Stroke-and-Systemic-Embolism-in-Patients-with-Atrial-Fibrillation-Unsuitable-for-Warfarin-Therapy/default.aspxThu, 10 Feb 2011 13:15:00 -0500051b036b-8c8d-454a-bfb4-8dc3c2677b81https://news.bms.com/news/details/2011/FDA-Approves-Labeling-Update-for-REYATAZ-atazanavir-sulfate-Capsules-to-Include-Data-Supporting-the-Recommended-Adult-Dose-of-REYATAZritonavir-300100-mg-for-HIV-1-Infected-Pregnant-Women/default.aspxMon, 07 Feb 2011 11:39:00 -05007f4999b6-b3fd-4311-96d6-90d4044d3119https://news.bms.com/news/details/2011/Lilly-Bristol-Myers-Squibb-Stop-Enrollment-in-One-of-Two-Phase-III-Lung-Cancer-Trials-of-Necitumumab/default.aspxWed, 02 Feb 2011 10:47:00 -0500c50aba82-b848-40ba-9604-d793f475aa46https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-Delivers-Solid-Fourth-Quarter-Results-in-a-Year-Highlighted-by-Robust-Clinical-Data-Continued-Execution-of-Strategic-Transactions-and-Good-Operating-Performance/default.aspxThu, 27 Jan 2011 08:30:00 -0500d7601419-bc09-4155-9061-b4972f4ec500https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-and-sanofi-aventis-Announce-US-FDA-Decision-to-Grant-Pediatric-Exclusivity-For-PLAVIX/default.aspxTue, 25 Jan 2011 13:00:00 -05004263d815-bd44-4df9-920b-ced2a228b055https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-to-Announce-Results-for-Fourth-Quarter-Full-Year-2010-on-January-27/default.aspxFri, 14 Jan 2011 17:27:00 -0500be67b59b-0b92-485b-886d-4e6b6953e3abhttps://news.bms.com/news/details/2011/The-Type-2-Talk-Public-Health-Initiative-Launches-to-Motivate-People-to-Actively-Manage-Their-Type-2-Diabetes/default.aspxTue, 11 Jan 2011 10:00:00 -05004be8afb5-266a-4d96-ad1c-d09cbb4425echttps://news.bms.com/news/details/2011/Bristol-Myers-Squibb-and-Pharmasset-Enter-into-a-Clinical-Collaboration-Agreement-for-Proof-of-Concept-Combination-Study-in-Patients-Chronically-Infected-with-Hepatitis-C/default.aspxMon, 10 Jan 2011 08:18:00 -0500ba49f951-1c2f-474e-bb91-8e54ab2625d3https://news.bms.com/news/details/2011/KOMBIGLYZE-XR-Saxagliptin-and-Metformin-HCl-Extended-Release-Tablets-a-New-Treatment-for-Type-2-Diabetes-Mellitus-in-Adults-Now-Available-in-US-Pharmacies/default.aspxFri, 07 Jan 2011 09:00:00 -05007d2a154f-0eb3-4c15-a1ac-f480c31e8e84https://news.bms.com/news/details/2011/Bristol-Myers-Squibb-to-Present-at-JP-Morgan-Healthcare-Conference/default.aspxTue, 04 Jan 2011 11:59:00 -0500c9e87a83-85f2-4e05-ad11-70432b527628https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-to-Present-at-Goldman-Sachs-Healthcare-CEOs-Unscripted-Conference/default.aspxThu, 30 Dec 2010 10:00:00 -05000dd74a4c-5af2-45fa-a0a2-9bbeb0ba2447https://news.bms.com/news/details/2010/Newly-Published-Investigational-Apixaban-ADVANCE-3-Study-Results-Demonstrate-Statistical-Superiority-to-Enoxaparin-with-Comparable-Rates-of-Bleeding-in-the-Prevention-of-Venous-Thromboembolism-Following-Total-Hip-Replacement-Surgery/default.aspxWed, 22 Dec 2010 18:05:00 -05005a5b849b-64e2-4c17-a0c7-d6abc0369086https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-and-Oncolys-BioPharma-Enter-Global-Licensing-Agreement-for-Investigational-HIV-Compound/default.aspxMon, 20 Dec 2010 09:00:00 -050086dc06d3-7356-48aa-9721-bb53b15d3fefhttps://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Announces-Dividend-Increase/default.aspxTue, 14 Dec 2010 17:47:00 -05007f26afa3-d526-4a98-97e7-d57f312800bdhttps://news.bms.com/news/details/2010/Encouraging-Phase-2-Interim-Data-for-Elotuzumab-in-Relapsed-Multiple-Myeloma-Presented-at-52nd-American-Society-of-Hematology-Annual-Meeting/default.aspxTue, 07 Dec 2010 08:48:00 -0500e55c79e3-9564-4ca2-b31b-048232711f26https://news.bms.com/news/details/2010/US-Food-and-Drug-Administration-Accepts-Supplemental-Biologics-License-Application-for-Subcutaneous-Formulation-of-ORENCIA-abatacept-for-Adult-Patients-with-Moderate-to-Severe-Rheumatoid-Arthritis/default.aspxMon, 06 Dec 2010 16:00:00 -050018a8670a-33e2-4434-9f26-01be1b753dc1https://news.bms.com/news/details/2010/Follow-Up-Results-from-Study-Comparing-SPRYCEL-dasatinib-to-Imatinib-in-First-Line-Treatment-of-Adults-with-Ph-CP-CML-Demonstrate-Improved-Response-Rates-Consistent-with-12-Month-Data/default.aspxMon, 06 Dec 2010 08:18:00 -05007a84c128-14d2-45fd-8514-014d75a19ee1https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Announces-the-Expiration-and-Final-Results-of-its-Cash-Tender-Offer/default.aspxFri, 03 Dec 2010 09:50:00 -050035e31d8e-74a9-40b7-8bd2-9e6432bb79bfhttps://news.bms.com/news/details/2010/Bristol-Myers-Squibb-and-Alvin-Ailey-American-Dance-Theater-Announce-First-of-Its-Kind-Collaboration-to-Express-the-Stories-of-People-Impacted-by-HIVAIDS-Through-Dance/default.aspxWed, 01 Dec 2010 11:30:00 -05000fa9905c-0a49-4527-bf78-2c07217e4f6ehttps://news.bms.com/news/details/2010/APPRAISE-2-Study-with-Investigational-Compound-Apixaban-in-Acute-Coronary-Syndrome-Discontinued/default.aspxThu, 18 Nov 2010 19:17:00 -0500f3af8d24-bc57-4966-8226-664848fd9f3fhttps://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Announces-the-Pricing-Terms-of-its-Cash-Tender-Offer-For-Up-to-750-Million-Aggregate-Principal-Amount-of-its-Outstanding-Debt-Securities/default.aspxThu, 18 Nov 2010 12:39:00 -05008d177c1f-7093-4f32-9af2-ddf334879fcahttps://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Announces-the-Early-Results-of-its-Cash-Tender-Offer-For-Up-to-750-Million-Aggregate-Principal-Amount-of-its-Outstanding-Debt-Securities/default.aspxWed, 17 Nov 2010 19:33:00 -0500d89c7445-7204-4a60-8f93-f5e663bb0c01https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Foundation-Launches-100-Million-Initiative-Targeting-Americas-Type-2-Diabetes-Crisis/default.aspxThu, 11 Nov 2010 09:30:00 -0500b58c8244-0cd5-49c3-b325-6383dea7072ehttps://news.bms.com/news/details/2010/New-Data-Show-That-Subcutaneous-Injection-of-an-Investigational-Formulation-of-ORENCIA-abatacept-Provided-Similar-Improvements-in-Disease-Activity-Compared-to-Intravenous-Administration-of-ORENCIA/default.aspxMon, 08 Nov 2010 09:00:00 -050081d8919a-99e5-4f08-a984-6564dc31887chttps://news.bms.com/news/details/2010/Data-on-Two-Novel-Investigational-Bristol-Myers-Squibb-Compounds-in-Clinical-Development-for-Patients-with-Rheumatoid-Arthritis-to-Be-Presented-at-the-American-College-of-Rheumatology-Annual-Scientific-Meeting/default.aspxSat, 06 Nov 2010 09:00:00 -040019beed09-b0d1-48e6-b09b-bb164c952dbahttps://news.bms.com/news/details/2010/KOMBIGLYZE-XR-Saxagliptin-and-Metformin-HCl-Extended-Release-Tablets-Approved-in-the-US-for-the-Treatment-of-Type-2-Diabetes-Mellitus-in-Adults/default.aspxFri, 05 Nov 2010 14:31:00 -0400a92f0520-a91e-4180-9f95-5ffce031a4dahttps://news.bms.com/news/details/2010/Bristol-Myers-Squibb-to-Present-at-the-2010-Annual-Credit-Suisse-Health-Care-Conference/default.aspxThu, 04 Nov 2010 11:36:00 -04008c1b88cc-2653-40e9-9cf4-251520bb698chttps://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Announces-Cash-Tender-Offer-For-Up-to-750-Million-Aggregate-Principal-Amount-of-its-Outstanding-Debt-Securities/default.aspxWed, 03 Nov 2010 17:26:00 -040004f86823-f545-4968-a1c6-e5658955ceffhttps://news.bms.com/news/details/2010/Simcere-and-Bristol-Myers-Squibb-Enter-Innovative-Partnership-to-Develop-Early-Stage-Oncology-Compound/default.aspxWed, 03 Nov 2010 09:35:00 -0400b2fb3425-46f9-4f7b-ba00-418ed72eff98https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Posts-New-Data-on-Combination-of-Investigational-Compounds-BMS-790052-and-BMS-650032-for-the-Treatment-of-Chronic-Hepatitis-C/default.aspxMon, 01 Nov 2010 09:00:00 -040061d41a13-7060-46da-babb-16d1862629b3https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Posts-Data-Update-on-PEG-Interferon-Lambda-A-Novel-Interferon-in-Development-for-the-Treatment-of-Hepatitis-C/default.aspxSun, 31 Oct 2010 09:00:00 -04002d21f99e-66ba-48ae-b8c4-79d17b7eea86https://news.bms.com/news/details/2010/FDA-Approves-SPRYCEL-dasatinib-as-Treatment-for-Adult-Patients-with-Newly-Diagnosed-Ph-Chronic-Myeloid-Leukemia-in-Chronic-Phase/default.aspxThu, 28 Oct 2010 13:13:00 -04006b0a1642-97fe-4e53-90d4-ce7494c45754https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Third-Quarter-Featured-Solid-Operating-Performance-Robust-Clinical-Data-and-the-Strategic-Acquisition-of-ZymoGenetics/default.aspxTue, 26 Oct 2010 07:30:00 -04007634be91-02c4-456f-8fcf-d4c0d1b6f758https://news.bms.com/news/details/2010/US-Food-and-Drug-Administration-Approves-BARACLUDE-entecavir-as-a-Treatment-for-Chronic-Hepatitis-B-Patients-with-Evidence-of-Decompensated-Liver-Disease/default.aspxMon, 18 Oct 2010 10:06:00 -040093923b0e-f45b-4642-8605-a9c87b7ad079https://news.bms.com/news/details/2010/My-SPRYCEL-dasatinib-Support-Program-Now-Available-for-Patients/default.aspxThu, 14 Oct 2010 11:00:00 -0400f36812ab-7b85-4d06-bcdb-2a15666fb738https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Completes-Acquisition-of-ZymoGenetics-Inc/default.aspxTue, 12 Oct 2010 16:58:00 -0400861266f6-0d83-4157-a438-0ae70549b763https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-to-Announce-Results-for-Third-Quarter-2010-on-October-26/default.aspxTue, 12 Oct 2010 12:01:00 -0400a4e2fdd0-caef-4ac2-9d0a-712c18da25bchttps://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Completes-Tender-Offer-for-ZymoGenetics-Inc-with-949-of-Shares-Tendered/default.aspxFri, 08 Oct 2010 08:27:00 -04008f3618b7-13a9-477c-8b63-170d5f3e8d39https://news.bms.com/news/details/2010/New-Data-on-Multiple-Bristol-Myers-Squibb-Compounds-to-be-Presented-at-AASLD-2010/default.aspxFri, 01 Oct 2010 14:16:00 -040096f44813-7e6c-4f9e-a1fd-ba91bdecc341https://news.bms.com/news/details/2010/ZymoGenetics-and-Bristol-Myers-Squibb-to-Present-PEG-Interferon-Lambda-Phase-2a-Interim-Clinical-Trial-Results-at-AASLD-2010/default.aspxFri, 01 Oct 2010 13:30:00 -040041273132-80e9-48b5-8850-c8e0a2243846https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Announces-Expiration-of-Hart-Scott-Rodino-Waiting-Period-for-Acquisition-of-ZymoGenetics-Inc/default.aspxTue, 28 Sep 2010 07:30:00 -0400970510fd-281c-4921-a8e6-1fc083b86524https://news.bms.com/news/details/2010/52-Week-Phase-3-Study-Found-Investigational-Drug-Dapagliflozin-Plus-Metformin-Similar-to-Glipizide-Plus-Metformin-in-Improving-Glycosylated-Hemoglobin-HbA1c-in-Adults-with-Type-2-Diabetes-Mellitus/default.aspxFri, 24 Sep 2010 05:31:00 -0400cc537569-4ff2-48f4-9691-2c557b79ff52https://news.bms.com/news/details/2010/24-Week-Phase-3-Study-Found-Investigational-Drug-Dapagliflozin-Improved-Glycosylated-Hemoglobin-HbA1c-When-Added-to-Glimepiride-in-Adults-with-Type-2-Diabetes-Mellitus/default.aspxMon, 20 Sep 2010 05:59:00 -0400caf5f6b0-924a-4cd5-b2d5-06f2b2418aeahttps://news.bms.com/news/details/2010/Bristol-Myers-Squibb-to-Present-at-the-UBS-Global-Life-Sciences-Conference/default.aspxMon, 13 Sep 2010 12:00:00 -04006c2f912a-550b-48e8-a778-a9cbd8d87fcdhttps://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Begins-Tender-Offer-to-Acquire-ZymoGenetics-Inc/default.aspxFri, 10 Sep 2010 07:30:00 -04006e44f36a-b99a-4969-b775-0fc48c23793dhttps://news.bms.com/news/details/2010/Bristol-Myers-Squibb-to-Present-at-the-Morgan-Stanley-Global-Healthcare-Unplugged-Conference/default.aspxWed, 08 Sep 2010 12:00:00 -040091bc210e-ab86-4eeb-a9cc-677330ddfd34https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-to-Acquire-ZymoGenetics/default.aspxTue, 07 Sep 2010 17:25:00 -040007d25526-cf5b-4721-920c-69bf73af59a8https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Announces-Dividend/default.aspxTue, 07 Sep 2010 16:42:00 -040042e00852-6a5c-46bf-95b4-5c924719c541https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-and-Pfizer-Inc-Evaluate-Unmet-Need-in-Patients-with-Atrial-Fibrillation/default.aspxWed, 25 Aug 2010 08:00:00 -0400496b52d7-2246-449b-bf11-87a7c1479863https://news.bms.com/news/details/2010/Ipilimumab-Receives-FDA-Priority-Review-Designation-for-Adult-Patients-with-Previously-Treated-Advanced-Melanoma/default.aspxWed, 18 Aug 2010 13:00:00 -0400f6ed075c-ea80-470c-932c-763ead986334https://news.bms.com/news/details/2010/Data-on-Investigational-Drug-Belatacept-in-Kidney-Transplant-Recipients-to-Be-Presented-at-23rd-International-Congress-of-The-Transplantation-Society/default.aspxSat, 14 Aug 2010 09:08:00 -040048ac7274-4282-44ac-ac1b-bbf7916ac053https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-and-ADAP-Crisis-Task-Force-Announce-Enhanced-Multi-year-Support-for-AIDS-Drug-Assistance-Programs-ADAPs-in-the-United-States/default.aspxWed, 11 Aug 2010 10:55:00 -04005ee2d656-191e-4fac-a630-6b982b0e903chttps://news.bms.com/news/details/2010/Bristol-Myers-Squibb-National-Survey-Finds-a-Disparity-Between-Health-Care-Providers-and-HIV-Positive-Patients-Perspectives-on-the-Emotional-Barriers-to-Seeking-HIV-Care-and-Treatment/default.aspxThu, 22 Jul 2010 12:00:00 -0400e5c95873-f5c7-432c-ba58-3640399144e2https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Second-Quarter-Featured-Robust-Clinical-Data-and-Double-Digit-EPS-Growth/default.aspxThu, 22 Jul 2010 07:30:00 -0400424d96b9-fe2e-4f8b-8db4-fa15251b5363https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-to-Announce-Results-for-Second-Quarter-2010-on-July-22/default.aspxTue, 13 Jul 2010 12:10:00 -0400980aaec3-4641-4c05-a050-6710ff6371a4https://news.bms.com/news/details/2010/SPRYCEL-dasatinib-Receives-FDA-Priority-Review-for-the-Treatment-of-Adult-Patients-with-Newly-Diagnosed-Chronic-Myeloid-Leukemia-CML-in-Chronic-Phase/default.aspxFri, 09 Jul 2010 17:51:00 -040063c0810a-cbb6-440a-bf84-56e89b34187dhttps://news.bms.com/news/details/2010/Dapagliflozin-As-Add-On-Therapy-To-Insulin-Demonstrated-Improved-Glycemic-Control-in-Patients-With-Type-2-Diabetes-Inadequately-Controlled-With-Insulin/default.aspxSat, 26 Jun 2010 14:45:00 -04005259a93b-23d5-47bf-9f83-ede9ac332a19https://news.bms.com/news/details/2010/52-Week-Study-Finds-ONGLYZA-saxagliptin-When-Added-to-Metformin-Was-Non-Inferior-to-Titrated-Glipizide-When-Added-to-Metformin-in-Reducing-Glycosylated-Hemoglobin-HbA1c-in-Adults-with-Type-2-Diabetes-Mellitus/default.aspxSat, 26 Jun 2010 10:00:00 -04009d6ffc88-dfdb-4e7b-88a9-e64683acc5cehttps://news.bms.com/news/details/2010/ONGLYZA-saxagliptin-With-Metformin-as-Initial-Combination-Therapy-Provided-76-Week-Long-Term-Glycemic-Control-in-Treatment-Nave-Adults-With-Type-2-Diabetes/default.aspxSat, 26 Jun 2010 09:30:00 -0400111a43fa-6b53-4d83-821f-b3573b267458https://news.bms.com/news/details/2010/Dapagliflozin-as-Monotherapy-Demonstrated-Improved-Glycemic-Control-in-Treatment-Nave-Adults-with-Type-2-Diabetes/default.aspxTue, 22 Jun 2010 10:00:00 -04007253fe99-96f5-4f94-bc65-28725e649699https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-to-Present-at-the-2010-Wells-Fargo-Securities-Health-Care-Conference/default.aspxWed, 16 Jun 2010 10:00:00 -0400e18070b7-f061-4732-a39a-68f316874e56https://news.bms.com/news/details/2010/New-Data-for-Investigational-Antibody-Blocking-IL-6-in-Rheumatoid-Arthritis-Patients-to-be-Presented-at-Annual-Congress-of-European-League-Against-Rheumatism/default.aspxTue, 15 Jun 2010 18:02:00 -040078751a55-ab9c-433b-8cad-4b691967906bhttps://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Signs-Agreements-with-ICON-and-PAREXEL-to-Support-Greater-Efficiencies-in-Clinical-Development/default.aspxMon, 14 Jun 2010 09:00:00 -04005fcd5717-2e0a-4849-9c12-57d5022a29dchttps://news.bms.com/news/details/2010/AVERROES-Study-of-Investigational-Agent-Apixaban-Closes-Early-Due-to-Clear-Evidence-of-Efficacy/default.aspxThu, 10 Jun 2010 16:30:00 -0400b24d4ebb-dc35-460f-bff5-24cffb2a3055https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Announces-Dividend-44469e14c/default.aspxWed, 09 Jun 2010 16:01:00 -04003360a319-d6b1-4033-a177-c3d10021ad30https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Posts-Data-Update-on-BMS-901608-an-anti-CS-1-Antibody-Under-Investigation-for-the-Treatment-of-Multiple-Myeloma/default.aspxTue, 08 Jun 2010 14:30:00 -040000726fd0-93e7-4a3f-8410-384eebfbc75fhttps://news.bms.com/news/details/2010/Bristol-Myers-Squibb-to-Present-at-the-Goldman-Sachs-Global-Health-Care-Conference/default.aspxTue, 08 Jun 2010 12:00:00 -0400490f771a-bae9-483b-a97a-3c66d74874f4https://news.bms.com/news/details/2010/Four-Year-Follow-Up-Data-for-SPRYCEL-dasatinib-Demonstrate-82-Percent-Overall-Survival-in-Patients-with-Chronic-Myeloid-Leukemia-Who-Failed-Gleevec1/default.aspxMon, 07 Jun 2010 15:00:00 -040020042a30-49de-44f9-a77a-5523d01c8036https://news.bms.com/news/details/2010/SPRYCEL-dasatinib-Demonstrates-Superior-Confirmed-Complete-Cytogenetic-Response-Rates-Compared-to-Gleevec-in-Study-of-Adult-Patients-with-Newly-Diagnosed-Chronic-Myeloid-Leukemia-in-Chronic-Phase/default.aspxSat, 05 Jun 2010 10:30:00 -0400ed3bf260-32ea-4896-84b1-7aa27ba008bchttps://news.bms.com/news/details/2010/Investigational-Compound-Ipilimumab-Demonstrates-Improved-Overall-Survival-in-Phase-3-Trial-of-Previously-Treated-Patients-with-Metastatic-Melanoma/default.aspxSat, 05 Jun 2010 10:30:00 -04004ff6d87e-333c-4f8c-a92c-eb335993077chttps://news.bms.com/news/details/2010/Bristol-Myers-Squibb-to-Hold-Investor-Teleconference-to-Discuss-ASCO-Highlights/default.aspxThu, 27 May 2010 10:00:00 -0400151b2aa7-e0dc-4dd6-b468-121b21b24540https://news.bms.com/news/details/2010/Controlled-Phase-2-Study-of-Ipilimumab-Shows-Clinical-Activity-in-Advanced-Non-Small-Cell-Lung-Cancer/default.aspxFri, 21 May 2010 11:10:00 -0400f0401d86-d020-4cf9-9ace-83ec860e7c10https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-to-Present-Data-on-13-Oncology-Compounds-During-2010-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting/default.aspxThu, 20 May 2010 18:00:00 -040097ba43df-e918-4d6f-a2a1-2203452f9eeehttps://news.bms.com/news/details/2010/Bristol-Myers-Squibb-to-Present-at-Citi-Global-Health-Care-Conference/default.aspxWed, 19 May 2010 12:00:00 -04005df261ed-7e76-48b8-9020-3653cd2560f1https://news.bms.com/news/details/2010/National-AIDS-Fund-Announces-Major-Grants-Enabling-More-Than-35-Community-Based-Organizations-to-Help-Improve-Access-to-HIV-Care-in-their-Communities/default.aspxThu, 13 May 2010 09:00:00 -0400dbdabe2f-fdb2-4a6c-9834-a59ac6476f54https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-to-Present-at-Bank-of-America-Merrill-Lynch-Health-Care-Conference/default.aspxMon, 10 May 2010 15:00:00 -0400f52a9703-f3bd-4552-b233-45991acaba0fhttps://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Announces-Authorization-of-Up-to-3-Billion-Share-Repurchase-Program/default.aspxTue, 04 May 2010 09:06:00 -0400dd850fdc-f1bb-46f4-bb0d-b5ed70b2eb60https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Receives-Complete-Response-Letter-from-FDA-for-Belatacept/default.aspxSat, 01 May 2010 18:54:00 -040047c90f4b-af3e-4fe7-9247-5b4fe3ee46bfhttps://news.bms.com/news/details/2010/Bristol-Myers-Squibb-to-Present-at-Deutsche-Bank-Conference/default.aspxFri, 30 Apr 2010 13:00:00 -040061f1a0a6-e460-4e46-8051-ec36a7876b5ahttps://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Invites-Public-to-Listen-to-Webcast-of-2010-Annual-Meeting/default.aspxFri, 30 Apr 2010 12:00:00 -0400b083c2ab-eba1-4356-8ffe-f79a7610a2a1https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Reports-Strong-Sales-Earnings-Performance-in-First-Quarter/default.aspxThu, 29 Apr 2010 07:30:00 -04000af38941-3a4a-4f5e-9cc5-81a06c4ce69fhttps://news.bms.com/news/details/2010/New-Data-on-the-Use-of-Investigational-Agent-Belatacept-in-Kidney-Transplant-Recipients-to-Be-Presented-at-2010-American-Transplant-Congress/default.aspxWed, 28 Apr 2010 09:00:00 -040017fb8a68-f0e3-4cbf-8c86-32092b3a5a65https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-to-Announce-Results-For-the-First-Quarter-2010-on-April-29/default.aspxThu, 22 Apr 2010 08:30:00 -0400d01af7e0-fff4-4879-a3be-9224777a0a8ahttps://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Receives-LEED-Silver-Certification-for-its-Biologics-Manufacturing-Facility-in-Devens-Massachusetts/default.aspxWed, 21 Apr 2010 12:01:00 -040041c3def3-951c-4820-b115-a63ce6a69eafhttps://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Posts-Data-Update-on-BMS-790052-an-NS5A-Inhibitor-in-Phase-2-Development-for-the-Treatment-of-Hepatitis-C/default.aspxSat, 17 Apr 2010 12:00:00 -040019f7feb5-aa8c-4386-a5b1-0813a1cdabd7https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-to-Post-Select-Investigational-Compound-Data-Updates-on-Company-Website/default.aspxFri, 16 Apr 2010 10:00:00 -040047398d35-82c0-4007-87e5-427d99330703https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Board-Elects-Charles-Bancroft-Chief-Financial-Officer/default.aspxThu, 08 Apr 2010 15:32:00 -040002128423-44b0-4e47-95e1-7d4379bd8fbchttps://news.bms.com/news/details/2010/US-Food-And-Drug-Administration-Accepts-New-Drug-Application-For-Once-Daily-Fixed-Dose-Combination-Of-Onglyza-Saxagliptin-And-Extended-Release-Metformin-For-The-Treatment-Of-Type-2-Diabetes-Mellitus-In-Adults/default.aspxWed, 17 Mar 2010 10:00:00 -04005f5c1e4f-37f0-4693-aea2-cb41004614b3https://news.bms.com/news/details/2010/Sanofi-aventis-and-Bristol-Myers-Squibb-Announce-Important-Updates-to-PLAVIX-US-Prescribing-Information/default.aspxFri, 12 Mar 2010 14:08:00 -0500891734f2-7976-4bde-bffb-a1a3402929c0https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-and-AstraZeneca-Announce-the-Commencement-of-the-Saxagliptin-Assessment-of-Vascular-Outcomes-Recorded-in-Patients-with-Diabetes-Mellitus-Trial-SAVOR-TIMI-53/default.aspxTue, 09 Mar 2010 10:00:00 -0500283e10ab-c2f8-45d8-81dc-e31849ae3d21https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-to-Present-at-Cowen-and-Company-Health-Care-Conference/default.aspxMon, 08 Mar 2010 13:00:00 -0500cb316960-8e14-4712-a0a3-2e6d199c1da3https://news.bms.com/news/details/2010/ADVANCE-2-Study-Results-Demonstrate-Investigational-Anticoagulant-Apixaban-Was-Statistically-Superior-to-Enoxaparin-in-the-Prevention-of-Venous-Thromboembolism-Following-Knee-Replacement-Surgery/default.aspxThu, 04 Mar 2010 19:30:00 -0500276c169d-c81c-41f0-beaa-3d1147e9c992https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-to-Highlight-Strong-Pipeline-and-Execution-of-BioPharma-Strategy-in-Meeting-with-Investment-Community/default.aspxThu, 04 Mar 2010 08:30:00 -050021c5845b-c6ee-4b03-93b6-207d824d3c67https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-and-Allergan-Enter-Global-Agreement-on-Investigational-Neuropathic-Pain-Medicine/default.aspxWed, 03 Mar 2010 08:30:00 -0500af5e682d-dd86-4ff9-b3ab-10cb158b9c73https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Announces-Dividend-48b0cb2ce/default.aspxTue, 02 Mar 2010 17:30:00 -05005e71cd15-e77d-43fd-b523-b2817feef53ehttps://news.bms.com/news/details/2010/Bristol-Myers-Squibb-Names-Lamberto-Andreotti-CEO-Effective-May-4-James-Cornelius-to-Retire-as-CEO-Remain-as-Chairman/default.aspxTue, 02 Mar 2010 17:00:00 -05009bba9bcf-5124-4552-a3f3-058c52502dcfhttps://news.bms.com/news/details/2010/FDA-Advisory-Committee-Recommends-Approval-of-Belatacept-an-Investigational-Agent-for-Prophylaxis-of-Acute-Rejection-in-De-Novo-Kidney-Transplant-Patients/default.aspxMon, 01 Mar 2010 20:49:00 -05005dd125cc-ef10-4f51-b7bb-1b2a0c03d739https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-to-Provide-Business-Update-to-Investment-Community-on-March-4/default.aspxMon, 22 Feb 2010 13:12:00 -05006831d84a-d8ae-47c9-a3cf-4ebd9cd0c374https://news.bms.com/news/details/2010/Strong-Operational-and-Strategic-Performance-in-Fourth-Quarter-Caps-Transformative-2009/default.aspxThu, 28 Jan 2010 08:30:00 -0500b3f093a9-2722-457e-aad2-a40964f314fdhttps://news.bms.com/news/details/2010/Bristol-Myers-Squibb-to-Present-at-JP-Morgan-Healthcare-Conference/default.aspxWed, 06 Jan 2010 10:00:00 -050066c9eb41-f0f3-411a-8795-117a593d5192https://news.bms.com/news/details/2010/Bristol-Myers-Squibb-to-Announce-Results-For-the-Fourth-Quarter-and-Full-Year-of-2009-on-January-28/default.aspxTue, 05 Jan 2010 10:00:00 -05005cb27a39-79a4-4395-83d4-7049b9393f9fhttps://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Updates-2009-Continuing-Operations-Financial-Guidance/default.aspxWed, 23 Dec 2009 09:31:00 -0500533cffb0-7036-4e50-9ef8-9fb11123ec91https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-and-Mead-Johnson-Announce-Final-Results-of-the-Exchange-Offer/default.aspxWed, 23 Dec 2009 09:30:00 -0500a3c5b6c6-953c-4c3c-b99d-213135aba086https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Announces-Dividend-Increase/default.aspxMon, 21 Dec 2009 17:01:00 -050016ac4ce6-c248-4142-8989-87e203fb3a4fhttps://news.bms.com/news/details/2009/Bristol-Myers-Squibb-and-Mead-Johnson-Announce-Preliminary-Results-of-the-Exchange-Offer/default.aspxFri, 18 Dec 2009 09:30:00 -0500c2d64ede-acc7-4c41-8d82-7f92887911d6https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Sets-Exchange-Ratio-of-06313-for-the-Exchange-Offer/default.aspxWed, 16 Dec 2009 09:30:00 -0500e0a09386-c1c6-448f-aef8-a56289c3c092https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Announces-Appointment-of-Charles-Bancroft-as-Acting-Chief-Financial-Officer/default.aspxMon, 14 Dec 2009 08:30:00 -05008040e70d-071f-4741-8f8f-6c26b25a1a16https://news.bms.com/news/details/2009/Facet-Biotech-and-Bristol-Myers-Squibb-Report-Promising-Phase-III-Interim-Data-for-Elotuzumab-in-Patients-with-Relapsed-Multiple-Myeloma/default.aspxMon, 07 Dec 2009 12:30:00 -050058a94267-11ec-41dc-960e-a79224ba4096https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-And-Pfizer-Announce-Plans-To-Submit-Regulatory-Filing-For-Apixaban-In-Europe/default.aspxFri, 04 Dec 2009 20:35:00 -05005fbe3237-0e5e-4294-aa36-4f8700a3645ehttps://news.bms.com/news/details/2009/Bristol-Myers-Squibb-and-Mead-Johnson-Announce-Amendment-and-Extension-of-Exchange-Offer/default.aspxFri, 04 Dec 2009 19:30:00 -05007d88a016-55cc-447a-9752-79cebaccf284https://news.bms.com/news/details/2009/New-Data-on-Bristol-Myers-Squibb-Oncology-Compounds-to-be-Featured-in-Oral-Presentations-at-51st-Annual-Meeting-of-the-American-Society-of-Hematology/default.aspxWed, 02 Dec 2009 14:34:00 -0500d9e1d1fa-4861-48da-b9e5-159d6b782d9ahttps://news.bms.com/news/details/2009/US-Food-and-Drug-Administration-Approves-ABILIFY-aripiprazole-for-the-Treatment-of-Irritability-Associated-with-Autistic-Disorder-in-Pediatric-Patients-Ages-6-to-17-Years/default.aspxFri, 20 Nov 2009 19:50:00 -05005fc9466b-8a21-449c-a97c-1fe54b4eb1b1https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Announces-Split-Off-of-Mead-Johnson/default.aspxSun, 15 Nov 2009 20:00:00 -05006df74fb4-1ce1-48a4-80e6-f1e9b115a2fahttps://news.bms.com/news/details/2009/Bristol-Myers-Squibb-to-Present-at-Credit-Suisse-Healthcare-Conference/default.aspxTue, 10 Nov 2009 10:00:00 -0500556cc035-63af-4d3a-abef-4e2e23d9b2a6https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-and-Alder-Biopharmaceuticals-Enter-Global-Agreement-on-Rheumatoid-Arthritis-Biologic/default.aspxTue, 10 Nov 2009 08:00:00 -05003569129a-d07c-4aef-89db-55b2e3644f3bhttps://news.bms.com/news/details/2009/FDA-Approves-Labeling-Update-for-REYATAZ-atazanavir-sulfate-Capsules-to-Include-96-Week-Data-for-Previously-Untreated-HIV-1-Infected-Adult-Patients/default.aspxThu, 05 Nov 2009 19:09:00 -0500226234af-4c27-4044-a138-87069accea24https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-and-ZymoGenetics-Present-Final-Phase-1b-Results-for-PEG-Interferon-Lambda-in-Hepatitis-C/default.aspxSat, 31 Oct 2009 18:30:00 -0400a1a737d1-b240-4ede-ba72-eb00941720cbhttps://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Donation-to-Benefit-Students-at-The-Pennington-School-and-Beyond/default.aspxThu, 29 Oct 2009 10:00:00 -040056c3f8e8-5c07-44f6-9230-1bf5c40d15fdhttps://news.bms.com/news/details/2009/Medarex-Inc-Announces-Expiration-of-Offer-to-Repurchase-its-225-Convertible-Senior-Notes-due-May-15-2011/default.aspxMon, 26 Oct 2009 10:00:00 -040038fe2991-e965-423c-9fc2-d5f0f7c43c82https://news.bms.com/news/details/2009/Exelixis-and-Bristol-Myers-Squibb-Report-New-Phase-2-Data-for-XL184-in-Patients-With-the-Most-Common-and-Aggressive-Form-of-Brain-Cancer/default.aspxFri, 23 Oct 2009 18:40:00 -0400304e51dd-88a0-4d87-94eb-a5669f45f454https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Achieves-Strong-Sales-Earnings-Performance-in-Third-Quarter/default.aspxThu, 22 Oct 2009 07:30:00 -0400147c9436-ad82-497f-a270-ee79fc872bcehttps://news.bms.com/news/details/2009/New-Data-Describe-Safety-of-Subcutaneous-Administration-of-ORENCIA-abatacept-For-Patients-with-Moderate-to-Severe-Rheumatoid-Arthritis/default.aspxTue, 20 Oct 2009 08:44:00 -040015d662b0-6295-45a8-bd29-8233279d98f7https://news.bms.com/news/details/2009/ORENCIA-abatacept-Demonstrated-Sustained-Clinical-Response-in-a-Study-of-Adult-Patients-with-Moderate-to-Severe-Early-Rheumatoid-Arthritis-Less-Than-Two-Years-Duration/default.aspxMon, 19 Oct 2009 08:00:00 -040069f33f53-bf2a-4a43-8c60-5508d5895aafhttps://news.bms.com/news/details/2009/ONGLYZA-saxagliptin-Receives-Marketing-Authorisation-In-Europe-For-The-Treatment-Of-Type-2-Diabetes/default.aspxMon, 05 Oct 2009 16:15:00 -04005e7378a5-97e4-4d9d-b018-57ab48e3facehttps://news.bms.com/news/details/2009/Study-Finds-That-ONGLYZA-saxagliptin-When-Added-To-Metformin-Was-Non-Inferior-To-JANUVIA-SITAGLIPTIN-When-Added-To-Metformin-In-Reducing-Hemoglobin-HbA1c-In-Adults-With-Type-2-Diabetes-Mellitus/default.aspxMon, 05 Oct 2009 09:39:00 -0400b5be2753-c0b5-4341-ad55-e186ba843a85https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-to-Announce-Results-for-the-Third-Quarter-of-2009-on-October-22/default.aspxFri, 02 Oct 2009 10:00:00 -04002e6d6fd4-e4da-4928-b166-5669598963c0https://news.bms.com/news/details/2009/Dapagliflozin-Study-Demonstrated-Significantly-Improved-Glycemic-Control-and-Weight-Reduction-in-Type-2-Diabetes-Patients-Inadequately-Controlled-with-Metformin/default.aspxFri, 02 Oct 2009 05:01:00 -0400b1d2ecaf-21d1-498e-be0d-2f8a36a90b29https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-and-ZymoGenetics-to-Present-Final-Phase-Ib-Data-on-PEG-Interferon-Lambda-at-AASLD-2009/default.aspxThu, 01 Oct 2009 10:45:00 -04003626e0b6-a7fb-4595-8529-7ca0cc7869aahttps://news.bms.com/news/details/2009/Medarex-Inc-Issues-Notice-of-Change-in-Control-to-Holders-of-its-Convertible-Notes/default.aspxThu, 24 Sep 2009 14:41:00 -04006cef257c-b3df-4e39-add2-c3702b8b5023https://news.bms.com/news/details/2009/Data-Presented-from-Two-Phase-3-ERBITUX-Studies-in-First-Line-Metastatic-Colorectal-Cancer-Patients-at-Joint-15th-European-Cancer-Organisation-and-34th-European-Society-for-Medical-Oncology-Multidisciplinary-Congress/default.aspxWed, 23 Sep 2009 08:15:00 -04000511374e-2459-43dc-bb30-4c74914eaafehttps://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Company-Announces-Sale-to-Taisho-Pharmaceutical-Co-Ltd-of-Its-OTC-Assets-in-Asia-Pacific-Excl-China--Japan-and-Shares-in-PT-Bristol-Myers-Squibb-Indonesia-Tbk/default.aspxTue, 15 Sep 2009 23:00:00 -040069924245-8ddd-4412-8e43-5b6d50dfbf84https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-to-Present-at-Morgan-Stanley-Global-Healthcare-Unplugged-Conference/default.aspxFri, 11 Sep 2009 09:45:00 -0400b8878318-94fd-45e7-9ca3-4908fc026928https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Announces-Dividend/default.aspxWed, 09 Sep 2009 16:05:00 -040038af4564-02ec-4d13-a2e3-a3bd6f80be76https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Announces-Acceptance-of-Submission-for-Belatacept-Biologic-License-Application/default.aspxThu, 03 Sep 2009 17:03:00 -04002c9828cf-2205-457f-ad6e-a6c6287b1a2dhttps://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Completes-Acquisition-of-Medarex-Inc/default.aspxTue, 01 Sep 2009 17:11:00 -0400c19da6d2-70c1-42d3-b868-77fbeb57122dhttps://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Completes-Tender-Offer-for-Medarex-Inc/default.aspxTue, 01 Sep 2009 08:10:00 -04009c1c7289-cc4c-4b94-a068-f6a4bb837cc4https://news.bms.com/news/details/2009/New-Large-Scale-Global-Study-Provides-Additional-Information-About-an-Intensified-Dose-Regimen-of-Plavix-in-Acute-Coronary-Syndrome-Patients-Undergoing-Angioplasty/default.aspxSun, 30 Aug 2009 02:00:00 -0400cf72c69a-b4b3-491c-babf-2d3acc931269https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Completes-Initial-Tender-Offer-for-Medarex-Inc-with-877-of-Shares-Tendered-Announces-Subsequent-Offering-Period/default.aspxThu, 27 Aug 2009 08:10:00 -04007b39cb41-2afe-4f19-8262-8ecb8f56a80fhttps://news.bms.com/news/details/2009/Updated-ORENCIA-abatacept-Labeling-Includes-Data-to-Support-Earlier-Use-in-Adult-Patients-with-Moderate-to-Severe-Rheumatoid-Arthritis/default.aspxWed, 26 Aug 2009 09:00:00 -0400b46c8e2b-0d91-4b77-a740-e25de2f0e116https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Extends-Tender-Offer-for-Medarex-Inc/default.aspxThu, 20 Aug 2009 16:53:00 -0400044e523c-7a54-4624-8e69-e62806c2235dhttps://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Announces-Preliminary-Court-Approval-of-Derivative-Settlement/default.aspxThu, 20 Aug 2009 09:10:00 -04009ba3e00a-cddf-4011-b6b3-a39a59008bf0https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Announces-Expiration-of-Hart-Scott-Rodino-Review-Period-for-Acquisition-of-Medarex-Inc/default.aspxWed, 12 Aug 2009 08:30:00 -04004b7d83df-258f-4fd0-b877-c95a558c2ceehttps://news.bms.com/news/details/2009/US-Food-and-Drug-Administration-Approves-ONGLYZA-saxagliptin-for-the-Treatment-of-Type-2-Diabetes-Mellitus-in-Adults-1/default.aspxFri, 31 Jul 2009 19:18:00 -040060a4ce00-73ab-4b61-a017-fa2a550cb4cdhttps://news.bms.com/news/details/2009/US-Food-and-Drug-Administration-Approves-ONGLYZA-saxagliptin-for-the-Treatment-of-Type-2-Diabetes-Mellitus-in-Adults/default.aspxFri, 31 Jul 2009 19:18:00 -0400c32bf3a9-f432-4c55-9cfd-7e0b8ce9149bhttps://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Begins-Tender-Offer-to-Acquire-Medarex-Inc/default.aspxTue, 28 Jul 2009 05:00:00 -0400d870a00e-fbbd-46e4-b12e-12595f12759fhttps://news.bms.com/news/details/2009/Excellent-Performance-Highlights-Second-Quarter-for-Bristol-Myers-Squibb/default.aspxThu, 23 Jul 2009 07:30:00 -0400791686bb-5a5d-410c-9b88-c1c479d31d33https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-to-Acquire-Medarex/default.aspxWed, 22 Jul 2009 11:04:00 -0400c13fc95f-97bb-4412-9ad7-24f7dbba5428https://news.bms.com/news/details/2009/ImClone-Systems-and-Bristol-Myers-Squibb-Announce-Revisions-to-ERBITUX-cetuximab-US-Product-Labeling-for-Metastatic-Colorectal-Cancer/default.aspxMon, 20 Jul 2009 07:30:00 -0400d7847068-841c-4a61-b6e5-eecdda83027chttps://news.bms.com/news/details/2009/Bristol-Myers-Squibbs-SECURE-THE-FUTURE-Announces-13-Million-in-New-Grants-to-Enhance-Community-Based-HIVAIDS-Care-and-Support-in-Africa/default.aspxMon, 20 Jul 2009 04:00:00 -04007809c6fc-378a-4750-808f-514e33d7aa62https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-to-Announce-Results-for-the-Second-Quarter-and-First-Six-Months-of-2009-on-July-23/default.aspxThu, 09 Jul 2009 16:00:00 -040070063c6a-4e16-4543-9df0-105846cdeab2https://news.bms.com/news/details/2009/New-Online-Resource-Launches-For-Patients-With-Chronic-Myeloid-Leukemia/default.aspxMon, 06 Jul 2009 09:00:00 -0400ddeb78ae-12db-4804-acfe-c1e938810f5ahttps://news.bms.com/news/details/2009/ONGLYZA-Saxagliptin-Receives-Positive-Opinion-in-Europe-for-the-Treatment-of-Type-2-Diabetes/default.aspxThu, 25 Jun 2009 12:04:00 -04000d92385f-710a-48e5-bf18-c31e7d9d38dfhttps://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Announces-Dividend-914a07709/default.aspxWed, 10 Jun 2009 16:00:00 -0400147bc99e-d652-4318-a7cc-51e29361e5a9https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-to-Present-at-Goldman-Sachs-Global-Healthcare-Conference/default.aspxWed, 10 Jun 2009 09:00:00 -0400b76e4442-d773-420c-b84a-2a722e13f7b6https://news.bms.com/news/details/2009/Dapagliflozin-Study-Demonstrated-Improved-Glycemic-Control-In-Type-2-Diabetes-Patients-Treated-With-High-Doses-of-Insulin-and-Common-Oral-Anti-Diabetic-Medicines/default.aspxSat, 06 Jun 2009 11:00:00 -04006531f08e-d3b4-403f-a0df-c7214882d1e3https://news.bms.com/news/details/2009/Interim-Analysis-of-Long-Term-Data-with-ONGLYZA-saxagliptin-When-Added-to-Metformin-in-People-with-Inadequately-Controlled-Type-2-Diabetes-Presented-at-ADA-Annual-Scientific-Sessions/default.aspxSat, 06 Jun 2009 11:00:00 -04009641f420-c127-4435-9b6b-a4a7a0248dd0https://news.bms.com/news/details/2009/Exelixis-and-BMS-Report-Phase-2-Data-to-Be-Presented-at-ASCO-for-XL184-in-Patients-with-Previously-Treated-Glioblastoma-Multiforme/default.aspxSun, 31 May 2009 09:05:00 -04003cb30283-f0ff-46c1-a7f7-b7775bb1e6f6https://news.bms.com/news/details/2009/Results-from-Three-Phase-2-Studies-Reported-a-Two-Year-Survival-Rate-Ranging-from-30-to-42-Percent-in-Metastatic-Melanoma-Patients-Treated-with-Ipilimumab-10-mgkg/default.aspxSun, 31 May 2009 08:00:00 -0400803b43d3-bbd4-4a40-bb68-6bd441739ae3https://news.bms.com/news/details/2009/First-Phase-III-Data-on-Innovative-Compound-for-Solid-Organ-Transplantation-To-be-Featured-at-American-Transplant-Congress/default.aspxThu, 28 May 2009 14:00:00 -04001a30fb8d-12e2-4d04-b7c8-3fdeb43d301fhttps://news.bms.com/news/details/2009/FDA-Grants-Full-Approval-for-SPRYCEL-dasatinib-for-the-Treatment-of-Adults-with-Chronic-Myeloid-Leukemia-Who-Are-Resistant-or-Intolerant-to-Prior-Therapies-Including-Gleevec/default.aspxTue, 26 May 2009 15:00:00 -0400f776bf0d-4310-46c7-8347-9a26943e5326https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-to-Present-at-Bernstein-Strategic-Decisions-Conference/default.aspxTue, 26 May 2009 13:00:00 -0400b326ff51-288e-4c04-8de8-8ece80dacc21https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Welcomes-Help-is-Here-Express-to-New-Brunswick/default.aspxFri, 22 May 2009 10:56:00 -04004b739ee1-7ba8-4067-b526-d70ebeff543dhttps://news.bms.com/news/details/2009/Bristol-Myers-Squibb-to-Present-at-Deutsche-Bank-Healthcare-Conference/default.aspxMon, 18 May 2009 15:00:00 -040068fc11fa-2c55-4b26-b41e-18351ccc074ehttps://news.bms.com/news/details/2009/SPRYCEL-Dasatinib-Shows-Potential-as-Treatment-for-Prostate-Cancer/default.aspxThu, 14 May 2009 18:00:00 -04000e89a37f-aa84-476b-b87c-373e0c29ad4dhttps://news.bms.com/news/details/2009/Bristol-Myers-Squibb-to-Present-at-Bank-of-America-and-Merrill-Lynch-Health-Care-Conference/default.aspxTue, 12 May 2009 09:00:00 -040078a547c8-30c4-45a6-a605-91b1fdaaddbehttps://news.bms.com/news/details/2009/Bristol-Myers-Squibb-to-Present-at-Bernstein-Pharmaceutical-Emerging-Markets-Conference/default.aspxTue, 05 May 2009 10:00:00 -04005afde504-818c-40af-b56f-2eaa09637053https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Invites-Public-to-Listen-to-Webcast-of-2009-Annual-Meeting/default.aspxWed, 29 Apr 2009 10:30:00 -0400df1ff813-e8c6-475d-871f-eac09f9e7bc1https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Reports-Excellent-First-Quarter-Financial-Results-Delivers-on-Two-Significant-Strategic-Initiatives/default.aspxTue, 28 Apr 2009 07:30:00 -0400a76e0713-8293-4f51-835d-0454139c3afahttps://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Announces-Call-for-Entries-for-the-2009-REYATAZ-atazanavir-sulfate-Fight-HIV-Your-Way-Contest/default.aspxMon, 27 Apr 2009 11:00:00 -04003b852656-8d11-4ee6-a2c7-67607dbcf3f9https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-and-ZymoGenetics-Present-Positive-4-week-Results-of-PEG-Interferon-lambda-with-Ribavirin-in-Hepatitis-C/default.aspxFri, 24 Apr 2009 06:00:00 -0400a5ff77ca-40ed-43a1-8a00-5465cafbbb76https://news.bms.com/news/details/2009/US-Food-and-Drug-Administration-Extends-Review-Timeline-for-ONGLYZA-saxagliptin-New-Drug-Application/default.aspxThu, 23 Apr 2009 08:00:00 -0400dfcf7362-db2b-4c7f-84ae-ee7636053b3ahttps://news.bms.com/news/details/2009/Bristol-Myers-Squibb-to-Announce-Results-for-the-First-Quarter-of-2009-on-April-28/default.aspxMon, 20 Apr 2009 16:09:00 -040032245287-ba94-4bb1-bedb-997c88c70ad9https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Announces-Extension-of-US-Agreement-for-ABILIFY-and-Establishment-of-an-Oncology-Collaboration-with-Otsuka/default.aspxMon, 06 Apr 2009 04:00:00 -04005498ec9e-72c2-4e24-89fc-fbe7b7976318https://news.bms.com/news/details/2009/ONGLYZA-saxagliptin-Cardiovascular-Profile-Acceptable-According-to-FDA-Advisory-Committee/default.aspxWed, 01 Apr 2009 18:19:00 -0400f367a7ba-19e2-44af-9b0c-7996d0aa6022https://news.bms.com/news/details/2009/Plavix-Plus-Aspirin-More-Effective-Than-Aspirin-Alone-in-Preventing-Major-Vascular-Events-in-Patients-with-Atrial-Fibrillation-Who-Cannot-Take-Oral-Anticoagulants/default.aspxTue, 31 Mar 2009 09:23:00 -0400d60563ef-35ee-42fb-a469-9f01c930cc1chttps://news.bms.com/news/details/2009/Dapagliflozin-Clinical-Trial-Results-Indicate-Improvement-In-Key-Glycemic-Measures-In-Treatment-Nave-Type-2-Diabetes-Patients/default.aspxFri, 27 Mar 2009 11:00:00 -0400fe4d7a74-ce1f-4136-bc5d-650ac9cffaf6https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-to-Present-at-Healthcare-Conference/default.aspxMon, 16 Mar 2009 16:46:00 -0400fc1a6c01-3632-4407-8a8c-14336d8b9d66https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-to-Present-at-Healthcare-Conference-280cdd503/default.aspxMon, 09 Mar 2009 17:50:00 -0400bf8f0fa9-ca39-4734-aa88-14603ebe3fc6https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Enters-Global-Collaboration-with-Nissan-Chemical-and-Teijin-Pharma-on-Novel-Atrial-Fibrillation-Compound/default.aspxWed, 04 Mar 2009 21:00:00 -05008613694f-ca97-485b-bb64-02cec6c2bdbehttps://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Announces-Dividend-65a7771fd/default.aspxTue, 03 Mar 2009 18:00:00 -0500f862c755-8c79-4496-95bf-aa4dbfe4d1e0https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Announces-Organizational-Changes-Names-Four-to-Companys-Executive-Committee/default.aspxTue, 03 Mar 2009 17:07:00 -0500b450205b-c674-4025-9f13-f2f6853326dahttps://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Names-Andreotti-President-and-Chief-Operating-Officer/default.aspxTue, 03 Mar 2009 17:01:00 -05006efe3727-c0a4-4cab-b04a-52fc9c328f43https://news.bms.com/news/details/2009/ImClone-Systems-and-Bristol-Myers-Squibb-Update-Status-of-First-Line-Squamous-Cell-Carcinoma-of-the-Head-and-Neck-Supplemental-Biologics-Application-for-ERBITUX-in-US/default.aspxMon, 02 Mar 2009 11:45:00 -0500f5845f15-10c6-4c5c-a8ec-636121ae8f52https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Foundation-Announces-Funding-of-More-Than-117-Million-to-Bridge-Gaps-in-Hepatitis-C-Awareness-Prevention-and-Care-in-China-India-and-Taiwan/default.aspxFri, 13 Feb 2009 01:01:00 -05008cf33acd-273a-4d70-8a49-914ee76f241fhttps://news.bms.com/news/details/2009/Bristol-Myers-Squibb-Statement-on-Mead-Johnson-Nutrition-Company-IPO/default.aspxWed, 11 Feb 2009 11:06:00 -0500991b8d56-00b6-434f-a9f6-4b9fb14a67d5https://news.bms.com/news/details/2009/Strong-Fourth-Quarter-Supports-Excellent-2008-for-Bristol-Myers-Squibb/default.aspxTue, 27 Jan 2009 08:30:00 -0500111ad7ae-25f5-4f12-aa5f-02c01c026acfhttps://news.bms.com/news/details/2009/ImClone-Systems-and-Bristol-Myers-Squibb-Update-the-Status-of-Non-Small-Cell-Lung-Cancer-Supplemental-Biologics-Application-Submission-for-ERBITUX/default.aspxFri, 23 Jan 2009 16:29:00 -0500a58bc368-7967-4d88-ab1a-4a2b4db99a27https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-To-Announce-Results-For-The-Fourth-Quarter-And-Full-Year-Of-2008-On-January-27/default.aspxFri, 16 Jan 2009 10:20:00 -0500ddd2f49f-0aef-4ad7-9bb5-fa842cd67f70https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-to-Present-at-Healthcare-Conference-5d25e9656/default.aspxTue, 13 Jan 2009 10:00:00 -05005894d5b5-8ef8-418b-b110-cae1cc03b270https://news.bms.com/news/details/2009/Bristol-Myers-Squibb-and-ZymoGenetics-Enter-Global-Collaboration-on-Novel-Hepatitis-C-Compound/default.aspxMon, 12 Jan 2009 17:00:00 -050028ab772a-f6d8-41f5-8cd2-1502b1b71be6https://news.bms.com/news/details/2009/Howard-Feldman-Joins-Bristol-Myers-Squibb-as-Vice-President-and-Therapeutic-Area-Head-Global-Clinical-Research-Neuroscience/default.aspxThu, 08 Jan 2009 10:00:00 -050079afe751-e3e2-4669-9907-efc56a5f2119https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Announces-Dividend/default.aspxThu, 18 Dec 2008 18:15:00 -0500f1179430-0b71-4546-b1da-386458d866cdhttps://news.bms.com/news/details/2008/Exelixis-And-Bristol-Myers-Squibb-Sign-New-Collaboration-Agreement-To-Develop-Novel-Cardiovascular-Disease-Treatments-Focus-on-LXR-Targeted-Therapies-for-Atherosclerosis-and-Coronary-Artery-Disease/default.aspxMon, 15 Dec 2008 22:39:00 -05004df6ed7c-f405-42f8-8204-d4b90d77e374https://news.bms.com/news/details/2008/New-Data-Demonstrate-Significant-Improvement-in-Progression-Free-Survival-for-Triple-Negative-Metastatic-Breast-Cancer-Patients-Treated-with-IXEMPRA-Plus-Capecitabine/default.aspxSat, 13 Dec 2008 00:00:00 -0500ff09376d-d2f8-41b6-b680-0fd498dc5e9dhttps://news.bms.com/news/details/2008/Sanofi-Aventis-and-Bristol-Myers-Squibb-Prevail-before-the-US-Court-of-Appeals-for-the-Federal-Circuit-in-the-US-Plavix-Patent-Infringement-Case/default.aspxFri, 12 Dec 2008 13:30:00 -05008cf4e81d-6afe-458a-a72e-cd1154029294https://news.bms.com/news/details/2008/New-Jersey-Youth-Get-Rapid-Access-to-Mental-Health-Services/default.aspxFri, 12 Dec 2008 09:00:00 -05000d820b9b-d7d1-4d59-9ef4-f5cfed4aa3d8https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-and-Exelixis-Enter-Global-Collaboration-on-Two-Novel-Cancer-Programs/default.aspxFri, 12 Dec 2008 06:54:00 -050091874e71-6bdc-4d87-9743-5bdc5dfd8d94https://news.bms.com/news/details/2008/ERBITUX-Supplemental-Biologics-License-Application-for-Advanced-Non-Small-Cell-Lung-Cancer-Submitted-to-US-Food-and-Drug-Administration/default.aspxMon, 08 Dec 2008 11:05:00 -0500f8b6db87-7d80-4ec4-ad58-2f89b30f19fchttps://news.bms.com/news/details/2008/Bristol-Myers-Squibb-and-AstraZeneca-Announce-Expansion-of-Worldwide-Collaboration-to-Develop-and-Commercialize-Dapagliflozin-in-Japan/default.aspxMon, 08 Dec 2008 08:30:00 -0500ba8b8e8a-9cc9-4597-a42d-266fe0d99da5https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-to-Present-at-Healthcare-Conference/default.aspxThu, 13 Nov 2008 10:00:00 -0500d475ca76-a155-4c9a-8cd2-aead44a54c72https://news.bms.com/news/details/2008/Rationale-and-Design-of-CURRENT-OASIS-7-Study-Published-in-American-Heart-Journal/default.aspxThu, 06 Nov 2008 03:00:00 -05008dfa5a96-e713-4dc3-af25-9cb94c283091https://news.bms.com/news/details/2008/New-Data-Suggest-Long-Term-Treatment-with-BARACLUDER-entecavir-May-Reduce-Liver-Damage-Caused-by-Chronic-Hepatitis-B/default.aspxSun, 02 Nov 2008 12:00:00 -050019b0b5c4-b223-4946-9c35-76a2309d447ahttps://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Foundation-to-Award-14-Million-in-Grants-to-Bridge-Gaps-in-Hepatitis-C-Awareness-Prevention-and-Care-in-Asia/default.aspxFri, 31 Oct 2008 11:00:00 -0400387efac8-dd99-4de4-953c-3ae8d57c946dhttps://news.bms.com/news/details/2008/ERBITUXR-Supplemental-Biologics-License-Application-for-First-Line-Recurrent-or-Metastatic-Head-and-Neck-Cancer-Accepted-for-Priority-Review-by-US-Food-and-Drug-Administration/default.aspxThu, 30 Oct 2008 17:55:00 -040049f388d9-f864-4e91-8f5d-df6ee47351d9https://news.bms.com/news/details/2008/Use-of-Investigational-Agent-Entecavir-Demonstrated-Statistically-Significant-Improvement-in-Liver-Histology-and-Viral-Suppression-Compared-to-Lamivudine-in-Chronically-Infected-Hepatitis-B-E-Antigen-HBeAg-Positive-Patients/default.aspxWed, 29 Oct 2008 09:00:00 -040028113378-1ada-4618-826a-a81329b42f02https://news.bms.com/news/details/2008/Data-Demonstrate-ORENCIAR-abatacept-Improves-Health-Related-Quality-of-Life-Pain-and-Sleep-Quality-in-Children-With-Juvenile-Idiopathic-Arthritis/default.aspxMon, 27 Oct 2008 21:39:00 -04000fe11151-13cd-4e99-9a74-504442e229f6https://news.bms.com/news/details/2008/Study-Results-Demonstrate-More-Patients-With-Early-Erosive-Rheumatoid-Arthritis-Treated-With-ORENCIAR-abatacept-and-Methotrexate-MTX-Achieved-DAS28-CRP-Defined-Remission-Compared-to-MTX-Alone/default.aspxMon, 27 Oct 2008 19:45:00 -0400540da73d-c3f4-4238-a6fd-2cf71d8e0348https://news.bms.com/news/details/2008/96-Week-Data-From-CASTLE-Study-Continue-to-Show-Similar-Efficacy-Between-Once-Daily-REYATAZR-atazanavir-sulfateRitonavir-and-Twice-Daily-LopinavirRitonavir-In-Previously-Untreated-HIV-1-Infected-Adult-Patients/default.aspxSun, 26 Oct 2008 13:30:00 -0400fef5ace1-f5f5-4c63-8b25-08217d834821https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Continues-Excellent-Financial-Performance-Led-By-Double-Digit-Global-Net-Sales-Growth-and-Strong-Earnings-Results/default.aspxThu, 23 Oct 2008 07:30:00 -0400156bcdce-2604-4558-a1d5-69974af2a848https://news.bms.com/news/details/2008/Study-Published-in-New-England-Journal-of-Medicine-Shows-K-ras-Gene-Mutation-Status-May-Affect-Response-to-ERBITUXR-Treatment/default.aspxWed, 22 Oct 2008 17:00:00 -0400ebc1b6da-13bd-465f-8c2f-aac71e37862bhttps://news.bms.com/news/details/2008/Bristol-Myers-Squibb-to-Announce-Results-for-the-Third-Quarter-of-2008-on-October-23/default.aspxTue, 14 Oct 2008 16:15:00 -040066378b1e-844f-4895-b266-628ebff9bd74https://news.bms.com/news/details/2008/Introducing-Pediatric-Care-OnlineTM/default.aspxFri, 10 Oct 2008 10:30:00 -0400ac49537b-b9e6-4823-9918-da01769d146dhttps://news.bms.com/news/details/2008/Bristol-Myers-Squibb-and-Capital-Health-System-to-Host-Health-Fair-and-Visits-by-Hollywood-Star-Joey-Pantoliano-and-Help-Is-Here-Express-Bus-to-Raise-Awareness-about-Chronic-Diseases-and-Prescription-Drug-Assistance/default.aspxFri, 10 Oct 2008 08:00:00 -0400ec014b5b-0fe7-49cf-a1b4-ea58befd039chttps://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Comments-on-Eli-Lilly-as-New-Erbitux-Marketing-Partner/default.aspxMon, 06 Oct 2008 11:41:00 -0400f37e9b7c-0b61-4fe8-a296-405f6b3f9411https://news.bms.com/news/details/2008/BIPAI-Opens-New-Childrens-AIDS-Center-in-Uganda/default.aspxThu, 02 Oct 2008 10:00:00 -0400668f2723-d5d1-4391-b67a-62e155c7337fhttps://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Appoints-Christopher-Perley-as-Devens-General-Manager/default.aspxThu, 02 Oct 2008 08:00:00 -04003fb1130d-cf3c-4d70-a5b8-da67462fa58ehttps://news.bms.com/news/details/2008/US-Food--Drug-Administration-Approved-the-use-of-REYATAZR-atazanavir-sulfate-Boosted-with-Ritonavir-in-Combination-Therapy-for-Previously-Untreated-HIV-1-Infected-Adult-Patients/default.aspxWed, 01 Oct 2008 18:01:00 -04005595e4bd-f47e-4e3e-8346-dd2450841d8fhttps://news.bms.com/news/details/2008/Bristol-Myers-Squibb-to-Commence-Cash-Tender-Offer-for-ImClone-Systems-at-6200-per-share/default.aspxMon, 22 Sep 2008 19:01:00 -040090402e11-33f0-4d59-b8be-5b909a9edc10https://news.bms.com/news/details/2008/ERBITUXR-Five-Year-Data-Show-Significant-Improvement-in-Overall-Survival-for-Patients-with-Locally-or-Regionally-Advanced-Head-and-Neck-Cancer/default.aspxMon, 22 Sep 2008 15:00:00 -0400daa64e96-41eb-4313-a61d-9e3775650a5chttps://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Announces-Filing-of-IPO-Registration-Statement-for-Mead-Johnson-Nutrition-Company/default.aspxMon, 15 Sep 2008 17:16:00 -04003a629d9b-ca90-4c34-948f-f8509f0e05d8https://news.bms.com/news/details/2008/Updated-Survival-Data-from-Three-Phase-2-Ipilimumab-Studies-Showed-Almost-Half-of-Previously-Treated-Metastatic-Melanoma-Patients-Alive-Beyond-One-Year/default.aspxMon, 15 Sep 2008 10:00:00 -040025ae9cc4-2543-433f-876f-c76832afc509https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-to-Present-at-Healthcare-Conference-5029a1d2b/default.aspxMon, 15 Sep 2008 09:00:00 -0400d7c3e012-0b26-406a-8b61-c84d70b84af8https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Submits-Letter-to-ImClone-Board-of-Directors/default.aspxThu, 11 Sep 2008 10:54:00 -04000b1edafb-f341-4764-8b55-346497471019https://news.bms.com/news/details/2008/Study-Published-in-New-England-Journal-of-Medicine-Shows-ERBITUXR-Improved-Survival-in-First-Line-Recurrent-AndOr-Metastatic-Head-and-Neck-Cancer/default.aspxWed, 10 Sep 2008 17:02:00 -0400f7943d53-4b62-4fab-80c6-f6873aec8826https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Announces-Dividend-a78549fb3/default.aspxTue, 09 Sep 2008 16:15:00 -0400f8b57258-cb75-4103-ae91-a238227ecc06https://news.bms.com/news/details/2008/ONGLYZATM-saxagliptin-With-Metformin-as-Initial-Combination-Therapy-Significantly-Lowered-A1C-and-Demonstrated-Significant-Improvements-Across-Key-Measures-of-Glucose-Control-in-Treatment-Nave-People-With-Type-2-Diabetes/default.aspxTue, 09 Sep 2008 08:00:00 -040088187bae-bdba-4890-9678-cb108cacdf00https://news.bms.com/news/details/2008/ONGLYZATM-saxagliptin-With-Metformin-as-Initial-Combination-Therapy-Significantly-Lowered-A1C-and-Demonstrated-Significant-Improvements-Across-Key-Measures-of-Glucose-Control-in-Treatment-Naive-People-With-Type-2-Diabetes/default.aspxTue, 09 Sep 2008 06:01:00 -040027b5149b-56ba-4f26-a6f1-2f2d8a6439a1https://news.bms.com/news/details/2008/ONGLYZATM-saxagliptin-Demonstrated-Significant-Improvements-Across-Key-Measures-of-Glucose-Control-When-Added-to-a-Sulfonylurea-or-Thiazolidinedione-in-People-With-Inadequately-Controlled-Type-2-Diabetes/default.aspxMon, 08 Sep 2008 07:00:00 -04001b87de79-7e39-4052-a874-2cf461e9c363https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-and-AstraZeneca-to-Hold-Investor-Teleconference-to-Discuss-EASD-Highlights/default.aspxWed, 03 Sep 2008 09:15:00 -040041f1ee08-cf2d-4d65-9018-c118ac9beec8https://news.bms.com/news/details/2008/New-Data-is-Presented-on-Investigational-Oral-Anticoagulant-Apixaban-in-Acute-Coronary-Syndrome-Patients/default.aspxTue, 02 Sep 2008 08:00:00 -0400c9d882a5-9f74-436b-92a5-f24004ef7e2chttps://news.bms.com/news/details/2008/Bristol-Myers-Squibb-to-Hold-Investor-Teleconference-to-Discuss-ESC-Highlights/default.aspxThu, 28 Aug 2008 12:30:00 -0400f40880d3-9899-452d-8904-a2048c2f1329https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-and-Pfizer-Provide-Update-on-Apixaban-Clinical-Development-Program/default.aspxTue, 26 Aug 2008 08:00:00 -0400ee8f55fc-056d-4b2e-a9f5-72f5f3283d16https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-and-PDL-BioPharma-Enter-Global-Alliance-to-Develop-Novel-Treatment-for-Multiple-Myeloma/default.aspxTue, 19 Aug 2008 16:00:00 -040033da6995-0b1d-4317-96b9-e075f79c0000https://news.bms.com/news/details/2008/NJ-CT-NY--MD-School-Districts-Join-Program-That-Teaches-High-School-Students-How-Medicines-Are-Made/default.aspxWed, 13 Aug 2008 08:00:00 -0400ed30b3f7-e282-483a-b878-49145424355ahttps://news.bms.com/news/details/2008/CORRECTING-and-REPLACING-CASTLE-Data-Showed-Boosted-REYATAZR-atazanavir-sulfate-and-Lopinavirr-Achieved-Similar-Results-for-Undetectable-Viral-Load-in-Treatment-Naive-HIV-1-Infected-Patients-Regardless-of-Gender/default.aspxTue, 05 Aug 2008 21:23:00 -040065eb0496-f7d4-407f-a5bf-e20467f6795chttps://news.bms.com/news/details/2008/BRISTOL-MYERS-SQUIBB-LAUNCHES-SECURE-THE-FUTURER-TECHNICAL-ASSISTANCE-PROGRAM-TO-OPTIMIZE-COMMUNITY-SERVICES-FOR-COMPREHENSIVE-HIV-MANAGEMENT-IN-SUB-SAHARAN-AFRICA/default.aspxTue, 05 Aug 2008 13:00:00 -04004ab0cdd1-c43d-4daf-8961-a3414a44ab08https://news.bms.com/news/details/2008/CASTLE-Data-Showed-Boosted-REYATAZ-atazanavir-sulfate-and-Lopinavirr-Achieved-Similar-Results-for-Undetectable-Viral-Load-in-Treatment-Naive-HIV-1-Infected-Patients-Regardless-of-Gender/default.aspxTue, 05 Aug 2008 08:00:00 -0400f306bd4a-8b18-4a37-8cf7-2b532d42e92ahttps://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Announces-Completion-of-ConvaTec-Divestiture/default.aspxFri, 01 Aug 2008 13:00:00 -040067383dfc-d691-44b5-ad7b-fb5c940c0ab5https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Proposes-to-Acquire-ImClone-Systems-for-6000-Per-Share-in-Cash/default.aspxThu, 31 Jul 2008 07:59:00 -0400a9d8b48d-761d-425d-9a17-ff912e762052https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Continues-Strong-Financial-Performance-Led-by-Double-Digit-Global-Sales-Growth/default.aspxThu, 24 Jul 2008 07:29:00 -040054f5db18-0443-482c-9398-691798ae0b56https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-and-AstraZeneca-Submit-New-Drug-Application-in-the-United-States-and-Marketing-Authorization-Application-in-Europe-for-ONGLYZATM-saxagliptin-for-the-Treatment-of-Type-2-Diabetes/default.aspxWed, 23 Jul 2008 08:00:00 -040004a54f03-acec-4e95-9641-9a48a6630778https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Names-Chief-Procurement-Officer/default.aspxMon, 21 Jul 2008 07:30:00 -04001f03d6a0-6eae-4b06-a500-1e38f5271827https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-to-Announce-Results-for-the-Second-Quarter-of-2008-on-July-24/default.aspxTue, 15 Jul 2008 13:00:00 -040095b1e63e-5843-4a26-935b-378415501fb6https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Endorses-PhRMAs-Code-on-Interactions-with-Health-Care-Professionals/default.aspxThu, 10 Jul 2008 08:00:00 -0400170c8558-2209-4e22-8b2a-708f5951f619https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Completes-Acquisition-of-Kosan-Biosciences-Incorporated/default.aspxThu, 26 Jun 2008 17:39:00 -0400150d7684-1669-4845-8868-58b4bfbbb5f7https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Completes-Tender-Offer-for-Kosan-Biosciences-Incorporated/default.aspxThu, 26 Jun 2008 08:00:00 -040023e529b3-e4be-49c8-9391-0786043b1755https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Announces-Expiration-of-Hart-Scott-Rodino-Review-Period-for-Acquisition-of-Kosan-Biosciences-Incorporated/default.aspxWed, 18 Jun 2008 08:00:00 -040000ad297e-770f-45bd-8967-b748aa44d5dahttps://news.bms.com/news/details/2008/Data-from-Phase-II-Exploratory-Study-Suggest-That-ORENCIAR-abatacept-May-Delay-Development-of-Rheumatoid-Arthritis-in-Adults-with-Undifferentiated-Inflammatory-Arthritis/default.aspxFri, 13 Jun 2008 12:37:00 -04006c798b91-a39c-407e-a1b0-3abac5e2312fhttps://news.bms.com/news/details/2008/ORENCIAR-abatacept-Provided-an-Increasing-Degree-of-Inhibition-of-Structural-Damage-Through-Three-Years-in-Adults-with-Moderate-to-Severe-Rheumatoid-Arthritis/default.aspxThu, 12 Jun 2008 08:02:00 -040001952dad-47f2-4f72-983a-37ab995520c2https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Announces-Dividend-5c995da89/default.aspxTue, 10 Jun 2008 16:30:00 -04003ad41db9-bc8d-41c1-8d99-ed004c039cb3https://news.bms.com/news/details/2008/ONGLYZATM-saxagliptin-Demonstrated-Significant-Reductions-in-Key-Measures-of-Glucose-Control-in-Treatment-Naive-People-with-Type-2-Diabetes/default.aspxSat, 07 Jun 2008 13:03:00 -0400e9ca48b3-0f4e-4e67-ad7c-85eff048c279https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-to-Hold-Investor-Teleconference-to-Discuss-ADA-Highlights/default.aspxThu, 05 Jun 2008 09:00:00 -040056f9b40d-321e-479d-90f6-717c38c840f7https://news.bms.com/news/details/2008/Newark-High-School-Students-and-Research-Scientists-Discuss-Challenges-of-Making-Medicines/default.aspxMon, 02 Jun 2008 16:55:00 -0400b4c9ae8b-26ac-4fad-aac0-4764c3374f4ahttps://news.bms.com/news/details/2008/New-Ipilimumab-Survival-Data-in-Patients-with-Metastatic-Melanoma-Presented-at-American-Society-of-Clinical-Oncology-Annual-Meeting/default.aspxSun, 01 Jun 2008 15:00:00 -0400c17bc133-bb40-49bf-b76b-ac403321d50bhttps://news.bms.com/news/details/2008/ERBITUXR-Cetuximab-Data-Demonstrate-Improved-Overall-Survival-in-First-Line-Treatment-of-Advanced-Non-Small-Cell-Lung-Cancer/default.aspxSat, 31 May 2008 13:37:00 -04002d00b4b5-4769-42f6-954d-98e8afb5f4d1https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Reaffirms-2008-Earnings-Guidance/default.aspxThu, 29 May 2008 16:30:00 -04006c798043-274a-488e-8be5-986bd28485dfhttps://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Begins-Tender-Offer-to-Acquire-Kosan-Biosciences-Inc/default.aspxThu, 29 May 2008 15:20:00 -04007d54a14c-a015-49f1-87ed-ad4728aec707https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-to-Acquire-Kosan-Biosciences/default.aspxThu, 29 May 2008 09:22:00 -0400591f97d8-9ae9-402d-8717-6847346fff4bhttps://news.bms.com/news/details/2008/Bristol-Myers-Squibb-to-Hold-Investor-Teleconference-to-Discuss-ASCO-Highlights/default.aspxWed, 28 May 2008 09:00:00 -0400e783be1b-4fc5-4b42-ae9b-445a9127d6aahttps://news.bms.com/news/details/2008/Bristol-Myers-Squibb-to-Present-at-Healthcare-Conference-0354243a5/default.aspxTue, 27 May 2008 09:00:00 -04004fa88692-66ec-440f-a1fa-782766ec63d0https://news.bms.com/news/details/2008/New-Data-on-Bristol-Myers-Squibb-Oncology-Compounds-to-Be-Featured-in-More-Than-100-Abstracts-at-ASCO-2008/default.aspxThu, 15 May 2008 09:00:00 -0400ff71984e-af8b-4159-ac73-a813f9d5e706https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-and-KAI-Pharmaceuticals-Enter-Global-Alliance-to-Develop-and-Commercialize-KAI-9803-for-Cardiovascular-Disease/default.aspxTue, 13 May 2008 09:00:00 -04007af73cfe-e978-4b30-8ec3-d165747f15ebhttps://news.bms.com/news/details/2008/ABILIFYR-aripiprazole-Receives-Expanded-Indications-for-Maintenance-Treatment-in-Both-Pediatric-Patients-Aged-10-17-With-Manic-and-Mixed-Episodes-of-Bipolar-I-Disorder-and-Adolescents-Aged-13-17-With-Schizophrenia/default.aspxThu, 08 May 2008 17:20:00 -0400c8b8f82c-d4ae-4033-b88e-708c2294e443https://news.bms.com/news/details/2008/US-Food-and-Drug-Administration-Approves-ABILIFYR-aripiprazole-for-Add-On-Treatment-to-Lithium-or-Valproate-in-the-Acute-Treatment-of-Adults-With-Manic-and-Mixed-Episodes-of-Bipolar-I-Disorder-With-or-Without-Psychotic-Features/default.aspxThu, 08 May 2008 17:13:00 -0400b6fe050e-ba94-4ae6-9cb4-728a7fdb1767https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-to-Present-at-Healthcare-Conference-43cbf0ad0/default.aspxWed, 07 May 2008 08:30:00 -040002cfd3e9-209b-4aeb-b261-13db9f78d01bhttps://news.bms.com/news/details/2008/Nordic-Capital-Fund-VII-and-Avista-Capital-Partners-Agree-to-Acquire-ConvaTec-Business-for-approximately-41-Billion/default.aspxFri, 02 May 2008 15:59:00 -0400051d3c09-bd91-4a50-a64a-cbde744d515dhttps://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Invites-Public-to-Listen-to-Webcast-of-2008-Annual-Meeting/default.aspxWed, 30 Apr 2008 08:00:00 -0400a4266343-bf3a-4f10-a4ce-fa08f500ada8https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Issues-16-Billion-of-Senior-Notes/default.aspxTue, 29 Apr 2008 08:00:00 -04003ccdff4b-d832-4f16-8dae-1ee45692059fhttps://news.bms.com/news/details/2008/BARACLUDE-Entecavir-Treatment-Resulted-In-Greater-Viral-Load-Suppression-Compared-to-Adefovir-at-96-Weeks-In-Antiviral-Naive-Adult-Chronic-Hepatitis-B-E-Antigen-Positive-Patients/default.aspxSat, 26 Apr 2008 08:00:00 -04008f83c5e7-8b73-4e10-be7a-d5164acaacc0https://news.bms.com/news/details/2008/Medarex-and-Bristol-Myers-Squibb-Joint-Statement-on-Submission-Status-of-Ipilimumab/default.aspxFri, 25 Apr 2008 08:00:00 -0400888de77d-b86a-4cc6-80f0-1a3b6e562284https://news.bms.com/news/details/2008/Strong-Double-Digit-Net-Sales-Growth-and-Solid-Earnings-Growth-Highlight-First-Quarter-for-Bristol-Myers-Squibb-Company/default.aspxThu, 24 Apr 2008 08:00:00 -040098e2535d-dfda-4350-96ab-9bd0be86412fhttps://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Appoints-Treasurer/default.aspxWed, 23 Apr 2008 08:00:00 -0400bbe6c0d3-60aa-41e6-9c2d-e8b43023604bhttps://news.bms.com/news/details/2008/Mead-Johnson-Announces-Renewable-Energy-Project/default.aspxTue, 22 Apr 2008 08:00:00 -04009d5d5ee4-2b2e-4c0a-bf96-1e8a499a495dhttps://news.bms.com/news/details/2008/Bristol-Myers-Squibb-to-Announce-Results-for-the-First-Quarter-of-2008-on-April-24/default.aspxThu, 17 Apr 2008 08:00:00 -0400c18f457c-f304-4076-a962-2ac169d3f890https://news.bms.com/news/details/2008/US-Food-and-Drug-Administration-Approves-ORENCIA-abatacept-for-the-Treatment-of-Moderate-to-Severe-Polyarticular-Juvenile-Idiopathic-Arthritis-JIA-in-Patients-Six-Years-and-Older/default.aspxTue, 08 Apr 2008 08:00:00 -0400b90e114c-745f-4149-b604-42e814a8048fhttps://news.bms.com/news/details/2008/BARACLUDE-entecavir-Data-Continue-to-Demonstrate-Low-Incidence-of-Resistance-Through-Five-Years-of-Treatment-in-Nucleoside-naive-Chronic-Hepatitis-B-Patients/default.aspxMon, 24 Mar 2008 09:00:00 -040066a0ef0c-6446-49ca-aa52-b6726fd60733https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-to-Present-at-Healthcare-Conferences/default.aspxMon, 17 Mar 2008 09:00:00 -04008467d6f2-72cf-42ab-a276-4bf08efe8785https://news.bms.com/news/details/2008/New-300mg-Loading-Dose-Tablet-For-Plavix-Receives-Positive-Opinion-From-The-European-Committee-For-Medicinal-Products-CHMP/default.aspxWed, 05 Mar 2008 09:00:00 -050073453d24-ff59-4f60-8b12-af825134bd00https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Board-Elects-Jean-Marc-Huet-Senior-Vice-President-and-Chief-Financial-Officer/default.aspxWed, 05 Mar 2008 09:00:00 -0500c42f99a4-7708-4a14-b47a-f8f3d9a3858ahttps://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Announces-Dividend-9be4b955f/default.aspxTue, 04 Mar 2008 09:00:00 -05007f99b23e-4a29-454b-be1d-a4b8fa7d413ehttps://news.bms.com/news/details/2008/US-Food-and-Drug-Administration-Approves-ABILIFY-aripiprazole-for-the-Acute-Treatment-of-Manic-and-Mixed-Episodes-Associated-with-Bipolar-I-Disorder-in-Pediatric-Patients-10-to-17-Years-of-Age/default.aspxFri, 29 Feb 2008 09:00:00 -0500fd6bee0e-7471-4d6e-95f9-4873f2052a7fhttps://news.bms.com/news/details/2008/Great-Comebacks-Program-Announces-2007-National-Award-Winner/default.aspxWed, 27 Feb 2008 09:00:00 -0500cd13b86b-3a44-4a23-b739-cadf7f4a4e9chttps://news.bms.com/news/details/2008/Celebrity-Chef-Sandra-Lee-Offers-Recipes-and-Shortcuts-in-the-Kitchen-to-People-with-Rheumatoid-Arthritis/default.aspxWed, 27 Feb 2008 09:00:00 -0500ada6cf20-5de9-4958-9a62-ac0a86b149edhttps://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Board-Elects-James-M-Cornelius-Chairman-of-the-Board/default.aspxTue, 12 Feb 2008 09:00:00 -0500dc8a3f32-7178-4a39-bef0-cbed951859ffhttps://news.bms.com/news/details/2008/CASTLE-Study-Showed-Similar-Efficacy-Between-Once-Daily-REYATAZ-atazanavir-sulfateritonavir-and-Twice-Daily-lopinavirritonavir-at-48-Weeks-in-Previously-Untreated-HIV-Infected-Adult-Patients/default.aspxWed, 06 Feb 2008 09:00:00 -0500da5881ff-16ba-4011-aa5d-f836ec0d6783https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Company-Reports-Financial-Results-for-the-Fourth-Quarter-and-Twelve-Months-of-2007/default.aspxThu, 31 Jan 2008 09:00:00 -0500870aeef8-2bac-4068-92cd-b8ad69d35c29https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Names-Togo-D-West-Jr-to-Board-of-Directors/default.aspxTue, 22 Jan 2008 09:00:00 -0500c7b5380f-2e46-447c-88ab-12b58c1500e7https://news.bms.com/news/details/2008/Bristol-Myers-Squibb-Announces-Closing-of-Its-Barceloneta-Puerto-Rico-Plant/default.aspxFri, 18 Jan 2008 09:00:00 -0500737efb81-5cc0-4d22-ba47-5245e51f2d5ehttps://news.bms.com/news/details/2008/Bristol-Myers-Squibb-to-Announce-Results-for-the-Fourth-Quarter-and-Full-Year-of-2007-on-January-31/default.aspxWed, 16 Jan 2008 09:00:00 -0500381623ac-c5ab-43b9-ba26-8f2a3d31c903https://news.bms.com/news/details/2008/Avista-Capital-Partners-Completes-Acquisition-of-Bristol-Myers-Squibb-Medical-Imaging/default.aspxTue, 08 Jan 2008 09:00:00 -0500